

# Supplement to the Carcinogenic Potency Database (CPDB): Results of Animal Bioassays Published in the General Literature through 1997 and by the National Toxicology Program in 1997–1998

Lois Swirsky Gold,<sup>\*,†1</sup> Neela B. Manley,<sup>†</sup> Thomas H. Slone,<sup>\*</sup> Lars Rohrbach,<sup>‡</sup> and Georganne Backman Garfinkel<sup>†</sup>

<sup>\*</sup>Department of Molecular and Cell Biology, University of California, Berkeley, California 94720; <sup>†</sup>Life Sciences Division, E.O. Lawrence Berkeley National Laboratory, Berkeley, California 94720; and <sup>‡</sup>Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, California 94720

Received January 31, 2005; accepted March 23, 2005

The Carcinogenic Potency Database (CPDB) is a systematic and unifying resource that standardizes the results of chronic, long-term animal cancer tests which have been conducted since the 1950s. The analyses include sufficient information on each experiment to permit research into many areas of carcinogenesis. Both qualitative and quantitative information is reported on positive and negative experiments that meet a set of inclusion criteria. A measure of carcinogenic potency, TD<sub>50</sub> (daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose), is estimated for each tissue-tumor combination reported. This article is the ninth publication of a chronological plot of the CPDB; it presents results on 560 experiments of 188 chemicals in mice, rats, and hamsters from 185 publications in the general literature updated through 1997, and from 15 Reports of the National Toxicology Program in 1997–1998. The test agents cover a wide variety of uses and chemical classes. The CPDB Web Site (<http://potency.berkeley.edu/>) presents the combined database of all published plots in a variety of formats as well as summary tables by chemical and by target organ, supplemental materials on dosing and survival, a detailed guide to using the plot formats, and documentation of methods and publications. The overall CPDB, including the results in this article, presents easily accessible results of 6153 experiments on 1485 chemicals from 1426 papers and 429 NCI/NTP (National Cancer Institute/National Toxicology program) Technical Reports. A tab-separated format of the full CPDB for reading the data into spreadsheets or database applications is available on the Web Site.

**Key Words:** carcinogenic potency; TD<sub>50</sub>; database; chronic animal cancer test.

The Carcinogenic Potency Database (CPDB) is a systematic and unifying analysis of the published results of the diverse literature of chronic, long-term animal cancer tests on

individual chemicals. A detailed set of inclusion rules is designed to restrict the database to reasonably thorough experiments for evaluating carcinogenic activity and carcinogenic potency. The CPDB standardizes the experimental results and creates an easily accessible resource that has been widely used to address a variety of research and regulatory issues in carcinogenesis. The CPDB is expanded chronologically, and the present article is a supplement that reports bioassay results that were published in the general literature through 1997 and in Technical Reports of the National Toxicology Program in 1997–1998. Our analyses are presented in the same plot format as earlier publications (Gold *et al.*, 1984, 1986, 1987, 1990, 1993, 1995, 1997, 1999). Data are reported here for 560 experiments on 188 chemicals. When added to the data published earlier, the CPDB now includes results of 6153 experiments on 1485 chemicals that have been reported in 1426 published papers and 429 NCI/NTP Technical Reports.

In this article, as in earlier publications of the CPDB, a plot format is used to report detailed information on each experiment (whether positive or negative for carcinogenicity), which is important in the interpretation of bioassays including qualitative data on strain, sex, target organ, histopathology and author's opinion as to carcinogenicity, as well as quantitative information on average daily dose rate, duration of dosing, carcinogenic potency, statistical significance, tumor incidence, dose response curve, and length of experiment. Each set of experimental results references the original published paper. A series of appendices describes the fields in the plot and defines the codes in each field.

A numerical description of carcinogenic potency, the TD<sub>50</sub> (Peto *et al.*, 1984; Sawyer *et al.*, 1984), is estimated for each set of tumor incidence data reported in the CPDB, thus providing a standardized quantitative measure for comparisons. In a simplified way, TD<sub>50</sub> may be defined as that dose-rate in mg/kg body weight/day which, if administered chronically for the standard lifespan of the species, will halve the probability of remaining tumorless throughout that period. Put differently, TD<sub>50</sub> is the daily dose-rate that will induce tumors in half of test

<sup>1</sup> To whom correspondence should be addressed: Fax: (510) 547-7073. E-mail: [lois@potency.berkeley.edu](mailto:lois@potency.berkeley.edu). Web Site: <http://potency.berkeley.edu/>.

animals that would have remained tumor-free at zero dose. We estimate  $TD_{50}$  using a one-hit model (Peto *et al.*, 1984).  $TD_{50}$  is analogous to  $LD_{50}$ , and a low value of  $TD_{50}$  indicates a potent carcinogen, whereas a high value indicates a weak one.  $TD_{50}$  is often within the range of doses tested, and does not indicate anything about carcinogenic effects at low doses because bioassays are usually conducted at or near the maximum tolerated dose (MTD). Among the 751 rodent carcinogens in the overall CPDB, the range of  $TD_{50}$  values (mg/kg/day) is at least 10-million-fold in each sex of rat or mouse.

The CPDB is exhaustive in that it includes all published results of experiments that meet a set of inclusion criteria designed to include reasonably thorough tests and to measure carcinogenic potency; however, since many tests do not meet the criteria, not all cancer tests are included. No attempt has been made to perform an evaluation of whether or not a compound induced tumors in any given experiment; rather, the opinion of the published authors is presented as well as the statistical significance of the  $TD_{50}$  calculated from the experimental results. The CPDB augments the published literature because we have had correspondence with about half the authors of published papers and have obtained tumor incidence data in addition to what has been published and have confirmed opinions about carcinogenicity at particular target sites.

There is great diversity in the extent of testing of the chemicals reported in the database; while most chemicals have been tested in rats or mice, some have been tested in hamsters, dogs, prosimians, or monkeys. Among the 1485 chemicals in the CPDB, 52% have been tested in only a single species, 44% in two species, and 4% in more than two. Experiments with 120 different mouse strains and 91 rat strains are included. For a given chemical, the database may have only a single experiment or several experiments. For example, among the 1165 chemicals tested in rats, 26% have only one rat test and 51% have two tests; however, 26 chemicals have more than 10 tests. For the 957 chemicals tested in mice, the parallel numbers are 11% with 1 test, 59% with 2 tests, and 18 chemicals with more than 10 tests. Chronologically, the CPDB reflects trends in bioassay design; for example, in the 1990s compared to earlier decades, fewer experiments have only a single dose level and a higher proportion have three or more groups in addition to controls. Seventy-two percent of the experiments in the CPDB are from papers in the general literature, and 28% are from NCI/NTP Technical Reports.

The CPDB is readily amenable to analyses ranging from large-scale investigations of the literature of chronic cancer bioassays to studies of individual chemicals or target organs or routes of administration. One major goal of the CPDB is to facilitate the use of bioassay results in carcinogenesis research. We, as well as hundreds of other researchers and agencies, have used the CPDB to address important issues in toxicology. The widely accessed CPDB Web Site presents the database in a variety of formats and also gives the text of papers using the database that our group has published since the 1980s.

## Plot in This Supplement

The supplement to the CPDB presented in this article includes results on 188 chemicals and 560 long-term, chronic experiments in rats, mice, and hamsters. NTP Technical Reports are from 1997–1998. For the general literature, about 60% of experiments are from papers published in 1995–1997. The rest of the papers are from earlier years but were not included in the CPDB earlier because they were identified recently, mainly from two sources we had not used previously in our extensive literature searches: the Japanese Science and Technology Database (JICST-EPlus) and the U.S. FDA database on Food Additives: Toxicology, Regulation and Properties (Clydesdale, 1997). This supplement, like the overall CPDB, is exhaustive in that it includes all published results of experiments that meet a set of inclusion criteria. In the general literature, experimental designs as well as the author's choice of information to report are quite diverse, and bioassays have been included only if they meet all of the following conditions:

1. Animals on test were mammals.
2. Administration was begun early in life (100 days of age or less for rats, mice, and hamsters).
3. Route of administration was diet, water, gavage, inhalation, iv or ip injection (i.e., where the whole body was more likely to have been exposed rather than only a specific site, as with sc injection or skin painting).
4. Test agent was administered alone, rather than in combination with other chemicals.
5. Exposure was chronic, with not more than seven days between administrations.
6. Duration of exposure was at least one-fourth the standard lifespan for that species. For rodents the standard lifespan is two years.
7. Duration of experiment was at least half the standard lifespan for that species.
8. Research design included a concurrent control group.
9. Research design included at least five animals per group.
10. Surgical intervention was not performed.
11. Pathology data were reported for the number of animals with tumors rather than the total number of tumors.
12. Results reported were original data, rather than secondary analyses of experiments already reported by other authors.
13. For studies with interim sacrifices, data are reported as a separate experiment for each sacrifice time.

Because we have adhered strictly to the standard inclusion criteria, bioassays of particulate or fibrous matters are not in the CPDB, e.g., asbestos, cigarette smoke, and dusts. There are no studies using a single administration of a test agent, no experiments by skin painting, sc injection, or *in utero* exposure, and no co-carcinogenesis experiments.

The selection of tissue-tumor combinations to report in the CPDB for each experiment is determined by a set of rules used

throughout the database. Whenever the published paper has the following information, it is included:

1. Each target site evaluated by the author as evidence of a carcinogenic effect
2. Liver for all species, and lung for mice, whenever reported
3. The category "all tumor-bearing animals"
4. For completeness, the CPDB also includes sites with a statistically significant increase in tumors that the author of the published paper did not consider treatment-related.

The plot format in this article is designed to facilitate use of the data. Appendix 1 describes each of the fields in the plot. Other Appendices define codes, e.g., tissue, tumor, note codes. Appendices 12 and 13 provide a bibliography of papers that are the source of data reported in the plot. Further details and a guide to using the plot, are given on our Web Site. For 67 of the 188 chemicals in this plot, additional bioassay results were reported earlier in the CPDB, and these are indicated with \*\*\* following the chemical name. In the plot, experiments are ordered alphabetically by chemical name. Within each chemical, the experiments are ordered alphabetically by species, within a species by strain, and within strain by sex. Each line of the plot reports results for a particular tissue-tumor combination. Each experiment is assigned a consecutive number, and within an experiment each tissue-tumor combination is assigned a letter.

In the field of carcinogenicity bioassays, over time fewer experiments have only a single dose group in addition to controls, and in this plot only 25% of experiments have a single dose group, 15% have two dose groups, and 60% have more than two dose groups. NTP bioassays now routinely use three dose groups. As in the CPDB overall, the chemicals in this plot induce tumors in a variety of target sites. Liver is the most frequent target site for both rats and mice, as in the CPDB overall (Gold *et al.*, 2001).

Naturally occurring and synthetic compounds from a variety of chemical classes and with a variety of uses are included in this supplement to the CPDB. A few examples follow: (1) In inhalation bioassays of three genotoxic synthetic, industrial chemicals (chloroprene, tetrafluorethylene, and vinyl fluoride) tumors were induced at multiple target sites in both sexes of rats and mice. (2) Arsenic in drinking water is a human carcinogen (International Agency for Research on Cancer, 2004); most arsenic in groundwater is the result of natural occurrence. We report here the first positive results for arsenic compounds in the CPDB. Two methylated arsenic compounds that are urinary metabolites of ingested inorganic arsenic induced tumors in male rats when administered in drinking water: dimethylarsinic acid induced bladder tumors, and trimethylarsine oxide induced hepatocellular adenomas. Another urinary metabolite, monomethylarsonic acid, gave negative results in both sexes of rats and mice when adminis-

tered in the diet, and in male rats when administered in water. (3) Results are also reported here for another human carcinogen, aristolochic acid (AA) (International Agency for Research on Cancer, 2002), which is a naturally occurring constituent of plants commonly used in traditional Chinese herbal medicine. We recently showed that despite FDA warnings and an import alert for aristolochic acid under the Dietary Supplement Safety and Health Act (DSHEA), two years later more than 100 U.S. web sites were selling products listing botanical ingredients known or suspected to contain AA (Gold and Slone, 2003). (4) Two by-products of water chlorination, dichloroacetic acid and 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), are also carcinogenic. (5) About 30% of the chemicals in this supplement are pharmaceuticals; examples of some that are positive for carcinogenicity are lovastatin, AZT, and salicylazosulfapyridine. (6) Bioassays of three food additives found no evidence of carcinogenicity: olestra, monosodium glutamate, and aspartame. (7) Acrylamide is a genotoxic, industrial chemical that was recently identified as a product of cooking; it is widespread in the food supply. Acrylamide is also a constituent of cigarette smoke. The plot reports positive results at multiple target sites in male and female rats for acrylamide administered by drinking water.

The range of TD<sub>50</sub> values (mg/kg/day) for carcinogens in this plot is 2-million fold across chemicals. At the two extremes in female rats, for example, are the most potent TD<sub>50</sub> values for aristolochic acid (TD<sub>50</sub> = 14.1 µg/kg/day), and hydrochlorofluorocarbon 123 (TD<sub>50</sub> = 22.7 gm/kg/day).

### Analyses That Use the CPDB

During the past 20 years we have published many papers based on results in the CPDB, including methodological analyses of bioassay results such as reproducibility of results and methods for summarizing potency of a chemical; species comparisons in positivity, target site, and potency; frequency and type of target organs in each species; constraints on potency estimation; mechanism of carcinogenesis; carcinogenicity of natural vs. synthetic chemicals and comparisons of possible cancer hazards; permitted occupational exposures and possible cancer hazards; disparities in cancer risk estimates of pesticide residues in food; and comparison of cancer risk assessments based on a variety of methodologies. The text of these papers is given on our Web Site.

One persistent finding has been that half or more of the chemicals tested in chronic, long-term tests are carcinogenic in at least one experiment. Results are similar for a variety of subsets of the data, including naturally occurring chemicals in the diet and synthetic chemicals (Table 1). Human exposures to rodent carcinogens are thus ubiquitous. We have discussed in several papers the plausible explanations for this high positivity

**TABLE 1**  
**Proportion of Chemicals in the CPDB That Are Evaluated as Carcinogenic**

Chemicals tested in both rats and mice	
Chemicals in the CPDB	379/648 (58%)
Naturally occurring chemicals	86/155 (55%)
Synthetic chemicals	293/493 (59%)
Chemicals tested in rats or mice	
Chemicals in the CPDB	751/1456 (52%)
Natural pesticides	41/75 (55%)
Commercial pesticides	79/198 (40%)
Mold toxins	15/25 (60%)
Naturally occurring chemicals in roasted coffee	23/32 (72%)

*Note.* A chemical is classified as positive if the author of at least one published experiment evaluated results as evidence of a carcinogenic effect.

rate, including a variety of high dose effects (Ames and Gold, 1990, 2000; Gold *et al.*, 1998, 2002).

### The CPDB Web Site

One goal of the CPDB has been to facilitate the use of bioassay results in carcinogenesis research and regulatory policy. Our highly accessed Web Site (<http://potency.berkeley.edu/>) is designed to provide user-friendly access to CPDB results for 6153 experiments on 1485 chemicals. The Web Site can be searched for results on a particular chemical, a particular target organ, or a particular published paper or experiment. A plot of the full CPDB is on the Web in the format presented in this paper and is suitable for printing. A compact format is designed for viewing on a single computer screen, and a tab-separated format is designed for reading into spreadsheets or database applications.

Two tables on the Web Site summarize each chemical using all experiments in the CPDB. Separate tables summarize the results of NCI/NTP bioassays only.

The Summary Table by Chemical (<http://potency.berkeley.edu/chemicalsummary.html>) is an alphabetical index of chemicals in the CPDB and a tabular compilation of positivity, target sites, and carcinogenic potency on each chemical based on data from all experiments. It can be used to investigate associations between carcinogenic potency or target sites and other factors such as mutagenicity, teratogenicity, chemical structure, and human exposure. It is readily downloadable to spreadsheets or other databases.

The Summary Table by Target Organ (<http://potency.berkeley.edu/pathology.table.html>) is a compendium of bioassay results organized by target site in each species for chemicals with a positive result. It lists, for example, each chemical that induces tumors in the lung or liver or hematopoietic system, and superscripts indicate whether the chemical is tested in both rats and mice and whether it is positive in both species. Target organs are also summarized for hamsters, dogs, and nonhuman primates.

Additional information on the Web Site for each chemical includes mutagenicity in *Salmonella*, chemical structure, and SMILES code. A supplementary database reports details of dosing and survival in each experiment. Documentation is provided on the methods used to develop the CPDB, a detailed guide to each field in the plot, and details of the tab-separated database for reading into spreadsheets.

### ACKNOWLEDGMENTS

We thank the hundreds of scientists who have assisted us in developing the CPDB over the past 20 years by providing additional information on their experiments. We thank Bruce N. Ames and Jerrold Ward for their many years of advice. This work was supported by the National Institute of Environmental Health Sciences through the E.O. Lawrence Berkeley National Laboratory (LBNL) Interagency Agreement (YIES101901) with the U.S. Department of Energy (DOE) DE-AC-03-76SF00098, and through the University of California, Berkeley by a grant for research in disease prevention through the Dean's Office of the College of Letters and Science.

### REFERENCES

- Ames, B. N., and Gold, L. S. (1990). Perspective: Too many rodent carcinogens: Mitogenesis increases mutagenesis. *Science* **249**, 970–971.
- Ames, B. N., and Gold, L. S. (2000). Paracelsus to parascience: The environmental cancer distraction. *Mutat. Res.* **447**, 3–13.
- Clydesdale, F. M., Ed. (1997). *Food Additives: Toxicology, Regulation, and Properties*. CRC Press, Boca Raton, FL.
- Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de Veciana, M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., Peto, R., Pike, M. C., and Ames, B. N. (1984). A Carcinogenic Potency Database of the standardized results of animal bioassays. *Environ. Health Perspect.* **58**, 9–319.
- Gold, L. S., de Veciana, M., Backman, G. M., Magaw, R., Lopipero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B. N. (1986). Chronological supplement to the Carcinogenic Potency Database: Standardized results of animal bioassays published through December 1982. *Environ. Health Perspect.* **67**, 161–200.
- Gold, L. S., Slone, T. H., Backman, G. M., Magaw, R., Da Costa, M., Lopipero, P., Blumenthal, M., and Ames, B. N. (1987). Second chronological supplement to the Carcinogenic Potency Database: Standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986. *Environ. Health Perspect.* **74**, 237–329.
- Gold, L. S., Slone, T. H., Backman, G. M., Eisenberg, S., Da Costa, M., Wong, M., Manley, N. B., Rohrbach, L., and Ames, B. N. (1990). Third chronological supplement to the Carcinogenic Potency Database: Standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987. *Environ. Health Perspect.* **84**, 215–286.
- Gold, L. S., Manley, N. B., Slone, T. H., Garfinkel, G. B., Rohrbach, L., and Ames, B. N. (1993). The fifth plot of the Carcinogenic Potency Database: Results of animal bioassays published in the general literature through 1988 and by the National Toxicology Program through 1989. *Environ. Health Perspect.* **100**, 65–135.
- Gold, L. S., Manley, N. B., Slone, T. H., Garfinkel, G. B., Ames, B. N., Rohrbach, L., Stern, B. R., and Chow, K. (1995). Sixth plot of the Carcinogenic Potency Database: Results of animal bioassays published in

- the general literature 1989–1990 and by the National Toxicology Program 1990–1993. *Environ. Health Perspect.* **103**(Suppl. 8), 3–122.
- Gold, L. S., Slone, T. H., Ames, B. N., Manley, N. B., Garfinkel, G. B., and Rohrbach, L. (1997). Carcinogenic Potency Database. In *Handbook of Carcinogenic Potency and Genotoxicity Databases* (L. S. Gold and E. Zeiger, Eds.), pp. 1–605. CRC Press, Boca Raton, FL.
- Gold, L. S., Slone, T. H., and Ames, B. N. (1998). What do animal cancer tests tell us about human cancer risk? Overview of analyses of the Carcinogenic Potency Database. *Drug Metab. Rev.* **30**, 359–404.
- Gold, L. S., Manley, N. B., Slone, T. H., and Rohrbach, L. (1999). Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. *Environ. Health Perspect.* **107**(Suppl. 4), 527–600.
- Gold, L. S., Manley, N. B., Slone, T. H., and Ward, J. M. (2001). Compendium of chemical carcinogens by target organ: Results of chronic bioassays in rats, mice, hamsters, dogs and monkeys. *Toxicol. Pathol.* **29**, 639–652.
- Gold, L. S., Slone, T. H., Manley, N. M., and Ames, B. N. (2002). *Misconceptions about the Causes of Cancer*. Fraser Institute, Vancouver, British Columbia.
- Gold, L. S., and Slone, T. H. (2003). Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. *N. Engl. J. Med.* **349**, 1576–1577.
- International Agency for Research on Cancer (2002). *Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene*. IARC, Lyon, France.
- International Agency for Research on Cancer (2004). *Some Drinking-water Disinfectants and Contaminants, Including Arsenic*. IARC, Lyon, France.
- Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N. (1984). The TD<sub>50</sub>: A proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. *Environ. Health Perspect.* **58**, 1–8.
- Sawyer, C., Peto, R., Bernstein, L., and Pike, M. C. (1984). Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. *Biometrics* **40**, 27–40.

## SUPPLEMENTAL PLOT OF THE CARCINOGENIC POTENCY DATABASE

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
4-ACETYLAMINOPHENYLACETIC ACID					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1	M f	b6c eat	liv hpa	78w78 e	.no dre	P=1. -
a	M f	b6c eat	liv hpc	78w78 e	no dre	P=1. -
b	M f	b6c eat	lun mix	78w78 e	no dre	P=1. -
2	M m	b6c eat	lun a/a	78w78 e	> 27.7gm	P<.3 -
a	M m	b6c eat	lun a/c	78w78 e	56.1gm	P<.6 -
b	M m	b6c eat	liv hpa	78w78 e	no dre	P=1. -
3	R f	f34 eat	liv mix	24m24 e	no dre	P=1. -
4	R m	f34 eat	liv hpc	24m24 e	no dre	P=1. -
a	R m	f34 eat	liv hpa	24m24 e	no dre	P=1. -
N-ACETYLCYSTEINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
5	R m	f34 eat	liv mix	98w98 e	>	no dre P=1. -
ACRYLAMIDE***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
6	R f	f34 wat	mgl ben	24m24 ej	4.21mg *	P<.002 +
a	R f	f34 wat	cns glx	24m24 ej	17.3mg *	P<.007 +
b	R f	f34 wat	tyf mix	24m24 ej	19.1mg *	P<.01 +
c	R f	f34 wat	cns ast	24m24 ej	19.5mg *	P<.004 +
d	R f	f34 wat	mam fib	24m24 ej	20.9mg *	P<.0005 +
e	R f	f34 wat	mgl fba	24m24 ej	8.73mg *	P<.07 +
f	R f	f34 wat	orc sqp	24m24 ej	16.2mg *	P<.02 +
g	R f	f34 wat	mgl adc	24m24 ej	17.6mg *	P<.02 +
h	R f	f34 wat	cli ade	24m24 j	19.0mg *	P<.04 +
i	R f	f34 wat	ute adc	24m24 ej	26.5mg *	P<.05 +
j	R f	f34 wat	bra ast	24m24 ej	38.8mg *	P<.04 +
k	R f	f34 wat	thy fdc	24m24 ej	39.5mg *	P<.05 +
l	R f	f34 wat	spd ast	24m24 ej	40.3mg *	P<.05 +
m	R f	f34 wat	bra oli	24m24 ej	259.mg *	P<.8 +
7	R f	f34 wat	mgl mix	25m25 e	8.18mg *	P<.002 +
a	R f	f34 wat	tyf mix	25m25 e	8.92mg *	P<.0005+
b	R f	f34 wat	mgl fba	25m25 e	9.33mg *	P<.003+
c	R f	f34 wat	thy fca	25m25 e	11.7mg *	P<.0005+
d	R f	f34 wat	thy fdc	25m25 e	42.8mg *	P<.07 +
e	R f	f34 wat	cns glx	25m25 e	57.2mg *	P<.06 +
f	R f	f34 wat	bra ast	25m25 e	71.8mg *	P<.2 +
g	R f	f34 wat	mgl adc	25m25 e	100.mg *	P<.4 +
h	R f	f34 wat	spd ast	25m25 e	210.mg *	P<.3 +
8	R m	f34 wat	tnv msm	24m24 ej	1.75mg Z	P<.002 +
a	R m	f34 wat	thy fca	24m24 ej	13.5mg *	P<.003 +
b	R m	f34 wat	cns ast	24m24 ej	23.5mg Z	P<.06 +
c	R m	f34 wat	spd ast	24m24 ej	39.7mg *	P<.05 +
d	R m	f34 wat	adr pob	24m24 ej	18.1mg *	P<.2 +
e	R m	f34 wat	cns glx	24m24 ej	24.8mg *	P<.2 +
f	R m	f34 wat	spl leu	24m24 ej	45.8mg *	P<.8 +
g	R m	f34 wat	bra ast	24m24 ej	82.6mg *	P<.6 +
h	R m	f34 wat	bra oli	24m24 ej	339.mg *	P<.8 +
i	R m	f34 wat	adr phm	24m24 ej	no dre	P=1. -
9	R m	f34 wat	tyf mix	25m25 e	7.35mg *	P<.0005+
a	R m	f34 wat	thy fca	25m25 e	7.49mg *	P<.0005+
b	R m	f34 wat	tnv msb	25m25 e	9.45mg *	P<.0005+
c	R m	f34 wat	bra ast	25m25 e	76.8mg *	P<.1 +
d	R m	f34 wat	cns glx	25m25 e	48.9mg *	P<.2 +
e	R m	f34 wat	thy fdc	25m25 e	77.2mg *	P<.3 +
f	R m	f34 wat	spd ast	25m25 e	82.5mg *	P<.3 +
g	R m	f34 wat	bra oli	25m25 e	no dre	P=1. -
ALCLOFENAC					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
10	R f	wis eat	ova mix	24m24 e	390.mg Z	P<.005 -
a	R f	wis eat	liv mix	24m24 e	no dre	P=1. -
b	R f	wis eat	tba mix	24m24 e	no dre	P=1. -
11	R m	wis eat	liv mix	24m24 e	>	no dre P=1. -
a	R m	wis eat	tba mix	24m24 e	no dre	P=1. -
3-AMINO-4-[2-[(2-GUANIDINOTHIAZOL-4-YL)METHYLTHIO], ETHYLAMINO]-1,2,5-THIADIAZOLE 1-OXIDE.HCl					100.....1g.....10	
12	R f	cdr gav	gam cnd	24m24 r	± 6.27gm *	P<.02 +
13	R m	cdr gav	gam cnd	24m24 r	+ 4.14gm *	P<.004 +
1-(AMINOMETHYL)CYCLOHEXANECETIC ACID***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
14	R f	wis eat	kid rcc	24m24 j	no dre	P=1. -
a	R f	wis eat	tba mix	24m24 j	7.99gm *	P<.8 -
15	R m	wis eat	pan ana	24m24 j	+ 5.85gm *	P<.01 +
a	R m	wis eat	pan acc	24m24 j	8.61gm *	P<.007 +
b	R m	wis eat	kid rct	24m24 j	no dre	P=1. -
c	R m	wis eat	tba mix	24m24 j	7.12gm *	P<.6 -
2,2'-[(4-AMINOPHENYL)IMINO]BISETHANOL SULFATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
16	R f	f3d eat	liv hpa	24m24 e	>	7.31gm * P<.2 -
17	R m	f3d eat	liv hpa	24m24 e	>	no dre P=1. -
a	R m	f3d eat	liv hpc	24m24 e	no dre	P=1. -
ARISTOLOCHIC ACID, SODIUM SALT (77% AA I, 21% AA II)					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
18	R f	wis gav	for mix	52w69 Ae	+ 14.1ug	P<.008 +
a	R f	wis gav	for sqp	52w69 Ae	24.7ug	P<.04 +
b	R f	wis gav	for sqc	52w69 Ae	.101mg	P<.3 +
19	R m	wis gav	for sqc	52w69 Ae	noTD50	P<.02 +
ARSENIOS OXIDE***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
20	M f	c3s wat	mql adc	24m24 Ler	>	no dre P=1. -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology			Brkly Code	
<b>4-ACETYLAMINOPHENYLACETIC ACID 18699-02-0</b>												
1	2381	8.53gm n.s.s.	2/50	3.00gm		2/50		Truttrer;phrm,40,325-335;1990				
a	2381	10.6gm n.s.s.	1/50	3.00gm	1/50							
b	2381	10.6gm n.s.s.	1/50	3.00gm	1/50							
2	2381	6.12gm n.s.s.	1/50	3.00gm	3/50							
a	2381	7.66gm n.s.s.	1/50	3.00gm	2/50							
b	2381	6.75gm n.s.s.	9/50	3.00gm	6/50							
3	2385	18.8gm n.s.s.	1/50	3.00gm	1/50			Truttrer;phrm,40,337-349;1990				
4	2385	18.8gm n.s.s.	1/50	3.00gm	1/50							
a	2385	22.2gm n.s.s.	3/50	3.00gm	1/50							
<b>N-ACETYLCYSTEINE 616-91-1</b>												
5	2405	1.15gm n.s.s.	0/12	522.mg	0/12			Chung;canr,56,772-778;1996				
<b>ACRYLAMIDE*** (2-propenamide) 79-06-1</b>												
6	1787m	2.08mg 22.0mg	10/60	10.0ug	11/60	.100mg	9/60	.500mg	19/58	2.00mg	23/61	Johnson;txap,85,154-168;1986/pers.comm.
a	1787m	6.59mg 361.mg	1/60	10.0ug	2/60	.100mg	1/60	.500mg	0/60	2.00mg	7/61	
b	1787m	7.00mg 1.33gm	1/58	10.0ug	0/59	.100mg	1/59	.500mg	1/58	2.00mg	5/60	
c	1787m	7.35mg 197.mg	1/60	10.0ug	1/60	.100mg	0/60	.500mg	0/60	2.00mg	6/61	
d	1787m	7.94mg 87.1mg	0/60	10.0ug	0/60	.100mg	0/60	.500mg	0/58	2.00mg	5/61	
e	1787m	3.15mg n.s.s.	10/60	10.0ug	11/60	.100mg	9/60	.500mg	16/58	2.00mg	17/61	
f	1787m	6.10mg n.s.s.	0/60	10.0ug	3/60	.100mg	2/60	.500mg	1/60	2.00mg	7/61	
g	1787m	6.42mg n.s.s.	2/60	10.0ug	1/60	.100mg	1/60	.500mg	2/58	2.00mg	6/61	
h	1787m	6.38mg n.s.s.	0/60	10.0ug	1/60	.100mg	3/60	.500mg	2/60	2.00mg	5/60	
i	1787m	8.21mg n.s.s.	1/60	10.0ug	2/60	.100mg	1/60	.500mg	0/59	2.00mg	5/60	
j	1787m	12.9mg n.s.s.	0/60	10.0ug	1/60	.100mg	0/60	.500mg	0/60	2.00mg	3/60	
k	1787m	10.9mg n.s.s.	1/58	10.0ug	0/59	.100mg	0/59	.500mg	0/58	2.00mg	3/60	
l	1787m	11.1mg n.s.s.	1/60	10.0ug	0/59	.100mg	0/60	.500mg	0/60	2.00mg	3/61	
m	1787m	17.3mg n.s.s.	0/60	10.0ug	1/60	.100mg	1/60	.500mg	0/60	2.00mg	1/60	
7	2253	4.42mg 35.8mg	11/96	1.00mg	21/94	3.00mg	30/95		Friedman;faat,27,95-105;1995/Damjanov 1998/pers.comm.			
a	2253	5.52mg 18.9mg	2/100	1.00mg	10/100	3.00mg	23/100					
b	2253	4.88mg 54.9mg	9/96	1.00mg	20/94	3.00mg	26/95					
c	2253	7.15mg 22.5mg	0/100	1.00mg	7/100	3.00mg	16/100					
d	2253	15.8mg n.s.s.	2/100	1.00mg	3/100	3.00mg	7/100					
e	2253	21.7mg n.s.s.	0/100	1.00mg	2/100	3.00mg	3/100					
f	2253	24.8mg n.s.s.	0/100	1.00mg	2/100	3.00mg	2/100					
g	2253	22.2mg n.s.s.	2/96	1.00mg	2/94	3.00mg	4/95					
h	2253	34.2mg n.s.s.	0/89	1.00mg	0/21	3.00mg	1/90					
8	1787m	.844mg 8.55mg	3/60	10.0ug	0/60	.100mg	7/60	.500mg	11/60	(2.00mg	10/60)	Johnson;txap,85,154-168;1986/pers.comm.
a	1787m	5.60mg 91.2mg	1/60	10.0ug	0/60	.100mg	2/60	.500mg	1/60	2.00mg	7/60	
b	1787m	7.49mg n.s.s.	4/60	10.0ug	0/60	.100mg	0/60	.500mg	2/60	2.00mg	5/60	
c	1787m	11.0mg n.s.s.	1/60	10.0ug	0/60	.100mg	0/60	.500mg	0/60	2.00mg	3/60	
d	1787m	5.19mg n.s.s.	3/60	10.0ug	8/59	.100mg	7/60	.500mg	5/60	2.00mg	10/60	
e	1787m	7.30mg n.s.s.	5/60	10.0ug	2/60	.100mg	0/60	.500mg	2/60	2.00mg	6/60	
f	1787m	4.68mg n.s.s.	10/60	10.0ug	20/60	.100mg	14/60	.500mg	14/60	2.00mg	16/60	
g	1787m	11.7mg n.s.s.	3/60	10.0ug	0/60	.100mg	0/60	.500mg	2/60	2.00mg	2/60	
h	1787m	18.9mg n.s.s.	0/60	10.0ug	2/60	.100mg	0/60	.500mg	0/60	2.00mg	1/60	
i	1787m	25.0mg n.s.s.	2/60	10.0ug	0/59	.100mg	2/60	.500mg	1/60	2.00mg	0/60	
9	2253	3.95mg 19.3mg	6/202	1.00mg	12/203	.500mg	5/101	2.00mg	17/75			Friedman;faat,27,95-105;1995/Damjanov 1998/pers.comm.
a	2253	4.07mg 18.8mg	3/202	.100mg	9/203	.500mg	5/101	2.00mg	15/75			
b	2253	4.66mg 35.2mg	8/204	.100mg	9/204	.500mg	8/102	2.00mg	13/75			
c	2253	16.8mg n.s.s.	1/204	.100mg	0/98	.500mg	0/50	2.00mg	2/75			
d	2253	11.9mg n.s.s.	2/204	.100mg	2/98	.500mg	1/50	2.00mg	3/75			
e	2253	15.9mg n.s.s.	3/203	.100mg	3/203	.500mg	0/101	2.00mg	3/75			
f	2253	12.0mg n.s.s.	0/172	.100mg	1/68	.500mg	0/37	2.00mg	1/51			
g	2253	27.3mg n.s.s.	1/204	.100mg	1/98	.500mg	1/50	2.00mg	0/75			
<b>ALCLOFENAC ((4-allyloxy-3-chlorophenyl)acetic acid) 22131-79-9</b>												
10	2432	148.mg 3.07gm	0/95	20.0mg	1/47	40.0mg	4/50	(80.0mg	0/50)	Everett;iyke,18,201-217;1987		
a	2432	610.mg n.s.s.	8/94	20.0mg	1/46	40.0mg	1/50	80.0mg	3/48			
b	2432	54.2mg n.s.s.	84/95	20.0mg	43/48	40.0mg	43/50	80.0mg	43/50			
11	2432	328.mg n.s.s.	9/86	20.0mg	4/44	40.0mg	5/46	80.0mg	4/44			
a	2432	58.2mg n.s.s.	81/94	20.0mg	42/46	40.0mg	44/48	80.0mg	39/48			
<b>3-AMINO-4-[2-[(2-GUANIDINOTHIAZOL-4-YL)METHYLTHIO], ETHYLAMINO]-1,2,5-THIADIAZOLE 1-OXIDE.HCl (BL-6341.HCl) ---</b>												
12	2449	1.54gm n.s.s.	0/100	10.0mg	0/50	55.0mg	0/50	300.mg	2/50	Hirth;txpy,16,273-287;1988		
13	2449	1.25gm 40.8gm	0/100	10.0mg	0/50	55.0mg	0/50	300.mg	3/50			
<b>1-(AMINOMETHYL)CYCLOHEXANECACETIC ACID*** (gabapentin) 60142-96-3</b>												
14	2026m	23.7gm n.s.s.	0/50	250.mg	1/50	1.00gm	0/50	2.00gm	0/50	Dominick;txap,111,375-387;1991/Sigler 1995		
a	2026m	804.mg n.s.s.	43/50	250.mg	46/50	1.00gm	45/50	2.00gm	45/50			
15	2026m	2.72gm 437.gm	7/50	250.mg	6/50	1.00gm	10/50	2.00gm	16/50			
a	2026m	3.91gm 150.gm	0/50	250.mg	4/50	1.00gm	3/50	2.00gm	8/50			
b	2026m	1.87gm n.s.s.	0/50	250.mg	0/50	1.00gm	0/50	2.00gm	0/50			
c	2026m	1.31gm n.s.s.	35/50	250.mg	38/50	1.00gm	35/50	2.00gm	39/50			
<b>2,2'-(4-AMINOPHENYL)IMINO]BISETHANOL SULFATE (N,N-bis(2-hydroxyethyl)-p-phenylenediamine sulfate) 54381-16-7</b>												
16	2269	1.19gm n.s.s.	0/50	15.0mg	0/50	50.0mg	0/50	150.mg	1/50	Hagiwara;fctx,34,537-546;1996		
17	2269	1.08gm n.s.s.	2/50	12.0mg	2/50	40.0mg	0/50	120.mg	1/50			
a	2269	1.56gm n.s.s.	1/50	12.0mg	1/50	40.0mg	0/50	120.mg	0/50			
<b>ARISTOLOCHIC ACID, SODIUM SALT (77% AA I, 21% AA II) 10190-99-5</b>												
18	2424	3.89ug .254mg	0/4	75.0ug	4/5			Mengs;artx,51,107-119;1982/pers.comm.				
a	2424	6.88ug n.s.s.	0/4	75.0ug	3/5							
b	2424	16.3ug n.s.s.	0/4	75.0ug	1/5							
19	2424	n.s.s. n.s.s.	0/5	75.0ug	4/4							
<b>ARSENIOS OXIDE*** 1327-53-3</b>												
20	2367	1.48mg n.s.s.	12/29	1.06mg	10/28			Schrauzer;bnch,9,245-253;1978				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
<b>ARSENITE, SODIUM***</b>						
21	M f	c3s wat	mgl adc	65w65 Ler	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1.
22	M f	c3s wat	mgl adc	24m24 Ler	.	no dre P=1.
<b>ASPARTAME***</b>						
23	R f	cdr eat	bra mix	24m24 ev	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	118.gm * P<.2 -
a	R f	cdr eat	liv bhp	24m24 ev	.	no dre P=1. -
b	R f	cdr eat	tba mix	24m24 ev	.	no dre P=1. -
24	R m	cdr eat	bra mix	24m24 ev	.	666.gm * P<.9 -
a	R m	cdr eat	liv bhp	24m24 ev	.	1.29kg P<.9 -
b	R m	cdr eat	tba mix	24m24 ev	.	no dre P=1. -
<b>ASTEMIZOLE</b>						
25	M f	swi eat	liv hpa	78w78	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
a	M f	swi eat	liv hpa	78w78	.	no dre P=1. -
b	M f	swi eat	tba mix	78w78	.	164.mg * P<.6 -
26	M m	swi eat	liv hpc	78w78	.	788.mg * P<.3 -
a	M m	swi eat	liv hpa	78w78	.	8.77gm * P<.1 -
b	M m	swi eat	liv hpa	78w78	.	no dre P=1. -
c	M m	swi eat	tba mix	78w78	.	no dre P=1. -
27	R f	crw eat	liv nnd	24m24	.	309.mg * P<.2 -
a	R f	crw eat	tba mix	24m24	.	no dre P=1. -
28	R m	crw eat	liv nnd	24m24	.	no dre P=1. -
a	R m	crw eat	tba mix	24m24	.	32.5mg * P<.2 -
<b>AZELNIDIPINE</b>						
29	M f	b6c gav	liv hpa	78w78	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	217.mg * P<.3 -
a	M f	b6c gav	liv hpc	78w78	.	no dre P=1. -
b	M f	b6c gav	liv hpa	78w78	.	no dre P=1. -
c	M f	b6c gav	liv hpa	78w78	.	no dre P=1. -
d	M f	b6c gav	tba mix	78w78	.	no dre P=1. -
30	M m	b6c gav	liv hpa	78w78	.	65.0mg * P<.05 -
a	M m	b6c gav	liv hpa	78w78	.	227.mg * P<.4 -
b	M m	b6c gav	liv hpc	78w78	.	no dre P=1. -
c	M m	b6c gav	liv hpa	78w78	.	no dre P=1. -
d	M m	b6c gav	tba mix	78w78	.	83.5mg * P<.7 -
31	R f	f3d gav	liv hpa	24m24	.	no dre P=1. -
a	R f	f3d gav	liv hpc	24m24	.	no dre P=1. -
b	R f	f3d gav	tba mix	24m24	.	no dre P=1. -
32	R m	f3d gav	liv hpa	24m24	.	117.mg P<.3 -
a	R m	f3d gav	liv hpc	24m24	.	237.mg P<.6 -
b	R m	f3d gav	tba mix	24m24	.	no dre P=1. -
<b>AZT</b>						
33	M f	b6c gav	vag MXA	24m24	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	209.mg * P<.0005c
a	M f	b6c gav	vag sqc	24m24	.	246.mg * P<.0005c
b	M f	b6c gav	TBA MXB	24m24	.	221.mg * P<.5
c	M f	b6c gav	liv MXB	24m24	.	139.mg * P<.2
d	M f	b6c gav	liv MXB	24m24	.	510.mg * P<.3
34	M m	b6c gav	kid MXA	24m24	.	929.mg * P<.02 e
a	M m	b6c gav	kid rua	24m24	.	1.25gm * P<.04 e
b	M m	b6c gav	hag MXA	24m24	.	458.mg * P<.2 e
c	M m	b6c gav	TBA MXB	24m24	.	no dre P=1.
d	M m	b6c gav	liv MXB	24m24	.	no dre P=1.
e	M m	b6c gav	liv MXB	24m24	.	no dre P=1.
35	M m	b6c gav	kid MXA	24m24	with step	929.mg * P<.02 e
36	M f	cd1 gav	vag mix	95w95 ev	.	508.mg * P<.005 +
a	M f	cd1 gav	vag sqc	95w95 ev	.	715.mg * P<.02
b	M f	cd1 gav	tba mix	95w95 ev	.	131.mg P<.3
37	M m	cd1 gav	tba mix	82w82 ev	.	no dre P=1. -
38	R f	cdr gav	vag sqc	95w95 ev	.	+hist 11.6gm * P<.08 +
a	R f	cdr gav	tba mix	95w95 ev	.	no dre P=1. -
39	R m	cdr gav	tba mix	24m24 ev	.	no dre P=1. -
<b>BARBITAL, SODIUM***</b>						
40	R f	f34 wat	liv tum	75w75	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1.
41	R m	f34 wat	kid mix	75w75	.	29.2mg P<.04 +
a	R m	f34 wat	kid rca	75w75	.	54.8mg P<.04
b	R m	f34 wat	k/p tpp	75w75	.	51.8mg P<.2
c	R m	f34 wat	liv hpa	75w75	.	165.mg P<.6
<b>BENZIDINE***</b>						
42	M m	icr eat	liv hpt	60w60	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	19.9mg P<.02 +
<b>3-BENZYLSDYNONE-4-ACETAMIDE</b>						
43	M f	ddd wat	liv hpa	52w52 r	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	10.2mg Z P<.0005
a	M f	ddd wat	liv mix	52w52 r	.	10.2mg Z P<.0005+
b	M f	ddd wat	liv hpc	52w52 r	.	22.6mg * P<.002 +
c	M f	ddd wat	liv hpa	52w52 r	.	31.4mg * P<.02
44	R m	don wat	liv hpc	41w91 r	.	4.24mg P<.0005+
a	R m	don wat	liv mix	41w91 r	.	4.24mg P<.0005+
b	R m	don wat	liv nnd	41w91 r	.	15.1mg P<.005
45	R m	don eat	liv tum	24m24 r	.	no dre P=1. -
<b>BIFENTHRIN</b>						
46	M f	sww eat	ubl mnp	92w92 er	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1.
47	M m	sww eat	ubl mnp	86w86 er	.	286.mg * P<.2
<b>5,5'-(1,1'-BIPHENYL)-2,5-DIYLBIS(OXY)(2,2-DIMETHYLPENTANOIC ACID)</b>						
48	M f	b6c eat	liv mix	24m24 er	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	72.3mg * P<.0005+
a	M f	b6c eat	liv hpa	24m24 er	.	90.6mg * P<.0005
b	M f	b6c eat	liv hpc	24m24 er	.	402.mg * P<.02



RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology			Brkly Code	
<b>ARSENITE, SODIUM*** 7784-46-5</b>												
21	2369m	8.66mg n.s.s.	22/27	16.0mg	6/15			Schrauzer;ancl,4,441-447;1974/1976				
22	2369n	6.01mg n.s.s.	22/30	2.00mg	8/30							
<b>ASPARTAME*** 22839-47-0</b>												
23	2387	30.4gm n.s.s.	0/60	1.00gm	2/40	2.00gm	0/40	4.00gm	1/40	7.42gm	2/40	Koestner;apab,447-457;1984/Cornell 1984/Hazleton 1973
a	2387	21.4gm n.s.s.	2/60	4.00gm	0/40	7.42gm	0/40					
b	2387	11.9gm n.s.s.	49/60	4.00gm	27/40	7.42gm	26/40					
24	2387	33.9gm n.s.s.	1/59	1.00gm	1/40	2.00gm	1/40	4.00gm	4/40	7.42gm	0/40	
a	2387	54.1gm n.s.s.	1/59	4.00gm	0/40	7.42gm	1/38					
b	2387	10.6gm n.s.s.	28/60	4.00gm	19/40	7.42gm	18/40					
<b>ASTEMIZOLE (hismanal) 68844-77-9</b>												
25	2349	37.2mg n.s.s.	10/50	3.25mg	4/50	13.0mg	5/50	(52.0mg	2/50)	Benze;canr,55,5589-5594;1995		
a	2349	137. mg n.s.s.	4/50	3.25mg	5/50	13.0mg	7/50	52.0mg	3/50			
b	2349	28.5mg n.s.s.	30/50	3.25mg	28/50	13.0mg	23/50	52.0mg	31/50			
26	2349	155. mg n.s.s.	1/50	3.00mg	0/50	12.0mg	0/50	48.0mg	2/50			
a	2349	55.4mg n.s.s.	15/50	3.00mg	12/50	12.0mg	16/50	48.0mg	14/50			
b	2349	104. mg n.s.s.	9/50	3.00mg	11/50	12.0mg	9/50	48.0mg	7/50			
c	2349	36.7mg n.s.s.	34/50	3.00mg	31/50	12.0mg	27/50	48.0mg	30/50			
27	2349	89.2mg n.s.s.	6/50	2.50mg	4/50	10.0mg	5/50	40.0mg	9/50			
a	2349	28.1mg n.s.s.	45/50	2.50mg	46/50	10.0mg	42/50	40.0mg	43/50			
28	2349	228. mg n.s.s.	4/50	2.00mg	1/50	8.00mg	4/50	32.0mg	1/50			
a	2349	9.56mg n.s.s.	43/50	2.00mg	41/50	8.00mg	43/50	32.0mg	46/50			
<b>AZELNIDIPINE 123524-52-7</b>												
29	2591	51.5mg n.s.s.	3/50	2.14mg	0/50	7.14mg	1/50	21.4mg	4/50	Takaoka;jjpt,25,S1113-S1126;1997/pers. comm.		
a	2591	66.9mg n.s.s.	2/50	2.14mg	3/50	7.14mg	2/50	21.4mg	2/50			
b	2591	162. mg n.s.s.	4/50	2.14mg	2/50	7.14mg	0/50	21.4mg	0/50			
c	2591	96.5mg n.s.s.	2/50	2.14mg	3/50	7.14mg	1/50	21.4mg	1/50			
d	2591	25.0mg n.s.s.	25/50	2.14mg	18/50	7.14mg	24/50	21.4mg	19/50			
30	2591	24.5mg n.s.s.	3/50	2.14mg	4/50	7.14mg	4/50	21.4mg	9/50			
a	2591	46.3mg n.s.s.	1/50	2.14mg	2/50	7.14mg	2/50	21.4mg	3/50			
b	2591	31.9mg n.s.s.	14/50	2.14mg	15/50	7.14mg	16/50	21.4mg	12/50			
c	2591	39.9mg n.s.s.	14/50	2.14mg	8/50	7.14mg	12/50	21.4mg	9/50			
d	2591	11.9mg n.s.s.	25/50	2.14mg	27/50	7.14mg	30/50	21.4mg	28/50			
31	2591	36.1mg n.s.s.	2/50	7.14mg	2/50							
a	2591	73.6mg n.s.s.	1/50	7.14mg	0/50							
b	2591	6.85mg n.s.s.	37/50	7.14mg	35/50							
32	2591	25.9mg n.s.s.	1/50	7.14mg	3/50							
a	2591	32.4mg n.s.s.	1/50	7.14mg	2/50							
b	2591	2.19mg n.s.s.	50/50	7.14mg	48/50							
<b>AZT (3'-azido-3'-deoxythymidine, ZDV, zidovudine) 30516-87-1</b>												
33	TR469	116. mg 445. mg	0/50	21.4mg	0/50	42.9mg	5/50	85.7mg	11/50	vag: sqc, sqp.		
a	TR469	132. mg 577. mg	0/50	21.4mg	0/50	42.9mg	5/50	85.7mg	9/50			
b	TR469	46.2mg n.s.s.	41/50	21.4mg	42/50	42.9mg	41/50	85.7mg	43/50			
c	TR469	49.2mg n.s.s.	27/50	21.4mg	29/50	42.9mg	23/50	85.7mg	36/50	liv:hpa,hpb,hpc.		
d	TR469	147. mg n.s.s.	6/50	21.4mg	8/50	42.9mg	2/50	85.7mg	11/50	lun:a/a,a/c.		
34	TR469	321. mg n.s.s.	0/50	21.4mg	0/50	42.9mg	0/50	85.7mg	4/50	kid: rua, ruc.		
a	TR469	378. mg n.s.s.	0/50	21.4mg	0/50	42.9mg	0/50	85.7mg	3/50	S		
b	TR469	159. mg n.s.s.	3/50	21.4mg	5/50	42.9mg	2/50	85.7mg	10/50	hag: ade, car.		
c	TR469	64.1mg n.s.s.	43/50	21.4mg	49/50	42.9mg	45/50	85.7mg	50/50			
d	TR469	87.5mg n.s.s.	36/50	21.4mg	39/50	42.9mg	36/50	85.7mg	39/50	liv:hpa,hpb,hpc.		
e	TR469	209. mg n.s.s.	14/50	21.4mg	9/50	42.9mg	14/50	85.7mg	11/50	lun:a/a,a/c.		
35	TR469	321. mg n.s.s.	0/50	21.4mg	0/50	42.9mg	0/50	85.7mg	4/50	kid: rua, ruc.		
36	2299	219. mg 3.30gm	0/60	21.4mg	0/60	34.1mg	1/60	50.9mg	6/60	Ayers;faat,32,148-158;1996/pers. comm.		
a	2299	272. mg n.s.s.	0/60	21.4mg	0/60	34.1mg	0/60	50.9mg	5/60			
b	2299	41.2mg n.s.s.	25/60	50.9mg	32/60							
37	2299	99.3mg n.s.s.	19/60	52.7mg	15/60							
38	2299	2.86gm n.s.s.	0/60	80.0mg	0/60	220. mg	0/60	384. mg	2/60			
a	2299	208. mg n.s.s.	56/60	384. mg	53/60							
39	2299	442. mg n.s.s.	51/60	377. mg	45/60							
<b>BARBITAL, SODIUM*** 144-02-5</b>												
40	2228	58.2mg n.s.s.	0/16	28.6mg	0/19					Diwan;txap,132,115-121;1995/pers. comm.		
41	2228	10.6mg n.s.s.	1/20	25.0mg	6/20							
a	2228	16.6mg n.s.s.	0/20	25.0mg	3/20							
b	2228	14.7mg n.s.s.	1/20	25.0mg	4/20							
c	2228	22.8mg n.s.s.	1/20	25.0mg	2/20							
<b>BENZIDINE*** 92-87-5</b>												
42	2594	7.02mg n.s.s.	7/34	120. mg	10/10					Osanai;jsol,52,179-201;1976		
<b>3-BENZYLSDYDNE-4-ACETAMIDE 14504-15-5</b>												
43	2395	5.53mg 21.8mg	0/9	4.00mg	0/16	20.0mg	2/25	40.0mg	13/16	Ohtsubo;jtxp,4,45-54;1991/pers. comm.		
a	2395	5.53mg 21.8mg	0/9	4.00mg	0/16	20.0mg	2/25	40.0mg	13/16			
b	2395	10.2mg 88.0mg	0/9	4.00mg	0/16	20.0mg	2/25	40.0mg	6/16			
c	2395	12.8mg n.s.s.	0/6	4.00mg	0/16	20.0mg	2/25	40.0mg	4/16			
44	2375m	1.99mg 10.2mg	0/13	13.5mg	13/16					Ohtsubo;jtxp,7,35-41;1994/pers. comm.		
a	2375m	1.99mg 10.2mg	0/13	13.5mg	13/16							
b	2375m	6.07mg 105. mg	0/13	13.5mg	6/16							
45	2375n	28.0mg n.s.s.	0/21	8.00mg	0/17							
<b>BIFENTHRIN 82657-04-3</b>												
46	2534	480. mg n.s.s.	1/48	6.50mg	2/50	26.0mg	4/49	65.0mg	1/46	78.0mg	1/49	Butler;txpy,25,268-274;1997
47	2534	105. mg n.s.s.	6/48	6.00mg	7/50	24.0mg	8/50	60.0mg	8/50	72.0mg	13/49	
<b>5,5'-(1,1'-BIPHENYL)-2,5-DIYLBIS(OXY)(2,2-DIMETHYLPENTANOIC ACID) (CI-924) 79520-77-7</b>												
48	2283	46.7mg 127. mg	2/50	5.00mg	5/50	25.0mg	8/50	75.0mg	29/50	Walker;txpy,24,265-272;1996		
a	2283	59.0mg 167. mg	0/50	5.00mg	4/50	25.0mg	5/50	75.0mg	23/50			
b	2283	164. mg n.s.s.	2/50	5.00mg	2/50	25.0mg	3/50	75.0mg	8/50			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
49	M m b6c	eat liv mix	24m24 er	. + .	45.0mg	* P<.0005+
a	M m b6c	eat liv hpa	24m24 er		107.mg	* P<.0005
b	M m b6c	eat liv hpc	24m24 er		167.mg	* P<.02
1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE .1ug.....10.....100.....1mg.....10.....100.....1g.....10						
50	R m f34	eat liv hpa	72w72	±	112.mg	P<.09
BROMATE, POTASSIUM*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
51	H m syg	wat kid rct	89w89	.	>	+hist 533.mg * P<.2 +
a	H m syg	wat liv nnd	89w89			no dre P=1.
b	H m syg	wat tba mix	89w89			no dre P=1.
52	M m b6c	wat kid tum	52w53 ek	.	>	no dre P=1.
53	M m b6c	wat kid tum	78w78 ek	.	>	no dre P=1.
54	M m b6c	wat kid mix	23m23	.	:	53.8mg Z P<.008 +
a	M m b6c	wat kid rcc	23m23	.	:	92.5mg Z P<.04
55	R m f34	wat kid rca	52w52 ek	.	±	16.7mg * P<.04
a	R m f34	wat tnv mso	52w52 ek	.		36.1mg * P<.5
56	R m f34	wat kid rca	77w77 ek	.	+	15.3mg * P<.003
a	R m f34	wat tnv mso	77w77 ek	.		15.3mg * P<.003
b	R m f34	wat thy mix	77w77 ek	.		21.8mg * P<.01
c	R m f34	wat thy fcc	77w77 ek	.		34.8mg * P<.04
57	R m f34	wat tnv mso	23m23 as	.	+	11.1mg Z P<.0005+
a	R m f34	wat kid mix	23m23 as	.	:	20.8mg Z P<.0005+
b	R m f34	wat thy mix	23m23 as	.	:	22.2mg Z P<.0005+
c	R m f34	wat kid rca	23m23 as	.		31.1mg Z P<.0005
d	R m f34	wat thy fca	23m23 as	.		35.2mg Z P<.0005
e	R m f34	wat kid rcc	23m23 as	.		62.2mg * P<.0005
f	R m f34	wat thy fcc	23m23 as	.		62.9mg * P<.002
BUTYL BENZYL PHTHALATE*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
58	R f f34	eat pan ana	24m24	.	:	23.5gm * P<.07 e
a	R f f34	eat ubl tpp	24m24	.		47.0gm * P<.5 e
b	R f f34	eat TBA MXB	24m24	.		no dre P=1.
c	R f f34	eat liv MXB	24m24	.		14.0gm * P<.07
59	R m f34	eat pan MXA	24m24	.	+	1.04gm * P<.008 p
a	R m f34	eat pre car	24m24	.		347.mg Z P<.03
b	R m f34	eat pan ana	24m24	.		1.13gm * P<.02 p
c	R m f34	eat thy MXA	24m24	.		3.58gm * P<.05
d	R m f34	eat TBA MXB	24m24	.		1.08gm * P<.6
e	R m f34	eat liv MXB	24m24	.		5.16gm * P<.4
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*** .1ug.....10.....100.....1mg.....10.....100.....1g.....10						
60	R m f3d	wat liv hnd	25m26 aej	.	+	.169mg Z P<.008
a	R m f3d	wat ubl tcc	25m26 aej	.		.432mg * P<.0005+
b	R m f3d	wat ubl pam	25m26 aej	.		.447mg * P<.0005+
c	R m f3d	wat k/p tum	25m26 Caej	.		no dre P=1.
d	R m f3d	wat liv hpc	25m26 aej	.		no dre P=1.
BUTYLATED HYDROXYANISOLE*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
61	M f lca	eat tba tum	52w52	.	>	no dre P=1. -
tert-BUTYLHYDROQUINONE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
62	M f b6c	eat hag MXA	24m24	.	+	#1.76gm Z P<.005 -
a	M f b6c	eat hag ade	24m24	.		2.06gm Z P<.005
b	M f b6c	eat liv hpa	24m24	.		293.mg Z P<.03
c	M f b6c	eat TBA MXB	24m24	.		no dre P=1.
d	M f b6c	eat liv MXB	24m24	.		283.mg Z P<.07
e	M f b6c	eat lun MXB	24m24	.		no dre P=1.
63	M m b6c	eat TBA MXB	24m24	.	>	no dre P=1. -
a	M m b6c	eat liv MXB	24m24	.		no dre P=1.
b	M m b6c	eat lun MXB	24m24	.		no dre P=1.
CANDESARTAN CILEXETIL 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
64	R f f3j	eat liv hpa	24m24 e	.		no dre P=1. -
a	R f f3j	eat tba mix	24m24 e	.		11.2gm * P<.9 -
65	R m f3j	eat liv hpa	24m24 e	.		no dre P=1. -
a	R m f3j	eat tba mix	24m24 e	.		noTD50 P=1. -
CARBOFURAN 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
66	M f icm	wat lun ade	52w78	.	±	11.1mg * P<.1 -
67	M m icm	wat lun ade	52w78	.	>	no dre P=1. -
beta-CAROTENE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
68	M f cd1	eat liv hpa	24m24 e	.		15.9gm * P<.002 -
a	M f cd1	eat lun ade	24m24 e	.		93.6gm * P<.9 -
b	M f cd1	eat liv hpc	24m24 e	.		no dre P=1. -
c	M f cd1	eat lun adc	24m24 e	.		no dre P=1. -
69	M m cd1	eat lun adc	24m24 e	.	>	26.4gm * P<.7 -
a	M m cd1	eat liv hpc	24m24 e	.		49.7gm * P<.9 -
b	M m cd1	eat lun ade	24m24 e	.		71.4gm * P<.8 -
c	M m cd1	eat liv hpa	24m24 e	.		no dre P=1. -
70	R m wis	eat liv nnd	52w52 ev	.	>	no dre P=1. -
CATECHINS, COMMERCIAL MIXTURE FROM GREEN TEA (91% CATECHINS) .100.....1mg.....10.....100.....1g.....10						
71	R f f3d	eat liv tum	52w52 e	.	>	no dre P=1.
CELIPROLOL*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
72	R f sda	eat liv hpa	24m24 ev	.	>	38.1gm P<.3 -
a	R f sda	eat liv hpc	24m24 ev	.		38.1gm P<.3 -
b	R f sda	eat tba mix	24m24 ev	.		2.48gm P<.8 -
73	R m sda	eat liv hpa	24m24 ev	.	>	12.4gm P<.2 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology			Brkly Code	
49	2283	27.0mg 97.6mg	16/50	5.00mg	20/50	25.0mg	25/50	75.0mg	40/50			
a	2283	56.8mg 370.3mg	10/50	5.00mg	13/50	25.0mg	12/50	75.0mg	27/50			
b	2283	73.7mg n.s.s.	7/50	5.00mg	11/50	25.0mg	18/50	75.0mg	18/50			
1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE					76150-91-9							
50	2322	27.4mg n.s.s.	0/18	40.0mg	2/18						Diwan;carc,17,37-43;1996	
BROMATE, POTASSIUM*** 7758-01-2												
51	2318	202.mg n.s.s.	0/20	15.0mg	0/20	30.0mg	1/20	60.0mg	4/20	240.mg	2/20	
a	2318	577.mg n.s.s.	0/20	15.0mg	0/20	30.0mg	0/20	60.0mg	1/20	240.mg	0/20	
b	2318	196.mg n.s.s.	10/20	15.0mg	14/20	30.0mg	7/20	60.0mg	8/20	240.mg	9/20	
52	2348m	3.79mg n.s.s.	0/7	13.3mg	0/7	66.7mg	0/7	133.mg	0/6	DeAngelo;txpy,26,587-594;1998/pers.comm.		
53	2348n	8.07mg n.s.s.	0/7	13.3mg	0/7	66.7mg	0/7	133.mg	0/5			
54	2348o	20.4mg 861.mg	0/40	13.3mg	5/38	(66.7mg)	3/41	133.mg	1/44	Takamura;srutu,32,43-46;1985		
a	2348o	28.0mg n.s.s.	0/40	13.3mg	3/38	(66.7mg)	1/41	133.mg	0/44			
55	2348m	4.09mg n.s.s.	0/6	1.00mg	0/6	5.00mg	0/6	10.0mg	0/6	20.0mg	2/6	
a	2348m	5.88mg n.s.s.	0/6	1.00mg	0/6	5.00mg	0/6	10.0mg	1/6	20.0mg	0/6	
56	2348n	5.18mg 98.3mg	0/6	1.00mg	0/6	5.00mg	0/6	10.0mg	0/5	20.0mg	4/6	
a	2348n	5.18mg 98.3mg	0/6	1.00mg	0/6	5.00mg	0/6	10.0mg	0/5	20.0mg	4/6	
b	2348n	6.53mg 1.32gm	0/6	1.00mg	0/6	5.00mg	0/6	10.0mg	0/5	20.0mg	3/6	
c	2348n	8.51mg n.s.s.	0/6	1.00mg	0/6	5.00mg	0/6	10.0mg	0/5	20.0mg	2/6	
57	2348o	7.49mg 17.8mg	0/47	1.00mg	4/49	5.00mg	5/48	10.0mg	9/47	20.0mg	27/43	
a	2348o	11.8mg 45.6mg	1/45	1.00mg	1/41	5.00mg	6/45	10.0mg	3/38	20.0mg	12/31	
b	2348o	12.2mg 52.2mg	0/36	1.00mg	4/38	5.00mg	1/42	10.0mg	4/36	20.0mg	14/30	
c	2348o	15.7mg 87.6mg	1/45	1.00mg	1/41	5.00mg	4/45	10.0mg	2/38	20.0mg	9/31	
d	2348o	17.4mg 116.mg	0/36	1.00mg	2/38	5.00mg	1/42	10.0mg	2/36	20.0mg	8/30	
e	2348o	25.6mg 239.mg	0/45	1.00mg	0/41	5.00mg	2/45	10.0mg	1/38	20.0mg	4/31	
f	2348o	25.7mg 350.mg	0/36	1.00mg	2/38	5.00mg	0/42	10.0mg	2/36	20.0mg	6/30	
BUTYL BENZYL PHTHALATE*** 85-68-7												
58	TR458	5.73gm n.s.s.	0/50	300.mg	0/50	600.mg	0/50	1.20gm	2/50			
a	TR458	7.42gm n.s.s.	1/50	300.mg	0/50	600.mg	0/50	1.20gm	2/50			
b	TR458	1.10gm n.s.s.	49/50	300.mg	48/50	600.mg	45/50	1.20gm	42/50			
c	TR458	4.23gm n.s.s.	0/50	300.mg	0/50	600.mg	1/50	1.20gm	2/50	liv:hpa,hpb,hpc.		
59	TR458	475.mg 20.9gm	3/50	120.mg	2/50	240.mg	3/50	480.mg	11/50	pan:acc,ana.		
a	TR458	127.mg n.s.s.	1/50	120.mg	6/50	(240.mg)	1/50	480.mg	0/50	S		
b	TR458	492.mg n.s.s.	3/50	120.mg	2/50	240.mg	3/50	480.mg	10/50			
c	TR458	1.22gm n.s.s.	0/50	120.mg	1/50	240.mg	0/50	480.mg	3/50	thy:fca,fcc. S		
d	TR458	204.mg n.s.s.	46/50	120.mg	44/50	240.mg	47/50	480.mg	49/50			
e	TR458	1.13gm n.s.s.	2/50	120.mg	2/50	240.mg	1/50	480.mg	4/50	liv:hpa,hpb,hpc.		
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*** (butyl-butanol-nitrosamine) 3817-11-6												
60	1606m	65.6ug 4.76mg	2/50	50.0ug	7/29	(.250mg)	5/30	.500mg	1/30	2.50mg	0/30	
a	1606m	.281mg .680mg	0/50	50.0ug	0/29	.250mg	6/30	.500mg	23/30	2.50mg	30/30	
b	1606m	.298mg .691mg	0/50	50.0ug	2/29	.250mg	7/30	.500mg	23/30	2.50mg	29/30	
c	1606m	.265mg n.s.s.	0/50	50.0ug	0/29	.250mg	0/30	.500mg	0/30	2.50mg	0/30	
d	1606m	14.2mg n.s.s.	0/50	50.0ug	2/29	.250mg	1/30	.500mg	2/30	2.50mg	0/30	
BUTYLATED HYDROXYANISOLE*** (BHA, 2(3)-tert-butyl-4-hydroxyanisole) 25013-16-5												
61	2402	1.00gm n.s.s.	0/60	325.mg	0/60						Gao;scch,37,419-428;1994	
tert-BUTYLHYDROQUINONE 1948-33-0												
62	TR459	760.mg 14.5gm	0/51	162.mg	1/52	325.mg	6/51	(650.mg)	1/54	hag:ade,car. S		
a	TR459	841.mg 16.8gm	0/51	162.mg	0/52	325.mg	6/51	(650.mg)	1/54	S		
b	TR459	124.mg n.s.s.	9/51	162.mg	20/52	(325.mg)	16/51	650.mg	5/54	S		
c	TR459	869.mg n.s.s.	32/51	162.mg	41/52	325.mg	36/51	650.mg	33/54			
d	TR459	110.mg n.s.s.	17/51	162.mg	28/52	(325.mg)	23/51	650.mg	10/54	liv:hpa,hpb,hpc.		
e	TR459	2.98gm n.s.s.	5/51	162.mg	2/52	325.mg	5/51	650.mg	3/54	lun:a/a,a/c.		
63	TR459	605.mg n.s.s.	39/50	150.mg	44/50	300.mg	42/51	600.mg	36/51			
a	TR459	349.mg n.s.s.	31/50	150.mg	28/50	300.mg	29/51	(600.mg)	17/51	liv:hpa,hpb,hpc.		
b	TR459	1.33gm n.s.s.	15/50	150.mg	15/50	300.mg	11/51	600.mg	14/51	lun:a/a,a/c.		
CANDESARTAN CILEXETIL (TCV-116) 145040-37-5												
64	2418	9.56gm n.s.s.	3/100	100.mg	1/50	300.mg	2/50	1.00gm	0/50	Nonoyama;jjpt,24,8899-913;1996		
a	2418	462.mg n.s.s.	89/100	100.mg	45/50	300.mg	43/50	1.00gm	45/50			
65	2418	8.68gm n.s.s.	2/100	100.mg	2/50	300.mg	2/50	1.00gm	0/50			
a	2418	n.s.s. n.s.s.	100/100	100.mg	50/50	300.mg	50/50	1.00gm	50/50			
CARBOFURAN (Furadan) 1563-66-2												
66	2592	3.37mg n.s.s.	0/60	.400mg	1/60	1.07mg	2/60					
67	2592	4.25mg n.s.s.	2/60	.333mg	2/60	.889mg	1/60	Wang;hjcx,9,505-508;1989				
beta-CAROTENE 7235-40-7												
68	2391	7.19gm 55.7gm	0/100	100.mg	0/100	250.mg	0/100	500.mg	3/100	1.00gm	5/100	
a	2391	7.33gm n.s.s.	10/100	100.mg	1/100	250.mg	6/100	500.mg	6/100	1.00gm	7/100	
b	2391	25.8gm n.s.s.	1/100	100.mg	0/100	250.mg	0/100	500.mg	1/100	1.00gm	0/100	
c	2391	6.30gm n.s.s.	14/100	100.mg	18/100	250.mg	12/100	500.mg	10/100	1.00gm	14/100	
69	2391	3.49gm n.s.s.	15/100	100.mg	18/100	250.mg	17/100	500.mg	23/100	1.00gm	17/100	
a	2391	3.28gm n.s.s.	19/100	100.mg	28/100	250.mg	17/100	500.mg	31/100	1.00gm	21/100	
b	2391	6.93gm n.s.s.	5/100	100.mg	7/100	250.mg	3/100	500.mg	7/100	1.00gm	6/100	
c	2391	5.45gm n.s.s.	20/100	100.mg	17/100	250.mg	25/100	500.mg	13/100	1.00gm	18/100	
70	2331	59.9mg n.s.s.	0/15	83.1mg	0/14						Jones;jnut,119,508-514;1989	
CATECHINS, COMMERCIAL MIXTURE FROM GREEN TEA (91% CATECHINS) (Camellia sinensis, Polyphenon 100) 136511-29-0												
71	2249	258.mg n.s.s.	0/10	500.mg	0/10						Hirose;carc,16,217-221;1995/pers.comm.	
CELIPROLOL*** (3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea.HCl) 56980-93-9												
72	2384	6.21gm n.s.s.	0/100	559.mg	1/100						Markiewicz;phrm,38,407-420;1989	
a	2384	6.21gm n.s.s.	0/100	559.mg	1/100							
b	2384	234.mg n.s.s.	93/100	559.mg	94/100							
73	2384	3.47gm n.s.s.	1/100	559.mg	4/100							

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	R m sda	eat liv	hpc 24m24	ev	no dre	P=1. -
b	R m sda	eat tba	mix 24m24	ev	684.mg	P<.2 -
CHLORINE***						
74	M f b6c	inh liv	mix 24m24	e	38.5mg	P<.5 -
a	M f b6c	inh lun	mix 24m24	e	no dre	P=1. -
b	M f b6c	inh nas	tum 24m24	e	no dre	P=1. -
75	M m b6c	inh liv	mix 24m24	e	12.1mg	P<.5 -
a	M m b6c	inh lun	mix 24m24	e	28.8mg	P<.6 -
b	M m b6c	inh nas	tum 24m24	e	no dre	P=1. -
76	R f f34	inh nas	tum 52w52	ek	no dre	P=1. -
a	R f f34	inh liv	hpa 52w52	ek	no dre	P=1. -
77	R f f34	inh liv	hpa 24m24	e	3.15mg	P<.2 -
a	R f f34	inh nas	tum 24m24	e	no dre	P=1. -
78	R m f34	inh nas	tum 52w52	ek	no dre	P=1. -
a	R m f34	inh liv	hpa 52w52	ek	no dre	P=1. -
79	R m f34	inh nas	tum 24m24	e	no dre	P=1. -
a	R m f34	inh liv	hpa 24m24	e	no dre	P=1. -
3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE .10.....100.....1mg.....10.....100.....1g.....10						
80	R f wis	wat thy	fca 24m24	e	.645mg	Z P<.0005+
a	R f wis	wat thy	mix 24m24	e	.741mg	* P<.0005+
b	R f wis	wat liv	caa 24m24	e	2.73mg	* P<.0005+
c	R f wis	wat liv	cho 24m24	e	2.73mg	* P<.0005+
d	R f wis	wat thy	fcc 24m24	e	5.20mg	* P<.0005+
e	R f wis	wat mgl	mix 24m24	e	13.0mg	* P<.004 +
f	R f wis	wat mgl	adc 24m24	e	14.0mg	* P<.004 +
g	R f wis	wat liv	hct 24m24	e	14.9mg	* P<.003 +
h	R f wis	wat liv	hpa 24m24	e	16.0mg	* P<.0005+
i	R f wis	wat mgl	fba 24m24	e	5.13mg	* P<.03 +
j	R f wis	wat adr	coa 24m24	e	10.6mg	* P<.02 +
k	R f wis	wat ---	lkm 24m24	e	41.5mg	* P<.1 +
l	R f wis	wat liv	clc 24m24	e	122.mg	* P<.3
m	R f wis	wat liv	hpc 24m24	e	no dre	P=1.
81	R m wis	wat thy	fca 24m24	e	.532mg	Z P<.0005+
a	R m wis	wat thy	mix 24m24	e	.678mg	* P<.0005+
b	R m wis	wat thy	fcc 24m24	e	3.25mg	* P<.0005+
c	R m wis	wat adr	coa 24m24	e	9.68mg	* P<.002 +
d	R m wis	wat liv	hct 24m24	e	17.7mg	* P<.009 +
e	R m wis	wat liv	cho 24m24	e	31.4mg	* P<.005 +
f	R m wis	wat pni	isa 24m24	e	16.0mg	* P<.09 +
g	R m wis	wat lun	a/a 24m24	e	23.4mg	* P<.02 +
h	R m wis	wat liv	hpa 24m24	e	24.4mg	* P<.03 +
i	R m wis	wat pni	mix 24m24	e	16.6mg	* P<.2
j	R m wis	wat ---	lkm 24m24	e	53.1mg	* P<.4 +
k	R m wis	wat liv	hpc 24m24	e	53.4mg	* P<.3
l	R m wis	wat liv	clc 24m24	e	no dre	P=1.
1-CHLORO-2-PROPANOL, TECHNICAL GRADE (~75% 1-CHLORO-2-PROPANOL; ~25% 2-CHLORO-1-PROPANOL).....100.....1g.....10						
82	M f b6c	wat TBA	MXB 24m24		no dre	P=1. -
a	M f b6c	wat liv	MXB 24m24		1.04gm	* P<.8
b	M f b6c	wat lun	MXB 24m24		no dre	P=1. -
83	M m b6c	wat TBA	MXB 24m24		no dre	P=1. -
a	M m b6c	wat liv	MXB 24m24		no dre	P=1. -
b	M m b6c	wat lun	MXB 24m24		no dre	P=1. -
84	R f f34	wat TBA	MXB 24m24		no dre	P=1. -
a	R f f34	wat liv	MXB 24m24		707.mg	* P<.2
85	R m f34	wat TBA	MXB 24m24		no dre	P=1. -
a	R m f34	wat liv	MXB 24m24		427.mg	* P<.6
(+-)-(4)-(2-CHLOROPHENYL)-2-[2-(4-ISOBUTYLPHENYL)ETHYL]-6,9-DIMETHYL-6H-THIENO[3,2-f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINE						
86	R f sdj	gav liv	tum 52w52		no dre	P=1. -
87	R m sdj	gav liv	tum 52w52		no dre	P=1. -
CHLOROPRENE						
88	M f b6c	inh MXB	MXB 24m24		4.00mg	Z P<.0005
a	M f b6c	inh lun	MXA 24m24		5.36mg	Z P<.0005c
b	M f b6c	inh liv	MXA 24m24		7.07mg	Z P<.0005c
c	M f b6c	inh lun	a/a 24m24		8.65mg	Z P<.0005c
d	M f b6c	inh lun	a/c 24m24		14.6mg	* P<.0005c
e	M f b6c	inh liv	hpc 24m24		15.2mg	Z P<.0005c
f	M f b6c	inh liv	hpa 24m24		19.8mg	* P<.0005
g	M f b6c	inh ---	MXA 24m24		21.5mg	Z P<.0005c
h	M f b6c	inh ---	hes 24m24		22.2mg	Z P<.0005c
i	M f b6c	inh mey	MXA 24m24		25.9mg	Z P<.0005
j	M f b6c	inh sub	sar 24m24		28.9mg	* P<.0005c
k	M f b6c	inh mey	hes 24m24		32.2mg	Z P<.0005
l	M f b6c	inh mey	sar 24m24		40.0mg	Z P<.0005c
m	M f b6c	inh hag	MXA 24m24		55.2mg	* P<.0005c
n	M f b6c	inh hag	ade 24m24		61.3mg	* P<.0005c
o	M f b6c	inh mgl	MXA 24m24		65.6mg	* P<.0005c
p	M f b6c	inh pit	pda 24m24		68.1mg	* P<.006
q	M f b6c	inh mgl	car 24m24		75.3mg	* P<.0005c
r	M f b6c	inh ---	hem 24m24		134.mg	* P<.0005c
s	M f b6c	inh for	MXA 24m24		332.mg	* P<.01 c
t	M f b6c	inh zym	car 24m24		864.mg	* P<.01 c
u	M f b6c	inh ute	esp 24m24		133.mg	* P<.04
v	M f b6c	inh TBA	MXB 24m24		3.92mg	Z P<.0005
w	M f b6c	inh liv	MXB 24m24		7.07mg	Z P<.0005
x	M f b6c	inh lun	MXB 24m24		5.36mg	Z P<.0005

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
a	2384	6.30gm	n.s.s.	3/100	559.mg	2/100					
b	2384	219.mg	n.s.s.	86/100	559.mg	92/100					
CHLORINE*** 7782-50-5											
74	2356n	7.45mg	n.s.s.	4/62	2.28mg	6/59		Wolf;faat,24,111-131;1995/Popp 1993/pers.comm.			
a	2356n	16.1mg	n.s.s.	4/62	2.28mg	2/59					
b	2356n	3.03mg	n.s.s.	0/64	.365mg	0/66	.912mg	0/57	2.28mg 0/61		
75	2356n	2.70mg	n.s.s.	21/62	1.90mg	26/64					
a	2356n	5.32mg	n.s.s.	7/61	1.90mg	10/65					
b	2356n	2.63mg	n.s.s.	0/61	.304mg	0/65	.760mg	0/67	1.90mg 0/66		
76	2356m	17.2ug	n.s.s.	0/10	52.1ug	0/10	.130mg	0/10	.326mg 0/10		
a	2356m	.168mg	n.s.s.	0/10	.326mg	0/10					
77	2356n	.965mg	n.s.s.	2/59	.326mg	6/60					
a	2356n	.407mg	n.s.s.	0/59	52.1ug	0/59	.130mg	0/59	.326mg 0/60		
78	2356m	18.7ug	n.s.s.	0/10	60.8ug	0/9	.152mg	0/10	.380mg 0/10		
a	2356m	.196mg	n.s.s.	0/10	.380mg	0/10					
79	2356n	.479mg	n.s.s.	0/59	60.8ug	0/60	.152mg	0/59	.380mg 0/59		
a	2356n	1.72mg	n.s.s.	4/58	.380mg	4/58					
3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE (MX) 77439-76-0											
80	2447	.432mg	1.07mg	4/50	.337mg	16/49	1.07mg	36/50	(4.00mg 36/50)	Komulainen;jnci,89,848-856;1997/McDonald 2000/pers.comm.	
a	2447	.513mg	1.14mg	5/50	.337mg	18/49	1.07mg	38/50	4.00mg 47/50		
b	2447	1.87mg	4.30mg	1/50	.337mg	4/50	1.07mg	10/50	4.00mg 34/50		
c	2447	1.89mg	4.12mg	0/50	.337mg	4/50	1.07mg	10/50	4.00mg 33/50		
d	2447	3.24mg	9.87mg	1/50	.337mg	3/49	1.07mg	6/50	4.00mg 22/50		
e	2447	6.00mg	122.mg	3/50	.337mg	2/50	1.07mg	7/50	4.00mg 11/50		
f	2447	6.43mg	111.mg	3/50	.337mg	2/50	1.07mg	5/50	4.00mg 11/50		
g	2447	6.84mg	106.mg	2/50	.337mg	2/50	1.07mg	4/50	4.00mg 10/50		
h	2447	7.69mg	55.4mg	1/50	.337mg	1/50	1.07mg	1/50	4.00mg 10/50		
i	2447	2.17mg	n.s.s.	23/50	.337mg	25/50	1.07mg	32/50	4.00mg 34/50		
j	2447	4.50mg	n.s.s.	5/50	.337mg	10/50	1.07mg	12/50	4.00mg 16/50		
k	2447	12.8mg	n.s.s.	1/50	.337mg	1/50	1.07mg	2/50	4.00mg 4/50		
l	2447	23.7mg	n.s.s.	1/50	.337mg	0/50	1.07mg	0/50	4.00mg 2/50		
m	2447	30.5mg	n.s.s.	1/50	.337mg	1/50	1.07mg	3/50	4.00mg 0/50		
81	2447	.364mg	.856mg	2/49	.295mg	20/50	.935mg	34/50	(3.50mg 21/49)		
a	2447	.481mg	1.04mg	2/49	.295mg	20/50	.935mg	38/50	3.50mg 44/49		
b	2447	2.17mg	5.16mg	0/49	.295mg	1/50	.935mg	9/50	3.50mg 27/49		
c	2447	4.69mg	53.8mg	5/50	.295mg	2/50	.935mg	7/50	3.50mg 14/50		
d	2447	8.11mg	706.mg	0/50	.295mg	1/50	.935mg	3/50	3.50mg 5/50		
e	2447	11.9mg	272.mg	0/50	.295mg	0/50	.935mg	1/50	3.50mg 4/50		
f	2447	5.57mg	n.s.s.	5/50	.295mg	8/50	.935mg	8/50	3.50mg 12/50		
g	2447	9.07mg	n.s.s.	2/50	.295mg	1/50	.935mg	1/50	3.50mg 7/50		
h	2447	9.69mg	n.s.s.	0/50	.295mg	1/50	.935mg	2/50	3.50mg 4/50		
i	2447	5.06mg	n.s.s.	9/50	.295mg	11/50	.935mg	12/50	3.50mg 15/50		
j	2447	10.0mg	n.s.s.	0/50	.295mg	3/50	.935mg	4/50	3.50mg 3/50		
k	2447	16.2mg	n.s.s.	0/50	.295mg	0/50	.935mg	2/50	3.50mg 1/50		
l	2447	36.6mg	n.s.s.	0/50	.295mg	1/50	.935mg	0/50	3.50mg 0/50		
1-CHLORO-2-PROPANOL, TECHNICAL GRADE (~75% 1-CHLORO-2-PROPANOL; ~25% 2-CHLORO-1-PROPANOL) 127-00-4											
82	TR477	124.mg	n.s.s.	46/50	50.0mg	49/50	100.mg	47/50	200.mg 44/50		
a	TR477	111.mg	n.s.s.	41/50	50.0mg	41/50	100.mg	43/50	200.mg 42/50	liv:hpa,hpb,hpc.	
b	TR477	676.mg	n.s.s.	9/50	50.0mg	2/50	100.mg	5/50	200.mg 6/50	lun:a/a,a/c.	
83	TR477	123.mg	n.s.s.	48/50	41.7mg	44/50	83.3mg	40/50	167.mg 42/50		
a	TR477	132.mg	n.s.s.	40/50	41.7mg	39/50	83.3mg	37/50	167.mg 36/50	liv:hpa,hpb,hpc.	
b	TR477	513.mg	n.s.s.	16/50	41.7mg	11/50	83.3mg	9/50	167.mg 9/50	lun:a/a,a/c.	
84	TR477	24.5mg	n.s.s.	48/50	8.57mg	46/50	18.6mg	49/50	37.1mg 48/50		
a	TR477	174.mg	n.s.s.	0/50	8.57mg	0/50	18.6mg	1/50	37.1mg 1/50	liv:hpa,hpb,hpc.	
85	TR477	17.4mg	n.s.s.	48/50	7.50mg	50/50	16.3mg	50/50	32.5mg 50/50		
a	TR477	73.9mg	n.s.s.	1/50	7.50mg	3/50	16.3mg	2/50	32.5mg 3/50	liv:hpa,hpb,hpc.	
(+)-(4)-(2-CHLOROPHENYL)-2-[2-(4-ISOBUTYLPHENYL)ETHYL]-6,9-DIMETHYL-6H-THIENO[3,2-f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINE 117279-73-9											
86	2583	14.9mg	n.s.s.	0/14	30.0mg	0/14	100.mg	0/14	300.mg 0/14	600.mg 0/14	Nishimura;phrm,53,259-280;1997/pers.comm.
87	2583	14.9mg	n.s.s.	0/14	30.0mg	0/14	100.mg	0/14	300.mg 0/14	600.mg 0/14	
CHLOROPRENE 126-99-8											
88	TR467	2.58mg	6.74mg	28/50	14.6mg	43/50	36.4mg	47/50	(91.1mg 48/50)	---:hem,hes; for:scq,scp; hag:ade,car; liv:hpa,hpc; lun:a/a,a/c; mey:sar; mgl:ade,car; sub:sar; zym:car. C	
a	TR467	3.45mg	8.68mg	4/50	14.6mg	28/50	36.4mg	34/50	(91.1mg 42/50)	lun:a/a,a/c.	
b	TR467	4.03mg	15.4mg	20/50	14.6mg	26/50	36.4mg	20/50	(91.1mg 30/50)	liv:hpa,hpc.	
c	TR467	5.29mg	14.7mg	2/50	14.6mg	16/50	36.4mg	29/50	(91.1mg 26/50)		
d	TR467	9.17mg	24.6mg	2/50	14.6mg	14/50	36.4mg	16/50	91.1mg 28/50		
e	TR467	7.94mg	35.2mg	4/50	14.6mg	11/50	36.4mg	14/50	(91.1mg 19/50)		
f	TR467	10.5mg	51.3mg	17/50	14.6mg	19/50	36.4mg	11/50	91.1mg 16/50		
g	TR467	10.6mg	52.2mg	4/50	14.6mg	6/50	36.4mg	18/50	(91.1mg 8/50)	---:hem,hes.	
h	TR467	10.8mg	55.9mg	4/50	14.6mg	6/50	36.4mg	17/50	(91.1mg 5/50)		
i	TR467	12.7mg	53.4mg	0/50	14.6mg	4/50	36.4mg	15/50	(91.1mg 5/50)	mey:hem,hes. S	
j	TR467	17.1mg	49.5mg	0/50	14.6mg	11/50	36.4mg	11/50	91.1mg 18/50		
k	TR467	15.5mg	67.1mg	0/50	14.6mg	4/50	36.4mg	13/50	(91.1mg 4/50)	S	
l	TR467	17.5mg	98.8mg	0/50	14.6mg	4/50	36.4mg	8/50	(91.1mg 3/50)		
m	TR467	22.6mg	208.mg	2/50	14.6mg	5/50	36.4mg	3/50	91.1mg 9/50	hag:ade,car.	
n	TR467	24.1mg	231.mg	1/50	14.6mg	3/50	36.4mg	3/50	91.1mg 8/50		
o	TR467	29.4mg	199.mg	3/50	14.6mg	5/50	36.4mg	8/50	91.1mg 12/50	mgl:ade,car.	
p	TR467	26.0mg	1.13gm	4/50	14.6mg	6/50	36.4mg	4/50	91.1mg 4/50	S	
q	TR467	32.9mg	233.mg	3/50	14.6mg	4/50	36.4mg	7/50	91.1mg 12/50		
r	TR467	38.8mg	793.mg	0/50	14.6mg	0/50	36.4mg	2/50	91.1mg 3/50		
s	TR467	74.2mg	65.9gm	1/50	14.6mg	0/50	36.4mg	0/50	91.1mg 4/50	for:scq,scp.	
t	TR467	259.mg	68.6gm	0/50	14.6mg	0/50	36.4mg	0/50	91.1mg 3/50		
u	TR467	38.3mg	n.s.s.	2/50	14.6mg	4/50	36.4mg	2/50	91.1mg 3/50	S	
v	TR467	2.54mg	6.62mg	34/50	14.6mg	47/50	36.4mg	50/50	(91.1mg 48/50)		
w	TR467	4.03mg	15.4mg	20/50	14.6mg	26/50	36.4mg	20/50	(91.1mg 30/50)	liv:hpa,hpb,hpc.	
x	TR467	3.45mg	8.68mg	4/50	14.6mg	28/50	36.4mg	34/50	(91.1mg 42/50)	lun:a/a,a/c.	

	Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	
							Sex	Route
89	M m	b6c	inh	MXB	MXB 24m24	8.68mg	Z	P<.0005
a	M m	b6c	inh	lun	MXA 24m24	17.2mg	*	P<.0005c
b	M m	b6c	inh	---	MXA 24m24	17.9mg	Z	P<.0005c
c	M m	b6c	inh	---	hes 24m24	19.1mg	Z	P<.0005c
d	M m	b6c	inh	liv	MXA 24m24	19.5mg	Z	P<.0005
e	M m	b6c	inh	---	MXA 24m24	21.3mg	Z	P<.0005c
f	M m	b6c	inh	liv	hpc 24m24	21.6mg	Z	P<.002
g	M m	b6c	inh	---	hes 24m24	23.8mg	Z	P<.0005c
h	M m	b6c	inh	lun	a/c 24m24	26.4mg	*	P<.0005c
i	M m	b6c	inh	lun	a/a 24m24	30.7mg	*	P<.0005c
j	M m	b6c	inh	mey	MXA 24m24	37.6mg	Z	P<.0005
k	M m	b6c	inh	mey	hes 24m24	39.0mg	Z	P<.0005
l	M m	b6c	inh	liv	MXA 24m24	39.9mg	*	P<.009
m	M m	b6c	inh	hag	MXA 24m24	60.9mg	*	P<.0005c
n	M m	b6c	inh	hag	MXA 24m24	79.5mg	*	P<.0005c
o	M m	b6c	inh	liv	hes 24m24	123.mg	*	P<.005
p	M m	b6c	inh	sub	hes 24m24	177.mg	*	P<.006
q	M m	b6c	inh	for	MXA 24m24	291.mg	*	P<.008 c
r	M m	b6c	inh	liv	MXA 24m24	42.5mg	*	P<.02
s	M m	b6c	inh	liv	hpa 24m24	71.9mg	*	P<.03
t	M m	b6c	inh	kid	rua 24m24	301.mg	*	P<.02
u	M m	b6c	inh	for	sqp 24m24	335.mg	*	P<.02 c
v	M m	b6c	inh	TBA	MXB 24m24	28.4mg	*	P<.003
w	M m	b6c	inh	liv	MXB 24m24	39.9mg	*	P<.009
x	M m	b6c	inh	lun	MXB 24m24	17.2mg	*	P<.0005
90	M m	b6c	inh	kid	rua 24m24	129.mg	*	P<.0005c
91	R f	f34	inh	cli	MXA 24m24	7.14mg	Z	P<.007
a	R f	f34	inh	cli	MXA 24m24	12.4mg	Z	P<.005
b	R f	f34	inh	ton	MXA 24m24	32.9mg	*	P<.0005
c	R f	f34	inh	MXA	MXA 24m24	33.9mg	*	P<.0005c
d	R f	f34	inh	ton	sqp 24m24	53.5mg	*	P<.002
e	R f	f34	inh	MXA	sqp 24m24	61.2mg	*	P<.007 c
f	R f	f34	inh	MXA	sqc 24m24	77.8mg	*	P<.009 c
g	R f	f34	inh	ton	sqc 24m24	91.1mg	*	P<.01
h	R f	f34	inh	mgl	fa 24m24	16.3mg	*	P<.03 c
i	R f	f34	inh	mgl	MXA 24m24	20.4mg	*	P<.07 c
j	R f	f34	inh	---	mnl 24m24	30.4mg	*	P<.04
k	R f	f34	inh	thy	MXA 24m24	113.mg	*	P<.03 c
l	R f	f34	inh	kid	rua 24m24	461.mg	*	P<.06
m	R f	f34	inh	ubl	tcc 24m24	467.mg	*	P<.06 e
n	R f	f34	inh	MXB	MXB 24m24	23.3mg	*	P<.2
o	R f	f34	inh	lun	a/a 24m24	279.mg	*	P<.2 e
p	R f	f34	inh	TBA	MXB 24m24	25.4mg	*	P<.3
q	R f	f34	inh	liv	MXB 24m24	no dre		F=1.
92	R f	f34	inh	kid	rua 24m24	183.mg	*	P<.006
a	R f	f34	inh	kid	MXA 24m24	183.mg	*	P<.006 c
93	R m	f34	inh	MXB	MXB 24m24	5.79mg	*	P<.0005
a	R m	f34	inh	MXA	MXA 24m24	10.1mg	*	P<.0005c
b	R m	f34	inh	MXA	sqp 24m24	11.1mg	*	P<.0005c
c	R m	f34	inh	ton	MXA 24m24	13.6mg	*	P<.0005
d	R m	f34	inh	ton	sqp 24m24	15.6mg	*	P<.0005
e	R m	f34	inh	thy	MXA 24m24	18.7mg	*	P<.003 c
f	R m	f34	inh	thy	fca 24m24	22.0mg	*	P<.009
g	R m	f34	inh	lun	a/c 24m24	24.5mg	*	P<.009 c
h	R m	f34	inh	---	msm 24m24	27.1mg	*	P<.008
i	R m	f34	inh	thy	cca 24m24	20.0mg	*	P<.05
j	R m	f34	inh	lun	MXA 24m24	23.8mg	*	P<.02 c
k	R m	f34	inh	kid	rua 24m24	38.9mg	*	P<.05
l	R m	f34	inh	MXA	sqp 24m24	39.2mg	*	P<.02
m	R m	f34	inh	ubl	tcc 24m24	99.9mg	*	P<.4 e
n	R m	f34	inh	ubl	tpp 24m24	468.mg	*	P<.2 e
o	R m	f34	inh	TBA	MXB 24m24	6.12mg	*	P<.04
p	R m	f34	inh	liv	MXB 24m24	no dre		F=1.
94	R m	f34	inh	kid	rua 24m24	15.4mg	*	P<.008 c
a	R m	f34	inh	kid	MXA 24m24	16.1mg	*	P<.02
CIMETIDINE***						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
95	R f	cdr	gav	gam	cnd 24m24 r	no dre		F=1. -
96	R m	cdr	gav	gam	cnd 24m24 r	no dre		F=1. -
CIPROFIBRATE***						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
97	R m	f34	eat	liv	mix 95w95 er	<+	noTD50	P<.0005+
a	R m	f34	eat	tes	ldc 95w95 er		noTD50	P<.6 -
98	R m	f34	eat	liv	hpc 60w60 er	<+	noTD50	P<.0005+
a	R m	f34	eat	liv	mix 60w60 er		noTD50	P<.0005+
b	R m	f34	eat	liv	nnd 60w60 er		noTD50	P<.0005+
CLOBUZARIT						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
99	H f	syg	eat	liv	tum 24m24	>	no dre	F=1. -
a	H f	syg	eat	lun	tum 24m24		no dre	F=1. -
100	H m	syg	eat	lun	tum 24m24	>	1.51gm	* P<.3 -
a	H m	syg	eat	liv	tum 24m24		no dre	F=1. -
101	M f	c5j	eat	liv	hpc 78w78	±	870.mg	* P<.1
a	M f	c5j	eat	lun	tum 78w78		1.01gm	* P<.4
102	M m	c5j	eat	liv	hpa 78w78	+	154.mg	* P<.002 +
a	M m	c5j	eat	liv	hpc 78w78		214.mg	* P<.02 +
b	M m	c5j	eat	lun	tum 78w78		no dre	F=1.
103	R f	aap	eat	liv	tum 24m24	>	no dre	F=1.
104	R m	aap	eat	liv	hpa 24m24	±	62.5mg	* P<.05

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology		Brkly Code
89	TR467	5.45mg	17.3mg	16/50	12.1mg	33/50	30.4mg	44/50	(75.9mg 48/50)	---:hem,hes; for:scq,scp; hag:ade,anb,car; lun: a/a,a/c.
a	TR467	11.0mg	31.9mg	13/50	12.1mg	28/50	30.4mg	36/50	75.9mg 43/50	lun:a/a,a/c.
b	TR467	11.1mg	35.5mg	3/50	12.1mg	14/50	30.4mg	23/50	(75.9mg 21/50)	---:hem,hes.
c	TR467	11.7mg	39.0mg	3/50	12.1mg	13/50	30.4mg	22/50	(75.9mg 19/50)	
d	TR467	10.4mg	79.1mg	24/50	12.1mg	29/50	30.4mg	39/50	(75.9mg 34/50)	liv:hpb,hpc.
e	TR467	13.2mg	41.6mg	1/50	12.1mg	12/50	30.4mg	18/50	(75.9mg 17/50)	---:hem,hes.
f	TR467	11.1mg	112.6mg	24/50	12.1mg	28/50	30.4mg	37/50	(75.9mg 33/50)	S
g	TR467	14.3mg	49.6mg	1/50	12.1mg	11/50	30.4mg	16/50	(75.9mg 15/50)	
h	TR467	16.8mg	50.0mg	6/50	12.1mg	12/50	30.4mg	23/50	75.9mg 28/50	
i	TR467	18.4mg	67.9mg	8/50	12.1mg	18/50	30.4mg	22/50	75.9mg 28/50	
j	TR467	20.7mg	76.6mg	0/50	12.1mg	3/50	30.4mg	14/50	(75.9mg 9/50)	mey:hem,hes.
k	TR467	21.2mg	81.4mg	0/50	12.1mg	3/50	30.4mg	13/50	(75.9mg 7/50)	S
l	TR467	18.6mg	1.05gm	43/50	12.1mg	38/50	30.4mg	43/50	75.9mg 42/50	liv:hpa,hpb,hpc.
m	TR467	33.3mg	172.mg	2/50	12.1mg	5/50	30.4mg	10/50	75.9mg 12/50	hag:ade,anb,car.
n	TR467	40.4mg	309.mg	2/50	12.1mg	5/50	30.4mg	8/50	75.9mg 10/50	hag:ade,anb.
o	TR467	55.7mg	1.30gm	2/50	12.1mg	5/50	30.4mg	6/50	75.9mg 8/50	S
p	TR467	73.5mg	2.71gm	1/50	12.1mg	4/50	30.4mg	1/50	75.9mg 7/50	S
q	TR467	108.mg	7.29gm	1/50	12.1mg	0/50	30.4mg	2/50	75.9mg 5/50	for:scq,scp.
r	TR467	19.4mg	n.s.s.	43/50	12.1mg	37/50	30.4mg	42/50	75.9mg 41/50	liv:hpa,hpc.
s	TR467	30.1mg	n.s.s.	22/50	12.1mg	16/50	30.4mg	19/50	75.9mg 21/50	S
t	TR467	108.mg	n.s.s.	0/50	12.1mg	1/50	30.4mg	1/50	75.9mg 3/50	S
u	TR467	114.mg	n.s.s.	1/50	12.1mg	0/50	30.4mg	2/50	75.9mg 4/50	
v	TR467	14.2mg	182.mg	48/50	12.1mg	48/50	30.4mg	50/50	75.9mg 50/50	
w	TR467	18.6mg	1.05gm	43/50	12.1mg	38/50	30.4mg	43/50	75.9mg 42/50	liv:hpa,hpb,hpc.
x	TR467	11.0mg	31.9mg	13/50	12.1mg	28/50	30.4mg	36/50	75.9mg 43/50	lun:a/a,a/c.
90	TR467	65.9mg	327.mg	0/50	12.1mg	2/50	30.4mg	3/50	75.9mg 9/50	
91	TR467	3.30mg	99.4mg	2/50	3.47mg	12/50	(8.67mg 5/50)	21.7mg 3/50)		cli:ade,anb,car,cnb.
a	TR467	5.01mg	102.mg	0/50	3.47mg	6/50	(8.67mg 4/50)	21.7mg 2/50)		cli:car,cnb.
b	TR467	18.5mg	83.7mg	0/50	3.47mg	3/50	8.67mg 3/50	21.7mg 11/50		ton:scq,scp.
c	TR467	17.9mg	118.mg	1/50	3.47mg	3/50	8.67mg 5/50	21.7mg 11/50		gnv:scq; orm:scq; phr:scq,scp; ton:scq,scp.
d	TR467	25.9mg	230.mg	0/50	3.47mg	2/50	8.67mg 1/50	21.7mg 7/50		S
e	TR467	26.5mg	991.mg	1/50	3.47mg	2/50	8.67mg 2/50	21.7mg 7/50		gnv:scq; orm:scq; phr:scq; ton:scq.
f	TR467	34.8mg	2.24gm	0/50	3.47mg	1/50	8.67mg 3/50	21.7mg 4/50		phr:scq; ton:scq.
g	TR467	38.8mg	6.01gm	0/50	3.47mg	1/50	8.67mg 2/50	21.7mg 4/50		S
h	TR467	7.18mg	n.s.s.	24/50	3.47mg	32/50	8.67mg 36/50	21.7mg 36/50		
i	TR467	7.90mg	n.s.s.	28/50	3.47mg	34/50	8.67mg 36/50	21.7mg 36/50		mgl:car,fb.
j	TR467	12.3mg	n.s.s.	18/50	3.47mg	18/50	8.67mg 20/50	21.7mg 26/50		S
k	TR467	41.2mg	n.s.s.	1/50	3.47mg	1/50	8.67mg 1/50	21.7mg 5/50		thy:fca,fcc.
l	TR467	113.mg	n.s.s.	0/50	3.47mg	0/50	8.67mg 0/50	21.7mg 2/50		
m	TR467	115.mg	n.s.s.	0/50	3.47mg	0/50	8.67mg 0/50	21.7mg 2/50		
n	TR467	8.31mg	n.s.s.	30/50	3.47mg	35/50	8.67mg 36/50	21.7mg 36/50		gnv:scq; mgl:car,fb; orm:scq; phr:scq,scp; thy: fca,fcc; ton:scq,scp.
o	TR467	70.2mg	n.s.s.	1/50	3.47mg	0/50	8.67mg 0/50	21.7mg 3/50		C
p	TR467	7.49mg	n.s.s.	47/50	3.47mg	50/50	8.67mg 50/50	21.7mg 49/50		
q	TR467	n.s.s.	n.s.s.	0/50	3.47mg	0/50	8.67mg 0/50	21.7mg 0/50		liv:hpa,hpb,hpc.
92	TR467	61.4mg	1.92gm	0/50	3.47mg	0/50	8.67mg 0/50	21.7mg 4/50		S
a	TR467	61.4mg	1.92gm	0/50	3.47mg	0/50	8.67mg 0/50	21.7mg 4/50		kid:rua,ruc.
93	TR467	3.09mg	13.6mg	2/50	2.43mg	5/50	6.07mg 11/50	15.2mg 18/50		gnv:scq; lun:a/a,a/c; orm:scq; phr:scq; thy:fca, fcc; ton:scq,scp.
a	TR467	5.13mg	21.9mg	0/50	2.43mg	2/50	6.07mg 5/50	15.2mg 12/50		C
b	TR467	5.41mg	27.3mg	0/50	2.43mg	2/50	6.07mg 4/50	15.2mg 10/50		gnv:scq; orm:scq; phr:scq; ton:scq,scp.
c	TR467	6.02mg	35.9mg	0/50	2.43mg	0/50	6.07mg 4/50	15.2mg 8/50		S
d	TR467	6.39mg	50.6mg	0/50	2.43mg	0/50	6.07mg 3/50	15.2mg 6/50		S
e	TR467	7.52mg	134.mg	0/50	2.43mg	2/50	6.07mg 4/50	15.2mg 5/50		thy:fca,fcc.
f	TR467	7.98mg	1.25gm	0/50	2.43mg	2/50	6.07mg 2/50	15.2mg 4/50		S
g	TR467	9.02mg	961.mg	0/50	2.43mg	2/50	6.07mg 1/50	15.2mg 4/50		
h	TR467	11.6mg	575.mg	0/50	2.43mg	1/50	6.07mg 5/50	15.2mg 3/50		S
i	TR467	6.72mg	n.s.s.	3/50	2.43mg	6/50	6.07mg 4/50	15.2mg 7/50		S
j	TR467	8.34mg	n.s.s.	2/50	2.43mg	2/50	6.07mg 4/50	15.2mg 6/50		lun:a/a,a/c.
k	TR467	12.4mg	n.s.s.	0/50	2.43mg	1/50	6.07mg 1/50	15.2mg 2/50		S
l	TR467	15.3mg	n.s.s.	0/50	2.43mg	2/50	6.07mg 1/50	15.2mg 4/50		gnv:scq; orm:scq; phr:scq.
m	TR467	16.3mg	n.s.s.	0/50	2.43mg	0/50	6.07mg 1/50	15.2mg 0/50		S
n	TR467	76.2mg	n.s.s.	0/50	2.43mg	0/50	6.07mg 0/50	15.2mg 1/50		
o	TR467	2.52mg	n.s.s.	50/50	2.43mg	50/50	6.07mg 50/50	15.2mg 50/50		
p	TR467	n.s.s.	n.s.s.	0/50	2.43mg	0/50	6.07mg 0/50	15.2mg 0/50		liv:hpa,hpb,hpc.
94	TR467	6.18mg	462.mg	1/50	2.43mg	7/50	6.07mg 6/50	15.2mg 8/50		
a	TR467	6.26mg	n.s.s.	1/50	2.43mg	8/50	6.07mg 6/50	15.2mg 8/50		kid:rua,ruc.
CIMETIDINE*** 51481-61-9										
95	2449	12.0gm	n.s.s.	0/100	950.mg	0/60				Hirth;txpy,16,273-287;1988
96	2449	12.0gm	n.s.s.	0/100	950.mg	0/60				
CIPROFIBRATE*** 52214-84-3										
97	2234	n.s.s.	3.54mg	0/15	10.0mg	15/15				Rao;clct,97,185-188;1995/pers.comm.
a	2234	n.s.s.	n.s.s.	14/15	10.0mg	15/15				
98	2524	n.s.s.	1.61mg	0/10	10.0mg	12/12				Rao;vivo,11,495-498;1997/pers.comm.
a	2524	n.s.s.	1.61mg	0/10	10.0mg	12/12				
b	2524	n.s.s.	1.61mg	0/10	10.0mg	12/12				
CLOBUZARIT 22494-47-9										
99	2241	33.5mg	n.s.s.	1/156	5.00mg	0/52	12.5mg	0/52	25.0mg 0/52	Tucker;cthf,74-81;1995
a	2241	33.5mg	n.s.s.	1/156	5.00mg	0/52	12.5mg	0/52	25.0mg 0/52	
100	2241	246.mg	n.s.s.	0/156	5.00mg	0/52	12.5mg	1/52	25.0mg 0/52	
a	2241	33.5mg	n.s.s.	1/156	5.00mg	0/52	12.5mg	0/52	25.0mg 0/52	
101	2241	214.mg	n.s.s.	0/102	12.5mg	0/52	25.0mg	1/52	50.0mg 1/52	
a	2241	194.mg	n.s.s.	1/102	12.5mg	0/52	25.0mg	2/52	50.0mg 1/52	
102	2241	74.4mg	630.mg	1/102	12.5mg	2/52	25.0mg	2/52	50.0mg 8/52	
a	2241	89.5mg	n.s.s.	2/102	12.5mg	1/52	25.0mg	3/52	50.0mg 6/52	
b	2241	236.mg	n.s.s.	2/102	12.5mg	1/52	25.0mg	1/52	50.0mg 1/52	
103	2241	2.76mg	n.s.s.	0/25	1.00mg	0/25	1.50mg	0/25	5.00mg 0/25	
104	2241	15.4mg	n.s.s.	0/25	1.00mg	0/25	1.50mg	0/25	5.00mg 2/25	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
<b>CLOFIBRATE***</b>						
105	M f	aps	eat	liv hpa 78w78	100ng...1ug...10...100...1mg...10...100...1g...10	1.48gm Z P<.06 -
106	M m	aps	eat	liv hpa 78w78		313.mg Z P<.04 -
	a	M m	aps	eat	liv hpc 78w78	9.71gm * P<.2 -
107	M f	c5j	eat	liv hpa 78w78		14.7gm * P<.6 -
	a	M f	c5j	eat	lun tum 78w78	no dre P=1. -
108	M m	c5j	eat	liv hpa 78w78		3.64gm * P<.05 -
	a	M m	c5j	eat	lun tum 78w78	no dre P=1. -
<b>COBALT SULFATE HEPTAHYDRATE</b>						
109	M f	b6c	inh	lun MXA 24m24	100ng...1ug...10...100...1mg...10...100...1g...10	1.19mg * P<.0005c
	a	M f	b6c	inh	lun a/c 24m24	2.65mg * P<.002
	b	M f	b6c	inh	lun a/a 24m24	2.37mg * P<.03
	c	M f	b6c	inh	TBA MXB 24m24	3.67mg * P<.7
	d	M f	b6c	inh	liv MXB 24m24	21.9mg * P<.9
	e	M f	b6c	inh	lun MXB 24m24	1.19mg * P<.0005
110	M m	b6c	inh	lun MXA 24m24		.554mg * P<.0005c
	a	M m	b6c	inh	lun a/a 24m24	1.13mg * P<.02
	b	M m	b6c	inh	lun a/c 24m24	1.38mg * P<.02
	c	M m	b6c	inh	--- hes 24m24	1.85mg * P<.04
	d	M m	b6c	inh	liv hes 24m24	1.98mg * P<.04
	e	M m	b6c	inh	TBA MXB 24m24	1.08mg * P<.4
	f	M m	b6c	inh	liv MXB 24m24	1.28mg * P<.4
	g	M m	b6c	inh	lun MXB 24m24	.554mg * P<.0005
111	R f	f34	inh	lun MXA 24m24		82.6ug Z P<.0005c
	a	R f	f34	inh	MXB MXB 24m24	82.8ug Z P<.0005
	b	R f	f34	inh	lun MXA 24m24	89.0ug Z P<.0005c
	c	R f	f34	inh	lun a/a 24m24	.151mg Z P<.0005
	d	R f	f34	inh	amd MXA 24m24	.580mg * P<.003 c
	e	R f	f34	inh	lun a/c 24m24	.567mg * P<.02
	f	R f	f34	inh	amd MXA 24m24	.770mg * P<.02
	g	R f	f34	inh	TBA MXB 24m24	no dre P=1.
	h	R f	f34	inh	liv MXB 24m24	no dre P=1.
112	R m	f34	inh	lun MXA 24m24		.397mg * P<.04 p
	a	R m	f34	inh	sub MXA 24m24	.435mg * P<.05
	b	R m	f34	inh	lun a/a 24m24	.639mg * P<.09
	c	R m	f34	inh	amd MXA 24m24	.352mg * P<.4 e
	d	R m	f34	inh	TBA MXB 24m24	.452mg * P<.7
	e	R m	f34	inh	liv MXB 24m24	38.2mg * P<.1
<b>COUMARIN***</b>						
113	M f	cd1	eat	liv mix 25m25 e	100ng...1ug...10...100...1mg...10...100...1g...10	176.mg Z P<.002 -
	a	M f	cd1	eat	lun ade 25m25 e	4.50gm * P<.1 -
	b	M f	cd1	eat	lun adc 25m25 e	3.14gm * P<.4 -
114	M m	cd1	eat	lun adc 23m23 e		1.02gm * P<.04 -
	a	M m	cd1	eat	liv mix 23m23 e	no dre P=1. -
	b	M m	cd1	eat	lun ade 23m23 e	no dre P=1. -
115	R f	sda	eat	liv clc 26m26 e		767.mg / P<.0005+
	a	R f	sda	eat	liv mix 26m26 e	1.44gm / P<.0005+
116	R m	sda	eat	liv clc 24m24 e		302.mg / P<.0005+
	a	R m	sda	eat	liv mix 24m24 e	365.mg / P<.0005+
<b>CYANOQUANIDINE</b>						
117	R f	f3d	eat	liv tum 24m26	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
	a	R f	f3d	eat	tba mix 24m26	no dre P=1. -
118	R m	f3d	eat	sub lip 24m26		15.6gm * P<.03 -
	a	R m	f3d	eat	liv hpa 24m26	109.gm * P<.6 -
	b	R m	f3d	eat	tba mix 24m26	no dre P=1. -
<b>CYCLOCYTIDINE</b>						
119	R f	wis	ipj	tba tum 52w52 k	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
120	R f	wis	ipj	tba mix 24m24		no dre P=1. -
121	R m	wis	ipj	tba tum 52w52 k		no dre P=1. -
122	R m	wis	ipj	tba mix 24m24		no dre P=1. -
<b>beta-CYCLODEXTRIN</b>						
123	M f	cd1	eat	lun mix 24m24 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
124	M m	cd1	eat	lun mix 93w93 e		728.mg Z P<.05 -
125	R f	cdr	eat	liv tum 52w52 e		no dre P=1. -
126	R m	cdr	eat	liv tum 52w52 e		no dre P=1. -
127	R f	f34	eat	ute adc 30m30 e		22.7gm * P<.8 -
128	R m	f34	eat	tes ict 28m28 e		157.mg * P<.0005-
129	R f	f3d	eat	liv hpa 24m25 e		no dre P=1. -
	a	R f	f3d	eat	tba mix 24m25 e	85.9gm * P<.1 -
130	R m	f3d	eat	liv hpa 24m25		no dre P=1. -
	a	R m	f3d	eat	tba mix 24m25	no dre P=1. -
<b>CYCLOPENTANONE OXIME</b>						
131	R m	f34	gav	liv mix 50w83 er	100ng...1ug...10...100...1mg...10...100...1g...10	40.9mg P<.008 +
	a	R m	f34	gav	liv hpc 50w83 er	70.7mg P<.04 +
<b>CYPROTERONE ACETATE</b>						
132	M f	c5j	eat	pyl adp 97w97 es	100ng...1ug...10...100...1mg...10...100...1g...10	16.8mg P<.0005+
	a	M f	c5j	eat	liv hpc 97w97 Ces	254.mg P<.07 +
	b	M f	c5j	eat	liv mix 97w97 Ces	254.mg P<.07 +
	c	M f	c5j	eat	liv hpa 97w97 Ces	1.12gm P<.4
133	M m	c5j	eat	pyl adp 24m24 e		31.6mg P<.0005+
	a	M m	c5j	eat	liv mix 24m24 Ce	115.mg P<.005 +
	b	M m	c5j	eat	liv hpc 24m24 Ce	179.mg P<.03 +
	c	M m	c5j	eat	liv hpa 24m24 Ce	333.mg P<.1
<b>L-CYSTEINE.HCL</b>						
134	R f	f3d	wat	liv tum 25m25 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -



CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
<b>CLOFIBRATE*** 637-07-0</b>											
105	2239m	540. mg n. s. s.	4/25	130. mg	0/25	325. mg	2/25	650. mg	8/25	Tucker;cthf,13-16;1995/pers. comm.	
106	2239m	127. mg n. s. s.	8/25	120. mg	2/25	300. mg	15/25	(600. mg)	5/25		
a	2239m	1.58gm n. s. s.	0/25	120. mg	0/25	300. mg	0/25	600. mg	1/25		
107	2239n	2.40gm n. s. s.	0/151	150. mg	1/51	250. mg	0/51	350. mg	0/51		
a	2239n	3.15gm n. s. s.	4/151	150. mg	0/51	250. mg	0/51	350. mg	1/51		
108	2239n	1.26gm n. s. s.	0/151	150. mg	2/51	250. mg	1/51	350. mg	1/51		
a	2239n	3.57gm n. s. s.	6/151	150. mg	0/51	250. mg	1/51	350. mg	0/51		
<b>COBALT SULFATE HEPTAHYDRATE 10026-24-1</b>											
109	TR471	.629mg 4.44mg	4/50	94.3ug	7/50	.315mg	13/50	.942mg	18/50		lun:a/a,a/c.
a	TR471	1.30mg 11.1mg	1/50	94.3ug	1/50	.315mg	4/50	.942mg	9/50		S
b	TR471	.945mg n. s. s.	3/50	94.3ug	6/50	.315mg	9/50	.942mg	10/50		S
c	TR471	.546mg n. s. s.	42/50	94.3ug	41/50	.315mg	43/50	.942mg	39/50		
d	TR471	1.06mg n. s. s.	18/50	94.3ug	18/50	.315mg	24/50	.942mg	16/50		liv:hpa,hpb,hpc.
e	TR471	.629mg 4.44mg	4/50	94.3ug	7/50	.315mg	13/50	.942mg	18/50		lun:a/a,a/c.
110	TR471	.297mg 1.83mg	11/50	78.6ug	14/50	.262mg	19/50	.786mg	28/50		lun:a/a,a/c.
a	TR471	.488mg n. s. s.	9/50	78.6ug	12/50	.262mg	13/50	.786mg	18/50		S
b	TR471	.588mg 173. mg	4/50	78.6ug	5/50	.262mg	7/50	.786mg	11/50		S
c	TR471	.710mg n. s. s.	3/50	78.6ug	6/50	.262mg	8/50	.786mg	9/50		S
d	TR471	.762mg n. s. s.	2/50	78.6ug	4/50	.262mg	8/50	.786mg	7/50		S
e	TR471	.289mg n. s. s.	49/50	78.6ug	48/50	.262mg	47/50	.786mg	46/50		
f	TR471	.338mg n. s. s.	40/50	78.6ug	41/50	.262mg	44/50	.786mg	39/50		liv:hpa,hpb,hpc.
g	TR471	.297mg 1.83mg	11/50	78.6ug	14/50	.262mg	19/50	.786mg	28/50		lun:a/a,a/c.
111	TR471	47.9ug .165mg	0/50	22.4ug	3/50	74.9ug	16/50	.224mg	16/50		lun:a/a,a/c,sgc.
a	TR471	46.5ug .210mg	2/50	22.4ug	4/50	74.9ug	19/50	.224mg	23/50	amd:pbb,phc,phm,pob;	lun:a/a,a/c,sgc. C
b	TR471	50.8ug .182mg	0/50	22.4ug	3/50	74.9ug	15/50	.224mg	15/50		
c	TR471	75.5ug .398mg	0/50	22.4ug	1/50	74.9ug	10/50	.224mg	9/50		S
d	TR471	.271mg 4.01mg	2/50	22.4ug	1/50	74.9ug	4/50	.224mg	10/50	amd:pbb,phc,phm,pob.	
e	TR471	.255mg n. s. s.	0/50	22.4ug	2/50	74.9ug	6/50	.224mg	6/50		S
f	TR471	.321mg n. s. s.	2/50	22.4ug	1/50	74.9ug	3/50	.224mg	8/50	amd:pbb,pob.	S
g	TR471	.155mg n. s. s.	48/50	22.4ug	47/50	74.9ug	50/50	.224mg	46/50		
h	TR471	n. s. s. n. s. s.	0/50	22.4ug	0/50	74.9ug	0/50	.224mg	0/50		liv:hpa,hpb,hpc.
112	TR471	.144mg n. s. s.	1/50	15.7ug	4/50	52.5ug	4/50	.157mg	7/50		lun:a/a,a/c.
a	TR471	.148mg n. s. s.	0/50	15.7ug	3/50	52.5ug	2/50	.157mg	5/50		sub: fbs, fib, sar. S
b	TR471	.199mg n. s. s.	1/50	15.7ug	4/50	52.5ug	1/50	.157mg	6/50		
c	TR471	82.0ug n. s. s.	15/50	15.7ug	19/50	52.5ug	25/50	.157mg	20/50	amd:pbb,phc,phm,pob.	
d	TR471	60.5ug n. s. s.	50/50	15.7ug	50/50	52.5ug	49/50	.157mg	50/50		
e	TR471	.534mg n. s. s.	1/50	15.7ug	1/50	52.5ug	1/50	.157mg	1/50		liv:hpa,hpb,hpc.
<b>COUMARIN*** (1,2-benzopyrone) 91-64-5</b>											
113	2260	79.5mg 598. mg	0/52	39.0mg	8/52	(130. mg)	4/52	390. mg	3/52	Carlton;faat,30,145-151;1996/pers. comm.	
a	2260	1.42gm n. s. s.	2/52	39.0mg	1/52	130. mg	2/52	390. mg	5/52		
b	2260	760. mg n. s. s.	10/52	39.0mg	11/52	130. mg	11/52	390. mg	14/52		
114	2260	417. mg n. s. s.	11/52	36.0mg	12/52	120. mg	10/52	360. mg	20/52		
a	2260	1.36gm n. s. s.	20/52	36.0mg	22/52	120. mg	19/52	360. mg	12/52		
b	2260	2.23gm n. s. s.	0/52	36.0mg	1/52	120. mg	2/52	360. mg	0/52		
115	2260	467. mg 1.39gm	0/65	150. mg	0/65	250. mg	23/65				
a	2260	758. mg 3.41gm	0/65	150. mg	1/65	250. mg	12/65				
116	2260	204. mg 475. mg	0/65	120. mg	1/65	200. mg	37/65				
a	2260	234. mg 659. mg	2/65	120. mg	6/65	200. mg	29/65				
<b>CYANOGUANIDINE 157480-33-6</b>											
117	2522	9.33gm n. s. s.	0/50	1.15gm	0/50	2.30gm	0/50			Yasuhara;fctx,35,475-480;1997	
a	2522	3.76gm n. s. s.	38/50	1.15gm	36/50	2.30gm	32/50				
118	2522	6.33gm n. s. s.	1/50	920. mg	1/50	1.84gm	7/50				
a	2522	14.9gm n. s. s.	1/50	920. mg	0/50	1.84gm	2/50				
b	2522	577. mg n. s. s.	49/50	920. mg	49/50	1.84gm	48/50				
<b>CYCLOCYTIDINE 31698-14-3</b>											
119	2383m	1.47mg n. s. s.	0/5	10.7mg	0/5	21.4mg	0/5	42.9mg	0/5	85.7mg	0/5
120	2383n	310. mg n. s. s.	2/15	10.7mg	2/15	21.4mg	1/15	42.9mg	1/15	85.7mg	0/15
121	2383m	1.47mg n. s. s.	0/5	10.7mg	0/5	21.4mg	0/5	42.9mg	0/5	85.7mg	0/5
122	2383n	17.7mg n. s. s.	0/15	10.7mg	0/15	21.4mg	0/15	42.9mg	0/15	85.7mg	0/15
<b>beta-CYCLODEXTRIN 7585-39-9</b>											
123	2407	2.47gm n. s. s.	7/51	25.0mg	7/48	75.0mg	6/52	225. mg	9/52	675. mg	6/52
124	2407	284. mg n. s. s.	9/52	25.0mg	2/52	75.0mg	12/52	225. mg	13/52	(675. mg)	6/52
125	2237	357. mg n. s. s.	0/20	625. mg	0/19	1.25gm	0/20	2.50gm	0/20		
126	2237	294. mg n. s. s.	0/17	500. mg	0/20	1.00gm	0/20	2.00gm	0/20		Bellringer;fctx,33,367-376;1995
127	2407	2.18gm n. s. s.	12/50	25.0mg	15/50	75.0mg	14/50	225. mg	9/50	675. mg	15/50
128	2407	60.8mg 867. mg	42/50	25.0mg	46/50	75.0mg	44/50	225. mg	48/50	675. mg	50/50
129	2533	19.7gm n. s. s.	1/49	1.19gm	1/50	2.39gm	1/50				Toyoda;fctx,35,331-336;1997
a	2533	1.51gm n. s. s.	39/49	1.19gm	44/50	2.39gm	40/50				
130	2533	11.3gm n. s. s.	1/50	954. mg	3/50	1.91gm	1/50				
a	2533	525. mg n. s. s.	47/50	954. mg	50/50	1.91gm	47/50				
<b>CYCLOPENTANONE OXIME 1192-28-5</b>											
131	2265	15.5mg 607. mg	0/30	17.1mg	5/30					Fiala;txcy,99,89-97;1995/pers. comm.	
a	2265	21.4mg n. s. s.	0/30	17.1mg	3/30						
<b>CYPROTERONE ACETATE (androcour) 427-51-0</b>											
132	2290	7.76mg 32.0mg	0/8	104. mg	39/40					Tucker;carc,17,1473-1476;1996/pers. comm.	
a	2290	115. mg n. s. s.	0/8	104. mg	8/37						
b	2290	115. mg n. s. s.	0/8	104. mg	8/37						
c	2290	274. mg n. s. s.	0/8	104. mg	2/37						
133	2290	19.0mg 54.6mg	0/8	96.0mg	35/40						
a	2290	64.5mg 731. mg	0/8	96.0mg	17/39						
b	2290	91.7mg n. s. s.	0/8	96.0mg	12/39						
c	2290	143. mg n. s. s.	0/8	96.0mg	7/39						
<b>L-CYSTEINE.HCL 52-89-1</b>											
134	2538	872. mg n. s. s.	0/44	143. mg	0/43	286. mg	0/38			Kitahori;jtxp,10,83-89;1997	

Spe	Strain	Site	Xpo+Xpt	TD50	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
a	R f	f3d wat	tba mix 25m25 e	no dre	P=1. -
135	R m	f3d wat	liv tum 25m25 e	no dre	P=1. -
a	R m	f3d wat	tba mix 25m25 e	no dre	P=1. -
DDT***				100ng...1ug...10...100...1mg...10...100...1g...10	
136	H f	nss eat	liv tum 78w78	no dre	P=1. -
137	H m	nss eat	liv tum 78w78	no dre	P=1. -
DECABROMODIPHENYL OXIDE, TECHNICAL GRADE (77.4% DBDPO, 21.8% NONABROMODIPHENYL OXIDE, 0.8% OCTABROMODIPHENYL OXIDE)					
138	R f	sss eat	liv hct 24m24 e	no dre	P=1. -
a	R f	sss eat	tba mix 24m24 e	.987mg *	P<.5 -
139	R m	sss eat	liv hct 23m23 e	no dre	P=1. -
a	R m	sss eat	tba mix 23m23 e	no dre	P=1. -
DEFLAZACORT				100ng...1ug...10...100...1mg...10...100...1g...10	
140	R f	cdr eat	bon tum 52w52 r	no dre	P=1. -
141	R f	cdr eat	hed ost 24m24 rs	66.8mg *	P<.2
142	R m	cdr eat	bon tum 52w52 r	no dre	P=1. -
143	R m	cdr eat	bon mix 24m24 rs	no dre	P=1. +
a	R m	cdr eat	hed ost 24m24 rs	no dre	P=1. +
DEHYDROEPIANDROSTERONE***				100ng...1ug...10...100...1mg...10...100...1g...10	
144	R f	sda eat	liv mix 72w72 ekr	108.mg	P<.02 +
a	R f	sda eat	liv hpc 72w72 ekr	193.mg	P<.08 +
b	R f	sda eat	liv hpa 72w72 ekr	442.mg	P<.3
145	R f	sda eat	liv mix 84w84 er	83.3mg	P<.005 +
a	R f	sda eat	liv hpc 84w84 er	263.mg	P<.08 +
b	R f	sda eat	liv hpa 84w84 er	263.mg	P<.08
146	R m	sda eat	liv mix 72w72 ekr	274.mg	P<.5 +
a	R m	sda eat	liv hpc 72w72 ekr	353.mg	P<.3 +
b	R m	sda eat	liv hpa 72w72 ekr	no dre	P=1.
147	R m	sda eat	liv hpa 84w84 er	no dre	P=1.
a	R m	sda eat	liv hpc 84w84 er	no dre	P=1.
DEOXYNIVALENOL				100ng...1ug...10...100...1mg...10...100...1g...10	
148	M m	b6c eat	liv hpa 24m24 e	no dre	P=1. -
a	M m	b6c eat	liv hpc 24m24 e	no dre	P=1. -
1,1-DICHLORO-1-FLUOROETHANE				100ng...1ug...10...100...1mg...10...100...1g...10	
149	R f	sda inh	tba mix 24m24 ev	no dre	P=1.
150	R m	sda inh	tes ica 24m24 ev	5.26gm Z	P<.002 +
a	R m	sda inh	tba mix 24m24 ev	5.79gm *	P<.2
DICHLOROACETIC ACID***				100ng...1ug...10...100...1mg...10...100...1g...10	
151	M m	b6c wat	liv mix 52w52 Ck	143.mg *	P<.002 +
a	M m	b6c wat	liv hpc 52w52 Ck	242.mg *	P<.002 +
b	M m	b6c wat	liv hpa 52w52 Ck	247.mg *	P<.02
152	M m	b6c wat	liv mix 78w78 Ck	179.mg *	P<.003 +
a	M m	b6c wat	liv hpc 78w78 Ck	278.mg *	P<.003 +
b	M m	b6c wat	liv hpa 78w78 Ck	368.mg *	P<.03
153	M m	b6c wat	liv mix 23m23 C	176.mg *	P<.0005+
a	M m	b6c wat	liv hpc 23m23 C	188.mg *	P<.0005+
b	M m	b6c wat	liv hpa 23m23 C	313.mg *	P<.0005
154	R m	f34 wat	liv mix 53w53 Ckv	no dre	P=1.
155	R m	f34 wat	liv mix 78w78 Ckv	no dre	P=1.
156	R m	f34 wat	liv mix 24m24 Cv	278.mg	P<.004 +
a	R m	f34 wat	liv hpc 24m24 Cv	386.mg	P<.02
b	R m	f34 wat	liv hpa 24m24 Cv	795.mg	P<.03
157	R m	f34 wat	liv hpa 60w60 Ckv	251.mg *	P<.02
a	R m	f34 wat	liv mix 60w60 Ckv	251.mg *	P<.02 +
b	R m	f34 wat	liv hpc 60w60 Ckv	1.85gm *	P<.4
158	R m	f34 wat	liv mix 23m23 C	90.6mg *	P<.004 +
a	R m	f34 wat	liv hpa 23m23 C	138.mg *	P<.03
b	R m	f34 wat	liv hpc 23m23 C	212.mg *	P<.02
3,3'-DICHLOROBENZIDINE.2HCL				100ng...1ug...10...100...1mg...10...100...1g...10	
159	M m	icr eat	liv hpt 52w52 e	noTD50	P<.0005+
2,4-DICHLOROPHENOXYACETIC ACID***				100ng...1ug...10...100...1mg...10...100...1g...10	
160	M f	b6c eat	liv hpa 24m24	4.53gm *	P<.6 -
a	M f	b6c eat	liv hpc 24m24	no dre	P=1. -
161	M m	b6c eat	liv hpa 24m24	585.mg *	P<.2 -
a	M m	b6c eat	liv hpc 24m24	no dre	P=1. -
162	R f	f34 eat	bra ast 24m24	no dre	P=1. -
163	R m	f34 eat	bra ast 24m24	5.09gm	P<.3 -
(+) -4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-PHENYLACETATE.HCL MONOHYDRATE...				1g...10	
164	M f	b6c eat	liv hpa 78w78 e	8.70gm *	P<.8 -
a	M f	b6c eat	liv hpc 78w78 e	no dre	P=1. -
b	M f	b6c eat	tba mix 78w78 e	no dre	P=1. -
165	M m	b6c eat	liv hpa 78w78 e	no dre	P=1. -
a	M m	b6c eat	liv hpc 78w78 e	no dre	P=1. -
b	M m	b6c eat	tba mix 78w78 e	no dre	P=1. -
166	R f	f34 eat	thy cca 24m24 e	773.mg *	P<.2 -
a	R f	f34 eat	liv hpc 24m24 e	no dre	P=1. -
b	R f	f34 eat	liv hpa 24m24 e	no dre	P=1. -
c	R f	f34 eat	tba mix 24m24 e	152.mg	P<.3 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code	
a	2538	459.mg	n.s.s.	21/44	143.mg	14/43	286.mg	18/38					
135	2538	654.mg	n.s.s.	0/37	125.mg	0/33	250.mg	0/41					
a	2538	54.2mg	n.s.s.	37/37	125.mg	32/33	250.mg	40/41					
DDT*** 50-29-3													
136	2596	51.9mg	n.s.s.	0/30	26.1mg	0/30	52.3mg	0/30	105.mg	0/30	Graillet;ejtx,8,353-359;1975		
137	2596	45.7mg	n.s.s.	0/30	23.0mg	0/30	46.0mg	0/30	92.0mg	0/30			
DECABROMODIPHENYL OXIDE, TECHNICAL GRADE (77.4% DBDPO, 21.8% NONABROMODIPHENYL OXIDE, 0.8% OCTABROMODIPHENYL OXIDE) 1163-19-5													
138	2593	47.3ug	n.s.s.	0/25	10.0ug	0/25	.100mg	0/25	1.00mg	0/25	Kociba;jctx,2,267-285;1975		
a	2593	.138mg	n.s.s.	23/25	10.0ug	23/25	.100mg	23/25	1.00mg	24/25			
139	2593	42.9ug	n.s.s.	0/25	10.0ug	0/25	.100mg	0/25	1.00mg	0/25			
a	2593	1.21mg	n.s.s.	12/25	10.0ug	7/25	.100mg	10/25	1.00mg	9/25			
DEFLAZACORT 14484-47-0													
140	2420m	39.4ug	n.s.s.	0/50	30.0ug	0/50	60.0ug	0/50	.120mg	0/50	.250mg	0/50	
					1.00mg	0/50					Zwicker;txpy,24,246-250;1996		
141	2420n	10.9mg	n.s.s.	0/50	30.0ug	0/50	60.0ug	0/50	.120mg	0/50	.250mg	0/50	
					1.00mg	1/50							
142	2420m	39.4ug	n.s.s.	0/50	30.0ug	0/50	60.0ug	0/50	.120mg	0/50	.250mg	0/50	
					1.00mg	0/50							
143	2420n	5.27mg	n.s.s.	0/50	30.0ug	0/50	60.0ug	1/50	.120mg	0/50	.250mg	7/50	
					1.00mg	0/50							
a	2420n	5.46mg	n.s.s.	0/50	30.0ug	0/50	60.0ug	0/50	.120mg	0/50	.250mg	5/50	
					1.00mg	0/50							
DEHYDROEPIANDROSTERONE*** 53-43-0													
144	2562m	30.0mg	n.s.s.	0/5	300.mg	3/5					Metzger;clet,121,125-131;1997/pers.comm.		
a	2562m	45.9mg	n.s.s.	0/5	300.mg	2/5							
b	2562m	71.2mg	n.s.s.	0/5	300.mg	1/5							
145	2562n	23.1mg	742.mg	0/5	300.mg	4/5							
a	2562n	62.5mg	n.s.s.	0/5	300.mg	2/5							
b	2562n	62.5mg	n.s.s.	0/5	300.mg	2/5							
146	2562m	39.9mg	n.s.s.	1/5	240.mg	2/5							
a	2562m	56.9mg	n.s.s.	0/5	240.mg	1/5							
b	2562m	64.5mg	n.s.s.	1/5	240.mg	1/5							
147	2562n	161.mg	n.s.s.	0/5	240.mg	0/5							
a	2562n	161.mg	n.s.s.	0/5	240.mg	0/5							
DEOXYNIVALENOL (3-alpha,7-alpha,15-trihydroxy-12-13-epoxytrichothecene-9-en-8-one) 51481-10-8													
148	2359	8.78mg	n.s.s.	8/50	.120mg	8/48	.600mg	6/50	1.20mg	2/48	Iverson;tcam,15,283-306;1995		
a	2359	11.2mg	n.s.s.	7/50	.120mg	4/48	.600mg	3/50	1.20mg	1/48			
1,1-DICHLORO-1-FLUOROETHANE (HCFC 141b) 1717-00-6													
149	2231	6.52gm	n.s.s.	65/70	537.mg	59/70	1.79gm	60/70	6.87gm	59/70	Millischer;fctx,33,491-500;1995		
150	2231	2.61gm	27.9gm	3/70	376.mg	4/70	1.25gm	14/70	(4.81gm	12/70)			
a	2231	1.93gm	n.s.s.	62/70	376.mg	55/70	1.25gm	54/70	4.81gm	64/70			
DICHLOROACETIC ACID*** 79-43-6													
151	2453m	71.7mg	604.mg	0/10	83.3mg	1/10	167.mg	1/10	333.mg	2/10	583.mg	7/10	
a	2453m	104.mg	1.07gm	0/10	83.3mg	0/10	167.mg	0/10	333.mg	2/10	583.mg	5/10	
b	2453m	107.mg	n.s.s.	0/10	83.3mg	1/10	167.mg	1/10	333.mg	0/10	583.mg	5/10	
152	2453n	89.0mg	1.27gm	2/10	83.3mg	1/10	167.mg	4/10	333.mg	8/10	583.mg	9/10	
a	2453n	136.mg	1.66gm	1/10	83.3mg	0/10	167.mg	2/10	333.mg	5/10	583.mg	7/10	
b	2453n	159.mg	n.s.s.	1/10	83.3mg	1/10	167.mg	2/10	333.mg	5/10	583.mg	5/10	
153	2453o	103.mg	413.mg	18/50	8.33mg	11/33	83.3mg	14/25	167.mg	30/35	333.mg	21/21	
a	2453o	112.mg	418.mg	13/50	8.33mg	11/33	83.3mg	12/25	167.mg	25/35	333.mg	20/21	
b	2453o	184.mg	744.mg	5/50	8.33mg	1/33	83.3mg	5/25	167.mg	18/35	333.mg	9/21	
											DeAngelo;jtxe,58,485;1999/pers.comm.		
154	2261m	n.s.s.	n.s.s.	0/7	139.mg	0/7					DeAngelo;txcy,114,207-221;1996/pers.comm.		
155	2261n	75.1mg	n.s.s.	1/8	139.mg	1/8							
156	2261o	122.mg	1.99gm	1/43	139.mg	9/41							
a	2261o	151.mg	n.s.s.	1/43	139.mg	7/41							
b	2261o	241.mg	n.s.s.	0/43	139.mg	3/41							
157	2261r	108.mg	n.s.s.	0/10	3.60mg	0/13	40.2mg	0/13	296.mg	7/34			
a	2261r	108.mg	n.s.s.	0/10	3.60mg	0/13	40.2mg	0/13	296.mg	7/34			
b	2261r	301.mg	n.s.s.	0/10	3.60mg	0/13	40.2mg	0/13	296.mg	1/34			
158	2261s	36.6mg	768.mg	1/23	3.60mg	0/26	40.2mg	7/28					
a	2261s	47.8mg	n.s.s.	1/23	3.60mg	0/26	40.2mg	5/28					
b	2261s	64.1mg	n.s.s.	0/23	3.60mg	0/26	40.2mg	3/28					
3,3'-DICHLOROBENZIDINE.2HCl 612-83-9													
159	2594	n.s.s.	12.3mg	2/21	120.mg	18/18					Osani;jsol,52,179-201;1976		
2,4-DICHLOROPHENOXYACETIC ACID*** (2,4-D) 94-75-7													
160	2286	756.mg	n.s.s.	5/50	5.00mg	11/50	150.mg	8/50	300.mg	10/50	Charles;faat,33,166-172;1996		
a	2286	3.10gm	n.s.s.	1/50	5.00mg	2/50	150.mg	0/50	300.mg	1/50			
161	2286	193.mg	n.s.s.	12/50	5.00mg	9/50	62.5mg	13/50	125.mg	16/50			
a	2286	486.mg	n.s.s.	6/50	5.00mg	3/50	62.5mg	7/50	125.mg	4/50			
162	2286	940.mg	n.s.s.	1/50	150.mg	1/50							
163	2286	829.mg	n.s.s.	0/50	150.mg	1/50							
(+)-4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-PHENYLACETATE.HCl MONOHYDRATE (NS-21) ---													
164	2540	691.mg	n.s.s.	2/50	30.0mg	3/50	100.mg	3/50	300.mg	3/50	Hatch;jtxs,22,275-287;1997		
a	2540	1.79gm	n.s.s.	1/50	30.0mg	0/50	100.mg	1/50	300.mg	0/50			
b	2540	374.mg	n.s.s.	19/50	300.mg	16/50							
165	2540	733.mg	n.s.s.	6/50	30.0mg	11/50	100.mg	3/50	300.mg	6/50			
a	2540	904.mg	n.s.s.	3/50	30.0mg	1/50	100.mg	3/50	300.mg	2/50			
b	2540	400.mg	n.s.s.	22/50	300.mg	17/50							
166	2536	216.mg	n.s.s.	2/50	10.0mg	8/50	30.0mg	4/50	100.mg	8/50	Hatch;jtxs,22,289-309;1997		
a	2536	1.04gm	n.s.s.	0/50	10.0mg	1/50	30.0mg	0/50	100.mg	0/50			
b	2536	1.04gm	n.s.s.	0/50	10.0mg	1/50	30.0mg	0/50	100.mg	0/50			
c	2536	40.1mg	n.s.s.	39/50	100.mg	43/50							

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
167	R m f34	eat liv	hpa 24m24	e	.	no dre P=1. -
a	R m f34	eat tba	mix 24m24	e	.	noTD50 P=1. -
<b>DIETHYLENE GLYCOL***</b>						
168	R f f3d	wat liv	nnd 25m25		.	no dre P=1. -
a	R f f3d	wat tba	mix 25m25		.	no dre P=1. -
169	R m f3d	wat liv	nnd 25m25		.	.34.2gm * P<.1 -
a	R m f3d	wat tba	mix 25m25		.	no dre P=1. -
<b>2-(DIFLUOROMETHYL)-DL-ORNITHINE***</b>						
170	R m wis	eat stg	tum 70w70	e	.	no dre P=1. -
<b>3,3'-DIHYDROXYBENZIDINE.2HC1</b>						
171	M m icr	eat liv	hpt 65w65		.	353.mg P<.8 +
<b>24R,25-DIHYDROXYVITAMIN D3</b>						
172	R m s1s	eat stg	adc 57w57	e	.	no dre P=1. -
<b>DIMETHOATE***</b>						
173	R b wis	gav liv	hpc 24m24	e	.	215.mg * P<.4
a	R b wis	gav tba	mal 24m24	e	.	22.1mg * P<.004
b	R b wis	gav tba	ben 24m24	e	.	no dre P=1. -
<b>3,3'-DIMETHOXYBENZIDINE.2HC1***</b>						
174	M m icr	eat liv	hpt 65w65		.	73.8mg P<.3 +
<b>O,O-DIMETHYL S-2 (ACETYLAMINO)ETHYL DITHIOPHOSPHATE, TECHNICAL GRADE</b>						
175	R f sda	eat liv	tum 24m24		.	no dre P=1. -
176	R m sda	eat liv	tum 24m24		.	no dre P=1. -
<b>DIMETHYLACETAMIDE</b>						
177	M f cd1	inh liv	hpa 78w78	Ce	.	13.2gm * P<.2 -
178	M m cd1	inh liv	hpa 78w78	Ce	.	no dre P=1. -
a	M m cd1	inh liv	hpc 78w78	Ce	.	no dre P=1. -
179	R f cdr	inh liv	hpa 24m24	Ce	.	no dre P=1. -
180	R m cdr	inh liv	hpc 24m24	Ce	.	6.00gm * P<.7 -
a	R m cdr	inh liv	hpa 24m24	Ce	.	no dre P=1. -
<b>DIMETHYLARSINIC ACID***</b>						
181	R m f3d	wat ubl	mix 24m24	Ce	.	11.4mg * P<.0005+
a	R m f3d	wat ubl	tcc 24m24	Ce	.	12.8mg * P<.0005+
b	R m f3d	wat ubl	tpp 24m24	Ce	.	67.7mg * P<.07 +
c	R m f3d	wat liv	hpc 24m24	e	.	545.mg * P<.7
d	R m f3d	wat liv	nnd 24m24	e	.	no dre P=1. -
<b>1,4-DIOXANE***</b>						
182	M f bd1	wat liv	mix 24m24	e	.	65.5mg Z P<.0005+
a	M f bd1	wat liv	hpa 24m24	e	.	83.1mg Z P<.0005+
b	M f bd1	wat liv	hpc 24m24	e	.	404.mg * P<.0005+
c	M f bd1	wat nas	adc 24m24	e	.	72.1gm * P<.2
183	M m bd1	wat liv	hpa 24m24	e	.	519.mg Z P<.003 +
a	M m bd1	wat liv	mix 24m24	e	.	982.mg * P<.002 +
b	M m bd1	wat liv	hpc 24m24	e	.	1.04gm * P<.0005+
c	M m bd1	wat nas	ene 24m24	e	.	60.1gm * P<.2
184	R f f3d	wat liv	mix 24m24	e	.	167.mg Z P<.0005+
a	R f f3d	wat liv	hpa 24m24	e	.	182.mg Z P<.0005+
b	R f f3d	wat mgl	ade 24m24	e	.	772.mg * P<.008 +
c	R f f3d	wat liv	hpc 24m24	e	.	1.12gm * P<.0005+
d	R f f3d	wat nas	mal 24m24	e	.	1.43gm * P<.0005+
e	R f f3d	wat nas	sqc 24m24	e	.	1.65gm * P<.0005+
f	R f f3d	wat nas	ene 24m24	e	.	12.2gm * P<.2
185	R m f3d	wat liv	mix 24m24	e	.	189.mg * P<.0005+
a	R m f3d	wat per	mso 24m24	e	.	246.mg * P<.0005+
b	R m f3d	wat liv	hpa 24m24	e	.	279.mg * P<.0005+
c	R m f3d	wat liv	hpc 24m24	e	.	676.mg * P<.0005+
d	R m f3d	wat sub	fib 24m24	e	.	922.mg * P<.009 +
e	R m f3d	wat nas	mal 24m24	e	.	1.44gm * P<.0005+
f	R m f3d	wat nas	sqc 24m24	e	.	3.49gm * P<.009 +
g	R m f3d	wat mgl	faa 24m24	e	.	3.07gm * P<.06 +
h	R m f3d	wat nas	srn 24m24	e	.	5.27gm * P<.04
i	R m f3d	wat nas	ene 24m24	e	.	10.6gm * P<.2
j	R m f3d	wat nas	rhh 24m24	e	.	10.6gm * P<.2
<b>DISODIUM 5'-RIBONUCLEOTIDE</b>						
186	R f wis	eat liv	tum 24m24	e	.	no dre P=1. -
a	R f wis	eat tba	mix 24m24	e	.	no dre P=1. -
187	R m wis	eat liv	tum 24m24	e	.	no dre P=1. -
a	R m wis	eat tba	mix 24m24	e	.	no dre P=1. -
<b>EFONIDIPINE.HCl ETHANOLATE</b>						
188	M f b6c	eat lyd	mly 24m24	e	.	276.mg Z P<.04 -
a	M f b6c	eat liv	hpc 24m24	e	.	7.43gm * P<.3 -
b	M f b6c	eat liv	hpa 24m24	e	.	11.5gm * P<.7 -
c	M f b6c	eat lun	a/c 24m24	e	.	12.3gm * P<.5 -
d	M f b6c	eat lun	a/a 24m24	e	.	no dre P=1. -
e	M f b6c	eat tba	mix 24m24	e	.	no dre P=1. -
189	M m b6c	eat liv	hpa 24m24	e	.	no dre P=1. -
a	M m b6c	eat liv	hpc 24m24	e	.	no dre P=1. -
b	M m b6c	eat lun	a/c 24m24	e	.	no dre P=1. -
c	M m b6c	eat lun	a/a 24m24	e	.	no dre P=1. -
d	M m b6c	eat tba	mix 24m24	e	.	no dre P=1. -
190	R f f3d	eat liv	hpa 24m24	e	.	no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code		
167	2536	621.mg n.s.s.	0/50	10.0mg	4/50	30.0mg	1/50	100.mg	1/50					
a	2536	n.s.s. n.s.s.	50/50	100.mg	50/50									
DIETHYLENE GLYCOL*** 111-46-6														
168	2379	5.29gm n.s.s.	0/50	714.mg	0/50	1.43gm	0/50					Hiasa;jtxp,3,97-104;1990		
a	2379	2.60gm n.s.s.	31/50	714.mg	28/50	1.43gm	26/50							
169	2379	8.41gm n.s.s.	0/50	625.mg	0/50	1.25gm	2/50							
a	2379	1.42gm n.s.s.	46/50	625.mg	46/50	1.25gm	39/50							
2-(DIFLUOROMETHYL)-DL-ORNITHINE*** 70052-12-9														
170	2548	14.9mg n.s.s.	0/10	20.0mg	0/10	80.0mg	0/10						Tanakamaru;clet,120,95-100;1997	
3,3'-DIHYDROXYBENZIDINE.2HCl 1592-36-5														
171	2594	30.8mg n.s.s.	7/34	120.mg	9/20							Osanai;jsol,52,179-201;1976		
24R,25-DIHYDROXYVITAMIN D3 (SECALCIFEROL) 55721-11-4														
172	2406	.248mg n.s.s.	0/20	.200mg	0/20							Ikezaki;canr,56,2767-2770;1996		
DIMETHOATE*** 60-51-5														
173	2386	35.0mg n.s.s.	0/36	1.43mg	0/26	4.29mg	1/25	8.57mg	0/20				Stieglitz;ahae,52,70-76;1974/Gibel 1973/Gibel 1975	
a	2386	10.4mg 183.mg	0/36	1.43mg	2/26	4.29mg	3/25	8.57mg	4/20					
b	2386	14.9mg n.s.s.	3/36	1.43mg	7/26	4.29mg	5/25	8.57mg	2/20					
3,3'-DIMETHOXYBENZIDINE.2HCl*** 20325-40-0														
174	2594	21.4mg n.s.s.	7/34	120.mg	11/17							Osanai;jsol,52,179-201;1976		
O,O-DIMETHYL S-2(ACETYLAMINO)ETHYL DITHIOPHOSPHATE, TECHNICAL GRADE (Amiphos, DAEP) 13265-60-6														
175	2377	.528mg n.s.s.	0/20	.160mg	0/20	.800mg	0/20	4.00mg	0/20	20.0mg	0/20	100.mg	0/20	Hashimoto;phrm,6,1189-1205;1972
176	2377	.422mg n.s.s.	0/20	.128mg	0/20	.640mg	0/20	3.20mg	0/20	16.0mg	0/20	80.0mg	0/20	
DIMETHYLACETAMIDE 127-19-5														
177	2252	2.14gm n.s.s.	0/63	28.0mg	0/64	112.mg	0/63	392.mg	1/65					Malley;faat,28,80-93;1995
178	2252	1.04gm n.s.s.	14/64	23.3mg	12/64	93.4mg	10/64	327.mg	8/65					
a	2252	1.64gm n.s.s.	2/64	23.3mg	5/64	93.4mg	4/64	327.mg	1/65					
179	2252	895.mg n.s.s.	0/62	6.67mg	0/62	26.7mg	1/62	93.4mg	0/64					
180	2252	536.mg n.s.s.	1/65	4.67mg	0/63	18.7mg	1/63	65.4mg	1/62					
a	2252	636.mg n.s.s.	3/65	4.67mg	3/63	18.7mg	2/63	65.4mg	1/62					
DIMETHYLARSINIC ACID*** (cacodylic acid) 75-60-5														
181	2441	6.67mg 22.6mg	0/28	.625mg	0/33	2.50mg	8/31	10.0mg	12/31					Wei;carc,20,1873-1876;1999/2002/pers.comm.
a	2441	7.30mg 25.7mg	0/28	.625mg	0/33	2.50mg	6/31	10.0mg	12/31					
b	2441	23.4mg n.s.s.	0/28	.625mg	0/33	2.50mg	2/31	10.0mg	2/31					
c	2441	48.2mg n.s.s.	1/28	.625mg	0/33	2.50mg	0/31	10.0mg	1/31					
d	2441	63.3mg n.s.s.	1/28	.625mg	2/33	2.50mg	1/31	10.0mg	0/31					
1,4-DIOXANE*** (p-dioxane) 123-91-1														
182	2444	40.8mg 117.mg	4/50	99.0mg	34/50	(396.mg)	41/50	1.58gm	46/50					Yamazaki;icmr,1993,193-198;1994/pers.comm.
a	2444	50.5mg 159.mg	4/50	99.0mg	30/50	(396.mg)	20/50	1.58gm	2/50					
b	2444	292.mg 570.mg	0/50	99.0mg	6/50	396.mg	30/50	1.58gm	45/50					
c	2444	11.7gm n.s.s.	0/50	99.0mg	0/50	396.mg	0/50	1.58gm	1/50					
183	2444	262.mg 2.99gm	7/50	82.5mg	16/50	330.mg	22/50	(1.32gm)	8/50					
a	2444	480.mg 5.39gm	21/50	82.5mg	31/50	330.mg	37/50	1.32gm	39/50					
b	2444	581.mg 2.79gm	15/50	82.5mg	20/50	330.mg	23/50	1.32gm	36/50					
c	2444	9.78gm n.s.s.	0/50	82.5mg	0/50	330.mg	0/50	1.32gm	1/50					
184	2444	113.mg 258.mg	1/50	11.3mg	0/50	56.6mg	5/50	283.mg	40/50					
a	2444	123.mg 283.mg	1/50	11.3mg	0/50	56.6mg	5/50	283.mg	38/50					
b	2444	337.mg 24.1gm	6/50	11.3mg	7/50	56.6mg	10/50	283.mg	16/50					
c	2444	547.mg 2.89gm	0/50	11.3mg	0/50	56.6mg	0/50	283.mg	10/50					
d	2444	648.mg 4.19gm	0/50	11.3mg	0/50	56.6mg	0/50	283.mg	8/50					
e	2444	712.mg 5.28gm	0/50	11.3mg	0/50	56.6mg	0/50	283.mg	7/50					
f	2444	1.98gm n.s.s.	0/50	11.3mg	0/50	56.6mg	0/50	283.mg	1/50					
185	2444	126.mg 297.mg	0/50	9.90mg	2/50	49.5mg	4/50	248.mg	33/50					
a	2444	157.mg 430.mg	2/50	9.90mg	2/50	49.5mg	5/50	248.mg	28/50					
b	2444	179.mg 483.mg	0/50	9.90mg	2/50	49.5mg	4/50	248.mg	24/50					
c	2444	363.mg 1.47gm	0/50	9.90mg	0/50	49.5mg	0/50	248.mg	14/50					
d	2444	392.mg 34.7gm	5/50	9.90mg	3/50	49.5mg	5/50	248.mg	12/50					
e	2444	623.mg 4.62gm	0/50	9.90mg	0/50	49.5mg	0/50	248.mg	7/50					
f	2444	1.06gm 99.6gm	0/50	9.90mg	0/50	49.5mg	0/50	248.mg	3/50					
g	2444	906.mg n.s.s.	1/50	9.90mg	1/50	49.5mg	0/50	248.mg	4/50					
h	2444	1.30gm n.s.s.	0/50	9.90mg	0/50	49.5mg	0/50	248.mg	2/50					
i	2444	1.73gm n.s.s.	0/50	9.90mg	0/50	49.5mg	0/50	248.mg	1/50					
j	2444	1.73gm n.s.s.	0/50	9.90mg	0/50	49.5mg	0/50	248.mg	1/50					
DISODIUM 5'-RIBONUCLEOTIDE (ribotide) 80702-47-2														
186	2321	700.mg n.s.s.	0/10	500.mg	0/10	1.00gm	0/10						Usui;jtrl,30,614-635;1971	
a	2321	875.mg n.s.s.	6/10	500.mg	4/10	1.00gm	4/10							
187	2321	504.mg n.s.s.	0/9	400.mg	0/9	800.mg	0/9							
a	2321	666.mg n.s.s.	6/9	400.mg	3/9	800.mg	4/9							
EFONIDIPINE.HCl ETHANOLATE (NZ-105 ETHANOLATE) 111011-76-8														
188	2434	109.mg n.s.s.	3/50	65.0mg	10/50	(208.mg)	5/50	650.mg	2/50					Inoue;jjpt,20,1747-1773;1992
a	2434	1.78gm n.s.s.	3/50	65.0mg	4/50	208.mg	4/50	650.mg	6/50					
b	2434	1.60gm n.s.s.	5/50	65.0mg	6/50	208.mg	9/50	650.mg	7/50					
c	2434	2.22gm n.s.s.	2/50	65.0mg	3/50	208.mg	3/50	650.mg	4/50					
d	2434	3.46gm n.s.s.	2/50	65.0mg	2/50	208.mg	2/50	650.mg	2/50					
e	2434	1.22gm n.s.s.	34/50	65.0mg	36/50	208.mg	32/50	650.mg	28/50					
189	2434	1.52gm n.s.s.	23/50	60.0mg	22/50	192.mg	26/50	600.mg	17/50					
a	2434	1.71gm n.s.s.	13/50	60.0mg	10/50	192.mg	14/50	600.mg	10/50					
b	2434	3.36gm n.s.s.	5/50	60.0mg	6/50	192.mg	4/50	600.mg	3/50					
c	2434	3.66gm n.s.s.	8/50	60.0mg	4/50	192.mg	5/50	600.mg	3/50					
d	2434	819.mg n.s.s.	42/50	60.0mg	36/50	192.mg	42/50	600.mg	34/50					
190	2435	1.90gm n.s.s.	0/50	20.0mg	1/50	60.0mg	0/50	180.mg	0/50					Inoue;jjpt,20,1775-1803;1992

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
a	R f	f3d eat	tba mix	24m24 e		244. mg * P<.2 -
191	R m	f3d eat	liv mix	24m24 e	.	2.31gm * P<.2 -
a	R m	f3d eat	tba mix	24m24 e		no dre P=1. -
ENDOSULFAN***					100ng...1ug...10...100...1mg...10...100...1g...10	
192	M f	nmo eat	liv hpa	24m24	.	no dre P=1. -
a	M f	nmo eat	liv hpa	24m24	.	no dre P=1. -
b	M f	nmo eat	liv hpa	24m24	.	no dre P=1. -
193	M m	nmo eat	liv hpa	24m24	.	63.6mg * P<.2 -
a	M m	nmo eat	liv hpa	24m24	.	83.2mg * P<.6 -
b	M m	nmo eat	liv hpa	24m24	.	no dre P=1. -
194	R f	cdr eat	pni isa	24m24	.	7.13mg Z P<.2 -
a	R f	cdr eat	liv hpc	24m24	.	no dre P=1. -
195	R m	cdr eat	tyf mix	24m24	.	30.0mg * P<.1 -
a	R m	cdr eat	liv hpc	24m24	.	97.1mg * P<.5 -
DL-ETHIONINE***					100ng...1ug...10...100...1mg...10...100...1g...10	
196	R m	f34 eat	liv mix	76w78 ae	.	13.7mg Z P<.0005+
a	R m	f34 eat	liv hpc	76w78 ae	.	16.9mg Z P<.0005+
4-ETHOXY-PHENYLUREA					100ng...1ug...10...100...1mg...10...100...1g...10	
197	R b	osm eat	liv mix	24m24 e	.	537. mg * P<.0005+
ETHYL ALCOHOL***					100ng...1ug...10...100...1mg...10...100...1g...10	
198	H m	syg wat	trh tum	29w78 er	.	no dre P=1. -
199	M m	bal wat	for sqp	69w86	.	no dre P=1. -
200	M f	swi wat	for sqp	69w86 s	.	10.9gm P<.1 -
a	M f	swi wat	tba mix	69w86 s	.	21.4gm P<.6 -
201	M m	swi wat	liv hpc	69w86	.	no dre P=1. -
2-ETHYLHEXANOL					100ng...1ug...10...100...1mg...10...100...1g...10	
202	M f	b6c gav	liv hpc	80w80 e	.	1.68gm * P<.009 +
203	M m	b6c gav	liv mix	80w80 e	.	1.71gm * P<.09 -
204	R f	f34 gav	liv hpc	24m24 e	.	no dre P=1. -
205	R m	f34 gav	liv mix	24m24 e	.	no dre P=1. -
DI(2-ETHYLHEXYL) PHTHALATE***					100ng...1ug...10...100...1mg...10...100...1g...10	
206	M f	b6c eat	liv mix	78w79 Cekr	.	650. mg * P<.004 +
a	M f	b6c eat	liv hpa	78w79 Cekr	.	1.10gm * P<.04
b	M f	b6c eat	liv hpc	78w79 Cekr	.	2.66gm * P<.03
207	M f	b6c eat	liv mix	18m24 Cer	.	553. mg P<.0005+
a	M f	b6c eat	liv hpc	18m24 Cer	.	834. mg P<.0005
b	M f	b6c eat	liv hpa	18m24 Cer	.	1.50gm P<.0005
208	M f	b6c eat	liv mix	24m24 Cer	.	463. mg * P<.0005+
a	M f	b6c eat	liv hpa	24m24 Cer	.	721. mg * P<.0005
b	M f	b6c eat	liv hpc	24m24 Cer	.	1.88gm * P<.0005
209	M m	b6c eat	liv mix	78w79 Cekr	.	46.4gm * P<.1
210	M m	b6c eat	liv hpc	18m24 Cer	.	2.19gm P<.03
a	M m	b6c eat	liv mix	18m24 Cer	.	2.37gm P<.09 +
211	M m	b6c eat	liv mix	24m24 Cer	.	546. mg * P<.0005+
a	M m	b6c eat	liv hpc	24m24 Cer	.	1.14gm * P<.0005
b	M m	b6c eat	liv hpa	24m24 Cer	.	1.74gm * P<.004
212	R f	f34 eat	liv mix	78w79 Cek	.	848. mg * P<.02 +
a	R f	f34 eat	liv hpc	78w79 Cek	.	1.34gm * P<.05
213	R f	f34 eat	liv mix	18m24 Cer	.	1.62gm P<.0005+
a	R f	f34 eat	liv hpa	18m24 Cer	.	2.81gm P<.002
b	R f	f34 eat	liv hpc	18m24 Cer	.	4.29gm P<.01
214	R f	f34 eat	liv mix	24m24 Ce	.	1.56gm Z P<.0005+
a	R f	f34 eat	liv hpc	24m24 Ce	.	2.59gm * P<.0005
b	R f	f34 eat	liv hpa	24m24 Ce	.	5.19gm * P<.02
215	R f	f34 eat	liv mix	24m24 Cer	.	1.16gm * P<.002 +
a	R f	f34 eat	liv nnd	24m24 Cer	.	1.95gm * P<.03
b	R f	f34 eat	liv hpc	24m24 Cer	.	4.35gm * P<.03
216	R m	f34 eat	liv mix	78w79 Cek	.	360. mg * P<.03 +
a	R m	f34 eat	liv hpc	78w79 Cek	.	560. mg * P<.05
217	R m	f34 eat	liv mix	18m24 Cer	.	769. mg P<.0005+
a	R m	f34 eat	liv hpa	18m24 Cer	.	1.39gm P<.002
b	R m	f34 eat	liv hpc	18m24 Cer	.	1.91gm P<.002
218	R m	f34 eat	liv mix	24m24 Ce	.	725. mg * P<.0005+
a	R m	f34 eat	liv hpc	24m24 Ce	.	1.05gm * P<.0005
b	R m	f34 eat	liv hpa	24m24 Ce	.	1.28gm * P<.0005
c	R m	f34 eat	pan ana	24m24 e	.	3.91gm P<.008
d	R m	f34 eat	--- mnl	24m24 e	.	1.36gm * P<.04
FADROZOLE.HCl					100ng...1ug...10...100...1mg...10...100...1g...10	
219	R f	sda gav	mgl mix	24m24 e	.	no dre P=1. -
a	R f	sda gav	liv mix	24m24 e	.	no dre P=1. -
b	R f	sda gav	tba mix	24m24 e	.	no dre P=1. -
220	R m	sda gav	liv mix	24m24 e	.	no dre P=1. -
5-FLUOROURACIL***					100ng...1ug...10...100...1mg...10...100...1g...10	
221	M f	b6c wat	liv nnd	82w86 e	.	331. mg * P<.7 -
a	M f	b6c wat	liv nnd	82w86 e	.	no dre P=1. -
b	M f	b6c wat	liv hpc	82w86 e	.	no dre P=1. -
c	M f	b6c wat	liv hpc	82w86 e	.	no dre P=1. -
222	M m	b6c wat	liv hpc	82w86 e	.	48.7mg * P<.05 -
a	M m	b6c wat	liv hpc	82w86 e	.	35.7mg * P<.2 -
b	M m	b6c wat	liv hpc	82w86 e	.	no dre P=1. -
c	M m	b6c wat	liv hpc	82w86 e	.	no dre P=1. -
d	M m	b6c wat	liv hpc	82w86 e	.	no dre P=1. -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code
a	2435	78.7mg	n.s.s.	38/50	20.0mg	35/50	60.0mg	38/50	180.0mg	42/50		
191	2435	64.6mg	n.s.s.	1/50	16.0mg	0/50	48.0mg	1/50	144.0mg	3/50		
a	2435	20.0mg	n.s.s.	49/50	16.0mg	50/50	48.0mg	50/50	144.0mg	49/50		
ENDOSULFAN*** (thiodan) 115-29-7												
192	2230	2.23mg	n.s.s.	0/60	.260mg	0/60	.780mg	0/60	2.34mg	0/60	Hack;fctx,33,941-950;1995	
a	2230	16.0mg	n.s.s.	2/60	.260mg	4/60	.780mg	2/60	2.34mg	2/60		
b	2230	25.0mg	n.s.s.	1/60	.260mg	4/60	.780mg	2/60	2.34mg	0/60		
193	2230	15.7mg	n.s.s.	0/60	.240mg	0/60	.720mg	1/60	2.16mg	1/60		
a	2230	11.2mg	n.s.s.	2/60	.240mg	2/60	.720mg	2/60	2.16mg	3/60		
b	2230	13.9mg	n.s.s.	11/60	.240mg	5/60	.720mg	5/60	2.16mg	5/60		
194	2230	2.16mg	n.s.s.	0/50	.150mg	5/50	.375mg	0/50	.750mg	5/50	(3.75mg 5/50)	
a	2230	.942mg	n.s.s.	0/50	.150mg	0/50	.375mg	0/50	.750mg	0/50	3.75mg 0/50	
195	2230	8.45mg	n.s.s.	0/50	.120mg	3/50	.300mg	4/50	.600mg	0/50	3.00mg 5/50	
a	2230	14.4mg	n.s.s.	1/50	.120mg	1/50	.300mg	1/50	.600mg	1/50	3.00mg 2/50	
DL-ETHIONINE*** 67-21-0												
196	2535	8.42mg	24.1mg	0/28	1.20mg	0/28	4.00mg	0/28	12.0mg	0/28	40.0mg 27/28 (120.0mg 20/21)	Allen;carc,18,1103-1107;1997/pers.comm.
a	2535	10.2mg	30.5mg	0/28	1.20mg	0/28	4.00mg	0/28	12.0mg	0/28	40.0mg 24/28 (120.0mg 19/21)	
4-ETHOXY-PHENYLUREA (dulcin) 150-69-6												
197	2393	281.0mg	1.22gm	0/14	4.50mg	0/20	45.0mg	1/15	112.0mg	0/18	225.0mg 2/17 450.0mg 10/14	Fitzhugh;japa,40,583-586;1951
ETHYL ALCOHOL*** (ethanol) 64-17-5												
198	2345	7.36gm	n.s.s.	0/27	3.29gm	0/27	8.23gm	0/27			McCoy;clet,33,151-159;1986	
199	2510n	5.64gm	n.s.s.	1/30	1.33gm	0/30					Zariwala;ijeb,29,738-743;1991	
200	2510m	2.67gm	n.s.s.	0/30	1.60gm	2/30						
a	2510m	2.94gm	n.s.s.	1/30	1.60gm	2/30						
201	2510m	3.40gm	n.s.s.	1/30	1.33gm	1/30						
2-ETHYLHEXANOL 104-76-7												
202	2284	727.0mg	98.2gm	0/50	35.7mg	1/50	143.0mg	3/50	536.0mg	5/50	Astill;faat,31,29-41;1996/pers.comm.	
203	2284	590.0mg	n.s.s.	6/50	35.7mg	3/50	143.0mg	7/50	536.0mg	10/50		
204	2284	3.05gm	n.s.s.	1/50	35.7mg	1/50	107.0mg	2/50	357.0mg	0/50		
205	2284	2.92gm	n.s.s.	6/50	35.7mg	3/50	107.0mg	4/50	357.0mg	1/50		
DI(2-ETHYLHEXYL)PHTHALATE*** (di-sec-octyl phthalate, DEHP) 117-81-7												
206	2442m	260.0mg	5.48gm	0/15	12.8mg	1/10	64.2mg	1/10	193.0mg	1/10	770.0mg 6/15	David;faat,50,195-205;1999/2000
a	2442m	363.0mg	n.s.s.	0/15	12.8mg	1/10	64.2mg	1/10	193.0mg	1/10	770.0mg 4/15	
b	2442m	654.0mg	n.s.s.	0/15	12.8mg	0/10	64.2mg	0/10	193.0mg	0/10	770.0mg 2/15	
207	2442n	341.0mg	1.03gm	3/55	579.0mg	30/55						
a	2442n	479.0mg	1.87gm	3/55	579.0mg	23/55						
b	2442n	790.0mg	3.39gm	0/55	579.0mg	13/55						
208	2442o	321.0mg	723.0mg	3/55	12.9mg	3/50	64.4mg	6/55	193.0mg	18/55	773.0mg 38/55	
a	2442o	493.0mg	1.13gm	0/55	12.9mg	1/50	64.4mg	3/55	193.0mg	8/55	773.0mg 30/55	
b	2442o	986.0mg	6.21gm	3/55	12.9mg	2/50	64.4mg	3/55	193.0mg	10/55	773.0mg 14/55	
209	2442m	577.0mg	n.s.s.	1/15	11.8mg	1/10	59.2mg	3/10	178.0mg	1/10	711.0mg 2/15	
210	2442n	898.0mg	n.s.s.	4/55	535.0mg	12/55						
a	2442n	863.0mg	n.s.s.	7/55	535.0mg	14/55						
211	2442o	330.0mg	1.14gm	7/55	11.9mg	13/50	59.4mg	18/55	178.0mg	26/55	713.0mg 35/55	
a	2442o	634.0mg	3.07gm	4/55	11.9mg	5/50	59.4mg	8/55	178.0mg	14/55	713.0mg 21/55	
b	2442o	812.0mg	13.6gm	3/55	11.9mg	9/50	59.4mg	11/55	178.0mg	13/55	713.0mg 18/55	
212	2442m	255.0mg	n.s.s.	0/10	123.0mg	0/10	617.0mg	3/10				
a	2442m	328.0mg	n.s.s.	0/10	123.0mg	0/10	617.0mg	2/10				
213	2442n	787.0mg	4.17gm	0/70	464.0mg	10/55						
a	2442n	1.14gm	12.7gm	0/70	464.0mg	6/55						
b	2442n	1.48gm	524.0gm	0/70	464.0mg	4/55						
214	2442o	888.0mg	3.42gm	0/70	4.95mg	4/50	24.8mg	1/55	124.0mg	3/55	619.0mg 19/70	
a	2442o	1.35gm	6.39gm	0/70	4.95mg	1/50	24.8mg	0/55	124.0mg	1/55	619.0mg 12/70	
b	2442o	1.97gm	n.s.s.	0/70	4.95mg	3/50	24.8mg	1/55	124.0mg	2/55	619.0mg 7/70	
215	2463	457.0mg	7.23gm	0/20	15.0mg	1/20	50.0mg	1/20	600.0mg	6/20		Cattley;clet,38,15-22;1987/pers.comm.
a	2463	619.0mg	n.s.s.	0/20	15.0mg	1/20	50.0mg	1/20	600.0mg	4/20		
b	2463	1.07gm	n.s.s.	0/20	15.0mg	0/20	50.0mg	0/20	600.0mg	2/20		
216	2442m	126.0mg	n.s.s.	1/10	98.7mg	1/10	494.0mg	5/10				David;faat,50,195-205;1999/2000
a	2442m	171.0mg	n.s.s.	1/10	98.7mg	0/10	494.0mg	4/10				
217	2442n	405.0mg	2.24gm	4/70	371.0mg	18/55						
a	2442n	606.0mg	31.8gm	4/70	371.0mg	12/55						
b	2442n	823.0mg	6.76gm	0/70	371.0mg	7/55						
218	2442o	444.0mg	1.43gm	4/70	3.96mg	5/50	19.8mg	4/55	99.0mg	10/55	495.0mg 29/70	
a	2442o	644.0mg	1.88gm	0/70	3.96mg	0/50	19.8mg	1/55	99.0mg	3/55	495.0mg 20/70	
b	2442o	686.0mg	3.67gm	4/70	3.96mg	5/50	19.8mg	3/55	99.0mg	7/55	495.0mg 20/70	
c	2442o	1.48gm	70.5gm	0/60	495.0mg	5/59						
d	2442o	539.0mg	n.s.s.	15/65	3.96mg	13/50	19.8mg	16/55	99.0mg	32/65	495.0mg 27/65	
FADROZOLE HCl 102676-31-3												
219	2229	1.57mg	n.s.s.	29/60	50.0ug	20/60	.250mg	7/60	1.25mg	0/60		Gunson;bjca,72,72-75;1995/pers.comm.
a	2229	13.8mg	n.s.s.	4/60	50.0ug	4/60	.250mg	0/60	1.25mg	1/60		
b	2229	2.10mg	n.s.s.	58/60	50.0ug	60/60	.250mg	52/60	1.25mg	48/60		
220	2229	9.02mg	n.s.s.	10/60	50.0ug	8/60	.250mg	5/60	1.25mg	4/60		
5-FLUOROURACIL*** (fluracil) 51-21-8												
221	2366	42.4mg	n.s.s.	2/51	5.72mg	1/52	11.4mg	3/51				Iwagawa;jtxp,4,129-135;1991
a	2366	59.2mg	n.s.s.	2/51	5.72mg	2/52	11.4mg	1/51				
b	2366	27.8mg	n.s.s.	1/51	5.72mg	0/52	11.4mg	0/51				
c	2366	87.7mg	n.s.s.	1/51	5.72mg	1/52	11.4mg	0/51				
222	2366	18.8mg	n.s.s.	2/51	4.77mg	1/50	9.53mg	8/52				
a	2366	13.4mg	n.s.s.	3/51	4.77mg	8/50	9.53mg	8/52				
b	2366	17.1mg	n.s.s.	11/51	4.77mg	10/50	9.53mg	11/52				
c	2366	31.1mg	n.s.s.	6/51	4.77mg	1/50	9.53mg	6/52				
d	2366	50.3mg	n.s.s.	1/51	4.77mg	1/50	9.53mg	1/52				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
<b>FORMALDEHYDE***</b>						
223	R m	f34 inh nas sqc	52w52 Ckr	100ng...1ug...10...100...1mg...10...100...1g...10	2.37mg	* P<.06
224	R m	f34 inh nas sqc	80w80 Ckr		.895mg	* P<.0005+
225	R m	f34 inh nas sqc	24m24 Cr		.480mg	Z P<.0005+
226	R m	f3d inh nas tum	52w52 ek		no dre	P=1.
227	R m	f3d inh nas mix	78w78 ek		.874mg	* P<.02
228	R m	f3d inh nas mix	27m28 ae		.980mg	* P<.0005+
a	R m	f3d inh nas sqc	27m28 ae		1.24mg	* P<.0005+
b	R m	f3d inh nas sqp	27m28 ae		10.0mg	* P<.03
<b>GEMFIBROZIL***</b>						
229	M f	cd1 eat liv hpa	78w78 ej	100ng...1ug...10...100...1mg...10...100...1g...10	6.60gm	* P<.6 -
a	M f	cd1 eat lun mix	78w78 ej		11.8gm	* P<.9 -
b	M f	cd1 eat tba mix	78w78 ej		1.69gm	* P<.6 -
230	M m	cd1 eat liv mix	78w78 ej		1.66gm	* P<.5 -
a	M m	cd1 eat lun mix	78w78 ej		no dre	P=1. -
b	M m	cd1 eat tba mix	78w78 ej		no dre	P=1. -
231	R f	cdr eat liv hpc	24m24 ej		504.mg	\ P<.1 -
a	R f	cdr eat tba mix	24m24 ej		no dre	P=1. -
232	R m	cdr eat adr phe	24m24 ej		85.9mg	\ P<.006
a	R m	cdr eat pan mix	24m24 ej		161.mg	\ P<.004
b	R m	cdr eat tes ict	24m24 ej		516.mg	* P<.0005
c	R m	cdr eat liv hpc	24m24 ej		247.mg	\ P<.02 +
d	R m	cdr eat tba ben	24m24 ej		196.mg	* P<.02
e	R m	cdr eat tba mix	24m24 ej		202.mg	* P<.08
<b>GLYCERIN, NATURAL</b>						
233	R b	lev eat tba mix	24m24	100ng...1ug...10...100...1mg...10...100...1g...10	>38.3gm	* P<.6 -
<b>GLYCERIN, SYNTHETIC</b>						
234	R b	lev eat tba mix	24m24	100ng...1ug...10...100...1mg...10...100...1g...10	> 12.3gm	* P<.2 -
<b>GLYCINE</b>						
235	R f	f3d wat ute esp	25m25 e	100ng...1ug...10...100...1mg...10...100...1g...10	3.10gm	\ P<.003
a	R f	f3d wat k/p tpp	25m25 e		+hist 25.7gm	* P<.1 +
b	R f	f3d wat liv nnd	25m25 e		157.gm	* P<.3
c	R f	f3d wat tba mix	25m25 e		7.55gm	\ P<.6
236	R m	f3d wat liv nnd	25m25 e		no dre	P=1.
a	R m	f3d wat tba mix	25m25 e		no dre	P=1.
<b>GRISEOFULVIN***</b>						
237	M f	swa gav mgl idc	52w52 er	100ng...1ug...10...100...1mg...10...100...1g...10	13.8mg	P<.03 +
<b>HEXAMETHYLPHOSPHORAMIDE</b>						
238	R b	cdr inh nas mix	12m24 aemr	100ng...1ug...10...100...1mg...10...100...1g...10	34.5ug	Z P<.0005+
a	R b	cdr inh nas mal	12m24 aemr		41.6ug	Z P<.0005+
b	R b	cdr inh nas epc	12m24 aemr		58.1ug	Z P<.0005+
c	R b	cdr inh nsa sqc	12m24 aemr		.519mg	Z P<.0005+
239	R b	cdr inh nas mix	17m24 aemr		34.4ug	/ P<.0005+
a	R b	cdr inh nas mal	17m24 aemr		38.7ug	/ P<.0005+
b	R b	cdr inh nas epc	17m24 aemr		45.6ug	/ P<.0005+
c	R b	cdr inh nsa sqc	17m24 aemr		.608mg	* P<.004 +
<b>L-HISTIDINE.HCl</b>						
240	R f	f3d eat liv hpa	24m25 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre	P=1. -
241	R m	f3d eat liv hpa	24m25 e		.52.2gm	* P<.3 -
<b>HYDRAZINE***</b>						
242	R f	wis wat liv mix	36m36 e	100ng...1ug...10...100...1mg...10...100...1g...10	41.6mg	* P<.0005+
a	R f	wis wat mgl mal	36m36 e		1.13gm	Z P<.03
b	R f	wis wat liv hpc	36m36 e		129.mg	* P<.03
c	R f	wis wat tba mix	36m36 e		no dre	P=1.
243	R m	wis wat liv mix	36m36 e		43.7mg	* P<.03 +
a	R m	wis wat liv hpc	36m36 e		no dre	P=1.
b	R m	wis wat tba mix	36m36 e		9.64mg	* P<.3
<b>HYDRAZINE SULFATE***</b>						
244	H m	syg wat liv hpa	91w91 Cer	100ng...1ug...10...100...1mg...10...100...1g...10	87.5mg	* P<.002
a	H m	syg wat liv mix	91w91 Cer		87.5mg	* P<.002 +
b	H m	syg wat liv hpc	91w91 Cer		464.mg	* P<.2
<b>HYDROCHLOROFLUOROCARBON 123</b>						
245	R f	cdr inh liv cgf	24m24 Ce	100ng...1ug...10...100...1mg...10...100...1g...10	.22.7gm	* P<.0005+
a	R f	cdr inh liv hpa	24m24 Ce		20.3gm	* P<.04 +
b	R f	cdr inh pan ana	24m24 e		92.1gm	* P<.4
246	R m	cdr inh pan ana	24m24 e		1.26gm	Z P<.0005+
a	R m	cdr inh tes ica	24m24 e		9.05gm	* P<.07 +
b	R m	cdr inh liv hpa	24m24 Ce		13.1gm	* P<.03 +
c	R m	cdr inh pan acc	24m24 e		60.8gm	* P<.3
<b>1-HYDROXYANTHRAQUINONE***</b>						
247	R m	f34 eat lgi mix	78w78 er	100ng...1ug...10...100...1mg...10...100...1g...10	222.mg	P<.004 +
a	R m	f34 eat col adc	78w78 er		432.mg	P<.04
b	R m	f34 eat col mix	78w78 er		432.mg	P<.04 +
c	R m	f34 eat cec adc	78w78 er		432.mg	P<.04 +
<b>3-((IMINO((2,2,2-TRIFLUOROETHYL)AMINO)METHYL)AMINO)-1H-PYRAZOLE-1-PENTAMIDE</b>						
248	M f	b6c eat gam cnd	91w91 er	100ng...1ug...10...100...1mg...10...100...1g...10	956.mg	* P<.0005+
249	M m	b6c eat gam cnd	91w91 er		401.mg	Z P<.0005+
250	R f	sda eat gam cnd	24m24 er		1.35gm	* P<.0005+
251	R m	sda eat gam cnd	24m24 er		1.03gm	Z P<.003 +



CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code
<b>FORMALDEHYDE*** 50-00-0</b>												
223	2279m	.582mg n.s.s.	0/12	45.0ug	0/12	.129mg	0/12	.386mg	0/12	.643mg	0/10	.965mg 2/16 Monticello;canr,56,1012-1022;1996/CIIIF 1999/pers.comm.
224	2279n	.422mg 2.61mg	0/10	45.0ug	0/11	.129mg	0/12	.386mg	0/12	.643mg	3/10	.965mg 6/11
225	2279o	.357mg .656mg	0/46	45.0ug	0/48	.129mg	0/48	.386mg	1/48	.643mg	19/47	.965mg 71/97
226	2445m	4.25ug n.s.s.	0/5	19.3ug	0/5	.129mg	0/5	.965mg	0/5	Kamata;jtxs,22,239-254;1997/pers.comm.		
227	2445n	.210mg n.s.s.	0/5	19.3ug	0/5	.129mg	0/5	.965mg	2/5			
228	2445o	.512mg 2.17mg	0/22	19.3ug	0/22	.129mg	0/22	.965mg	14/20			
	a	2445o	0/22	19.3ug	0/22	.129mg	0/22	.965mg	12/20			
	b	2445o	0/22	19.3ug	0/22	.129mg	0/22	.965mg	2/20			
<b>GEMFIBROZIL*** 25812-30-0</b>												
229	1518n	922.mg n.s.s.	4/72	30.0mg	1/72	300.mg	4/72	Fitzgerald;jnci,67,1105-1115;1981/pers.comm.				
	a	1518n	9/72	30.0mg	10/72	300.mg	10/72					
	b	1518n	21/72	30.0mg	23/72	300.mg	25/72					
230	1518n	350.mg n.s.s.	16/72	30.0mg	17/72	300.mg	20/72					
	a	1518n	23/72	30.0mg	17/72	300.mg	13/72					
	b	1518n	47/72	30.0mg	46/72	300.mg	45/72					
231	1518m	124.mg n.s.s.	0/50	30.0mg	2/50	(300.mg	0/50)					
	a	1518m	47/50	30.0mg	50/50	300.mg	44/50					
232	1518m	39.5mg 974.mg	3/50	30.0mg	13/50	(300.mg	9/50)					
	a	1518m	0/50	30.0mg	6/50	(300.mg	2/50)					
	b	1518m	1/50	30.0mg	8/50	300.mg	17/50					
	c	1518m	0/50	30.0mg	4/50	(300.mg	5/50)					
	d	1518m	35/50	30.0mg	39/50	300.mg	45/50					
	e	1518m	41/50	30.0mg	44/50	300.mg	47/50					
<b>GLYCERIN, NATURAL 56-81-5</b>												
233	2389	6.59gm n.s.s.	5/26	2.25gm	3/22	4.50gm	6/22	Hine;aihm,7,282-291;1953				
<b>GLYCERIN, SYNTHETIC 56-81-5</b>												
234	2389	4.24gm n.s.s.	5/26	2.25gm	4/21	4.50gm	9/22	Hine;aihm,7,282-291;1953				
<b>GLYCINE 56-40-6</b>												
235	2352	1.53gm 16.5gm	5/50	1.43gm	18/50	(2.86gm	12/50)	Kitahori;jtxp,7,471-480;1994				
	a	2352	0/50	1.43gm	4/50	2.86gm	2/50					
	b	2352	0/50	1.43gm	0/50	2.86gm	1/50					
	c	2352	27/50	1.43gm	30/50	(2.86gm	12/50)					
236	2352	9.26gm n.s.s.	1/50	1.25gm	0/50	2.50gm	0/50					
	a	2352	36/50	1.25gm	44/50	2.50gm	36/50					
<b>GRISEOFULVIN*** 126-07-8</b>												
237	2408	5.96mg n.s.s.	0/25	10.0mg	7/60	El-Mofty;oncr,1,1079-1081;1994						
<b>HEXAMETHYLPHOSPHORAMIDE 680-31-9</b>												
238	2462m	28.7ug 41.8ug	0/196	16.9ug	39/194	75.3ug	180/219	(.678mg	179/215)	Lee;jnci,68,157-164;1982/1982a/1984/pers.comm.		
	a	2462m	0/196	16.9ug	30/194	75.3ug	167/219	(.678mg	168/215)			
	b	2462m	0/196	16.9ug	24/194	75.3ug	137/219	(.678mg	120/215)			
	c	2462m	0/196	16.9ug	4/194	75.3ug	21/219	(.678mg	41/215)			
239	2462n	25.9ug 47.2ug	0/200	4.52ug	0/200	17.9ug	75/200					
	a	2462n	0/200	4.52ug	0/200	17.9ug	68/200					
	b	2462n	0/200	4.52ug	0/200	17.9ug	59/200					
	c	2462n	0/200	4.52ug	0/200	17.9ug	5/200					
<b>L-HISTIDINE.HCl 645-35-2</b>												
240	2285	4.42gm n.s.s.	0/50	607.mg	0/50	1.21gm	0/50	Ikezaki;fctx,34,687-691;1996				
241	2285	8.50gm n.s.s.	0/50	486.mg	0/49	972.mg	1/50					
<b>HYDRAZINE*** 302-01-2</b>												
242	2390	17.0mg 149.mg	0/50	.114mg	0/50	.571mg	0/50	2.86mg	6/47	Steinhoff;expl,33,133-143;1988		
	a	2390	2/50	.114mg	9/50	(.571mg	2/50	2.86mg	1/47)			
	b	2390	0/50	.114mg	0/50	.571mg	0/50	2.86mg	2/47			
	c	2390	39/50	.114mg	44/50	.571mg	41/50	2.86mg	37/47			
243	2390	14.9mg n.s.s.	0/50	.100mg	1/49	.500mg	2/50	2.50mg	4/49			
	a	2390	0/50	.100mg	0/49	.500mg	1/50	2.50mg	0/49			
	b	2390	37/50	.100mg	35/49	.500mg	36/50	2.50mg	40/49			
<b>HYDRAZINE SULFATE*** 10034-93-2</b>												
244	2324	47.0mg 336.mg	0/8	20.4mg	1/17	40.8mg	3/24	61.2mg	10/23	FitzGerald;carc,17,2703-2709;1996/pers.comm.		
	a	2324	0/8	20.4mg	1/17	40.8mg	3/24	61.2mg	10/23			
	b	2324	0/8	20.4mg	0/17	40.8mg	1/24	61.2mg	2/23			
<b>HYDROCHLOROFLUOROCARBON 123 306-83-2</b>												
245	2240	9.27gm 82.2gm	0/65	140.mg	0/67	468.mg	0/67	2.34gm	6/69	Malley;faat,25,101-114;1995		
	a	2240	0/65	140.mg	5/67	468.mg	2/67	2.34gm	7/69			
	b	2240	0/65	140.mg	2/67	468.mg	0/67	2.34gm	2/69			
246	2240	661.mg 4.43gm	1/67	98.3mg	4/66	328.mg	12/66	(1.64gm	14/66)			
	a	2240	4/67	98.3mg	12/66	328.mg	9/66	1.64gm	14/66)			
	b	2240	3/67	98.3mg	2/66	328.mg	2/66	1.64gm	8/66			
	c	2240	1/67	98.3mg	0/66	328.mg	0/66	1.64gm	2/66			
<b>1-HYDROXYANTHRAQUINONE*** 129-43-1</b>												
247	2235	81.7mg 1.56gm	0/10	400.mg	5/10	Yoshimi;clet,97,75-82;1995/pers.comm.						
	a	2235	0/10	400.mg	3/10							
	b	2235	0/10	400.mg	3/10							
	c	2235	0/10	400.mg	3/10							
<b>3-( (IMINO ( (2,2,2-TRIFLUOROETHYL) AMINO) METHYL) AMINO) -1H-PYRAZOLE-1-PENTAMIDE (ICI 162846) 84545-30-2</b>												
248	1896	524.mg 2.04gm	0/100	20.0mg	1/50	100.mg	0/50	500.mg	14/50	Streett;ttxp,16,299-304;1988		
249	1896	257.mg 674.mg	0/100	20.0mg	1/50	100.mg	0/50	500.mg	29/50			
250	1896	686.mg 3.83gm	0/104	20.0mg	3/52	100.mg	3/52	500.mg	11/52			
251	1896	357.mg 6.30gm	0/104	20.0mg	0/52	100.mg	4/52	(500.mg	4/52)			

INDOLE	Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
	Sex	Route	Hist			DR	AuOp
252	M f	swa eat	ubl car	70w70	r	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
<b>INDOMETHACIN***</b>							
253	R f	sda wat	mgl mix	92w92	e	100ng...1ug...10...100...1mg...10...100...1g...10	1.15mg P<.01 +
a	R f	sda wat	mgl adc	92w92	e		5.32mg P<.08 +
b	R f	sda wat	liv tum	92w92	e		no dre P=1. -
<b>ISATIDINE</b>							
254	R f	wis wat	liv hpt	24m24	rv	100ng...1ug...10...100...1mg...10...100...1g...10	1.27mg P<.03 +
255	R m	wis wat	liv hpt	24m24	rv		.499mg P<.005 +
<b>ISOBUTENE</b>							
256	M f	b6c inh	TBA MXB	24m24		100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	M f	b6c inh	liv MXB	24m24			47.8gm * P<.8
b	M f	b6c inh	lun MXB	24m24			no dre P=1. -
257	M m	b6c inh	TBA MXB	24m24			8.84gm * P<.4 -
a	M m	b6c inh	liv MXB	24m24			no dre P=1. -
b	M m	b6c inh	lun MXB	24m24			no dre P=1. -
258	R f	f34 inh	TBA MXB	24m24			no dre P=1. -
a	R f	f34 inh	liv MXB	24m24			30.1gm * P<.2
259	R m	f34 inh	thy fcc	24m24			3.55gm * P<.02 p
a	R m	f34 inh	TBA MXB	24m24			no dre P=1. -
b	R m	f34 inh	liv MXB	24m24			no dre P=1. -
<b>ISOPROPANOL</b>							
260	M f	cd1 inh	kid tum	54w54	k	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
261	M f	cd1 inh	kid tum	78w78	a		no dre P=1. -
262	M m	cd1 inh	kid tum	54w54	k		no dre P=1. -
263	M m	cd1 inh	kid tum	78w78	a		no dre P=1. -
264	R f	f34 inh	kid tum	72w73	k		no dre P=1. -
265	R f	f34 inh	kid tum	24m24	a		no dre P=1. -
266	R m	f34 inh	tes ica	72w73	k		456. mg * P<.0005-
a	R m	f34 inh	kid tum	72w73	k		no dre P=1. -
267	R m	f34 inh	tes ica	24m24	a		46.4mg * P<.0005-
a	R m	f34 inh	kid tum	24m24	a		no dre P=1. -
<b>LORNOXICAM</b>							
268	R f	sda gav	kid tum	52w52		100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
269	R f	sda gav	kid tum	52w52			no dre P=1. -
270	R f	sda gav	liv hpa	24m24	esv		13.2mg * P<.2 -
a	R f	sda gav	tba mix	24m24	esv		no dre P=1. -
271	R m	sda gav	kid tum	52w52			no dre P=1. -
272	R m	sda gav	kid tum	52w52			no dre P=1. -
273	R m	sda gav	liv mix	24m24	e		no dre P=1. -
a	R m	sda gav	tba mix	24m24	e		no dre P=1. -
<b>LOVASTATIN</b>							
274	M f	cd1 gav	liv mix	92w92		100ng...1ug...10...100...1mg...10...100...1g...10	623. mg * P<.0005+
a	M f	cd1 gav	for sgp	92w92			1.02gm * P<.0005+
b	M f	cd1 gav	lun ala	92w92			1.22gm * P<.008 +
c	M f	cd1 gav	liv hpc	92w92			2.24gm * P<.0005
d	M f	cd1 gav	for sqc	92w92			38.4gm * P<.7
e	M f	cd1 gav	lun adc	92w92			57.4gm * P<.1
275	M m	cd1 gav	liv mix	92w92			439. mg * P<.0005+
a	M m	cd1 gav	liv hpc	92w92			708. mg * P<.0005
b	M m	cd1 gav	for sgp	92w92			8.55gm * P<.4
c	M m	cd1 gav	for sqc	92w92			no dre P=1. -
d	M m	cd1 gav	lun adc	92w92			no dre P=1. -
e	M m	cd1 gav	lun ala	92w92			no dre P=1. -
276	R f	cdr gav	liv hpa	24m24			19.9gm * P<.8 -
277	R m	cdr gav	liv hpc	24m24			2.33gm * P<.08 -
a	R m	cdr gav	liv hpa	24m24			no dre P=1. -
<b>LOXTIDINE</b>							
278	R f	cdr eat	stf cnd	27m27		100ng...1ug...10...100...1mg...10...100...1g...10	272. mg Z P<.0005+
a	R f	cdr eat	liv hpa	27m27			no dre P=1. -
279	R m	cdr eat	stf cnd	27m27			2.01gm Z P<.005 +
a	R m	cdr eat	liv mix	27m27			no dre P=1. -
<b>LUPITIDINE .3HC1</b>							
280	M f	ssk gav	gam cnd	91w91	er	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
281	M m	ssk gav	gam cnd	91w91	er		no dre P=1. -
282	R f	wsk gav	gam cnd	23m23	er		.2.99gm * P<.0005+
283	R m	wsk gav	gam cnd	23m23	er		3.83gm * P<.0005+
<b>MANIDIPINE .2HC1</b>							
284	M f	icm eat	lun a/a	78w78	e	100ng...1ug...10...100...1mg...10...100...1g...10	438. mg * P<.5 -
a	M f	icm eat	liv hpa	78w78	e		545. mg * P<.2 -
285	M m	icm eat	liv hpa	78w78	e		no dre P=1. -
a	M m	icm eat	lun a/a	78w78	e		no dre P=1. -
b	M m	icm eat	liv hpc	78w78	e		no dre P=1. -
286	R f	cdr eat	liv hpa	24m24	e		157. mg * P<.5 -
a	R f	cdr eat	liv hpc	24m24	e		no dre P=1. -
287	R m	cdr eat	liv hpc	24m24	e		405. mg * P<.8 -
a	R m	cdr eat	liv hpa	24m24	e		8.24gm Z P<.1 -
<b>MELOXICAM</b>							
288	R f	wis gav	sto tum	52w52		100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
289	R m	wis gav	sto tum	52w52			no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
INDOLE 120-72-9										
252	2401	3.03gm	n.s.s.	0/45	1.30gm	0/25			El-Aaser;ejca,14,645-648;1978	
INDOMETHACIN*** 53-86-1										
253	2251	.533mg	75.3mg	12/49	.887mg	24/48			Holmang;carc,16,1493-1498;1995	
a	2251	1.74mg	n.s.s.	1/49	.887mg	5/48				
b	2251	6.87mg	n.s.s.	0/49	.887mg	0/48				
ISATIDINE 15503-86-3										
254	1871	.474mg	n.s.s.	0/7	.816mg	5/14			Schoental;bjca,8,458-465;1954	
255	1871	.177mg	3.68mg	0/7	.714mg	5/8				
ISOBUTENE 115-11-7										
256	TR487	3.76gm	n.s.s.	47/50	360.mg	45/50	1.44gm	49/50	5.76gm	48/50
a	TR487	5.54gm	n.s.s.	23/50	360.mg	28/50	1.44gm	22/50	5.76gm	28/50
b	TR487	24.9gm	n.s.s.	6/50	360.mg	4/50	1.44gm	4/50	5.76gm	3/50
257	TR487	2.11gm	n.s.s.	41/50	300.mg	50/50	1.20gm	43/50	4.81gm	50/50
a	TR487	4.53gm	n.s.s.	30/50	300.mg	32/50	1.20gm	28/50	4.81gm	29/50
b	TR487	10.8gm	n.s.s.	17/50	300.mg	13/50	1.20gm	9/50	4.81gm	9/50
258	TR487	760.mg	n.s.s.	50/50	85.9mg	48/50	344.mg	50/50	1.37gm	48/50
a	TR487	4.90gm	n.s.s.	0/50	85.9mg	0/50	344.mg	0/50	1.37gm	1/50
259	TR487	1.17gm	n.s.s.	1/50	60.1mg	0/50	240.mg	0/50	962.mg	5/50
a	TR487	497.mg	n.s.s.	50/50	60.1mg	48/50	240.mg	50/50	962.mg	50/50
b	TR487	n.s.s.	n.s.s.	0/50	60.1mg	0/50	240.mg	0/50	962.mg	0/50
ISOPROPANOL 67-63-0										
260	2574m	165.mg	n.s.s.	0/10	386.mg	0/10	1.93gm	0/10	3.86gm	0/10
261	2574n	1.89gm	n.s.s.	0/55	386.mg	0/55	1.93gm	0/55	3.86gm	0/55
262	2574m	138.mg	n.s.s.	0/10	322.mg	0/10	1.61gm	0/10	3.22gm	0/10
263	2574n	1.58gm	n.s.s.	0/55	322.mg	0/55	1.61gm	0/55	3.22gm	0/55
264	2574m	70.9mg	n.s.s.	0/10	90.7mg	0/10	454.mg	0/10	907.mg	0/10
265	2574n	948.mg	n.s.s.	0/65	92.0mg	0/65	460.mg	0/65	920.mg	0/65
266	2574m	184.mg	1.72gm	0/10	63.5mg	0/10	318.mg	0/10	635.mg	6/10
a	2574m	49.6mg	n.s.s.	0/10	63.5mg	0/10	318.mg	0/10	635.mg	0/10
267	2574n	21.1mg	129.mg	49/65	64.4mg	58/65	322.mg	65/65	644.mg	65/65
a	2574n	663.mg	n.s.s.	0/65	64.4mg	0/65	322.mg	0/65	644.mg	0/65
LORNOXICAM 70374-39-9										
268	2532m	40.5ug	n.s.s.	0/20	60.0ug	0/20	.160mg	0/20	.400mg	0/20
269	2532n	8.83ug	n.s.s.	0/20	10.0ug	0/20	60.0ug	0/20		
270	2532o	2.14mg	n.s.s.	0/100	62.5ug	0/50	.125mg	0/50	.199mg	1/50
a	2532o	.252mg	n.s.s.	89/100	62.5ug	44/50	.125mg	33/50	.199mg	24/50
271	2532m	40.5ug	n.s.s.	0/20	60.0ug	0/20	.160mg	0/20	.400mg	0/20
272	2532n	8.83ug	n.s.s.	0/20	10.0ug	0/20	60.0ug	0/20		
273	2532o	2.79mg	n.s.s.	5/100	62.5ug	0/50	.125mg	1/50	.250mg	1/50
a	2532o	.204mg	n.s.s.	78/100	62.5ug	39/50	.125mg	41/50	.250mg	38/50
LOVASTATIN (Mevacor) 75330-75-5										
274	2365	374.mg	1.14gm	0/100	20.0mg	0/50	100.mg	2/50	500.mg	20/50
a	2365	544.mg	2.68gm	1/100	20.0mg	0/50	100.mg	6/50	500.mg	10/50
b	2365	520.mg	27.9gm	7/100	20.0mg	8/50	100.mg	9/50	500.mg	13/50
c	2365	966.mg	7.16gm	0/100	20.0mg	0/50	100.mg	0/50	500.mg	7/50
d	2365	2.74gm	n.s.s.	1/100	20.0mg	1/50	100.mg	0/50	500.mg	1/50
e	2365	1.88gm	n.s.s.	4/100	20.0mg	5/50	100.mg	1/50	500.mg	3/50
275	2365	254.mg	985.mg	16/100	20.0mg	6/50	100.mg	12/50	500.mg	27/50
a	2365	382.mg	1.88gm	8/100	20.0mg	5/50	100.mg	6/50	500.mg	19/50
b	2365	1.56gm	n.s.s.	2/100	20.0mg	0/50	100.mg	3/50	500.mg	2/50
c	2365	130.mg	n.s.s.	1/100	20.0mg	0/50	100.mg	0/50	500.mg	0/50
d	2365	3.81gm	n.s.s.	3/100	20.0mg	3/50	100.mg	2/50	500.mg	0/50
e	2365	1.20gm	n.s.s.	17/100	20.0mg	7/50	100.mg	8/50	500.mg	8/50
276	2365	1.33gm	n.s.s.	2/100	5.00mg	0/50	30.0mg	0/50	180.mg	1/50
277	2365	650.mg	n.s.s.	0/100	5.00mg	2/50	30.0mg	1/50	180.mg	3/50
a	2365	1.47gm	n.s.s.	4/100	5.00mg	0/50	30.0mg	0/50	180.mg	1/50
LOXTIDINE 76956-02-0										
278	2450	128.mg	741.mg	0/114	50.0mg	9/63	(185.mg	8/63	685.mg	10/63)
a	2450	10.8gm	n.s.s.	0/114	50.0mg	1/63	185.mg	0/63	685.mg	0/63
279	2450	819.mg	20.2gm	0/114	50.0mg	2/63	185.mg	4/63	(685.mg	1/63)
a	2450	6.67gm	n.s.s.	2/114	50.0mg	2/63	185.mg	2/63	685.mg	1/63
LUPITIDINE.3HC1 (SK&F 93479-A3) 72716-75-7										
280	2451	7.42gm	n.s.s.	0/50	1.00gm	0/47			Betton;txpy,16,288-298;1988/pers.comm.	
281	2451	7.42gm	n.s.s.	0/42	1.00gm	0/47				
282	2451	1.35gm	8.75gm	0/40	40.0mg	0/36	200.mg	0/17	1.00gm	8/37
283	2451	1.56gm	13.8gm	0/40	40.0mg	0/23	200.mg	0/22	1.00gm	6/34
MANIDIPINE.2HC1 (CV-4093.2HC1) 89226-75-5										
284	2430	81.5mg	n.s.s.	3/50	1.20mg	2/50	4.00mg	2/50	12.0mg	3/50
a	2430	134.mg	n.s.s.	0/50	1.20mg	0/50	4.00mg	0/49	12.0mg	1/50
285	2430	32.8mg	n.s.s.	5/50	1.20mg	9/50	4.00mg	1/49	12.0mg	5/50
a	2430	94.1mg	n.s.s.	10/50	1.20mg	6/50	4.00mg	9/50	12.0mg	8/50
b	2430	183.mg	n.s.s.	2/50	1.20mg	2/50	4.00mg	0/49	12.0mg	1/50
286	2431	25.5mg	n.s.s.	3/49	.600mg	2/49	2.00mg	1/50	6.00mg	4/50
a	2431	4.35mg	n.s.s.	1/49	.600mg	0/49	2.00mg	0/50	6.00mg	0/50
287	2431	35.2mg	n.s.s.	1/50	.600mg	0/50	2.00mg	2/50	6.00mg	1/50
a	2431	30.3mg	n.s.s.	1/50	.600mg	6/50	2.00mg	0/50	6.00mg	3/50
MELOXICAM 71125-38-7										
288	2537	.113mg	n.s.s.	0/16	.200mg	0/20	.400mg	0/18	.800mg	0/19
289	2537	.110mg	n.s.s.	0/18	.200mg	0/18	.400mg	0/20	.800mg	0/19

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
<b>MERCUROUS CHLORIDE</b>						
290	M m	bal eat	lun tum	14m24	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
a	M m	bal eat	liv tum	14m24	.	no dre P=1. -
<b>MERCURYMETHYL CHLORIDE***</b>						
291	M f	icm eat	kid tum	52w52 k	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
292	M f	icm eat	kid tum	78w78 k	.	no dre P=1. -
293	M f	icm eat	kid tum	24m24	.	no dre P=1. -
294	M m	icm eat	kid tum	52w52 k	.	no dre P=1. -
295	M m	icm eat	kid mix	78w78 k	.	.896mg * P<.006 +
a	M m	icm eat	kid adc	78w78 k	.	3.20mg * P<.2
296	M m	icm eat	kid mix	24m24 ae	.	1.69mg * P<.0005+
a	M m	icm eat	kid adc	24m24 ae	.	1.88mg * P<.0005
297	R f	sda eat	liv tum	52w52 k	.	no dre P=1. -
298	R f	sda eat	liv tum	78w78 k	.	no dre P=1. -
299	R f	sda eat	kid ade	30m30	.	15.7mg * P<.2
a	R f	sda eat	liv tum	30m30	.	no dre P=1. -
300	R m	sda eat	liv tum	52w52 k	.	no dre P=1. -
301	R m	sda eat	liv tum	78w78 k	.	no dre P=1. -
302	R m	sda eat	liv tum	30m30	.	no dre P=1. -
303	R f	wis eat	liv tum	24m24 eg	.	no dre P=1. -
304	R m	wis eat	liv tum	24m24 eg	.	no dre P=1. -
<b>METHYL CLOFENAPATE***</b>						
305	M f	aps eat	liv mix	26w78 r	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
306	M f	aps eat	liv mix	52w78 r	.	25.0mg P<.6
307	M f	aps eat	liv hpa	78w78 r	.	2.27mg Z P<.0005+
a	M f	aps eat	liv hpc	78w78 r	.	8.30mg * P<.0005+
308	M f	aps mix	liv hpc	78w78	.	13.4mg * P<.0005+
a	M f	aps mix	liv hpa	78w78	.	48.5mg * P<.2
b	M f	aps mix	liv ade	78w78	.	890.mg * P<.1
309	M m	aps eat	liv mix	26w78 r	.	2.08mg P<.02 +
310	M m	aps eat	liv mix	52w78 r	.	5.94mg P<.05 +
311	M m	aps eat	liv hpc	78w78 r	.	.858mg Z P<.0005+
a	M m	aps eat	liv hpa	78w78 r	.	2.75mg Z P<.0005+
312	M m	aps mix	liv hpc	78w78	.	16.8mg * P<.0005+
a	M m	aps mix	liv hpa	78w78	.	no dre P=1. -
b	M m	aps mix	liv ade	78w78	.	no dre P=1. -
313	R f	aap eat	liv tum	6m24	.	no dre P=1. -
314	R f	aap eat	liv tum	12m24	.	no dre P=1. -
315	R f	aap eat	liv hpc	24m24 e	.	5.88mg * P<.0005+
a	R f	aap eat	liv hpa	24m24 e	.	460.mg * P<.8
316	R m	aap eat	liv tum	6m24	.	no dre P=1. -
317	R m	aap eat	paee ade	12m24	.	1.44mg Z P<.007
a	R m	aap eat	liv tum	12m24	.	no dre P=1. -
318	R m	aap eat	liv hpc	24m24 e	.	2.87mg * P<.0005+
a	R m	aap eat	tes lya	24m24 e	.	2.93mg Z P<.002 +
b	R m	aap eat	liv hpa	24m24 e	.	17.4mg * P<.0005
c	R m	aap eat	paee ade	24m24 e	.	18.5mg * P<.03 +
<b>METHYL METHACRYLATE***</b>						
319	H f	syg inh	liv tum	73w73 e	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
a	H f	syg inh	lun tum	73w73 e	.	no dre P=1. -
320	H m	syg inh	lun pcy	78w78 e	.	3.29gm P<.3 -
a	H m	syg inh	liv tum	78w78 e	.	no dre P=1. -
321	R f	f34 inh	liv mix	24m24 e	.	4.15gm P<.3 -
a	R f	f34 inh	nre tum	24m24 e	.	no dre P=1. -
322	R m	f34 inh	nre ade	24m24 e	.	1.69gm * P<.2 -
a	R m	f34 inh	liv mix	24m24 e	.	no dre P=1. -
<b>N-METHYL-N'-NITRO-N-NITROSOGUANIDINE***</b>						
323	M f	cb6 wat	smi adc	27w52 e	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	2.03mg P<.004 +
324	M f	cb6 wat	smi adc	52w52 e	.	no dre P=1. -
<b>2-METHYLNAPHTHALENE</b>						
325	M f	b6c eat	lun mix	81w81 e	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	4.01gm * P<.8
a	M f	b6c eat	liv hpa	81w81 e	.	6.06gm * P=1. -
b	M f	b6c eat	tba mix	81w81 e	.	no dre P=1. -
326	M m	b6c eat	lun mix	81w81 e	.	205.mg \ P<.02
a	M m	b6c eat	lun a/a	81w81 e	.	735.mg * P<.3
b	M m	b6c eat	lun a/c	81w81 e	.	2.78gm * P<.3
c	M m	b6c eat	liv hpc	81w81 e	.	no dre P=1. -
d	M m	b6c eat	liv hpa	81w81 e	.	no dre P=1. -
e	M m	b6c eat	tba mix	81w81 e	.	no dre P=1. -
<b>MOLYBDENUM TRIOXIDE</b>						
327	M f	b6c inh	lun MXA	24m24	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	68.3mg * P<.02 p
a	M f	b6c inh	lun a/a	24m24	.	97.8mg * P<.06 p
b	M f	b6c inh	sub sar	24m24	.	162.mg * P<.05
c	M f	b6c inh	TBA MXB	24m24	.	no dre P=1. -
d	M f	b6c inh	liv MXB	24m24	.	4.45gm * P<.1
e	M f	b6c inh	lun MXB	24m24	.	68.3mg * P<.02
328	M m	b6c inh	lun MXA	24m24	.	3.21mg Z P<.007 p
a	M m	b6c inh	lun a/c	24m24	.	4.15mg Z P<.0005p
b	M m	b6c inh	liv hpc	24m24	.	14.8mg Z P<.04
c	M m	b6c inh	TBA MXB	24m24	.	no dre P=1. -
d	M m	b6c inh	liv MXB	24m24	.	11.7mg Z P<.1
e	M m	b6c inh	lun MXB	24m24	.	3.21mg Z P<.007
329	R f	f34 inh	mgl MXA	24m24	.	#.770mg Z P<.05 -
a	R f	f34 inh	cli MXA	24m24	.	5.04mg Z P<.04
b	R f	f34 inh	TBA MXB	24m24	.	14.0mg * P<.5
c	R f	f34 inh	liv MXB	24m24	.	no dre P=1. -
330	R m	f34 inh	lun MXA	24m24	.	21.8mg * P<.05 e

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
<b>MERCUROUS CHLORIDE (Calomel) 7546-30-7</b>											
290	2498	27.1mg	n.s.s.	9/33	21.1mg	3/14		O'Gara; canr, 28, 2272-2275; 1968			
a	2498	60.8mg	n.s.s.	0/33	21.1mg	0/14					
<b>MERCURYMETHYL CHLORIDE*** (methylmercuric chloride) 115-09-3</b>											
291	2035m	13.0ug	n.s.s.	0/6	52.0ug	0/6	.260mg	0/6	1.30mg	0/6	Hirano; jjvs, 48, 127-135; 1986/pers. comm.
292	2035n	29.2ug	n.s.s.	0/6	52.0ug	0/6	.260mg	0/6	1.30mg	0/6	
293	2035o	.363mg	n.s.s.	0/42	52.0ug	0/42	.260mg	0/42	1.30mg	0/42	
294	2035m	12.0ug	n.s.s.	0/6	48.0ug	0/6	.240mg	0/6	1.20mg	0/6	
295	2035n	.264mg	10.9mg	0/6	48.0ug	0/6	.240mg	0/6	1.20mg	3/6	
a	2035n	.520mg	n.s.s.	0/6	48.0ug	0/6	.240mg	0/6	1.20mg	1/6	
296	2035o	.802mg	4.78mg	1/26	48.0ug	0/19	.240mg	0/23	1.20mg	10/20	
a	2035o	.876mg	5.14mg	0/26	48.0ug	0/19	.240mg	0/23	1.20mg	9/20	
297	2541m	4.99ug	n.s.s.	0/6	20.0ug	0/6	.100mg	0/6	.500mg	0/6	Mitsumori; jjvs, 46, 549-557; 1984/pers. comm.
298	2541n	11.2ug	n.s.s.	0/6	20.0ug	0/6	.100mg	0/6	.500mg	0/6	
299	2541o	2.55mg	n.s.s.	0/24	20.0ug	0/24	.100mg	0/24	.500mg	1/24	
a	2541o	.125mg	n.s.s.	0/24	20.0ug	0/24	.100mg	0/24	.500mg	0/24	
300	2541m	3.99ug	n.s.s.	0/6	16.0ug	0/6	80.0ug	0/6	.400mg	0/6	
301	2541n	8.97ug	n.s.s.	0/6	16.0ug	0/6	80.0ug	0/6	.400mg	0/6	
302	2541o	99.7ug	n.s.s.	0/24	16.0ug	0/24	80.0ug	0/24	.400mg	0/24	
303	2303	20.1ug	n.s.s.	0/25	5.00ug	0/24	25.0ug	0/25	.125mg	0/25	Verschuren; txcy, 6, 107-123; 1976/1974/pers. comm.
304	2303	15.9ug	n.s.s.	0/23	4.00ug	0/25	20.0ug	0/20	.100mg	0/23	
<b>METHYL CLOFENAPATE*** 21340-68-1</b>											
305	2242m	2.33mg	n.s.s.	5/25	4.33mg	2/10					Tucker; cthf, 39-53; 1995
306	2242n	3.36mg	n.s.s.	5/25	8.67mg	3/10					
307	2242o	1.23mg	5.44mg	5/25	1.30mg	3/25	6.50mg	20/25	(13.0mg	2/25)	
a	2242o	4.81mg	16.3mg	0/25	1.30mg	1/25	6.50mg	5/25	13.0mg	13/25	
308	2242r	6.50mg	38.4mg	0/25	1.34mg	1/25	15.7mg	9/25			
a	2242r	12.6mg	n.s.s.	1/25	1.34mg	2/25	15.7mg	4/25			
b	2242r	22.9mg	n.s.s.	0/25	1.34mg	2/25	15.7mg	1/25			
309	2242m	.700mg	n.s.s.	4/25	4.00mg	6/10					
310	2242n	1.79mg	n.s.s.	4/25	8.00mg	5/10					
311	2242o	.407mg	3.14mg	1/25	1.20mg	11/25	(6.00mg	9/25	12.0mg	10/25)	
a	2242o	1.38mg	11.6mg	3/25	1.20mg	9/25	6.00mg	15/25	(12.0mg	4/25)	
312	2242r	7.55mg	66.9mg	0/25	1.27mg	1/25	14.9mg	7/25			
a	2242r	20.2mg	n.s.s.	5/25	1.27mg	2/25	14.9mg	3/25			
b	2242r	28.8mg	n.s.s.	2/25	1.27mg	1/25	14.9mg	1/25			
313	2242m	.208mg	n.s.s.	0/25	.125mg	0/10	.625mg	0/10	3.12mg	0/10	
314	2242n	13.1mg	n.s.s.	0/25	.250mg	1/10	1.25mg	0/10	6.25mg	0/10	
315	2242o	3.50mg	10.7mg	0/24	.500mg	1/24	2.50mg	4/25	12.5mg	20/24	
a	2242o	29.0mg	n.s.s.	0/24	.500mg	1/24	2.50mg	2/25	12.5mg	1/24	
316	2242m	.166mg	n.s.s.	0/25	.100mg	0/10	.500mg	0/10	2.50mg	0/10	
317	2242n	.493mg	31.2mg	2/25	.200mg	0/10	1.00mg	5/10	(5.00mg	2/10)	
a	2242n	.332mg	n.s.s.	0/25	.200mg	0/10	1.00mg	0/10	5.00mg	0/10	
318	2242o	1.70mg	5.05mg	0/24	.400mg	0/24	2.00mg	9/25	10.0mg	22/23	
a	2242o	1.41mg	13.4mg	1/24	.400mg	3/24	2.00mg	10/25	(10.0mg	9/23)	
b	2242o	8.44mg	68.7mg	0/24	.400mg	0/24	2.00mg	4/25	10.0mg	6/23	
c	2242o	6.99mg	n.s.s.	2/24	.400mg	5/24	2.00mg	6/25	10.0mg	9/23	
<b>METHYL METHACRYLATE*** 80-62-6</b>											
319	2544	1.24gm	n.s.s.	0/46	234. mg	0/52					Lomax; fctx, 35, 393-407; 1997
a	2544	1.24gm	n.s.s.	0/46	234. mg	0/52					
320	2544	536. mg	n.s.s.	0/48	206. mg	1/42					
a	2544	1.00gm	n.s.s.	0/48	206. mg	0/42					
321	2544	676. mg	n.s.s.	0/44	123. mg	1/49					
a	2544	54.0mg	n.s.s.	0/45	7.66mg	0/45	30.6mg	0/41	123. mg	0/42	
322	2544	415. mg	n.s.s.	0/44	5.36mg	0/47	21.5mg	1/48	85.8mg	1/42	
a	2544	528. mg	n.s.s.	4/49	85.8mg	2/50					
<b>N-METHYL-N'-NITRO-N-NITROSOGUANIDINE*** (MNNG) 70-25-7</b>											
323	2226m	.841mg	12.1mg	0/7	10.4mg	7/12					Ho; clet, 91, 177-183; 1995/pers. comm.
324	2226n	6.70mg	n.s.s.	0/7	10.0mg	0/13					
<b>2-METHYLNAPHTHALENE 91-57-6</b>											
325	2531	414. mg	n.s.s.	5/50	97.5mg	4/50	195. mg	6/50			Murata; faat, 36, 90-93; 1997/1993/pers. comm.
a	2531	987. mg	n.s.s.	0/50	97.5mg	1/50	195. mg	0/50			
b	2531	290. mg	n.s.s.	12/50	97.5mg	10/50	195. mg	12/50			
326	2531	88.0mg	n.s.s.	2/50	90.0mg	10/50	(180. mg	6/50)			
a	2531	243. mg	n.s.s.	2/50	90.0mg	9/50	180. mg	5/50			
b	2531	683. mg	n.s.s.	0/50	90.0mg	1/50	180. mg	1/50			
c	2531	524. mg	n.s.s.	10/50	90.0mg	6/50	180. mg	6/50			
d	2531	1.05gm	n.s.s.	9/50	90.0mg	2/50	180. mg	2/50			
e	2531	379. mg	n.s.s.	22/50	90.0mg	18/50	180. mg	13/50			
<b>MOLYBDENUM TRIOXIDE 1313-27-5</b>											
327	TR462	29.9mg	n.s.s.	3/50	3.15mg	6/50	9.44mg	8/50	31.5mg	15/50	liv: a/a, a/c.
a	TR462	36.5mg	n.s.s.	1/50	3.15mg	4/50	9.44mg	8/50	31.5mg	9/50	
b	TR462	64.7mg	n.s.s.	0/50	3.15mg	1/50	9.44mg	3/50	31.5mg	4/50	S
c	TR462	32.8mg	n.s.s.	40/50	3.15mg	39/50	9.44mg	43/50	31.5mg	40/50	
d	TR462	33.4mg	n.s.s.	23/50	3.15mg	22/50	9.44mg	25/50	31.5mg	27/50	liv: hpa, hpb, hpc.
e	TR462	29.9mg	n.s.s.	3/50	3.15mg	6/50	9.44mg	8/50	31.5mg	15/50	liv: a/a, a/c.
328	TR462	1.52mg	51.2mg	11/50	2.62mg	27/50	(7.87mg	21/50	26.2mg	18/50)	liv: a/a, a/c.
a	TR462	2.13mg	14.5mg	2/50	2.62mg	16/50	(7.87mg	14/50	26.2mg	10/50)	
b	TR462	6.23mg	n.s.s.	12/50	2.62mg	18/50	7.87mg	21/50	(26.2mg	13/50)	S
c	TR462	22.2mg	n.s.s.	40/50	2.62mg	44/50	7.87mg	45/50	26.2mg	42/50)	
d	TR462	4.28mg	n.s.s.	30/50	2.62mg	27/50	7.87mg	34/50	(26.2mg	28/50)	liv: hpa, hpb, hpc.
e	TR462	1.52mg	51.2mg	11/50	2.62mg	27/50	(7.87mg	21/50	26.2mg	18/50)	liv: a/a, a/c.
329	TR462	.312mg	n.s.s.	22/50	.749mg	33/50	(2.25mg	29/50	7.49mg	19/50)	mgl: ade, fba. S
a	TR462	2.07mg	n.s.s.	3/50	.749mg	7/50	2.25mg	10/50	(7.49mg	3/50)	cli: ade, car. S
b	TR462	2.96mg	n.s.s.	48/50	.749mg	50/50	2.25mg	49/50	7.49mg	49/50	
c	TR462	52.4mg	n.s.s.	1/50	.749mg	0/50	2.25mg	0/50	7.49mg	0/50	liv: hpa, hpb, hpc.
330	TR462	7.76mg	n.s.s.	0/50	.524mg	1/50	1.57mg	1/50	5.24mg	4/50	liv: a/a, a/c.

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	
Sex	Route	Hist	Notes		DR	AuOp	
a	R m f34	inh lun a/a	24m24		31.6mg	* P<.02	
b	R m f34	inh TBA	MXB 24m24		no dre	P=1.	
c	R m f34	inh liv	MXB 24m24		128.mg	* P<.8	
MONOMETHYLARSONIC ACID					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
331	M f b6c	eat liv hpa	24m24	e	751.mg	* P<.02 -	
a	M f b6c	eat lun a/a	24m24	e	2.19gm	* P<.7 -	
b	M f b6c	eat liv hpc	24m24	e	no dre	P=1. -	
c	M f b6c	eat lun a/c	24m24	e	no dre	P=1. -	
332	M m b6c	eat lun a/a	24m24	e	1.36gm	* P<.7 -	
a	M m b6c	eat liv hpc	24m24	e	no dre	P=1. -	
b	M m b6c	eat liv hpa	24m24	e	no dre	P=1. -	
c	M m b6c	eat lun a/c	24m24	e	no dre	P=1. -	
333	R f f34	eat liv tum	24m24	esv	no dre	P=1. -	
334	R m f34	eat --- mnl	24m24	esv	139.mg	Z P<.9 -	
a	R m f34	eat liv hpc	24m24	esv	no dre	P=1. -	
335	R m f3d	wat tes ict	24m24	e	3.36gm	* P<.02 -	
a	R m f3d	wat liv hpa	24m24	e	72.4mg	* P<.05 -	
b	R m f3d	wat ubl tcc	24m24	Ce	no dre	P=1. -	
c	R m f3d	wat tba mix	24m24	e	5.91mg	* P<.7 -	
MONOSODIUM ASPARTATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
336	R f f3d	wat liv tum	23m23		no dre	P=1. -	
a	R f f3d	wat tba mix	23m23		8.34gm	* P<.3 -	
337	R m f3d	wat liv tum	23m23		no dre	P=1. -	
a	R m f3d	wat tba mix	23m23		2.72gm	* P<.1 -	
L-MONOSODIUM GLUTAMATE***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
338	R f f3d	eat liv hpa	24m24	e	no dre	P=1. -	
339	R m f3d	eat liv hpa	24m24	e	no dre	P=1. -	
1-NAPHTHYLAMINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
340	M m icr	eat liv hpt	52w52	e	67.3mg	P<.07 +	
2-NAPHTHYLAMINE***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
341	M m icr	eat liv hpt	52w52	e	46.0mg	P<.02 +	
NITRITE, SODIUM***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
342	M f icr	wat lun tum	25m25		13.6gm	* P<.4 -	
a	M f icr	wat liv tum	25m25		no dre	P=1. -	
b	M f icr	wat tba mix	25m25		49.0gm	* P<.1 -	
343	M m icr	wat lun tum	25m25		17.4gm	* P<.7 -	
a	M m icr	wat liv tum	25m25		43.8gm	* P<.7 -	
b	M m icr	wat tba mix	25m25		no dre	P=1. -	
344	M f vms	wat bra gli	31m31	r	no dre	P=1. -	
345	M m vms	wat bra gli	26m26	r	no dre	P=1. -	
346	R m wis	wat liv tum	24m24	ej	no dre	P=1. -	
1-NITROBUTANE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
347	R m f34	gav liv tum	50w83	er	no dre	P=1. -	
2-NITROBUTANE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
348	R m f34	gav liv hpc	50w83	er	2.86mg	P<.0005+	
2-NITROFLUORENE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
349	R m wis	eat for mix	11m24	e	285mg	* P<.0005+	
a	R m wis	eat for sqc	11m24	e	1.12mg	Z P<.0005+	
b	R m wis	eat liv hpc	11m24	e	2.10mg	* P<.0005+	
c	R m wis	eat kid coc	11m24	e	2.35mg	Z P<.0005+	
d	R m wis	eat kid mix	11m24	e	3.00mg	* P<.0005+	
NITROMETHANE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
350	M f b6c	inh hag MXA	24m24		876.mg	* P<.02 c	
a	M f b6c	inh hag ade	24m24		968.mg	* P<.02 c	
b	M f b6c	inh lun MXA	24m24		1.97gm	* P<.07 p	
c	M f b6c	inh liv hpa	24m24		935.mg	* P<.2 c	
d	M f b6c	inh liv MXA	24m24		1.25gm	Z P<.3 c	
e	M f b6c	inh MXB MXB	24m24		1.81gm	* P<.6	
f	M f b6c	inh MXB MXB	24m24		2.74gm	* P<.7	
g	M f b6c	inh TBA MXB	24m24		no dre	P=1.	
h	M f b6c	inh liv MXB	24m24		1.25gm	Z P<.3	
i	M f b6c	inh lun MXB	24m24		1.97gm	* P<.07	
351	M m b6c	inh hag MXA	24m24		320.mg	* P<.0005c	
a	M m b6c	inh MXB MXB	24m24		399.mg	* P<.003	
b	M m b6c	inh hag ade	24m24		403.mg	* P<.0005c	
c	M m b6c	inh lun a/c	24m24		1.37gm	* P<.005	
d	M m b6c	inh hag car	24m24		2.11gm	* P<.03 c	
e	M m b6c	inh lun MXA	24m24		1.22gm	* P<.2 p	
f	M m b6c	inh TBA MXB	24m24		788.mg	* P<.3	
g	M m b6c	inh liv MXB	24m24		no dre	P=1.	
h	M m b6c	inh lun MXB	24m24		1.22gm	* P<.2	
352	R f f34	inh mgl MXA	24m24		40.4mg	* P<.002 c	
a	R f f34	inh mgl fba	24m24		44.1mg	* P<.003 c	
b	R f f34	inh mgl MXA	24m24		45.9mg	* P<.004	
c	R f f34	inh mgl MXA	24m24		196.mg	Z P<.03	
d	R f f34	inh mgl car	24m24		197.mg	Z P<.02 c	
e	R f f34	inh TBA MXB	24m24		168.mg	* P<.6	
f	R f f34	inh liv MXB	24m24		no dre	P=1.	
353	R m f34	inh pni isc	24m24		#138.mg	* P<.03 -	
a	R m f34	inh ski sqp	24m24		409.mg	* P<.03	
b	R m f34	inh TBA MXB	24m24		59.1mg	* P<.4	
c	R m f34	inh liv MXB	24m24		520.mg	* P<.5	

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology			Brkly Code		
a	TR462	9.53mg	n.s.s.	0/50	.524mg	0/50	1.57mg	0/50	5.24mg	3/50		S	
b	TR462	3.97mg	n.s.s.	50/50	.524mg	49/50	1.57mg	50/50	5.24mg	49/50			
c	TR462	9.85mg	n.s.s.	2/50	.524mg	2/50	1.57mg	1/50	5.24mg	3/50	liv:hpa,hpb,hpc.		
<b>MONOMETHYLARSONIC ACID 124-58-3</b>													
331	2632	259.mg	n.s.s.	0/52	1.30mg	0/52	6.50mg	0/52	26.0mg	2/52	52.0mg	2/52	Arnold;txcy,190,197-219;2003
a	2632	244.mg	n.s.s.	2/52	1.30mg	7/52	6.50mg	1/52	26.0mg	2/52	52.0mg	5/52	
b	2632	326.mg	n.s.s.	1/52	1.30mg	4/52	6.50mg	6/52	26.0mg	1/52	52.0mg	3/52	
c	2632	337.mg	n.s.s.	0/52	1.30mg	2/52	6.50mg	3/52	26.0mg	2/52	52.0mg	1/52	
332	2632	169.mg	n.s.s.	6/52	1.20mg	4/51	6.00mg	3/52	24.0mg	7/52	48.0mg	5/51	
a	2632	280.mg	n.s.s.	6/52	1.20mg	2/52	6.00mg	6/52	24.0mg	6/52	48.0mg	2/51	
b	2632	280.mg	n.s.s.	6/52	1.20mg	9/52	6.00mg	6/52	24.0mg	6/52	48.0mg	4/51	
c	2632	493.mg	n.s.s.	7/52	1.20mg	5/51	6.00mg	4/52	24.0mg	3/52	48.0mg	1/51	
333	2632	26.4mg	n.s.s.	0/60	2.50mg	0/60	20.0mg	0/60	53.2mg	0/60			
334	2632	9.91mg	n.s.s.	45/60	2.00mg	53/60	16.0mg	49/60	(42.5mg)	20/60)			
a	2632	21.1mg	n.s.s.	1/60	2.00mg	0/60	16.0mg	0/60	42.5mg	0/60			
335	2631	1.22mg	n.s.s.	35/42	2.50mg	38/42	10.0mg	44/45					Shen;txap,193,335-345;2003
a	2631	15.2mg	n.s.s.	6/42	2.50mg	12/42	10.0mg	11/45					
b	2631	69.2mg	n.s.s.	0/42	2.50mg	1/42	10.0mg	0/45					
c	2631	.396mg	n.s.s.	42/42	2.50mg	41/42	10.0mg	45/45					
<b>MONOSODIUM ASPARTATE 3792-50-5</b>													
336	2353	9.07gm	n.s.s.	0/50	1.43gm	0/50	2.86gm	0/50					Kitahori;jtxp,9,161-168;1996
a	2353	2.68gm	n.s.s.	17/50	1.43gm	23/50	2.86gm	23/50					
337	2353	7.94gm	n.s.s.	0/50	1.25gm	0/50	2.50gm	0/50					
a	2353	1.03gm	n.s.s.	31/50	1.25gm	42/50	2.50gm	38/50					
<b>L-MONOSODIUM GLUTAMATE*** 142-47-2</b>													
338	2236	30.8gm	n.s.s.	1/50	300.mg	1/50	625.mg	2/50	1.25gm	0/50	2.50gm	0/50	Shibata;fctx,33,383-391;1995
339	2236	1.34gm	n.s.s.	1/50	240.mg	0/50	500.mg	0/50	1.00gm	0/50	2.00gm	0/50	
<b>1-NAPHTHYLAMINE 134-32-7</b>													
340	2594	22.3mg	n.s.s.	2/21	120.mg	6/18							Osanai;jsol,52,179-201;1976
<b>2-NAPHTHYLAMINE*** 91-59-8</b>													
341	2594	18.0mg	n.s.s.	2/21	120.mg	8/19							Osanai;jsol,52,179-201;1976
<b>NITRITE, SODIUM*** 7632-00-0</b>													
342	2328	3.42gm	n.s.s.	3/20	250.mg	3/50	500.mg	2/50	1.00gm	8/50			Inai;gann,70,203-208;1979/pers.comm.
a	2328	12.2gm	n.s.s.	1/20	250.mg	0/50	500.mg	0/50	1.00gm	1/50			
b	2328	1.49gm	n.s.s.	10/20	250.mg	19/50	500.mg	21/50	1.00gm	22/50			
343	2328	2.57gm	n.s.s.	2/20	208.mg	6/50	417.mg	4/50	833.mg	7/50			
a	2328	5.62gm	n.s.s.	0/20	208.mg	1/50	417.mg	1/50	833.mg	1/50			
b	2328	2.00gm	n.s.s.	9/20	208.mg	23/50	417.mg	16/50	833.mg	18/50			
344	2320	8.36gm	n.s.s.	1/100	400.mg	1/100							Hawkes;huet,11,279-281;1992
345	2320	8.11gm	n.s.s.	0/100	333.mg	0/100							
346	1910m	168.mg	n.s.s.	0/17	75.0mg	0/17	150.mg	0/17					Yamamoto;clet,45,221-225;1989/1996/pers.comm.
<b>1-NITROBUTANE 627-05-4</b>													
347	2265	69.9mg	n.s.s.	0/30	17.8mg	0/30							Fiala;txcy,99,89-97;1995/pers.comm.
<b>2-NITROBUTANE 600-24-8</b>													
348	2265	1.47mg	5.50mg	0/30	17.8mg	28/30							Fiala;txcy,99,89-97;1995/pers.comm.
<b>2-NITROFLUORENE 607-57-8</b>													
349	2248	.133mg	.626mg	0/20	.917mg	16/18	3.83mg	19/19	16.3mg	20/20			Cui;carc,16,2135-2141;1995
a	2248	.650mg	2.08mg	0/20	.917mg	10/18	3.83mg	16/19	(16.3mg)	11/20)			
b	2248	1.17mg	3.90mg	0/20	.917mg	2/18	3.83mg	15/19	16.3mg	20/20			
c	2248	1.26mg	4.95mg	0/20	.917mg	1/18	3.83mg	15/19	(16.3mg)	10/20)			
d	2248	1.85mg	5.60mg	0/20	.917mg	4/18	3.83mg	17/19	16.3mg	17/20			
<b>NITROMETHANE 75-52-5</b>													
350	TR461	415.mg	n.s.s.	6/50	145.mg	9/50	288.mg	20/50	577.mg	21/50			hag:ade,car.
a	TR461	469.mg	n.s.s.	5/50	145.mg	7/50	288.mg	16/50	577.mg	19/50			
b	TR461	782.mg	n.s.s.	3/50	145.mg	6/50	288.mg	6/50	577.mg	12/50			lun:a/a,a/c.
c	TR461	343.mg	n.s.s.	14/50	145.mg	25/50	288.mg	17/50	577.mg	35/50			
d	TR461	347.mg	n.s.s.	19/50	145.mg	34/50	288.mg	22/50	577.mg	40/50			liv:hpa,hpc.
e	TR461	340.mg	n.s.s.	24/50	145.mg	36/50	288.mg	33/50	577.mg	42/50			hag:ade,car; liv:hpa,hpc. C
f	TR461	356.mg	n.s.s.	25/50	145.mg	38/50	288.mg	33/50	577.mg	42/50			hag:ade,car; liv:hpa,hpc; lun:a/a,a/c. M
g	TR461	472.mg	n.s.s.	38/50	145.mg	45/50	288.mg	43/50	577.mg	46/50			
h	TR461	347.mg	n.s.s.	19/50	145.mg	34/50	288.mg	22/50	577.mg	40/50			liv:hpa,hpb,hpc.
i	TR461	782.mg	n.s.s.	3/50	145.mg	6/50	288.mg	6/50	577.mg	12/50			lun:a/a,a/c.
351	TR461	201.mg	697.mg	10/50	120.mg	11/50	240.mg	25/50	481.mg	37/50			hag:ade,car.
a	TR461	206.mg	2.77gm	21/50	120.mg	21/50	240.mg	31/50	481.mg	39/50			hag:ade,car; lun:a/a,a/c. M
b	TR461	243.mg	1.00gm	9/50	120.mg	10/50	240.mg	19/50	481.mg	32/50			
c	TR461	665.mg	12.1gm	2/50	120.mg	3/50	240.mg	3/50	481.mg	11/50			S
d	TR461	916.mg	n.s.s.	1/50	120.mg	1/50	240.mg	6/50	481.mg	5/50			
e	TR461	436.mg	n.s.s.	13/50	120.mg	13/50	240.mg	12/50	481.mg	20/50			lun:a/a,a/c.
f	TR461	231.mg	n.s.s.	40/50	120.mg	39/50	240.mg	43/50	481.mg	46/50			
g	TR461	581.mg	n.s.s.	29/50	120.mg	24/50	240.mg	22/50	481.mg	26/50			liv:hpa,hpb,hpc.
h	TR461	436.mg	n.s.s.	13/50	120.mg	13/50	240.mg	12/50	481.mg	20/50			lun:a/a,a/c.
352	TR461	21.3mg	216.mg	21/50	17.2mg	25/50	34.5mg	34/50	68.8mg	41/50			mgl:ade,car,fb.
a	TR461	22.8mg	293.mg	19/50	17.2mg	21/50	34.5mg	33/50	68.8mg	36/50			
b	TR461	23.2mg	397.mg	20/50	17.2mg	21/50	34.5mg	33/50	68.8mg	36/50			mgl:ade,fb.
c	TR461	81.2mg	n.s.s.	4/50	17.2mg	7/50	34.5mg	1/50	68.8mg	13/50			mgl:ade,car. S
d	TR461	85.3mg	n.s.s.	2/50	17.2mg	7/50	34.5mg	1/50	68.8mg	11/50			
e	TR461	28.5mg	n.s.s.	49/50	17.2mg	50/50	34.5mg	50/50	68.8mg	50/50			
f	TR461	727.mg	n.s.s.	1/50	17.2mg	1/50	34.5mg	0/50	68.8mg	0/50			liv:hpa,hpb,hpc.
353	TR461	53.0mg	n.s.s.	1/50	12.1mg	1/50	24.1mg	3/50	48.1mg	5/50			S
a	TR461	122.mg	n.s.s.	0/50	12.1mg	0/50	24.1mg	0/50	48.1mg	3/50			S
b	TR461	14.1mg	n.s.s.	50/50	12.1mg	47/50	24.1mg	49/50	48.1mg	49/50			
c	TR461	105.mg	n.s.s.	1/50	12.1mg	1/50	24.1mg	3/50	48.1mg	2/50			liv:hpa,hpb,hpc.

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
354	R f	leb inh	liv hpc	24m24 e	.>	no dre P=1. -
355	R m	leb inh	liv hpc	24m24 e	.>	no dre P=1. -
<b>3-NITROPENTANE</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
356	R m	f34 gav	liv mix	50w83 ersv	.	2.37mg P<.0005+
a	R m	f34 gav	liv hpc	50w83 ersv	.	3.05mg P<.0005+
<b>NONABROMOBIPHENYL</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
357	M f	b6c eat	liv nnd	78w78 e	.	4.89mg * P<.0005+
a	M f	b6c eat	liv hpc	78w78 e	.	13.7mg * P<.0005+
b	M f	b6c eat	liv hpc	78w78 e	.	no dre P=1. -
c	M f	b6c eat	tba mix	78w78 e	.	4.90mg * P<.0005
358	M m	b6c eat	liv nnd	78w78 es	.	2.86mg * P<.0005+
a	M m	b6c eat	liv hpc	78w78 es	.	3.44mg \ P<.0005+
b	M m	b6c eat	liv hpc	78w78 es	.	35.4mg \ P<.004 +
c	M m	b6c eat	liv hpc	78w78 es	.	no dre P=1. -
d	M m	b6c eat	tba mix	78w78 es	.	2.07mg * P<.0005
<b>OLESTRA</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
359	M f	cd1 eat	liv hpa	24m24 e	.	259. gm * P<.3 -
a	M f	cd1 eat	liv hpa	24m24 e	.	661. gm * P<.9 -
360	M f	cd1 eat	liv hpa	24m24 e	.	196. gm P<.6 -
a	M f	cd1 eat	liv hpa	24m24 e	.	214. gm P<.3 -
361	M m	cd1 eat	liv hpa	24m24 e	.	50.9 gm * P<.1 -
a	M m	cd1 eat	liv hpa	24m24 e	.	266. gm * P<.8 -
362	M m	cd1 eat	liv hpa	24m24 e	.	116. gm P<.4 -
a	M m	cd1 eat	liv hpa	24m24 e	.	341. gm P<.8 -
363	R f	f34 eat	pit ade	24m24 e	.	± 6.66gm * P<.04 -
a	R f	f34 eat	liv hpa	24m24 e	.	50.3 gm P<.04 -
364	R f	f34 eat	liv hpa	24m24 e	.	58.6 gm P<.05 -
365	R m	f34 eat	pit ade	24m24 e	.	10.1 gm * P<.08 -
a	R m	f34 eat	liv hpa	24m24 e	.	123. gm P<.3 -
366	R m	f34 eat	liv hpa	24m24 e	.	no dre P=1. -
<b>OLTIPRAZ***</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
367	R f	cdr gav	liv tum	52w52 e	.	no dre P=1. -
368	R m	cdr gav	liv tum	52w52 e	.	no dre P=1. -
<b>OXAZEPAM***</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
369	R f	f34 eat	--- mnl	24m24	.	#114. mg Z P<.002 -
a	R f	f34 eat	TBA MXB	24m24	.	170. mg Z P<.3 -
b	R f	f34 eat	liv MXB	24m24	.	no dre P=1. -
370	R f	f34 eat	TBA MXB	6m24	.	no dre P=1. -
a	R f	f34 eat	liv MXB	6m24	.	no dre P=1. -
371	R m	f34 eat	tes MXA	23m23	.	#27.4 mg * P<.0005-
a	R m	f34 eat	--- mnl	23m23	.	79.1 mg * P<.005
b	R m	f34 eat	thy MXA	23m23	.	336. mg * P<.02
c	R m	f34 eat	kid rua	23m23	.	500. mg * P<.05
d	R m	f34 eat	TBA MXB	23m23	.	50.4 mg * P<.002
e	R m	f34 eat	liv MXB	23m23 C	.	1.79 gm * P<.2
372	R m	f34 eat	kid rua	23m23	.	1.01 gm * P<.03 e
373	R m	f34 eat	tes MXA	6m24	.	#16.9 mg P<.0005-
a	R m	f34 eat	--- mnl	6m24	.	31.0 mg P<.0005
b	R m	f34 eat	kid rua	6m24	.	no dre P=1. -
c	R m	f34 eat	TBA MXB	6m24	.	27.5 mg P<.004
d	R m	f34 eat	liv MXB	6m24 C	.	no dre P=1. -
374	R m	f34 eat	kid rua	6m24	.	779. mg P<.2 e
<b>PALONIDIPINE.HCl</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
375	R f	f34 eat	liv tum	24m24 e	.	no dre P=1. -
376	R m	f34 eat	--- mnl	24m24 e	.	no dre P=1. -
a	R m	f34 eat	liv hpa	24m24 e	.	no dre P=1. -
<b>PERHEXILINE MALEATE</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
377	R f	sda eat	liv tum	52w52 e	.	no dre P=1. -
378	R f	sda eat	liv tum	52w56 e	.	no dre P=1. -
379	R m	sda eat	liv tum	52w52 e	.	no dre P=1. -
380	R m	sda eat	liv tum	52w56 e	.	no dre P=1. -
<b>PHENOBARBITAL***</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
381	M m	b6c eat	liv hpc	96w96	.	20.4 mg P<.0005+
a	M m	b6c eat	liv mix	96w96	.	21.1 mg P<.0005+
b	M m	b6c eat	liv mix	96w96	.	no dre P=1. -
382	M m	d2b eat	liv hpa	26m26 ex	.	42.4 mg P<.0005+
a	M m	d2b eat	liv mix	26m26 ex	.	42.4 mg P<.0005+
b	M m	d2b eat	liv hpc	26m26 ex	.	101. mg P<.0005+
c	M m	d2b eat	liv hpc	26m26 ex	.	199. mg P<.02 +
383	R m	f34 eat	liv hpa	72w72	.	115. mg P<.3
384	R m	f34 eat	liv tum	78w78 e	.	no dre P=1. -
<b>PHENOLPHTHALEIN***</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
385	M m	bal eat	liv hpt	14m24	.	20.8 gm P<.2 -
a	M m	bal eat	liv hpt	14m24	.	no dre P=1. -
386	M m	c56 gav	liv hpt	16m24	.	no dre P=1. -
a	M m	c56 gav	liv hpt	16m24	.	no dre P=1. -
<b>(E)-7-PHENYL-7-(3-PYRIDYL)-6-HEPTENOIC ACID</b>						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
387	M f	cd1 eat	liv hpa	24m24 e	.	4.93 gm P<.3 -
a	M f	cd1 eat	liv hpa	24m24 e	.	no dre P=1. -
b	M f	cd1 eat	liv hpa	24m24 e	.	no dre P=1. -
c	M f	cd1 eat	liv hpa	24m24 e	.	no dre P=1. -
388	M m	cd1 eat	liv hpa	24m24 e	.	1.22 gm P<.06 -
a	M m	cd1 eat	liv hpa	24m24 e	.	2.05 gm P<.4 -



RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
354	2297	120.mg n.s.s.	0/40	21.8mg	0/40	43.6mg	0/40	Griffin;eas,34,109-117;1996/pers.comm.		
355	2297	266.mg n.s.s.	1/40	15.3mg	1/40	30.5mg	0/40			
3-NITROPENTANE 551-88-2										
356	2265	1.29mg 4.46mg	0/30	12.5mg	27/30			Fiala;txcy,99,89-97;1995/pers.comm.		
a	2265	1.73mg 5.67mg	0/30	12.5mg	25/30					
NONABROMOBIPHENYL (bromkal 80-9D) 27753-52-2										
357	2436	3.44mg 7.05mg	0/49	13.0mg	33/46	39.0mg	45/49	Momma;jjpt,14,5541-5563;1986		
a	2436	9.39mg 21.0mg	0/49	13.0mg	8/46	39.0mg	37/49			
b	2436	182.mg n.s.s.	3/49	13.0mg	1/46	39.0mg	1/49			
c	2436	3.37mg 7.40mg	4/49	13.0mg	35/46	39.0mg	45/49			
358	2436	1.70mg 5.29mg	19/50	12.0mg	48/49	36.0mg	44/46			
a	2436	2.13mg 6.22mg	7/50	12.0mg	38/49	(36.0mg)	13/46			
b	2436	14.4mg 212.mg	0/50	12.0mg	6/49	(36.0mg)	1/46			
c	2436	42.1mg n.s.s.	5/50	12.0mg	2/49	(36.0mg)	0/46			
d	2436	1.11mg 4.18mg	23/50	12.0mg	49/49	36.0mg	45/46			
OLESTRA 121854-29-3										
359	2154m	65.5gm n.s.s.	1/50	3.25gm	1/49	6.50gm	1/51		Lafranconi;fctx,32,789-798;1994/pers.comm.	
a	2154m	29.4gm n.s.s.	7/50	3.25gm	13/50	6.50gm	11/50			13.0gm
360	2154n	33.6gm n.s.s.	5/50	13.0gm	7/50					
a	2154n	47.1gm n.s.s.	1/50	13.0gm	3/50					
361	2154m	18.9gm n.s.s.	9/50	3.00gm	8/49	6.00gm	10/50	12.0gm		15/49
a	2154m	25.1gm n.s.s.	13/50	3.00gm	14/50	6.00gm	9/50	12.0gm		15/50
362	2154n	25.8gm n.s.s.	6/50	12.0gm	9/50					
a	2154n	29.3gm n.s.s.	8/50	12.0gm	9/50					
363	2037m	2.84gm n.s.s.	18/51	495.mg	29/48	2.38gm	35/52	4.54gm		30/50
a	2037m	15.2gm n.s.s.	0/51	4.54gm	3/50					
364	2037n	17.7gm n.s.s.	0/58	4.54gm	3/58					
365	2037m	3.88gm n.s.s.	18/50	396.mg	17/50	1.90gm	14/50	3.64gm		27/50
a	2037m	20.1gm n.s.s.	0/50	3.64gm	1/50					
366	2037n	18.4gm n.s.s.	2/50	3.64gm	2/50					
OLTIPRAZ*** (5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione) 64224-21-1										
367	2523	8.59mg n.s.s.	0/25	10.0mg	0/25	30.0mg	0/25	Crowell;faat,35,9-21;1997		
368	2523	8.59mg n.s.s.	0/25	10.0mg	0/25	30.0mg	0/25		60.0mg	0/25
OXAZEPAM*** 604-75-1										
369	TR468	57.8mg 575.mg	14/50	31.3mg	19/50	125.mg	29/50	(250.mg)	18/50	
a	TR468	46.2mg n.s.s.	49/50	31.3mg	49/50	125.mg	45/50	(250.mg)	38/50	
b	TR468	n.s.s. n.s.s.	0/50	31.3mg	0/50	125.mg	0/50	250.mg	0/50	
370	TR468a	75.0mg n.s.s.	49/50	124.mg	43/50				liv:hpa,hpb,hpc.	
a	TR468a	n.s.s. n.s.s.	0/50	124.mg	0/50				liv:hpa,hpb,hpc.	
371	TR468	16.6mg 56.3mg	45/50	25.0mg	48/50	100.mg	49/50	200.mg	47/50	
a	TR468	36.1mg 926.mg	27/50	25.0mg	36/50	100.mg	33/50	200.mg	19/50	
b	TR468	116.mg n.s.s.	4/50	25.0mg	3/50	100.mg	4/50	200.mg	6/50	
c	TR468	142.mg n.s.s.	1/50	25.0mg	0/50	100.mg	3/50	200.mg	1/50	
d	TR468	25.5mg 225.mg	47/50	25.0mg	45/50	100.mg	44/50	200.mg	32/50	
e	TR468	293.mg n.s.s.	2/50	25.0mg	0/50	100.mg	0/50	200.mg	3/50	
372	TR468	434.mg n.s.s.	2/50	25.0mg	1/50	100.mg	7/50	200.mg	6/50	
373	TR468a	8.32mg 52.9mg	45/50	101.mg	48/50				tes:iab,ica. S	
a	TR468a	14.3mg 115.mg	27/50	101.mg	34/50				S	
b	TR468a	62.0mg n.s.s.	1/50	101.mg	0/50					
c	TR468a	11.8mg 237.mg	47/50	101.mg	42/50					
d	TR468a	91.6mg n.s.s.	2/50	101.mg	1/50				liv:hpa,hpb,hpc.	
374	TR468a	241.mg n.s.s.	2/50	101.mg	6/50					
PALONIDIPINE.HCL (TC-81) ---										
375	2440	4.77mg n.s.s.	0/50	.670mg	0/50	2.00mg	0/50	Hamada;clnr,26,3075-3096;1992		
376	2440	9.51mg n.s.s.	18/50	.670mg	22/50	2.00mg	28/50		6.00mg	19/50
a	2440	51.5mg n.s.s.	2/50	.670mg	2/50	2.00mg	3/50		6.00mg	0/50
PERHEXILINE MALEATE (2-(2-DICYCLOHEXYLETHYL) PIPERIDINE MALEATE) 6724-53-4										
377	2404m	23.6mg n.s.s.	0/16	50.0mg	0/16	100.mg	0/16	Nagata;phrm,20,541-566;1980	0/16	
378	2404n	12.6mg n.s.s.	0/8	46.2mg	0/8	92.3mg	0/8		185.mg	0/8
379	2404m	23.6mg n.s.s.	0/16	50.0mg	0/16	100.mg	0/16		200.mg	0/16
380	2404n	12.6mg n.s.s.	0/8	46.2mg	0/8	92.3mg	0/8		185.mg	0/8
PHENOBARBITAL*** (phenobarbitone) 50-06-6										
381	2398	12.3mg 37.4mg	10/46	60.0mg	43/50			Nitta;jtxp,4,55-61;1991/pers.comm.		
a	2398	12.5mg 40.2mg	12/46	60.0mg	43/50					
b	2398	184.mg n.s.s.	9/46	60.0mg	7/50					
382	2227	21.0mg 161.mg	9/29	60.0mg	23/30			Diwan;clet,89,29-35;1995/pers.comm.		
a	2227	21.0mg 161.mg	9/29	60.0mg	23/30					
b	2227	50.1mg 250.mg	0/29	60.0mg	11/30					
c	2227	78.1mg n.s.s.	1/29	60.0mg	7/30					
383	2322	18.7mg n.s.s.	0/18	20.0mg	1/18			Diwan;carc,17,37-43;1996		
384	2535	64.9mg n.s.s.	0/28	20.0mg	0/28				Allen;carc,18,1103-1107;1997/pers.comm.	
PHENOLPHTHALEIN*** 77-09-8										
385	2498m	3.38gm n.s.s.	0/33	2.25gm	1/14			O'Gara;canr,28,2272-2275;1968		
a	2498m	2.89gm n.s.s.	9/33	2.25gm	3/14					
386	2498n	1.97gm n.s.s.	2/26	637.mg	0/15					
a	2498n	1.97gm n.s.s.	0/26	637.mg	0/15					
(E)-7-PHENYL-7-(3-PYRIDYL)-6-HEPTENOIC ACID (CV-4151, isbogrel) 89667-40-3										
387	2438	1.09gm n.s.s.	1/50	300.mg	3/50			Chatani;jjpt,23,1205-1223;1995/pers.comm.		
a	2438	722.mg n.s.s.	15/50	300.mg	13/50					
b	2438	1.88gm n.s.s.	1/50	300.mg	1/50					
c	2438	410.mg n.s.s.	36/50	300.mg	31/50					
388	2438	460.mg n.s.s.	5/50	300.mg	12/50					
a	2438	527.mg n.s.s.	8/50	300.mg	12/50					

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
b	M m	cd1 eat	liv hpc	24m24 e	10.2gm	P<.3 -
c	M m	cd1 eat	lun a/c	24m24 e	no dre	P=1. -
d	M m	cd1 eat	tba mix	24m24 e	1.09gm	P<.4 -
389	R f	cdr eat	liv hpa	24m24 e	.>	no dre P=1. -
390	R m	cdr eat	liv hpa	24m24 e	.>	no dre P=1. -
PHENYLETHYL-3-METHYLCAFFEATE					100ng...1ug...10...100...1mg...10...100...1g...10	
391	R m	f34 eat	col tum	55w55 r	.>	no dre P=1. -
6-PHENYLHEXYL ISOTHIOCYANATE***					100ng...1ug...10...100...1mg...10...100...1g...10	
392	R m	f34 eat	col tum	55w55 r	.>	no dre P=1. -
o-PHENYLPHENOL***					100ng...1ug...10...100...1mg...10...100...1g...10	
393	M m	b6c eat	liv hpa	52w52 e	.>	4.52gm * P<.3 -
a	M m	b6c eat	kid tum	52w52 e		no dre P=1. -
b	M m	b6c eat	lun ade	52w52 e		no dre P=1. -
o-PHENYLPHENOL, SODIUM***					100ng...1ug...10...100...1mg...10...100...1g...10	
394	R f	f3d eat	ubl mix	24m25 e	±	5.08gm * P<.02 +
a	R f	f3d eat	ubl tcc	24m25 e		26.0gm * P<.3 -
395	R f	f3d eat	ubl mix	24m29 e		±8.82gm * P<.08 +
a	R f	f3d eat	ubl tcc	24m29 e		17.8gm * P<.3 -
396	R m	f3d eat	ubl mix	24m25 e		442.mg / P<.0005+
a	R m	f3d eat	ubl tcc	24m25 e		461.mg / P<.0005
397	R m	f3d eat	ubl mix	24m28 e		610.mg Z P<.0005+
a	R m	f3d eat	ubl tcc	24m28 e		789.mg Z P<.0005
PhIP.HCl***					100ng...1ug...10...100...1mg...10...100...1g...10	
398	R f	sdf eat	mg1 mix	52w52 v	+	.826mg P<.0005+
a	R f	sdf eat	col adc	52w52 v		13.7mg P<.2 -
PIRMENOL.HCl					100ng...1ug...10...100...1mg...10...100...1g...10	
399	M f	b6c eat	--- lym	24m24 e	+	94.6mg Z P<.009 -
a	M f	b6c eat	liv hpc	24m24 e		978.mg * P<.3 -
b	M f	b6c eat	liv hpa	24m24 e		1.56gm * P<.6 -
c	M f	b6c eat	lun ade	24m24 e		1.98gm * P<.6 -
d	M f	b6c eat	lun car	24m24 e		no dre P=1. -
e	M f	b6c eat	tba mix	24m24 e		no dre P=1. -
400	M m	b6c eat	lun ade	24m24 e	.>	947.mg * P<.6 -
a	M m	b6c eat	lun car	24m24 e		4.04gm * P<.7 -
b	M m	b6c eat	liv hpc	24m24 e		no dre P=1. -
c	M m	b6c eat	liv hpa	24m24 e		no dre P=1. -
d	M m	b6c eat	tba mix	24m24 e		no dre P=1. -
401	R f	wis eat	pit ade	24m24 e	+	15.9mg Z P<.0005-
a	R f	wis eat	liv tum	24m24 e		no dre P=1. -
b	R f	wis eat	tba mix	24m24 e		440.mg * P<.9 -
402	R m	wis eat	adr coa	24m24 e	±	104.mg Z P<.05 -
a	R m	wis eat	liv tum	24m24 e		no dre P=1. -
b	R m	wis eat	tba mix	24m24 e		no dre P=1. -
PRACTOLOL					100ng...1ug...10...100...1mg...10...100...1g...10	
403	M f	aps mix	lun tum	78w78 e	.>	no dre P=1. -
a	M f	aps mix	liv tum	78w78 e		no dre P=1. -
404	M m	aps mix	lun tum	78w78 e	.>	383.mg * P<.4 -
a	M m	aps mix	liv tum	78w78 e		24.3gm * P<1. -
405	R f	aap eat	liv tum	24m24 e	.>	no dre P=1. -
406	R m	aap eat	pit tum	24m24 e	+	23.9mg \ P<.006 -
a	R m	aap eat	tes tum	24m24 e		194.mg * P<.004 -
b	R m	aap eat	liv tum	24m24 e		no dre P=1. -
FRANLUKAST HYDRATE					100ng...1ug...10...100...1mg...10...100...1g...10	
407	R f	sjd gav	liv tum	52w52 e	.>	no dre P=1. -
408	R f	sjd gav	liv tum	52w56 e	.>	no dre P=1. -
409	R m	sjd gav	liv tum	52w52 e	.>	no dre P=1. -
410	R m	sjd gav	liv nnd	52w56 e	.>	no dre P=1. -
SX PURPLE***					100ng...1ug...10...100...1mg...10...100...1g...10	
411	R f	sls eat	liv tum	52w52 e	.>	no dre P=1. -
a	R f	sls eat	tba mix	52w52 e		no dre P=1. -
412	R m	sls eat	liv tum	52w52 e	.>	no dre P=1. -
a	R m	sls eat	tba mix	52w52 e		no dre P=1. -
PURPURIN					100ng...1ug...10...100...1mg...10...100...1g...10	
413	R m	f34 eat	ubl mal	74w74 e	+	678.mg P<.007 +
a	R m	f34 eat	ubl tcc	74w74 e		865.mg P<.02 +
b	R m	f34 eat	ubl sqc	74w74 e		3.68gm P<.3 -
QUINAPRIL.HCl					100ng...1ug...10...100...1mg...10...100...1g...10	
414	M f	b6c gav	pit ade	24m24	+	128.mg Z P<.01 -
a	M f	b6c gav	liv hpc	24m24		966.mg * P<.04 -
b	M f	b6c gav	lun ade	24m24		5.07gm * P<.8 -
c	M f	b6c gav	liv hpa	24m24		no dre P=1. -
d	M f	b6c gav	tba mix	24m24		8.16gm * P<1. -
415	M m	b6c gav	liv hpa	24m24 s	.>	623.mg * P<.3 -
a	M m	b6c gav	liv hpc	24m24 s		1.64gm * P<.6 -
b	M m	b6c gav	lun ade	24m24 s		2.79gm * P<.9 -
c	M m	b6c gav	lun car	24m24 s		2.81gm * P<.4 -
d	M m	b6c gav	tba mix	24m24 s		221.mg * P<.3 -
416	R f	wis gav	liv mix	24m24 s	.>	no dre P=1. -
a	R f	wis gav	tba mix	24m24 s		no dre P=1. -
417	R m	wis gav	liv mix	24m24 s	.>	no dre P=1. -
a	R m	wis gav	tba mix	24m24 s		no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	2438	1.66gm	n.s.s.	0/50	300.mg	1/50			
c	2438	1.52gm	n.s.s.	2/50	300.mg	2/50			
d	2438	288.mg	n.s.s.	21/50	300.mg	26/50			
389	2437	1.03gm	n.s.s.	0/50	100.mg	0/50		Chatani;jjpt,23,1225-1238;1995/pers.comm.	
390	2437	1.03gm	n.s.s.	3/50	100.mg	0/50			
PHENYLETHYL-3-METHYLCAFFEATE ---									
391	2413	20.7mg	n.s.s.	0/12	30.0mg	0/12		Rao;canr,55,2310-2315;1995	
6-PHENYLHEXYL ISOTHIOCYANATE*** 133920-06-6									
392	2412	17.7mg	n.s.s.	0/12	25.6mg	0/12		Rao;canr,55,4311-4318;1995	
o-PHENYLPHENOL*** (ortho-xenol, Dowicide 1) 90-43-7									
393	2454	1.56gm	n.s.s.	0/20	780.mg	1/20	1.56gm	2/20	3.12gm 1/20
a	2454	459.mg	n.s.s.	0/20	780.mg	0/20	1.56gm	0/20	3.12gm 0/20
b	2454	459.mg	n.s.s.	1/20	780.mg	0/20	1.56gm	0/20	3.12gm 0/20
o-PHENYLPHENOL, SODIUM*** (o-phenylphenate, sodium) 132-27-4									
394	2457m	1.93gm	n.s.s.	0/50	245.mg	1/50	491.mg	4/50	
a	2457m	4.24gm	n.s.s.	0/50	245.mg	0/50	491.mg	1/50	
395	2457n	2.17gm	n.s.s.	0/25	117.mg	0/25	222.mg	0/24	423.mg 2/25
a	2457n	2.91gm	n.s.s.	0/25	117.mg	0/25	222.mg	0/24	423.mg 1/25
396	2457m	304.mg	669.mg	0/50	275.mg	2/50	785.mg	47/50	
a	2457m	316.mg	699.mg	0/50	275.mg	2/50	785.mg	46/50	
397	2457n	370.mg	1.09gm	0/25	86.0mg	0/25	255.mg	3/25	800.mg 23/25
a	2457n	465.mg	1.47gm	0/25	86.0mg	0/25	255.mg	1/25	800.mg 21/25
PhIP.HCl*** (2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine.HCl) ---									
398	2525	.462mg	1.80mg	1/18	5.53mg	21/30			
a	2525	3.38mg	n.s.s.	0/18	5.53mg	2/30			Weisburger;jepo,16,329-334;1997
PIRMENOL.HCl (cis-(+)-alpha-[3-(2,6-dimethyl-1-piperidiny)propyl]-alpha-phenyl-2-pyridinemethanol.HCl) 61477-94-9									
399	2414	46.6mg	3.02gm	3/65	11.1mg	11/65	27.7mg	13/65	(55.4mg 3/65)
a	2414	255.mg	n.s.s.	2/65	11.1mg	3/65	27.7mg	2/65	55.4mg 5/65
b	2414	254.mg	n.s.s.	5/65	11.1mg	3/65	27.7mg	4/65	55.4mg 6/65
c	2414	312.mg	n.s.s.	2/65	11.1mg	2/65	27.7mg	3/65	55.4mg 3/65
d	2414	611.mg	n.s.s.	4/65	11.1mg	0/65	27.7mg	1/65	55.4mg 2/65
e	2414	81.7mg	n.s.s.	36/65	11.1mg	36/65	27.7mg	41/65	55.4mg 34/65
400	2414	156.mg	n.s.s.	8/65	11.1mg	11/65	27.7mg	10/65	55.4mg 11/65
a	2414	484.mg	n.s.s.	1/65	11.1mg	0/65	27.7mg	2/65	55.4mg 1/65
b	2414	318.mg	n.s.s.	15/65	11.1mg	15/65	27.7mg	13/65	55.4mg 8/65
c	2414	189.mg	n.s.s.	14/65	11.1mg	18/65	27.7mg	21/65	55.4mg 11/65
d	2414	64.9mg	n.s.s.	46/65	11.1mg	45/65	27.7mg	50/65	55.4mg 43/65
401	2414	9.66mg	37.9mg	14/50	11.1mg	36/50	27.7mg	36/50	(55.4mg 32/50)
a	2414	617.mg	n.s.s.	0/50	11.1mg	1/50	27.7mg	0/50	55.4mg 0/50
b	2414	28.1mg	n.s.s.	40/50	11.1mg	43/50	27.7mg	46/50	55.4mg 41/50
402	2414	44.2mg	n.s.s.	3/50	11.1mg	9/50	27.7mg	10/50	(55.4mg 3/50)
a	2414	239.mg	n.s.s.	1/50	11.1mg	3/50	27.7mg	5/50	55.4mg 1/50
b	2414	113.mg	n.s.s.	33/50	11.1mg	36/50	27.7mg	36/50	55.4mg 25/50
PRACTOLOL (eraldin) 6673-35-4									
403	2358m	104.mg	n.s.s.	2/24	20.0mg	5/24	100.mg	3/25	
a	2358m	217.mg	n.s.s.	0/24	20.0mg	1/24	100.mg	0/25	
404	2358m	85.7mg	n.s.s.	2/25	20.0mg	2/23	100.mg	4/24	
a	2358m	130.mg	n.s.s.	4/25	20.0mg	1/23	100.mg	3/24	
405	2358n	68.1mg	n.s.s.	0/20	20.0mg	0/20	100.mg	0/19	
406	2358n	9.97mg	293.mg	1/20	16.0mg	8/20	(80.0mg 1/20)		
a	2358n	79.0mg	1.55gm	0/20	16.0mg	1/20	80.0mg	5/20	
b	2358n	55.0mg	n.s.s.	0/20	16.0mg	0/20	80.0mg	0/20	
FRANLUKAST HYDRATE (ONO-1078 HYDRATE) 150821-03-7									
407	2388m	1.03gm	n.s.s.	0/19	1.00gm	0/20			
408	2388n	276.mg	n.s.s.	0/5	923.mg	0/5			
409	2388m	979.mg	n.s.s.	0/19	1.00gm	0/19			
410	2388n	276.mg	n.s.s.	1/5	923.mg	0/5			Yonezawa;phrm,44,219-242;1992
SX PURPLE*** (ponceau 4R, food red no. 102) 2611-82-7									
411	2601	1.03gm	n.s.s.	0/20	1.00gm	0/20			
a	2601	617.mg	n.s.s.	1/20	1.00gm	1/20			
412	2601	824.mg	n.s.s.	0/20	800.mg	0/20			
a	2601	824.mg	n.s.s.	1/20	800.mg	0/20			Sekigawa;jnma,30,179-191;1979
PURPURIN 81-54-9									
413	2264	257.mg	7.89gm	0/28	400.mg	5/27			
a	2264	298.mg	n.s.s.	0/28	400.mg	4/27			
b	2264	599.mg	n.s.s.	0/28	400.mg	1/27			Mori;clet,102,193-198;1996/pers.comm.
QUINAPRIL.HCl 82586-55-8									
414	2330	54.5mg	12.2gm	3/50	5.00mg	4/50	35.0mg	11/50	(75.0mg 2/50)
a	2330	334.mg	n.s.s.	0/50	5.00mg	0/50	35.0mg	2/50	75.0mg 2/50
b	2330	435.mg	n.s.s.	4/50	5.00mg	0/50	35.0mg	1/50	75.0mg 3/50
c	2330	631.mg	n.s.s.	3/50	5.00mg	6/50	35.0mg	3/50	75.0mg 1/50
d	2330	89.7mg	n.s.s.	26/50	5.00mg	29/50	35.0mg	31/50	75.0mg 27/50
415	2330	175.mg	n.s.s.	8/50	5.00mg	5/50	35.0mg	5/50	75.0mg 11/50
a	2330	265.mg	n.s.s.	4/50	5.00mg	3/50	35.0mg	4/50	75.0mg 5/50
b	2330	203.mg	n.s.s.	3/50	5.00mg	11/50	35.0mg	9/50	75.0mg 7/50
c	2330	510.mg	n.s.s.	1/50	5.00mg	0/50	35.0mg	0/50	75.0mg 2/50
d	2330	67.3mg	n.s.s.	24/50	5.00mg	26/50	35.0mg	23/50	75.0mg 31/50
416	2330	103.mg	n.s.s.	0/65	10.0mg	0/65	50.0mg	0/65	100.mg 0/65
a	2330	98.2mg	n.s.s.	55/65	10.0mg	53/65	50.0mg	52/65	100.mg 52/65
417	2330	1.22gm	n.s.s.	1/65	10.0mg	1/65	50.0mg	0/65	100.mg 1/65
a	2330	334.mg	n.s.s.	43/65	10.0mg	41/65	50.0mg	40/65	100.mg 29/65

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	
Sex	Route	Hist			DR	AuOp	
RAMOSETRON.HCl					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
418	M f	b6c	gav	liv hpc 24m24 e	.	1.04gm P<.2 -	
a	M f	b6c	gav	liv hpa 24m24 e		no dre P=1. -	
b	M f	b6c	gav	liv ade 24m24 e		no dre P=1. -	
c	M f	b6c	gav	liv car 24m24 e		no dre P=1. -	
419	M m	b6c	gav	liv hpa 24m24 e	.	no dre P=1. -	
a	M m	b6c	gav	liv ade 24m24 e		no dre P=1. -	
b	M m	b6c	gav	liv hpc 24m24 e		no dre P=1. -	
c	M m	b6c	gav	liv car 24m24 e		no dre P=1. -	
420	R f	f34	gav	liv hpa 24m24 e	.	no dre P=1. -	
421	R m	f34	gav	liv hpa 24m24 e	.	no dre P=1. -	
FD & C RED NO. 2***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
422	R f	sda	eat	liv tum 52w52 e	.	no dre P=1. -	
a	R f	sda	eat	tba tum 52w52 e		no dre P=1. -	
FD & C RED NO. 3***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
423	R f	sda	eat	liv tum 52w52 e	.	no dre P=1. -	
a	R f	sda	eat	tba tum 52w52 e		no dre P=1. -	
424	R f	sls	eat	liv tum 52w52 e	.	no dre P=1. -	
a	R f	sls	eat	tba mix 52w52 e		no dre P=1. -	
425	R m	sls	eat	liv tum 52w52 e	.	no dre P=1. -	
a	R m	sls	eat	tba mix 52w52 e		no dre P=1. -	
FOOD RED NO. 106					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
426	R f	f3d	eat	liv tum 25m25 e	.	no dre P=1. -	
a	R f	f3d	eat	tba mix 25m25 e		4.10gm * P<.2 -	
427	R m	f3d	eat	liv nnd 25m25 e		no dre P=1. -	
a	R m	f3d	eat	tba mix 25m25 e		2.35gm * P<.6 -	
RETINOIC ACID***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
428	M f	swn	gav	liv tum 52w52 e	.	no dre P=1. -	
a	M f	swn	gav	liv ade 52w52 e		no dre P=1. -	
429	M m	swn	gav	liv tum 52w52 e	.	no dre P=1. -	
a	M m	swn	gav	liv ade 52w52 e		no dre P=1. -	
RETINOL PALMITATE***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
430	M m	icr	wat	for tum 66w66 er	.	no dre P=1. -	
RETRORSINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
431	R m	wis	wat	liv hpt 24m24 r	.	.862mg P<.03 +	
SACCHARIN, SODIUM***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
432	R m	f34	eat	ubl tum 72w72 r	.	no dre P=1. -	
SALICYLAZOSULFAPYRIDINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
433	M f	b6c	gav	liv MXA 24m24	.	1.03gm Z P<.02 c	
a	M f	b6c	gav	liv hpa 24m24		2.20gm * P<.02	
b	M f	b6c	gav	liv hpc 24m24		5.43gm * P<.06	
c	M f	b6c	gav	TBA MXB 24m24		5.98gm * P<.6	
d	M f	b6c	gav	liv MXB 24m24		1.03gm Z P<.02	
e	M f	b6c	gav	liv MXB 24m24		41.3gm * P<.7	
434	M m	b6c	gav	liv hpa 24m24	.	1.58gm Z P<.004 c	
a	M m	b6c	gav	liv MXA 24m24		2.62gm * P<.2 c	
b	M m	b6c	gav	TBA MXB 24m24		no dre P=1. -	
c	M m	b6c	gav	liv MXB 24m24		2.62gm * P<.2	
d	M m	b6c	gav	liv MXB 24m24		no dre P=1. -	
435	R f	f34	gav	MXB MXB 24m24	.	2.22gm * P<.04	
a	R f	f34	gav	kid tpp 24m24		4.26gm * P<.06 p	
b	R f	f34	gav	ubl tpp 24m24		+hist 4.72gm * P<.4 p	
c	R f	f34	gav	TBA MXB 24m24		no dre P=1. -	
d	R f	f34	gav	liv MXB 24m24		8.65gm * P<.6	
436	R m	f34	gav	ubl tpp 24m24	.	974.mg * P<.0005p	
a	R m	f34	gav	TBA MXB 24m24		447.mg * P<.4	
b	R m	f34	gav	liv MXB 24m24		no dre P=1. -	
437	R m	f34	gav	TBA MXB 6m24	.	144.mg P<.5 -	
a	R m	f34	gav	liv MXB 6m24		no dre P=1. -	
SCOPOLAMINE HYDROBROMIDE TRIHYDRATE					.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
438	M f	b6c	gav	TBA MXB 24m24	.	no dre P=1. -	
a	M f	b6c	gav	liv MXB 24m24		no dre P=1. -	
b	M f	b6c	gav	liv MXB 24m24		no dre P=1. -	
439	M m	b6c	gav	TBA MXB 24m24	.	no dre P=1. -	
a	M m	b6c	gav	liv MXB 24m24		no dre P=1. -	
b	M m	b6c	gav	liv MXB 24m24		no dre P=1. -	
440	R f	f34	gav	TBA MXB 24m24	.	312.mg * P<.1 -	
a	R f	f34	gav	liv MXB 24m24		no dre P=1. -	
441	R m	f34	gav	TBA MXB 24m24	.	no dre P=1. -	
a	R m	f34	gav	liv MXB 24m24		no dre P=1. -	
SELENIUM DIOXIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
442	M f	c3s	wat	mgl adc 24m24 Ler	.	no dre P=1. -	
443	M f	c3s	wat	mgl adc 24m25 Laer	.	no dre P=1. -	
SODIUM BICARBONATE***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
444	M m	b6c	wat	liv hpa 52w52 e	.	1.33gm P<.04 -	
STEVIOSIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
445	R f	f3d	eat	liv tum 24m25 e	.	no dre P=1. -	
a	R f	f3d	eat	tba mix 24m25 e		34.4gm * P<.9 -	
446	R m	f3d	eat	liv hpc 24m25 e	.	101.gm * P<.9 -	
a	R m	f3d	eat	liv hpa 24m25 e		no dre P=1. -	
b	R m	f3d	eat	tba mix 24m25 e		no dre P=1. -	

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
RAMOSETRON.HCl (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole.HCl 132907-72-3									
418	2419	314.mg n.s.s.	6/132	100.mg		100.mg	7/66	Tabata;arzn,46,560-566;1996	
a	2419	504.mg n.s.s.	18/132	100.mg		100.mg	7/66		
b	2419	1.36gm n.s.s.	4/132	100.mg		100.mg	0/66		
c	2419	1.36gm n.s.s.	2/132	100.mg		100.mg	0/66		
419	2419	235.mg n.s.s.	54/132	100.mg		100.mg	25/66		
a	2419	370.mg n.s.s.	24/132	100.mg		100.mg	11/66		
b	2419	543.mg n.s.s.	16/132	100.mg		100.mg	6/66		
c	2419	904.mg n.s.s.	3/132	100.mg		100.mg	1/66		
420	2419	869.mg n.s.s.	4/114	100.mg		100.mg	1/60		
421	2419	863.mg n.s.s.	4/120	100.mg		100.mg	1/60		
FD & C RED NO. 2*** (amaranth) 915-67-3									
422	2600	1.03gm n.s.s.	0/20	1.00gm	0/20			Sekigawa;jnma,29,709-721;1978	
a	2600	1.03gm n.s.s.	1/20	1.00gm	0/20				
FD & C RED NO. 3*** (erythrosine) 16423-68-0									
423	2600	1.03gm n.s.s.	0/20	1.00gm	0/20			Sekigawa;jnma,29,709-721;1978	
a	2600	1.03gm n.s.s.	1/20	1.00gm	0/20				
424	2601	1.03gm n.s.s.	0/20	1.00gm	0/20			Sekigawa;jnma,30,179-191;1979	
a	2601	617.mg n.s.s.	1/20	1.00gm	1/20				
425	2601	824.mg n.s.s.	0/20	800.mg	0/20				
a	2601	824.mg n.s.s.	1/20	800.mg	0/20				
FOOD RED NO. 106 (C.I. No. 45100, Red 106) 3520-42-1									
426	2376	8.13gm n.s.s.	0/47	1.25gm	0/47	2.50gm	0/43	Konishi;jtxp,5,157-165;1992/pers.comm.	
a	2376	1.51gm n.s.s.	28/47	1.25gm	26/47	2.50gm	33/43		
427	2376	21.8gm n.s.s.	3/48	1.00gm	0/45	2.00gm	1/48		
a	2376	363.mg n.s.s.	45/48	1.00gm	45/45	2.00gm	46/48		
RETINOIC ACID*** (vitamin A acid) 302-79-4									
428	2597	2.51mg n.s.s.	0/12	9.00mg	0/7	18.0mg	0/12	Yamamoto;jnma,27,437-451;1976	
a	2597	2.51mg n.s.s.	1/12	9.00mg	0/7	18.0mg	0/12		
429	2597	3.71mg n.s.s.	0/12	9.00mg	0/12	18.0mg	0/12		
a	2597	3.71mg n.s.s.	2/12	9.00mg	0/12	18.0mg	0/12		
RETINOL PALMITATE*** (vitamin A, palmitate) 79-81-2									
430	2415	3.49mg n.s.s.	0/28	1.50mg	0/28			Yamada;surg,25,729-736;1995	
RETRORSINE 480-54-6									
431	1871	.292mg n.s.s.	0/7	.643mg	4/10			Schoental;bjca,8,458-465;1954	
SACCHARIN, SODIUM*** 128-44-9									
432	2298	5.73gm n.s.s.	0/23	2.00gm	0/29			Ogawa;carc,17,961-965;1996/pers.comm.	
SALICYLAZOSULFAPYRIDINE 599-79-1									
433	TR457	490.mg n.s.s.	14/50	477.mg	32/50	954.mg	28/50 (1.91gm 29/50)	liv:hpa,hpc.	
a	TR457	999.mg n.s.s.	12/50	477.mg	28/50	954.mg	25/50 (1.91gm 28/50)		S
b	TR457	2.23gm n.s.s.	2/50	477.mg	10/50	954.mg	10/50 (1.91gm 9/50)		
c	TR457	1.16gm n.s.s.	34/50	477.mg	37/50	954.mg	42/50 (1.91gm 36/50)		
d	TR457	490.mg n.s.s.	14/50	477.mg	32/50	954.mg	28/50 (1.91gm 29/50)	liv:hpa,hpb,hpc.	
e	TR457	5.51gm n.s.s.	3/50	477.mg	4/50	954.mg	4/50 (1.91gm 4/50)	lun:a/a,a/c.	
434	TR457	807.mg 12.4gm	13/50	476.mg	32/50	952.mg	28/50 (1.90gm 42/50)		
a	TR457	953.mg n.s.s.	24/50	476.mg	38/50	952.mg	38/50 (1.90gm 44/50)	liv:hpa,hpc.	
b	TR457	1.52gm n.s.s.	40/50	476.mg	45/50	952.mg	41/50 (1.90gm 45/50)		
c	TR457	953.mg n.s.s.	24/50	476.mg	38/50	952.mg	38/50 (1.90gm 44/50)	liv:hpa,hpb,hpc.	
d	TR457	5.23gm n.s.s.	14/50	476.mg	18/50	952.mg	15/50 (1.90gm 11/50)	lun:a/a,a/c.	
435	TR457	765.mg n.s.s.	0/50	59.1mg	0/50	118.mg	2/50 (238.mg 2/50)	kid:tp; ubl:tp. P	
a	TR457	1.05gm n.s.s.	0/50	59.1mg	0/50	118.mg	0/50 (238.mg 2/50)		
b	TR457	1.15gm n.s.s.	0/50	59.1mg	0/50	118.mg	2/50 (238.mg 0/50)		
c	TR457	182.mg n.s.s.	44/50	59.1mg	41/50	118.mg	47/50 (238.mg 31/50)		
d	TR457	1.41gm n.s.s.	0/50	59.1mg	0/50	118.mg	1/50 (238.mg 0/50)	liv:hpa,hpb,hpc.	
436	TR457	439.mg 3.35gm	0/50	59.2mg	0/50	118.mg	2/50 (238.mg 6/50)		
a	TR457	111.mg n.s.s.	42/50	59.2mg	43/50	118.mg	43/50 (238.mg 38/50)	liv:hpa,hpb,hpc.	
b	TR457	1.53gm n.s.s.	2/50	59.2mg	1/50	118.mg	1/50 (238.mg 0/50)		
437	TR457a	29.3mg n.s.s.	42/50	60.2mg	41/50			liv:hpa,hpb,hpc.	
a	TR457a	376.mg n.s.s.	2/50	60.2mg	0/50				
SCOPOLAMINE HYDROBROMIDE TRIHYDRATE 6533-68-2									
438	TR445	30.2mg n.s.s.	40/51	.714mg	36/50	3.57mg	35/50 (17.9mg 29/51)	liv:hpa,hpb,hpc.	
a	TR445	7.28mg n.s.s.	22/51	.714mg	21/50	3.57mg	16/50 (17.9mg 9/51)	lun:a/a,a/c.	
b	TR445	82.9mg n.s.s.	4/51	.714mg	7/50	3.57mg	2/50 (17.9mg 3/51)		
439	TR445	4.81mg n.s.s.	43/50	.714mg	41/50	3.57mg	31/50 (17.9mg 29/50)	liv:hpa,hpb,hpc.	
a	TR445	55.8mg n.s.s.	30/50	.714mg	33/50	3.57mg	13/50 (17.9mg 15/50)	lun:a/a,a/c.	
b	TR445	55.4mg n.s.s.	15/50	.714mg	11/50	3.57mg	10/50 (17.9mg 8/50)		
440	TR445	9.88mg n.s.s.	48/50	.714mg	23/60	3.57mg	39/50 (17.9mg 31/50)	liv:hpa,hpb,hpc.	
a	TR445	103.mg n.s.s.	1/50	.714mg	0/60	3.57mg	0/50 (17.9mg 0/50)	liv:hpa,hpb,hpc.	
441	TR445	2.24mg n.s.s.	47/50	.714mg	48/50	3.57mg	46/50 (17.9mg 41/50)		
a	TR445	62.5mg n.s.s.	2/50	.714mg	3/50	3.57mg	2/50 (17.9mg 2/50)	liv:hpa,hpb,hpc.	
SELENIUM DIOXIDE (selenite) 7446-08-4									
442	2367	1.78mg n.s.s.	12/29	.562mg	5/30			Schrauzer;bnch,9,245-253;1978	
443	2369	3.11mg n.s.s.	22/30	.400mg	3/30	1.00mg	10/28 (3.00mg 15/46)	Schrauzer;ancl,4,441-447;1974/1976	
SODIUM BICARBONATE*** 144-55-8									
444	2455	401.mg n.s.s.	0/20	1.33gm	3/19			Fujii;tmrl,40,298-306;1989/pers.comm.	
STEVIOSIDE 57817-89-7									
445	2553	8.26gm n.s.s.	0/49	1.20gm	0/46	2.41gm	0/47	Toyoda;fctx,35,597-603;1997	
a	2553	1.68gm n.s.s.	37/49	1.20gm	37/46	2.41gm	36/47		
446	2553	16.4gm n.s.s.	0/49	963.mg	1/48	1.93gm	0/47		
a	2553	11.6gm n.s.s.	5/49	963.mg	3/48	1.93gm	3/47		
b	2553	163.mg n.s.s.	49/49	963.mg	47/48	1.93gm	47/47		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpv1
Sex	Route	Hist			DR	AuOp
<b>SUXIBUZONE</b>						
447	R f	f3d eat	liv tum	24m24	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
448	R m	f3d eat	adr phe	24m24		471.mg Z P<.02 -
a	R m	f3d eat	liv hpa	24m24		no dre P=1. -
b	R m	f3d eat	liv hpc	24m24		no dre P=1. -
<b>T-2 TOXIN</b>						
449	M f	cd1 eat	lun adc	71w71 e	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	1.53mg \ P<.1
a	M f	cd1 eat	lun ade	71w71 e		2.63mg * P<.5
b	M f	cd1 eat	liv hpc	71w71 e		9.31mg * P=1. -
c	M f	cd1 eat	liv hpa	71w71 e		no dre P=1. -
450	M m	cd1 eat	liv hpa	71w71 e		.883mg * P<.05 +
a	M m	cd1 eat	lun ade	71w71 e		.771mg * P<.2 +
b	M m	cd1 eat	lun adc	71w71 e		10.6mg * P<.8
c	M m	cd1 eat	liv hpc	71w71 e		no dre P=1. -
<b>TALTIRELIN TETRAHYDRATE</b>						
451	M f	cd1 gav	lun car	24m24 e	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	1.01gm P<.5 -
a	M f	cd1 gav	liv mix	24m24 e		2.08gm P<.6 -
b	M f	cd1 gav	lun ade	24m24 e		no dre P=1. -
452	M m	cd1 gav	liv hpa	24m24 e		796.mg P<.6 -
a	M m	cd1 gav	liv hpc	24m24 e		no dre P=1. -
b	M m	cd1 gav	lun ade	24m24 e		no dre P=1. -
c	M m	cd1 gav	lun car	24m24 e		no dre P=1. -
453	R f	cdr gav	liv hpa	94w94 e		no dre P=1. -
454	R m	cdr gav	liv hpa	90w90 e		2.61gm * P<.3 -
<b>TAURINE</b>						
455	R f	wis eat	mgl fba	78w78	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
456	R m	wis eat	mgl fba	78w78		no dre P=1. -
<b>TEGAFUR</b>						
457	M f	cb7 gav	liv tum	52w84 e	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
a	M f	cb7 gav	tba mix	52w84 e		no dre P=1. -
458	M m	cb7 gav	liv tum	52w86 e		no dre P=1. -
a	M m	cb7 gav	tba mix	52w86 e		no dre P=1. -
459	R f	wis gav	liv tum	12m27 e		no dre P=1. -
a	R f	wis gav	tba mix	12m27 e		no dre P=1. -
460	R m	wis gav	liv tum	12m29 e		no dre P=1. -
a	R m	wis gav	tba mix	12m29 e		no dre P=1. -
<b>TELONE II, TECHNICAL GRADE (WITHOUT EPICHLOROHYDRIN)</b>						
461	M f	b6c inh	lun tum	52w52 k	10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
462	M f	b6c inh	pit ade	24m24		19.0mg Z P<.02 -
a	M f	b6c inh	liv mix	24m24		1.81gm * P<.8 -
b	M f	b6c inh	lun a/a	24m24		no dre P=1. -
c	M f	b6c inh	mln lys	24m24		no dre P=1. -
d	M f	b6c inh	tba mix	24m24		no dre P=1. -
463	M m	b6c inh	lun tum	52w52 k		no dre P=1. -
464	M m	b6c inh	lun a/a	24m24		118.mg * P<.0005+
a	M m	b6c inh	lcg cye	24m24		82.2mg Z P<.02
b	M m	b6c inh	liv mix	24m24		no dre P=1. -
c	M m	b6c inh	tba mix	24m24		229.mg * P<.5
465	R f	f34 inh	tba tum	52w52 k		no dre P=1. -
466	R f	f34 inh	liv hpa	24m24		1.59gm * P<.7 -
a	R f	f34 inh	tba mix	24m24		no dre P=1. -
467	R m	f34 inh	tba tum	52w52 k		no dre P=1. -
468	R m	f34 inh	liv hpa	24m24		no dre P=1. -
a	R m	f34 inh	tba mix	24m24		no dre P=1. -
<b>1,1,1,2-TETRAFLUOROETHANE</b>						
469	M f	b6c inh	liv hpa	24m24 e	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre P=1. -
a	M f	b6c inh	lun abt	24m24 e		no dre P=1. -
b	M f	b6c inh	liv hpc	24m24 e		no dre P=1. -
470	M m	b6c inh	liv hpc	24m24 e		260.gm * P<.5 -
a	M m	b6c inh	liv hpa	24m24 e		1.50kg P<.9 -
b	M m	b6c inh	lun abt	24m24 e		no dre P=1. -
471	R m	aap inh	tes lya	52w52 k		no dre P=1. -
472	R m	aap inh	tes lya	24m24		29.9gm * P<.0005+
473	R f	whb inh	liv hpc	25m25 e		2.80kg P<.1 -
474	R m	whb inh	liv hpc	25m25 e		140.gm * P<.1 -
a	R m	whb inh	liv hpa	25m25 e		70.1gm * P<.2 -
b	R m	whb inh	tes ict	25m25 e		no dre P=1. -
<b>TETRAFLUOROETHYLENE</b>						
475	M f	b6c inh	MXB MXB	95w95	100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	54.0mg Z P<.0005
a	M f	b6c inh	--- MXA	95w95		61.3mg Z P<.0005
b	M f	b6c inh	liv MXA	95w95		61.3mg Z P<.0005c
c	M f	b6c inh	liv MXA	95w95		63.3mg Z P<.0005c
d	M f	b6c inh	liv hes	95w95		66.5mg Z P<.0005c
e	M f	b6c inh	--- hes	95w95		66.5mg Z P<.0005
f	M f	b6c inh	liv hpc	95w95		80.8mg Z P<.0005c
g	M f	b6c inh	--- hcs	95w95		176.mg Z P<.0005c
h	M f	b6c inh	liv hpa	95w95		217.mg Z P<.0005
i	M f	b6c inh	liv hem	95w95		530.mg Z P<.0005c
j	M f	b6c inh	--- hem	95w95		835.mg Z P<.0005
k	M f	b6c inh	pit pda	95w95		1.45gm * P<.006
l	M f	b6c inh	hag ade	95w95		1.47gm * P<.002
m	M f	b6c inh	lun MXA	95w95		1.64gm * P<.03
n	M f	b6c inh	TBA MXB	95w95		48.4mg Z P<.0005
o	M f	b6c inh	liv MXB	95w95		63.3mg Z P<.0005
p	M f	b6c inh	lun MXB	95w95		1.01gm Z P<.02
476	M m	b6c inh	MXB MXB	95w95		71.6mg Z P<.0005

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology			Brkly Code	
<b>SUXIBUZONE 27470-51-5</b>												
447	2439	172. mg n.s.s.	0/50	31.2mg	0/50	62.5mg	0/50	125. mg	0/50	250. mg	0/50	Inoue;iyke,18,345-359;1987
448	2439	211. mg n.s.s.	6/50	25.0mg	2/50	50.0mg	1/50	100. mg	15/50	(200. mg	8/50)	
a	2439	2.96gm n.s.s.	1/50	25.0mg	0/50	50.0mg	1/50	100. mg	0/50	200. mg	0/50	
b	2439	2.27gm n.s.s.	0/50	25.0mg	0/50	50.0mg	1/50	100. mg	0/50	200. mg	0/50	
<b>T-2 TOXIN (FUSARIOTOXIN T-2) 21259-20-1</b>												
449	2357	.375mg n.s.s.	0/50	.195mg	2/50	(.390mg	0/50)		Schiefer;fctx,25,593-601;1987			
a	2357	.563mg n.s.s.	3/50	.195mg	5/50	.390mg	5/50					
b	2357	1.52mg n.s.s.	0/50	.195mg	1/50	.390mg	0/50					
c	2357	1.05mg n.s.s.	2/50	.195mg	2/50	.390mg	2/50					
450	2357	.362mg n.s.s.	3/46	.180mg	3/50	.360mg	10/48					
a	2357	.295mg n.s.s.	4/40	.180mg	7/47	.360mg	11/48					
b	2357	.975mg n.s.s.	2/40	.180mg	0/47	.360mg	3/48					
c	2357	1.23mg n.s.s.	1/46	.180mg	1/50	.360mg	1/48					
<b>TALTIRELIN TETRAHYDRATE ---</b>												
451	2519	182. mg n.s.s.	3/58	50.0mg	5/60			Yamura;jtxs,22,II,419-430;1997				
a	2519	274. mg n.s.s.	1/58	50.0mg	2/60							
b	2519	338. mg n.s.s.	3/58	50.0mg	2/60							
452	2519	141. mg n.s.s.	6/60	50.0mg	8/58							
a	2519	317. mg n.s.s.	6/60	50.0mg	3/58							
b	2519	268. mg n.s.s.	9/60	50.0mg	5/58							
c	2519	250. mg n.s.s.	13/60	50.0mg	7/58							
453	2519	1.87gm n.s.s.	0/55	20.0mg	1/55	60.0mg	0/55	200. mg	0/55			
454	2519	789. mg n.s.s.	0/55	20.0mg	0/55	60.0mg	2/55	200. mg	1/55			
<b>TAURINE 107-35-7</b>												
455	2382	2.03gm n.s.s.	2/9	250. mg	1/7	2.50gm	0/7	Takahashi;phrm,6,529-534;1972				
456	2382	1.00gm n.s.s.	2/9	200. mg	1/7	2.00gm	1/7					
<b>TEGAFUR (Ftorafur, N1-2-FURAMIDYL-5-FLUOROURACIL) 37076-68-9</b>												
457	2545	38.8mg n.s.s.	0/29	7.03mg	0/41			Griciute;ponr,2,69-70;1996/pers.comm.				
a	2545	15.9mg n.s.s.	6/29	7.03mg	5/41							
458	2545	32.9mg n.s.s.	0/32	6.86mg	0/34							
a	2545	32.9mg n.s.s.	3/32	6.86mg	0/34							
459	2545	51.7mg n.s.s.	0/25	7.62mg	0/26							
a	2545	37.0mg n.s.s.	3/25	7.62mg	1/26							
460	2545	62.2mg n.s.s.	0/28	7.09mg	0/29							
a	2545	22.0mg n.s.s.	8/28	7.09mg	6/29							
<b>TELONE II, TECHNICAL GRADE (WITHOUT EPICHLOROHYDRIN) (1,3-dichloropropene) 542-75-6</b>												
461	2458m	2.76mg n.s.s.	0/10	7.13mg	0/10	28.5mg	0/10	85.6mg	0/10	Lomax;faat,12,418-431;1989/pers.comm.		
462	2458n	8.35mg n.s.s.	6/50	7.13mg	16/50	(28.5mg	11/50	85.6mg	7/50)			
a	2458n	206. mg n.s.s.	10/50	7.13mg	7/50	28.5mg	9/50	85.6mg	10/50			
b	2458n	384. mg n.s.s.	4/50	7.13mg	3/50	28.5mg	5/50	85.6mg	3/50			
c	2458n	294. mg n.s.s.	3/50	7.13mg	11/50	28.5mg	5/50	85.6mg	6/50			
d	2458n	96.6mg n.s.s.	39/50	7.13mg	40/50	28.5mg	36/50	85.6mg	36/50			
463	2458m	2.30mg n.s.s.	0/10	5.95mg	0/10	23.8mg	0/10	71.3mg	0/10			
464	2458n	62.9mg 426. mg	9/50	5.95mg	6/50	23.8mg	13/50	71.3mg	22/50			
a	2458n	37.4mg 19.8gm	1/50	5.95mg	6/50	23.8mg	9/50	(71.3mg	4/50)			
b	2458n	281. mg n.s.s.	25/50	5.95mg	22/50	23.8mg	16/50	71.3mg	14/50			
c	2458n	48.3mg n.s.s.	32/50	5.95mg	34/50	23.8mg	35/50	71.3mg	36/50			
465	2458m	.656mg n.s.s.	0/10	1.70mg	0/10	6.79mg	0/10	20.4mg	0/10			
466	2458n	142. mg n.s.s.	1/50	1.70mg	0/50	6.79mg	1/50	20.4mg	1/50			
a	2458n	19.6mg n.s.s.	45/50	1.70mg	46/50	6.79mg	43/50	20.4mg	41/50			
467	2458m	.459mg n.s.s.	0/10	1.19mg	0/10	4.76mg	0/10	14.3mg	0/10			
468	2458n	138. mg n.s.s.	3/50	1.19mg	3/50	4.76mg	3/50	14.3mg	0/50			
a	2458n	3.47mg n.s.s.	49/50	1.19mg	48/50	4.76mg	50/50	14.3mg	48/50			
<b>1,1,1,2-TETRAFLUOROETHANE (fluorocarbon 134a, HCFC 134a) 811-97-2</b>												
469	2417	119. gm n.s.s.	8/120	765. mg	1/60	4.59gm	6/60	23.0gm	3/60	Alexander;huet,14,706-714;1995		
a	2417	136. gm n.s.s.	3/120	765. mg	4/60	4.59gm	4/60	23.0gm	2/60			
b	2417	188. gm n.s.s.	4/120	765. mg	0/60	4.59gm	2/60	23.0gm	1/60			
470	2417	48.9gm n.s.s.	16/120	638. mg	6/60	3.83gm	12/60	19.1gm	10/60			
a	2417	61.3gm n.s.s.	18/120	638. mg	11/60	3.83gm	9/60	19.1gm	10/60			
b	2417	65.0gm n.s.s.	23/120	638. mg	11/60	3.83gm	7/60	19.1gm	11/60			
471	2355m	217. mg n.s.s.	0/10	549. mg	0/10	2.19gm	0/10	11.0gm	0/10	Collins;faat,25,271-280;1995		
472	2355n	15.1gm 127. gm	9/75	549. mg	7/69	2.19gm	12/75	11.0gm	23/75			
473	2417	35.6gm n.s.s.	2/120	182. mg	1/60	729. mg	0/60	3.64gm	1/60	Alexander;huet,14,706-714;1995		
474	2417	22.9gm n.s.s.	0/120	128. mg	0/60	510. mg	0/60	2.55gm	1/60			
a	2417	17.2gm n.s.s.	0/120	128. mg	0/60	510. mg	1/60	2.55gm	1/60			
b	2417	37.1gm n.s.s.	1/120	128. mg	2/60	510. mg	0/60	2.55gm	0/60			
<b>TETRAFLUOROETHYLENE 116-14-3</b>												
475	TR450	29.2mg 109. mg	18/48	400. mg	45/48	(801. mg	45/48	1.60gm	44/48)	---:hcs; liv:hcm,hes,hpa,hpc. C		
a	TR450	30.4mg 122. mg	0/48	400. mg	31/48	(801. mg	28/48	1.60gm	35/48)	---:hem,hes. S		
b	TR450	30.4mg 122. mg	0/48	400. mg	31/48	(801. mg	28/48	1.60gm	35/48)	liv:hcm,hes. S		
c	TR450	32.2mg 144. mg	17/48	400. mg	33/48	(801. mg	29/48	1.60gm	28/48)	liv:hpa,hpc. S		
d	TR450	31.6mg 141. mg	0/48	400. mg	27/48	(801. mg	27/48	1.60gm	34/48)			
e	TR450	31.6mg 141. mg	0/48	400. mg	27/48	(801. mg	27/48	1.60gm	34/48)			
f	TR450	40.6mg 176. mg	4/48	400. mg	28/48	(801. mg	22/48	1.60gm	20/48)			
g	TR450	85.8mg 376. mg	1/48	400. mg	21/48	(801. mg	19/48	1.60gm	18/48)			
h	TR450	111. mg 577. mg	15/48	400. mg	17/48	801. mg	20/48	(1.60gm	15/48)	S		
i	TR450	164. mg 2.64gm	0/48	400. mg	5/48	(801. mg	2/48	1.60gm	1/48)			
j	TR450	347. mg 2.69gm	0/48	400. mg	5/48	801. mg	4/48	(1.60gm	1/48)	S		
k	TR450	547. mg 26.4gm	4/48	400. mg	5/48	801. mg	2/48	1.60gm	6/48)	S		
l	TR450	542. mg 10.8gm	2/48	400. mg	3/48	801. mg	0/48	1.60gm	6/48)	S		
m	TR450	554. mg n.s.s.	6/48	400. mg	1/48	801. mg	8/48	1.60gm	4/48)	lun:a/a,a/c,car. S		
n	TR450	26.3mg 104. mg	34/48	400. mg	47/48	(801. mg	45/48	1.60gm	46/48)			
o	TR450	32.2mg 144. mg	17/48	400. mg	33/48	(801. mg	29/48	1.60gm	28/48)	liv:hpa,hpb,hpc.		
p	TR450	324. mg n.s.s.	6/48	400. mg	0/48	801. mg	8/48	(1.60gm	4/48)	lun:a/a,a/c.		
476	TR450	45.3mg 123. mg	26/48	334. mg	42/48	669. mg	48/48	(1.34gm	46/48)	---:hcs; liv:hcm,hes,hpa,hpc. C		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	M m	b6c inh liv	MXA 95w95		87.0mg	* P<.0005c
b	M m	b6c inh ---	MXA 95w95		88.3mg	* P<.0005
c	M m	b6c inh liv	MXA 95w95		91.0mg	Z P<.0005c
d	M m	b6c inh liv	hes 95w95		108.mg	* P<.0005c
e	M m	b6c inh ---	hes 95w95		109.mg	* P<.0005
f	M m	b6c inh liv	hpc 95w95		190.mg	Z P<.0005c
g	M m	b6c inh lun	MXA 95w95		216.mg	Z P<.0005
h	M m	b6c inh liv	hpa 95w95		222.mg	* P<.0005
i	M m	b6c inh ---	hem 95w95		297.mg	Z P<.0005
j	M m	b6c inh liv	hem 95w95		308.mg	Z P<.0005c
k	M m	b6c inh lun	a/a 95w95		348.mg	Z P<.0005
l	M m	b6c inh ---	hcs 95w95		429.mg	Z P<.0005c
m	M m	b6c inh lun	MXA 95w95		830.mg	* P<.005
n	M m	b6c inh thy	MXA 95w95		988.mg	* P<.01
o	M m	b6c inh hag	MXA 95w95		1.27gm	* P<.04
p	M m	b6c inh hag	ade 95w95		1.39gm	* P<.05
q	M m	b6c inh thy	fca 95w95		1.44gm	* P<.03
r	M m	b6c inh TBA	MXB 95w95		69.9mg	Z P<.0005
s	M m	b6c inh liv	MXB 95w95		91.0mg	Z P<.0005
t	M m	b6c inh lun	MXB 95w95		220.mg	Z P<.0005
477	R f	f34 inh MXB	MXB 24m24	: + :	56.3mg	Z P<.0005
a	R f	f34 inh liv	MXA 24m24		156.mg	Z P<.0005c
b	R f	f34 inh ---	mnl 24m24		228.mg	Z P<.0005c
c	R f	f34 inh liv	hpc 24m24		251.mg	Z P<.0005c
d	R f	f34 inh liv	hpa 24m24		528.mg	* P<.002 c
e	R f	f34 inh liv	hes 24m24		886.mg	Z P<.005 c
f	R f	f34 inh ---	hes 24m24		886.mg	Z P<.005
g	R f	f34 inh kid	MXA 24m24		958.mg	* P<.008
h	R f	f34 inh TBA	MXB 24m24		287.mg	* P<.2
i	R f	f34 inh liv	MXB 24m24		156.mg	Z P<.0005
478	R f	f34 inh kid	MXA 24m24	with step	1.31gm	* P<.0005c
a	R f	f34 inh kid	rua 24m24		1.51gm	* P<.002
b	R f	f34 inh kid	ruc 24m24		7.38gm	* P<.03
479	R m	f34 inh tes	MXA 24m24	: + :	27.5mg	Z P<.0005e
a	R m	f34 inh ---	mnl 24m24		59.7mg	* P<.01 e
b	R m	f34 inh liv	MXA 24m24		81.6mg	* P<.002 c
c	R m	f34 inh liv	hpc 24m24		163.mg	* P<.003 c
d	R m	f34 inh kid	MXA 24m24		242.mg	* P<.002
e	R m	f34 inh kid	MXA 24m24		292.mg	* P<.01
f	R m	f34 inh liv	hpa 24m24		136.mg	* P<.02
g	R m	f34 inh TBA	MXB 24m24		35.4mg	Z P<.0005
h	R m	f34 inh liv	MXB 24m24		81.6mg	* P<.002
480	R m	f34 inh kid	MXA 24m24	with step	334.mg	* P<.0005
a	R m	f34 inh kid	MXA 24m24		367.mg	* P<.003 c
TETRAHYDROFURAN					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
481	M f	b6c inh liv	MXA 24m24		1.30gm	* P<.003 c
a	M f	b6c inh liv	hpa 24m24		1.72gm	* P<.005
b	M f	b6c inh sub	sar 24m24		14.1gm	* P<.02
c	M f	b6c inh TBA	MXB 24m24		3.60gm	* P<.5
d	M f	b6c inh liv	MXB 24m24		1.30gm	* P<.003
e	M f	b6c inh lun	MXB 24m24		12.5gm	* P<.4
482	M m	b6c inh TBA	MXB 24m24		2.93gm	* P<.6 -
a	M m	b6c inh liv	MXB 24m24		3.17gm	* P<.5
b	M m	b6c inh lun	MXB 24m24		no dre	P=1.
483	R f	f34 inh TBA	MXB 24m24		3.44gm	* P<.9 -
a	R f	f34 inh liv	MXB 24m24		no dre	P=1.
484	R m	f34 inh tes	MXA 24m24	: ±	40.1mg	Z P<.03
a	R m	f34 inh kid	MXA 24m24		407.mg	* P<.03 p
b	R m	f34 inh mgl	fbn 24m24		629.mg	* P<.05
c	R m	f34 inh TBA	MXB 24m24		369.mg	* P<.5
d	R m	f34 inh liv	MXB 24m24		no dre	P=1.
THEOPHYLLINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
485	M f	b6c gav ---	hcs 24m24	: ±	#20.5mg	Z P<.02 -
a	M f	b6c gav TBA	MXB 24m24		no dre	P=1.
b	M f	b6c gav liv	MXB 24m24		no dre	P=1.
c	M f	b6c gav lun	MXB 24m24		no dre	P=1.
486	M m	b6c gav TBA	MXB 24m24	:>	no dre	P=1. -
a	M m	b6c gav liv	MXB 24m24		no dre	P=1.
b	M m	b6c gav lun	MXB 24m24		no dre	P=1.
487	R f	f34 gav TBA	MXB 24m24	:>	no dre	P=1. -
a	R f	f34 gav liv	MXB 24m24		no dre	P=1.
488	R m	f34 gav TBA	MXB 24m24	:>	no dre	P=1. -
a	R m	f34 gav liv	MXB 24m24		no dre	P=1.
THIABENDAZOLE***					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
489	M m	b6c eat liv	hpa 52w52 e		390.mg	P<.1 -
THIAMPHENICOL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
490	R f	f3d wat liv	tum 24m25 e	:>	no dre	P=1. -
a	R f	f3d wat tba	tum 24m25 e		43.2mg	* P<.4 -
491	R m	f3d wat liv	hpa 24m25 e	:>	683.mg	* P<.5 -
a	R m	f3d wat tba	tum 24m25 e		noTD50	P=1. -
TILISOLOL.HCl					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
492	M f	cd1 gav lun	ade 80w80 e	:>	843.mg	* P<.9 -
a	M f	cd1 gav lun	adc 80w80 e		no dre	P=1. -
b	M f	cd1 gav liv	tum 80w80 e		no dre	P=1. -
c	M f	cd1 gav tba	mix 80w80 e		no dre	P=1. -
493	M m	cd1 gav lun	adc 80w80 e	: ±	99.2mg	* P<.03 -
a	M m	cd1 gav liv	hpa 80w80 e		131.mg	* P<.3 -
b	M m	cd1 gav lun	ade 80w80 e		7.20gm	* P<.1. -



RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	TR450	56.3mg	136.mg	0/48	334.mg	26/48	669.mg	30/48 1.34gm	38/48
b	TR450	56.7mg	142.mg	2/48	334.mg	27/48	669.mg	30/48 1.34gm	38/48
c	TR450	54.7mg	171.mg	26/48	334.mg	34/48	669.mg	39/48 (1.34gm)	35/48
d	TR450	69.6mg	170.mg	0/48	334.mg	21/48	669.mg	27/48 1.34gm	37/48
e	TR450	69.6mg	176.mg	2/48	334.mg	21/48	669.mg	27/48 1.34gm	37/48
f	TR450	113.mg	361.mg	11/48	334.mg	20/48	669.mg	33/48 (1.34gm)	26/48
g	TR450	110.mg	577.mg	12/48	334.mg	13/48	669.mg	16/48 (1.34gm)	7/48
h	TR450	118.mg	520.mg	17/48	334.mg	17/48	669.mg	12/48 1.34gm	20/48
i	TR450	143.mg	669.mg	0/48	334.mg	11/48	669.mg	6/48 (1.34gm)	3/48
j	TR450	146.mg	722.mg	0/48	334.mg	10/48	669.mg	5/48 (1.34gm)	2/48
k	TR450	159.mg	1.33gm	10/48	334.mg	8/48	669.mg	13/48 (1.34gm)	5/48
l	TR450	223.mg	868.mg	0/48	334.mg	12/48	669.mg	7/48 (1.34gm)	7/48
m	TR450	307.mg	10.7gm	2/48	334.mg	5/48	669.mg	3/48 1.34gm	2/48
n	TR450	325.mg	73.6gm	0/48	334.mg	4/48	669.mg	0/48 1.34gm	0/48
o	TR450	380.mg	n.s.s.	6/48	334.mg	8/48	669.mg	4/48 1.34gm	5/48
p	TR450	398.mg	n.s.s.	5/48	334.mg	7/48	669.mg	4/48 1.34gm	4/48
q	TR450	406.mg	n.s.s.	0/48	334.mg	3/48	669.mg	0/48 1.34gm	0/48
r	TR450	44.0mg	124.mg	37/48	334.mg	44/48	669.mg	48/48 (1.34gm)	46/48
s	TR450	54.7mg	171.mg	26/48	334.mg	34/48	669.mg	39/48 (1.34gm)	35/48
t	TR450	111.mg	597.mg	12/48	334.mg	12/48	669.mg	16/48 (1.34gm)	6/48
477	TR450	29.8mg	185.mg	16/50	93.7mg	33/50	(188.mg)	31/50 376.mg	39/50
a	TR450	89.9mg	317.mg	0/50	93.7mg	7/50	188.mg	12/50 (376.mg)	8/50
b	TR450	127.mg	803.mg	16/50	93.7mg	31/50	188.mg	23/50 376.mg	36/50
c	TR450	130.mg	630.mg	0/50	93.7mg	4/50	188.mg	9/50 (376.mg)	2/50
d	TR450	289.mg	2.30gm	0/50	93.7mg	4/50	188.mg	5/50 376.mg	6/50
e	TR450	326.mg	7.22gm	0/50	93.7mg	0/50	188.mg	5/50 (376.mg)	1/50
f	TR450	326.mg	7.22gm	0/50	93.7mg	0/50	188.mg	5/50 (376.mg)	1/50
g	TR450	444.mg	22.2gm	0/50	93.7mg	3/50	188.mg	1/50 376.mg	5/50
h	TR450	106.mg	n.s.s.	49/50	93.7mg	50/50	188.mg	49/50 376.mg	48/50
i	TR450	89.9mg	317.mg	0/50	93.7mg	7/50	188.mg	12/50 (376.mg)	8/50
478	TR450	729.mg	3.47gm	0/50	93.7mg	3/50	188.mg	3/50 376.mg	10/50
a	TR450	814.mg	5.72gm	0/50	93.7mg	3/50	188.mg	3/50 376.mg	8/50
b	TR450	2.23gm	n.s.s.	0/50	93.7mg	0/50	188.mg	0/50 376.mg	3/50
479	TR450	16.3mg	65.5mg	39/50	32.9mg	40/50	65.8mg	48/50 132.mg	47/50
a	TR450	27.6mg	3.51gm	34/50	32.9mg	43/50	65.8mg	38/50 132.mg	31/50
b	TR450	40.9mg	362.mg	4/50	32.9mg	7/50	65.8mg	15/50 132.mg	8/50
c	TR450	74.5mg	1.01gm	1/50	32.9mg	1/50	65.8mg	10/50 132.mg	3/50
d	TR450	103.mg	876.mg	0/50	32.9mg	0/50	65.8mg	6/50 132.mg	3/50
e	TR450	114.mg	25.5gm	1/50	32.9mg	0/50	65.8mg	6/50 132.mg	3/50
f	TR450	55.9mg	n.s.s.	3/50	32.9mg	6/50	65.8mg	8/50 132.mg	5/50
g	TR450	18.9mg	141.mg	48/50	32.9mg	49/50	65.8mg	50/50 132.mg	46/50
h	TR450	40.9mg	362.mg	4/50	32.9mg	7/50	65.8mg	15/50 132.mg	8/50
480	TR450	186.mg	1.22gm	2/50	32.9mg	4/50	65.8mg	9/50 132.mg	13/50
a	TR450	191.mg	2.40gm	3/50	32.9mg	5/50	65.8mg	9/50 132.mg	13/50
<b>TETRAHYDROFURAN 109-99-9</b>									
481	TR475	638.mg	9.47gm	17/50	185.mg	24/50	555.mg	26/50 1.67gm	41/50
a	TR475	816.mg	18.7gm	12/50	185.mg	17/50	555.mg	18/50 1.67gm	31/50
b	TR475	4.83gm	n.s.s.	0/50	185.mg	0/50	555.mg	1/50 1.67gm	3/50
c	TR475	824.mg	n.s.s.	34/50	185.mg	38/50	555.mg	41/50 1.67gm	44/50
d	TR475	638.mg	9.47gm	17/50	185.mg	24/50	555.mg	26/50 1.67gm	41/50
e	TR475	2.99gm	n.s.s.	2/50	185.mg	3/50	555.mg	5/50 1.67gm	5/50
482	TR475	524.mg	n.s.s.	47/50	154.mg	39/50	464.mg	44/50 1.39gm	21/50
a	TR475	697.mg	n.s.s.	35/50	154.mg	31/50	464.mg	30/50 1.39gm	18/50
b	TR475	1.37gm	n.s.s.	21/50	154.mg	16/50	464.mg	14/50 1.39gm	7/50
483	TR475	198.mg	n.s.s.	46/50	44.1mg	47/50	132.mg	49/50 397.mg	48/50
a	TR475	n.s.s.	n.s.s.	0/50	44.1mg	0/50	132.mg	0/50 397.mg	0/50
484	TR475	15.6mg	n.s.s.	23/50	30.9mg	31/50	92.7mg	31/50 (278.mg)	34/50
a	TR475	143.mg	n.s.s.	1/50	30.9mg	1/50	92.7mg	4/50 278.mg	5/50
b	TR475	202.mg	n.s.s.	0/50	30.9mg	2/50	92.7mg	3/50 278.mg	4/50
c	TR475	72.1mg	n.s.s.	48/50	30.9mg	48/50	92.7mg	48/50 278.mg	50/50
d	TR475	595.mg	n.s.s.	1/50	30.9mg	1/50	92.7mg	1/50 278.mg	0/50
<b>THEOPHYLLINE 58-55-9</b>									
485	TR473	8.45mg	n.s.s.	1/50	5.31mg	8/50	(17.7mg)	4/50 53.2mg	2/50
a	TR473	13.9mg	n.s.s.	46/50	5.31mg	39/50	17.7mg	41/50 (53.2mg)	28/50
b	TR473	35.2mg	n.s.s.	29/50	5.31mg	14/50	17.7mg	18/50 (53.2mg)	8/50
c	TR473	186.mg	n.s.s.	4/50	5.31mg	5/50	17.7mg	4/50 53.2mg	3/50
486	TR473	7.34mg	n.s.s.	44/50	10.7mg	42/50	(35.5mg)	38/50 107.mg	13/50
a	TR473	13.4mg	n.s.s.	34/50	10.7mg	27/50	(35.5mg)	22/50 107.mg	4/50
b	TR473	239.mg	n.s.s.	13/50	10.7mg	9/50	35.5mg	15/50 107.mg	5/50
487	TR473	61.0mg	n.s.s.	44/50	5.31mg	41/50	17.8mg	40/50 53.3mg	36/50
a	TR473	284.mg	n.s.s.	0/50	5.31mg	0/50	17.8mg	1/50 53.3mg	0/50
488	TR473	33.8mg	n.s.s.	43/50	5.34mg	41/50	17.8mg	39/50 53.5mg	34/50
a	TR473	267.mg	n.s.s.	2/50	5.34mg	2/50	17.8mg	0/50 53.5mg	1/50
<b>THIABENDAZOLE*** (2-(4-thiazolyl)-benzimidazole) 148-79-8</b>									
489	2456	95.9mg	n.s.s.	0/20	240.mg	2/20		Mikuriya;tmrl,40,289-297;1989/pers.comm.	
<b>THIAMPHENICOL 15318-45-3</b>									
490	2521	60.2mg	n.s.s.	0/50	6.88mg	0/49	27.5mg	0/50	
a	2521	10.1mg	n.s.s.	42/50	6.88mg	42/49	27.5mg	45/50	Kitamura;fctx,35,1075-1080;1997
491	2521	111.mg	n.s.s.	2/50	6.02mg	1/49	24.1mg	3/49	
a	2521	n.s.s.	n.s.s.	50/50	6.02mg	49/49	24.1mg	49/49	
<b>TILISOLOL.HCL (N-696) 62774-96-3</b>									
492	2373	53.2mg	n.s.s.	7/52	3.00mg	8/52	10.0mg	6/52 30.0mg	8/52
a	2373	109.mg	n.s.s.	2/52	3.00mg	2/52	10.0mg	4/52 30.0mg	1/52
b	2373	13.6mg	n.s.s.	0/52	3.00mg	0/52	10.0mg	0/52 30.0mg	0/52
c	2373	29.5mg	n.s.s.	23/52	3.00mg	19/52	10.0mg	24/52 30.0mg	21/52
493	2373	45.7mg	n.s.s.	0/52	3.00mg	1/52	10.0mg	4/52 30.0mg	4/52
a	2373	36.9mg	n.s.s.	4/52	3.00mg	5/52	10.0mg	9/52 30.0mg	8/52
b	2373	47.7mg	n.s.s.	6/52	3.00mg	13/52	10.0mg	9/52 30.0mg	9/52

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
c	M m	cd1	gav	liv hpc 80w80 e	no dre	P=1. -
d	M m	cd1	gav	tba mix 80w80 e	256.mg *	P<.8 -
494	R f	cdr	gav	liv hpa 24m24 e	no dre	P=1. -
a	R f	cdr	gav	tba mix 24m24 e	40.0mg *	P<.7 -
495	R m	cdr	gav	liv hpa 24m24 e	384.mg *	P<.05 -
a	R m	cdr	gav	liv hpc 24m24 e	no dre	P=1. -
b	R m	cdr	gav	tba mix 24m24 e	128.mg *	P<.8 -
DL-TOCOPHEROL, MIXTURE OF NATURAL ISOMERS (alpha, beta, gamma and delta) .1mg.....10.....100.....1g.....10						
496	M m	b6c	eat	liv mix 96w96	3.61gm	P<.0005+
a	M m	b6c	eat	liv hpc 96w96	5.22gm	P<.0005+
b	M m	b6c	eat	lun mix 96w96	no dre	P=1.
TOXAPHENE*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
497	M f	b6c	eat	liv MXA 80w90 jv	10.6mg /	P<.0005c
a	M f	b6c	eat	liv hpa 80w90 jv	11.4mg /	P<.0005
b	M f	b6c	eat	liv hpc 80w90 jv	273.mg *	P<.2
c	M f	b6c	eat	lun MXB 80w90 ejv	no dre	P=1.
498	M f	b6c	eat	liv MXA 80w90 jv pool	10.8mg /	P<.0005c
a	M f	b6c	eat	liv hpa 80w90 jv	11.6mg /	P<.0005
b	M f	b6c	eat	liv hpc 80w90 jv	273.mg *	P<.04
499	M f	b6c	eat	liv mix 18m24 er	37.0mg *	P<.08 +
a	M f	b6c	eat	liv hpc 18m24 er	66.2mg *	P<.3
b	M f	b6c	eat	liv hpa 18m24 er	91.6mg *	P<.3
500	M m	b6c	eat	liv MXA 80w90 jv	4.20mg *	P<.0005c
a	M m	b6c	eat	liv hpa 80w90 jv	6.12mg *	P<.0005
b	M m	b6c	eat	liv hpc 80w90 jv	248.mg *	P<.8
c	M m	b6c	eat	lun MXB 80w90 ejv	no dre	P=1.
501	M m	b6c	eat	liv MXA 80w90 jv pool	4.08mg *	P<.0005c
a	M m	b6c	eat	liv hpa 80w90 jv	5.76mg *	P<.0005
b	M m	b6c	eat	liv hpc 80w90 jv	168.mg *	P<.5
502	M m	b6c	eat	liv hpa 18m24 er	21.2mg Z	P<.002
a	M m	b6c	eat	liv mix 18m24 er	13.6mg *	P<.03 +
b	M m	b6c	eat	liv hpc 18m24 er	27.5mg *	P<.3
503	R f	osm	eat	TBA MXB 19m25 v	596.mg *	P<.1 -
a	R f	osm	eat	liv MXB 19m25 v	no dre	P=1.
504	R f	osm	eat	thy fca 19m25 v pool	209.mg *	P<.03 a
505	R m	osm	eat	TBA MXB 19m25 v	1.02gm *	P<.1 -
a	R m	osm	eat	liv MXB 19m25 v	949.mg *	P<.1
506	R m	osm	eat	thy MXA 19m25 v pool	58.9mg *	P<.002 a
a	R m	osm	eat	liv nnd 19m25 v	92.1mg *	P<.03
3,4,4'-TRIAMINODIPHENYL ETHER 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
507	M m	icr	eat	liv hpt 52w52 e	13.3mg	P<.0005+
TRICHLOROPHONE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
508	R b	wis	gav	liv hpc 24m24 e	80.7mg	P<.2
a	R b	wis	gav	tba ben 24m24 e	2.80mg	P<.0005
b	R b	wis	gav	tba mal 24m24 e	10.2mg	P<.0005
(+-)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID.....1mg.....10.....100.....1g.....10						
509	R f	f3j	eat	liv tum 52w52 e	no dre	P=1. -
510	R m	f3j	eat	liv tum 52w52 e	no dre	P=1. -
TRIMETHYLARSINE OXIDE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
511	R m	f3d	wat	liv hpa 24m24 Ce	24.1mg *	P<.03 +
a	R m	f3d	wat	liv hpc 24m24 Ce	no dre	P=1.
b	R m	f3d	wat	tba mix 24m24 e	5.95mg *	P<.6
TRIMETHYLPHOSPHATE*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
512	R f	wsb	wat	tba tum 52w52 ek	no dre	P=1. -
513	R f	wsb	wat	liv hpt 27m30 aes	no dre	P=1. -
a	R f	wsb	wat	tba mix 27m30 aes	no dre	P=1. -
514	R m	wsb	wat	tba tum 52w52 ek	no dre	P=1. -
515	R m	wsb	wat	liv hpt 27m30 aes	no dre	P=1. -
a	R m	wsb	wat	tba mix 27m30 aes	no dre	P=1. -
1,3,5-TRINITROBENZENE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
516	R f	f34	eat	liv tum 52w52 ek	no dre	P=1. -
517	R f	f34	eat	liv mix 24m24 e	no dre	P=1. -
518	R m	f34	eat	liv tum 52w52 ek	no dre	P=1. -
519	R m	f34	eat	liv mix 24m24 e	905.mg *	P<.8 -
TRINITROGLYCERIN*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
520	R m	f34	eat	liv mix 70w70 kr	113.mg	P<.01 +
a	R m	f34	eat	liv hpa 70w70 kr	179.mg	P<.04
b	R m	f34	eat	liv clc 70w70 kr	681.mg	P<.3
521	R m	f34	eat	liv hpa 76w76 r	106.mg	P<.009
a	R m	f34	eat	liv cho 76w76 r	211.mg	P<.05
b	R m	f34	eat	liv mix 76w76 r	noTD50	P<.02 +
c	R m	f34	eat	liv clc 76w76 r	509.mg	P<.2
TRIS (2-CHLOROETHYL) PHOSPHATE*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
522	M f	dds	eat	for mix 78w78 e	5.50gm *	P<.0005+
a	M f	dds	eat	for sqc 78w78 e	8.97gm *	P<.0005
b	M f	dds	eat	--- leu 78w78 e	4.79gm *	P<.04 +
c	M f	dds	eat	liv hpa 78w78 e	23.0gm *	P<.02
d	M f	dds	eat	tba mix 78w78 e	880.mg *	P<.006
523	M m	dds	eat	kid mix 78w78 e	539.mg Z	P<.0005+
a	M m	dds	eat	kid rcc 78w78 e	844.mg *	P<.0005
b	M m	dds	eat	liv mix 78w78 e	1.69gm *	P<.0005+
c	M m	dds	eat	liv hpc 78w78 e	28.8gm *	P<.6
d	M m	dds	eat	tba mix 78w78 e	185.mg *	P<.0005

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
c	2373	98.7mg	n.s.s.	4/52	3.00mg	3/52	10.0mg	2/52	30.0mg	3/52
d	2373	24.7mg	n.s.s.	20/52	3.00mg	24/52	10.0mg	22/52	30.0mg	23/52
494	2372	156.mg	n.s.s.	1/55	3.00mg	1/55	8.00mg	1/55	20.0mg	1/55
a	2372	4.62mg	n.s.s.	53/55	3.00mg	51/55	8.00mg	53/55	20.0mg	53/55
495	2372	116.mg	n.s.s.	0/55	3.00mg	0/55	8.00mg	1/55	20.0mg	2/55
a	2372	159.mg	n.s.s.	2/55	3.00mg	0/55	8.00mg	2/55	20.0mg	1/55
b	2372	13.1mg	n.s.s.	47/55	3.00mg	36/55	8.00mg	45/55	20.0mg	44/55
DL-TOCOPHEROL, MIXTURE OF NATURAL ISOMERS (alpha, beta, gamma and delta) (E-mix 80, natural vitamin E) 1406-66-2										
496	2398	2.07gm	8.62gm	12/46	6.00gm	36/50	Nitta;jtxp,4,55-61;1991/pers.comm.			
a	2398	2.85gm	15.9gm	10/46	6.00gm	30/50				
b	2398	16.0gm	n.s.s.	9/46	6.00gm	8/50				
TOXAPHENE*** 8001-35-2										
497	TR37r	7.40mg	16.0mg	0/10	11.3mg	11/49	22.9mg	39/47	NTP TR37/Goodman;faat,55,3-16;2000/NTP pers.comm.	
a	TR37r	7.91mg	17.4mg	0/10	11.3mg	11/49	22.9mg	37/47		
b	TR37r	82.6mg	n.s.s.	0/10	11.3mg	0/49	22.9mg	3/47		
c	TR37r	50.4mg	n.s.s.	1/9	11.3mg	0/47	22.9mg	0/37		
498	TR37r	7.49mg	16.5mg	1/50p	11.3mg	11/49	22.9mg	39/47		
a	TR37r	8.01mg	17.9mg	1/50p	11.3mg	11/49	22.9mg	37/47		
b	TR37r	82.6mg	n.s.s.	0/50p	11.3mg	0/49	22.9mg	3/47		
499	2448	13.2mg	n.s.s.	2/53	.683mg	2/53	1.95mg	4/52	4.88mg	6/52
a	2448	18.6mg	n.s.s.	1/53	.683mg	1/53	1.95mg	3/52	4.88mg	3/52
b	2448	22.9mg	n.s.s.	1/53	.683mg	1/53	1.95mg	1/52	4.88mg	3/52
NTP TR37/Goodman;faat,55,3-16;2000/NTP pers.comm.										
500	TR37r	2.82mg	7.68mg	2/10	10.4mg	37/50	21.1mg	45/47		
a	TR37r	4.10mg	12.4mg	2/10	10.4mg	30/50	21.1mg	42/47		
b	TR37r	30.7mg	n.s.s.	0/10	10.4mg	8/50	21.1mg	5/47		
c	TR37r	72.2mg	n.s.s.	1/10	10.4mg	1/45	21.1mg	2/33		
501	TR37r	2.81mg	6.19mg	7/48p	10.4mg	37/50	21.1mg	45/47		
a	TR37r	4.03mg	8.72mg	5/48p	10.4mg	30/50	21.1mg	42/47		
b	TR37r	38.9mg	n.s.s.	3/48p	10.4mg	8/50	21.1mg	5/47		
502	2448	10.0mg	106.mg	3/53	.630mg	0/54	1.80mg	2/53	4.50mg	11/51
a	2448	5.70mg	n.s.s.	10/53	.630mg	10/54	1.80mg	12/53	4.50mg	18/51
b	2448	7.66mg	n.s.s.	7/53	.630mg	11/54	1.80mg	12/53	4.50mg	12/51
Goodman;faat,55,3-16;2000/Litton 1978										
503	TR37	22.5mg	n.s.s.	6/10	20.0mg	31/50	40.0mg	40/50		
a	TR37	106.mg	n.s.s.	1/10	20.0mg	5/50	40.0mg	4/50	liv:hpa,hpc,nnd.	
504	TR37	84.2mg	n.s.s.	1/55p	20.0mg	1/50	40.0mg	7/50		
505	TR37	17.2mg	n.s.s.	7/10	16.5mg	33/50	33.0mg	24/50		
a	TR37	46.9mg	n.s.s.	1/10	16.5mg	6/50	33.0mg	4/50	liv:hpa,hpc,nnd.	
506	TR37	29.3mg	298.mg	2/55p	16.5mg	7/50	33.0mg	9/50	thy:fca,fcc.	
a	TR37	39.4mg	n.s.s.	1/55p	16.5mg	6/50	33.0mg	4/50	S	
3,4,4'-TRIAMINODIPHENYL ETHER 6264-66-0										
507	2594	7.08mg	29.3mg	2/21	120.mg	21/26	Osana;jsol,52,179-201;1976			
TRICHLOROPHENE 52-68-6										
508	2386	13.1mg	n.s.s.	0/36	4.29mg	1/28	Stieglitz;ahae,52,70-76;1974/Gibel 1973/Gibel 1975			
a	2386	1.51mg	6.37mg	3/36	4.29mg	19/28				
b	2386	4.39mg	35.0mg	0/36	4.29mg	7/28				
(+-)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID (AA-2414) 112665-43-7										
509	2590	1.62mg	n.s.s.	0/15	3.00mg	0/15	10.0mg	0/15	100.mg	0/15
510	2590	1.62mg	n.s.s.	0/15	3.00mg	0/15	10.0mg	0/15	100.mg	0/15
Nonoyama;jjpt,21,S1723-S1738;1993										
TRIMETHYLARSINE OXIDE 4964-14-1										
511	2630	10.2mg	n.s.s.	6/42	2.50mg	10/42	10.0mg	16/45	Shen;carc,24,1827-1835;2003	
a	2630	17.5mg	n.s.s.	0/42	2.50mg	0/42	10.0mg	0/45		
b	2630	.662mg	n.s.s.	42/42	2.50mg	40/42	10.0mg	45/45		
TRIMETHYLPHOSPHATE*** 512-56-1										
512	2549n	.464mg	n.s.s.	0/10	1.00mg	0/10	10.0mg	0/10	100.mg	0/10
513	2549n	883.mg	n.s.s.	0/49	1.00mg	0/49	10.0mg	1/50	77.0mg	0/50
a	2549n	430.mg	n.s.s.	29/49	1.00mg	29/49	10.0mg	35/50	77.0mg	18/50
514	2549n	.464mg	n.s.s.	0/10	1.00mg	0/10	10.0mg	0/10	100.mg	0/10
515	2549n	13.7mg	n.s.s.	4/50	1.00mg	0/49	10.0mg	0/48	77.0mg	0/47
a	2549n	424.mg	n.s.s.	24/50	1.00mg	25/49	10.0mg	26/48	77.0mg	14/47
1,3,5-TRINITROBENZENE 99-35-4										
516	2280n	.117mg	n.s.s.	0/10	.250mg	0/10	3.00mg	0/10	15.0mg	0/10
517	2280n	109.mg	n.s.s.	1/27	.250mg	3/43	3.00mg	0/39	15.0mg	1/44
518	2280n	93.7ug	n.s.s.	0/10	.200mg	0/10	2.40mg	0/10	12.0mg	0/10
519	2280n	54.3mg	n.s.s.	1/26	.200mg	0/35	2.40mg	1/36	12.0mg	1/37
Reddy;jtxe,52,447-460;1997/2001										
TRINITROGLYCERIN*** (glyceryl trinitrate, nitroglycerin) 55-63-0										
520	2288m	35.4mg	9.38gm	0/5	400.mg	4/6	Tamano;carc,17,2477-2486;1996			
a	2288m	51.7mg	n.s.s.	0/5	400.mg	3/6				
b	2288m	110.mg	n.s.s.	0/5	400.mg	1/6				
521	2288n	26.3mg	4.74gm	0/5	400.mg	3/4				
a	2288n	48.8mg	n.s.s.	0/5	400.mg	2/4				
b	2288n	n.s.s.	n.s.s.	0/5	400.mg	4/4				
c	2288n	81.4mg	n.s.s.	0/5	400.mg	1/4				
TRIS (2-CHLOROETHYL) PHOSPHATE*** 115-96-8										
522	2374	2.49gm	16.1gm	0/49	15.6mg	0/49	78.0mg	0/50	390.mg	1/49
a	2374	3.40gm	37.3gm	0/49	15.6mg	0/49	78.0mg	0/50	390.mg	0/49
b	2374	1.77gm	n.s.s.	1/49	15.6mg	3/49	78.0mg	6/50	390.mg	9/49
c	2374	5.66gm	n.s.s.	0/49	15.6mg	0/49	78.0mg	0/50	390.mg	0/49
d	2374	391.mg	13.3gm	30/49	15.6mg	28/49	78.0mg	33/50	390.mg	39/49
523	2374	366.mg	832.mg	2/50	14.4mg	0/49	72.0mg	2/49	360.mg	5/47
a	2374	552.mg	1.39gm	2/50	14.4mg	0/49	72.0mg	2/49	360.mg	3/47
b	2374	883.mg	5.29gm	4/50	14.4mg	5/49	72.0mg	7/49	360.mg	12/47
c	2374	3.96gm	n.s.s.	1/50	14.4mg	1/49	72.0mg	4/49	360.mg	2/47
d	2374	79.7mg	565.mg	34/50	14.4mg	38/49	72.0mg	39/49	360.mg	39/47
Takada;jtxp,2,213-222;1989										

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
<b>TRIS (2-HYDROXYPROPYL)AMINE***</b>						
524	R m	wis eat	liv tum	24m24 ej	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
<b>TURMERIC (&gt;98% CURCUMIN)</b>						
525	R m	f34 eat	col tum	55w55 r	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
<b>TYLOSIN LACTATE</b>						
526	M f	cb6 eat	liv tum	52w52 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
	a	M f	cb6 eat	lun tum	52w52 e	no dre P=1. -
527	M m	cb6 eat	liv tum	52w52 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
	a	M m	cb6 eat	lun tum	52w52 e	no dre P=1. -
<b>URAPIDIL</b>						
528	R f	sls gav	liv tum	52w52	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
529	R m	sls gav	liv tum	52w52	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
<b>VINYL FLUORIDE</b>						
530	M f	cd1 inh	mgl adc	67w74 ae	100ng...1ug...10...100...1mg...10...100...1g...10	13.6mg Z P<.0005+
	a	M f	cd1 inh	mgl mix	67w74 ae	13.6mg Z P<.0005+
	b	M f	cd1 inh	liv hes	67w74 Cae	25.4mg Z P<.0005+
	c	M f	cd1 inh	lun a/a	67w74 Cae	54.6mg Z P<.0005+
	d	M f	cd1 inh	lun mix	67w74 Cae	54.6mg Z P<.0005+
	e	M f	cd1 inh	hag ade	67w74 ae	4.01gm * P<.02 +
	f	M f	cd1 inh	liv hpa	67w74 Cae	no dre P=1.
531	M m	cd1 inh	lun a/a	63w78 Cae	100ng...1ug...10...100...1mg...10...100...1g...10	5.78mg Z P<.0005+
	a	M m	cd1 inh	lun mix	63w78 Cae	5.78mg Z P<.0005+
	b	M m	cd1 inh	liv hes	63w78 Cae	19.4mg Z P<.0005+
	c	M m	cd1 inh	hag ade	63w78 ae	1.00gm * P<.0005+
	d	M m	cd1 inh	liv hpa	63w78 Cae	34.6mg Z P<.06 +
	e	M m	cd1 inh	lun ach	63w78 Cae	12.3gm * P<.3
	f	M m	cd1 inh	liv hpc	63w78 Cae	no dre P=1.
532	R f	cdr inh	zym ssc	52w52 ek	100ng...1ug...10...100...1mg...10...100...1g...10	639.mg * P<.2
	a	R f	cdr inh	liv tum	52w52 Cek	no dre P=1.
533	R f	cdr inh	zym ssc	78w78 ek	100ng...1ug...10...100...1mg...10...100...1g...10	684.mg * P<.03
	a	R f	cdr inh	liv hpc	78w78 Cek	1.44gm * P<.2
	b	R f	cdr inh	liv mix	78w78 Cek	7.38gm * P<.9
	c	R f	cdr inh	liv hpa	78w78 Cek	no dre P=1.
	d	R f	cdr inh	liv hes	78w78 Cek	no dre P=1.
534	R f	cdr inh	liv hes	22m24 Cae	100ng...1ug...10...100...1mg...10...100...1g...10	16.6mg Z P<.002 +
	a	R f	cdr inh	liv hpa	22m24 Cae	183.mg Z P<.008
	b	R f	cdr inh	liv mix	22m24 Cae	183.mg Z P<.008 +
	c	R f	cdr inh	zym ssc	22m24 ae	1.47gm * P<.0005+
	d	R f	cdr inh	liv hpc	22m24 Cae	7.77gm * P<.03
535	R m	cdr inh	zym ssc	52w52 ek	100ng...1ug...10...100...1mg...10...100...1g...10	213.mg * P<.03
	a	R m	cdr inh	liv tum	52w52 Cek	no dre P=1.
536	R m	cdr inh	zym tum	78w78 ek	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1.
	a	R m	cdr inh	liv hpa	78w78 Cek	no dre P=1.
	b	R m	cdr inh	liv hes	78w78 Cek	no dre P=1.
	c	R m	cdr inh	liv hpc	78w78 Cek	no dre P=1.
537	R m	cdr inh	liv hes	22m24 Cae	100ng...1ug...10...100...1mg...10...100...1g...10	25.0mg Z P<.0005+
	a	R m	cdr inh	zym ssc	22m24 ae	1.09gm * P<.002 +
	b	R m	cdr inh	liv hpa	22m24 Cae	200.mg Z P<.05
	c	R m	cdr inh	liv hpc	22m24 Cae	no dre P=1.
<b>VINYLDIENE FLUORIDE</b>						
538	R f	sda gav	fat lip	12m33 e	100ng...1ug...10...100...1mg...10...100...1g...10	60.3mg * P<.2
	a	R f	sda gav	fat lps	12m33 e	122.mg * P<.3
	b	R f	sda gav	liv tum	12m33 e	no dre P=1.
539	R m	sda gav	fat lps	12m33 e	100ng...1ug...10...100...1mg...10...100...1g...10	38.8mg * P<.2
	a	R m	sda gav	fat lip	12m33 e	no dre P=1.
	b	R m	sda gav	liv tum	12m33 e	no dre P=1.
<b>N-VINYLPYRROLIDONE-2</b>						
540	R f	cdr inh	nre ade	52w52 e	100ng...1ug...10...100...1mg...10...100...1g...10	19.8mg * P<.2
	a	R f	cdr inh	liv tum	52w52 e	no dre P=1.
541	R f	cdr inh	liv hpc	24m24 e	100ng...1ug...10...100...1mg...10...100...1g...10	12.3mg Z P<.0005+
	a	R f	cdr inh	nre ade	24m24 e	20.4mg * P<.0005+
	b	R f	cdr inh	lar sqc	24m24 e	120.mg * P<.009 +
	c	R f	cdr inh	nof adc	24m24 e	120.mg * P<.009 +
	d	R f	cdr inh	tba mal	24m24 e	6.12mg P<.0005
	e	R f	cdr inh	tba mix	24m24 e	no dre P=1.
542	R m	cdr inh	nre ade	52w52 e	100ng...1ug...10...100...1mg...10...100...1g...10	8.56mg * P<.5
	a	R m	cdr inh	liv tum	52w52 e	no dre P=1.
543	R m	cdr inh	nre ade	24m24 e	100ng...1ug...10...100...1mg...10...100...1g...10	11.7mg * P<.0005+
	a	R m	cdr inh	liv hpc	24m24 e	12.0mg * P<.0005+
	b	R m	cdr inh	nof adc	24m24 e	32.9mg * P<.0005+
	c	R m	cdr inh	lar sqc	24m24 e	84.0mg * P<.009 +
	d	R m	cdr inh	tba mal	24m24 e	5.00mg P<.0005
	e	R m	cdr inh	tba mix	24m24 e	1.99mg P<.07
<b>VOGLIBOSE</b>						
544	M f	cd1 gav	lun a/a	23m23 ae	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
	a	M f	cd1 gav	liv hpa	23m23 ae	no dre P=1. -
545	M m	cd1 gav	lun a/a	83w83 e	100ng...1ug...10...100...1mg...10...100...1g...10	1.37gm P<.4 -
	a	M m	cd1 gav	liv hpc	83w83 e	no dre P=1. -
	b	M m	cd1 gav	liv hpa	83w83 e	no dre P=1. -
546	R f	f3d gav	mgl fba	24m24 e	100ng...1ug...10...100...1mg...10...100...1g...10	119.mg * P<.04 -
	a	R f	f3d gav	liv tum	24m24 e	no dre P=1. -
547	R m	f3d gav	tes ict	24m24 e	100ng...1ug...10...100...1mg...10...100...1g...10	9.27mg * P<.009 -
	a	R m	f3d gav	liv hpa	24m24 e	575.mg P<.3 -
	b	R m	f3d gav	liv hpc	24m24 e	1.74gm P<.7 -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
<b>TRIS (2-HYDROXYPROPYL)AMINE*** 122-20-3</b>									
524	1910m	3.01gm	n.s.s.	0/17	800.mg	0/19		Yamamoto;clet,45,221-225;1989/1996/pers.comm.	
<b>TURMERIC (&gt;98% CURCUMIN) (diferuloylmethane) 458-37-7</b>									
525	2409	55.3mg	n.s.s.	0/12	80.0mg	0/12		Rao;canr,55,259-266;1995	
<b>TYLOSIN LACTATE 11034-63-2</b>									
526	2595	36.5mg	n.s.s.	0/7	130.mg	0/6	1.30gm	0/6	Tsubura;jnma,30,506-517;1979
a	2595	36.5mg	n.s.s.	0/7	130.mg	0/6	1.30gm	0/6	
527	2595	34.2mg	n.s.s.	0/8	120.mg	0/6	1.20gm	0/7	
a	2595	34.2mg	n.s.s.	0/8	120.mg	0/6	1.20gm	0/7	
<b>URAPIDIL 6-[[3-[4-(o-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil 34661-75-1</b>									
528	2351	2.29mg	n.s.s.	0/20	2.50mg	0/20	25.0mg	0/19	125.mg 0/19
529	2351	2.20mg	n.s.s.	0/20	2.50mg	0/19	25.0mg	0/20	125.mg 0/20
<b>VINYL FLUORIDE 75-02-5</b>									
530	2354o	8.19mg	25.0mg	0/69	14.8mg	22/70	(148.mg)	20/68	1.48gm 19/69
a	2354o	8.19mg	25.0mg	0/69	14.8mg	22/70	(148.mg)	20/68	1.48gm 20/69
b	2354o	13.4mg	57.5mg	0/71	14.8mg	13/71	(148.mg)	25/70	1.48gm 32/71
c	2354o	34.6mg	101.mg	9/71	14.8mg	23/70	148.mg	46/70	(1.48gm 50/71)
d	2354o	34.6mg	101.mg	9/71	14.8mg	23/70	148.mg	46/70	(1.48gm 50/71)
e	2354o	1.63gm	n.s.s.	1/71	14.8mg	7/71	148.mg	6/69	1.48gm 12/71
f	2354o	8.26gm	n.s.s.	0/71	14.8mg	0/71	148.mg	1/70	1.48gm 0/71
531	2354o	3.66mg	10.8mg	11/71	12.3mg	44/70	(123.mg)	48/70	1.23gm 50/71
a	2354o	3.66mg	10.8mg	11/71	12.3mg	44/70	(123.mg)	48/70	1.23gm 50/71
b	2354o	10.5mg	48.2mg	1/71	12.3mg	16/70	(123.mg)	42/70	1.23gm 42/71
c	2354o	587.mg	2.21gm	3/70	12.3mg	13/69	123.mg	12/70	1.23gm 31/70
d	2354o	13.5mg	n.s.s.	7/71	12.3mg	15/70	(123.mg)	5/70	1.23gm 3/71
e	2354o	2.88gm	n.s.s.	1/71	12.3mg	1/70	123.mg	4/70	1.23gm 4/71
f	2354o	10.4gm	n.s.s.	2/71	12.3mg	2/70	123.mg	1/70	1.23gm 0/71
532	2354m	104.mg	n.s.s.	0/10	3.52mg	0/10	35.2mg	0/10	352.mg 1/10
a	2354m	1.64mg	n.s.s.	0/10	3.52mg	0/10	35.2mg	0/10	352.mg 0/10
533	2354n	167.mg	n.s.s.	0/10	3.52mg	0/10	35.2mg	0/10	352.mg 2/10
a	2354n	234.mg	n.s.s.	0/10	3.52mg	0/10	35.2mg	0/10	352.mg 1/10
b	2354n	206.mg	n.s.s.	0/10	3.52mg	1/10	35.2mg	2/10	352.mg 1/10
c	2354n	347.mg	n.s.s.	0/10	3.52mg	1/10	35.2mg	2/10	352.mg 0/10
d	2354n	307.mg	n.s.s.	0/10	3.52mg	0/10	35.2mg	1/10	352.mg 0/10
534	2354o	7.49mg	56.7mg	0/60	3.52mg	8/60	(35.2mg)	18/60	352.mg 15/60
a	2354o	73.8mg	4.10gm	0/60	3.52mg	3/60	35.2mg	7/60	(352.mg 5/60)
b	2354o	73.8mg	4.10gm	0/60	3.52mg	3/60	35.2mg	7/60	(352.mg 7/60)
c	2354o	715.mg	3.85gm	0/60	3.52mg	0/60	35.2mg	1/60	352.mg 9/60
d	2354o	1.91gm	n.s.s.	0/60	3.52mg	0/60	35.2mg	0/60	352.mg 2/60
535	2354m	52.1mg	n.s.s.	0/10	2.47mg	0/10	24.7mg	0/10	247.mg 2/10
a	2354m	1.15mg	n.s.s.	0/10	2.47mg	0/10	24.7mg	0/10	247.mg 0/10
536	2354n	2.58mg	n.s.s.	0/10	2.47mg	0/10	24.7mg	0/10	247.mg 0/10
a	2354n	165.mg	n.s.s.	1/10	2.47mg	1/10	24.7mg	2/10	247.mg 1/10
b	2354n	262.mg	n.s.s.	0/10	2.47mg	1/10	24.7mg	1/10	247.mg 0/10
c	2354n	269.mg	n.s.s.	1/10	2.47mg	0/10	24.7mg	1/10	247.mg 0/10
537	2354o	16.3mg	40.9mg	0/60	2.47mg	4/60	24.7mg	29/60	(247.mg 20/60)
a	2354o	686.mg	5.53gm	0/60	2.47mg	2/60	24.7mg	3/60	(247.mg 9/60)
b	2354o	64.0mg	n.s.s.	0/60	2.47mg	3/60	24.7mg	5/60	(247.mg 1/60)
c	2354o	1.24gm	n.s.s.	3/60	2.47mg	6/60	24.7mg	5/60	247.mg 4/60
<b>VINYLLIDENE FLUORIDE 75-38-7</b>									
538	BT801	14.8mg	n.s.s.	0/30	.977mg	0/30	1.96mg	2/35	Maltoni;lmdl,5,363-368;1979
a	BT801	19.9mg	n.s.s.	0/30	.977mg	0/30	1.96mg	1/35	
b	BT801	7.77mg	n.s.s.	0/30	.977mg	0/30	1.96mg	0/35	
539	BT801	11.7mg	n.s.s.	0/26	.977mg	1/27	1.96mg	2/35	
a	BT801	22.3mg	n.s.s.	1/26	.977mg	0/27	1.96mg	1/35	
b	BT801	7.21mg	n.s.s.	0/26	.977mg	0/27	1.96mg	0/35	
<b>N-VINYLPYRROLIDONE-2 88-12-0</b>									
540	2542m	3.22mg	n.s.s.	0/10	1.70mg	0/10	3.40mg	0/10	6.80mg 1/10
a	2542m	.501mg	n.s.s.	0/10	1.70mg	0/10	3.40mg	0/10	6.80mg 0/10
541	2542n	8.05mg	20.8mg	1/70	1.70mg	3/60	3.40mg	6/60	6.80mg 26/60
a	2542n	12.3mg	39.2mg	0/70	1.70mg	2/60	3.40mg	8/60	6.80mg 12/60
b	2542n	41.5mg	3.56gm	0/70	1.70mg	0/60	3.40mg	0/60	6.80mg 4/60
c	2542n	41.5mg	3.56gm	0/70	1.70mg	0/60	3.40mg	0/60	6.80mg 4/60
d	2542n	3.35mg	18.6mg	25/70	6.80mg			42/60	
e	2542n	8.60mg	n.s.s.	69/70	6.80mg			50/60	
542	2542m	1.70mg	n.s.s.	0/10	1.19mg	1/10	2.38mg	0/10	4.76mg 1/10
a	2542m	.351mg	n.s.s.	0/10	1.19mg	0/10	2.38mg	0/10	4.76mg 0/10
543	2542n	7.37mg	36.4mg	0/70	1.19mg	8/60	2.38mg	9/60	4.76mg 10/60
a	2542n	7.27mg	26.7mg	1/70	1.19mg	6/60	2.38mg	5/60	4.76mg 17/60
b	2542n	16.1mg	105.mg	0/70	1.19mg	0/60	2.38mg	4/60	4.76mg 6/60
c	2542n	29.0mg	2.49gm	0/70	1.19mg	0/60	2.38mg	0/60	4.76mg 4/60
d	2542n	2.88mg	12.1mg	14/70	4.76mg	35/60			
e	2542n	.543mg	n.s.s.	64/70	4.76mg	59/60			
<b>VOGLIBOSE (AO-128) 83480-29-9</b>									
544	2446	1.00gm	n.s.s.	6/61	107.mg	1/60			Atkinson;jjpt,19,4427-4438;1991/pers.comm.
a	2446	1.25gm	n.s.s.	1/61	107.mg	0/60			
545	2446	299.mg	n.s.s.	1/59	107.mg	3/60			
a	2446	417.mg	n.s.s.	2/59	107.mg	2/60			
b	2446	417.mg	n.s.s.	2/59	107.mg	2/60			
546	2433	46.1mg	n.s.s.	8/120	2.14mg	5/60	7.14mg	8/60	21.4mg 10/60
a	2433	265.mg	n.s.s.	0/120	2.14mg	0/60			Nonoyama;jjpt,19,4415-4425;1991/pers.comm.
547	2433	3.76mg	448.mg	101/120	2.14mg	55/60	7.14mg	55/60	21.4mg 58/60
a	2433	112.mg	n.s.s.	1/120	2.14mg	2/60			
b	2433	153.mg	n.s.s.	1/120	2.14mg	1/60			

Spe	Strain	Site	Xpo+Xpt							TD50	2Tailpvl	
Sex	Route	Hist	Notes							DR	AuOp	
<b>WATANIDIPINE. 2HCL</b>												
				100ng	1ug	10	100	1mg	10	100	1g	10
548	M f	b6c	eat lun a/a	78w78	e						243.mg	P<.04 -
a	M f	b6c	eat liv hpa	78w78	e						714.mg	P<.7 -
b	M f	b6c	eat lun adc	78w78	e						no dre	P=1. -
c	M f	b6c	eat tba mix	78w78	e						293.mg	P<.7 -
549	M m	b6c	eat liv hpc	78w78	e						898.mg *	P<.8 -
a	M m	b6c	eat liv hpa	78w78	e						no dre	P=1. -
b	M m	b6c	eat lun a/a	78w78	e						no dre	P=1. -
c	M m	b6c	eat lun adc	78w78	e						no dre	P=1. -
d	M m	b6c	eat tba mix	78w78	e						no dre	P=1. -
550	R f	f3d	eat liv hpa	24m24	e						509.mg	P<.3 -
a	R f	f3d	eat tba mix	24m24	e						46.1mg	P<.7 -
551	R m	f3d	eat liv hpa	24m24	e						no dre	P=1. -
a	R m	f3d	eat tba mix	24m24	e						noTD50	P=1. -
<b>WINGSTAY 100</b>												
				100ng	1ug	10	100	1mg	10	100	1g	10
552	R f	f34	eat liv tum	52w52	Cek						no dre	P=1. -
a	R f	f34	eat tba mix	52w52	ek						565.mg *	P<.7 -
553	R f	f34	eat liv tum	52w64	Ce						no dre	P=1. -
a	R f	f34	eat ubl tum	52w64	Ce						no dre	P=1. -
b	R f	f34	eat tba mix	52w64	e						66.8mg *	P<.3 -
554	R m	f34	eat liv tum	52w52	Cek						no dre	P=1. -
a	R m	f34	eat tba mix	52w52	ek						195.mg *	P<.3 -
555	R m	f34	eat liv tum	52w64	Ce						no dre	P=1. -
a	R m	f34	eat ubl tum	52w64	Ce						no dre	P=1. -
b	R m	f34	eat tba mix	52w64	e						113.mg *	P<.9 -
<b>XIBENOLOL.HCL</b>												
				100ng	1ug	10	100	1mg	10	100	1g	10
556	M f	b6c	eat liv mix	82w92	e						no dre	P=1. -
a	M f	b6c	eat lun mix	82w92	e						no dre	P=1. -
b	M f	b6c	eat tba mix	82w92	e						no dre	P=1. -
557	M m	b6c	eat lun mix	82w92	e						1.73gm *	P<.6 -
a	M m	b6c	eat liv mix	82w92	e						no dre	P=1. -
b	M m	b6c	eat tba mix	82w92	e						618.mg *	P<.6 -
<b>GARDENIA YELLOW</b>												
				100ng	1ug	10	100	1mg	10	100	1g	10
558	M f	c5n	wat lun tum	95w95	e						no dre	P=1. -
a	M f	c5n	wat liv hpt	95w95	e						no dre	P=1. -
559	M m	c5n	wat lun tum	95w95	e						no dre	P=1. -
a	M m	c5n	wat liv hpt	95w95	e						no dre	P=1. -
<b>ZINC (II) ACETATE DIHYDRATE</b>												
				100ng	1ug	10	100	1mg	10	100	1g	10
560	R m	crw	wat tes lya	24m24	e						no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
<b>WATANIDIPINE, 2HCL 133743-71-2</b>										
548	2576	73.5mg	n.s.s.	0/50	39.0mg	3/50		Ishida;jjpt,25,227-246;1997		
a	2576	86.7mg	n.s.s.	2/50	39.0mg	3/50				
b	2576	137.mg	n.s.s.	1/50	39.0mg	1/50				
c	2576	43.0mg	n.s.s.	10/50	39.0mg	12/50				
549	2576	84.6mg	n.s.s.	1/50	10.8mg	3/50	36.0mg 2/50	Ishida;jjpt,25,247-270;1997		
a	2576	n.s.s.	n.s.s.	10/50	10.8mg	10/50	36.0mg 10/50			
b	2576	123.mg	n.s.s.	6/50	10.8mg	2/50	36.0mg 3/50			
c	2576	158.mg	n.s.s.	0/50	10.8mg	1/50	36.0mg 0/50			
d	2576	47.7mg	n.s.s.	20/50	10.8mg	21/50	36.0mg 16/50			
550	2575	82.9mg	n.s.s.	0/50	15.0mg	1/50		Ishida;jjpt,25,247-270;1997		
a	2575	7.26mg	n.s.s.	40/50	15.0mg	42/50				
551	2575	52.2mg	n.s.s.	3/50	12.0mg	3/50				
a	2575	n.s.s.	n.s.s.	50/50	12.0mg	50/50				
<b>WINGSTAY 100 68953-84-4</b>										
552	2547m	2.28mg	n.s.s.	0/12	2.65mg	0/20	15.5mg 0/20	Iatropoulos;extp,49,153-165;1997/pers.comm.	95.0mg 0/20	
a	2547m	50.4mg	n.s.s.	1/12	2.65mg	2/20	15.5mg 0/20		95.0mg 2/20	
553	2547n	.841mg	n.s.s.	0/5	2.15mg	0/6	12.6mg 0/6		77.2mg 0/6	
a	2547n	.841mg	n.s.s.	0/5	2.15mg	0/6	12.6mg 0/6		77.2mg 0/6	
b	2547n	13.4mg	n.s.s.	1/5	2.15mg	0/6	12.6mg 1/6		77.2mg 2/6	
554	2547m	1.82mg	n.s.s.	0/12	2.12mg	0/20	12.4mg 0/20		76.0mg 0/20	
a	2547m	38.4mg	n.s.s.	1/12	2.12mg	0/20	12.4mg 0/20		76.0mg 2/20	
555	2547n	.673mg	n.s.s.	0/5	1.72mg	0/6	10.1mg 0/6		61.8mg 0/6	
a	2547n	.673mg	n.s.s.	0/5	1.72mg	0/6	10.1mg 0/6		61.8mg 0/6	
b	2547n	5.65mg	n.s.s.	5/5	1.72mg	1/6	10.1mg 5/6		61.8mg 4/6	
<b>XIBENOLOL, HCL 15263-30-6</b>										
556	2380	996.mg	n.s.s.	3/50	57.6mg	3/48	230.mg 2/50		Horiuchi;phrm,30,705-721;1985	
a	2380	1.01gm	n.s.s.	9/50	57.6mg	4/48	230.mg 4/50			
b	2380	279.mg	n.s.s.	28/50	57.6mg	26/48	230.mg 25/50			
557	2380	287.mg	n.s.s.	12/50	53.2mg	12/50	213.mg 14/49			
a	2380	431.mg	n.s.s.	19/50	53.2mg	14/50	213.mg 14/49			
b	2380	115.mg	n.s.s.	33/50	53.2mg	33/50	213.mg 35/49			
<b>GARDENIA YELLOW 94238-00-3</b>										
558	2397	9.19gm	n.s.s.	0/40	400.mg	1/45	1.60gm 0/44	Fujimoto;jtxp,7,455-460;1994/pers.comm.		
a	2397	11.9gm	n.s.s.	1/40	400.mg	1/45	1.60gm 0/44			
559	2397	2.15gm	n.s.s.	2/39	333.mg	0/47	1.33gm 0/46			
a	2397	6.68gm	n.s.s.	4/39	333.mg	2/47	1.33gm 2/46			
<b>ZINC (II) ACETATE DIHYDRATE 5970-45-6</b>										
560	2343	17.3mg	n.s.s.	9/83	5.00mg	2/29		Waalkes;canr,49,4282-4288;1989/pers.comm.		

**Appendix 1. Description of Plot Header Line**

Each page of the plot includes a header line with codes that define each field. The header codes are described in this Appendix.

Spe	Species. Rat (R), mouse (M), hamster (H).
Sex	Male (m), female (f), or both sexes combined (b) if only the combined data are given in the published paper.
Strain	Strain. Nomenclature is in Appendix 2.
Route	Route of administration definitions are in Appendix 3.
Site	Tissue codes are defined in Appendix 4.
Hist	Histopathology codes are defined in Appendix 5.
Xpo+Xpt	Duration of exposure and length of experiment (w=weeks, m=months).
Notes	Special information codes about the experiment are in Appendix 6.
Plot Scale	The logarithmic scale presents the values of TD <sub>50</sub> and its 99% confidence limits (in units/kg body wt/day). The scale extends from 100 nanograms to 10 grams. On the scale itself, the location of 100 nanograms, 1 microgram (μg), 10 μg, etc., is indicated by underscoring; the points for 5, 50, 500 are denoted by a “.”. For each experiment, only the TD <sub>50</sub> for the “most potent site” is plotted; this TD <sub>50</sub> is listed first. For other sites within an experiment, the TD <sub>50</sub> is not plotted, but all other information about it is given in the plot.
TD50	The value of each TD <sub>50</sub> is presented just to the right of the plot scale, and includes the appropriate units (per kg) of body weight per day.
DR	Dose-response curve definitions are in Appendix 7.
2Tailpvl	The statistical significance associated with testing whether the slope of the dose-response curve is different from zero.
AuOp	Author’s opinion from the published paper about the tumorigenicity of the test agent at the site for which the TD <sub>50</sub> was calculated. Definitions are in Appendix 8.
RefNum	The reference number is the unique reference number assigned to each paper in the CPDB. For NTP bioassays, RefNum is the Technical Report number.
LoConf, UpConf	99% lower and upper confidence limits for each TD <sub>50</sub> . When the abbreviation “n.s.s.” appears for either the lower or upper confidence limit, it denotes “not statistically significant.” Whenever the statistical significance of TD <sub>50</sub> is $p>0.01$ , then the upper confidence limit cannot be calculated.
Cntrl	The proportion of control animals with the tissue-tumor type in the TD <sub>50</sub> calculation.
1Dose, 2Dose	Values are the average daily dose-rates for each dose group, in units per kg body weight per day.
1Inc, 2Inc	The proportion of animals in each dose group with the tissue-tumor type in the TD <sub>50</sub> calculation.
Citation or Pathology	Citation to published paper for general literature. Journal codes are defined in Appendix 10. Full bibliography is in Appendix 14. For NTP bioassays, histopathology is reported here for mixes of tumor types included in the TD <sub>50</sub> calculation, and codes are defined in Appendices 4 and 5.
Brkly Code	Berkeley codes for tissues and tumors in NTP bioassays that are combined for the CPDB are defined in Appendix 9.

**Appendix 2: Strain Codes And Definitions**

Code	Strain	Code	Strain
aap	Alpk:APfSD	lca	LACA
aps	AP Alderly Park	leb	Long-Evans BLU:(LE)
b6c	B6C3F <sub>1</sub>	lev	Long-Evans
bal	BALB/c	nmo	Hoe:NMRKf (SPF71)
bd1	BDF <sub>1</sub>	nss	Not specified
c3s	C3H/St (MTV+)	osm	Osborne-Mendel
c56	C57BL/6J	sda	Sprague-Dawley
cb7	CBA × C57BL	sdf	SD × F344
c5j	C57BL/10J	sdj	SD(Crj:CD) Sprague-Dawley
c5n	C57BL/6N	sjd	Jcl:SD
cb6	C57BL/6	sls	Slc-Wistar
cd1	Charles River CD1	ssk	SK&F Swiss
cdr	Charles River CD (Sprague-Dawley)	sss	Sprague-Dawley Spartan
crw	Charles River CrI:COBS(WI)BR	swa	Swiss albino
d2b	D2B6F1 mice	swi	Swiss
ddd	DDD	swn	Swiss/NIH (Japan)
dds	Slc:ddY	sww	Swiss Webster
don	Donryu	syg	Syrian Golden
f34	Fischer 344	vms	VM
f3d	F344/DuCrj	whb	Han-lbm Wistar
f3j	Fischer 344/Jcl	wis	Wistar
icm	ICR	wsb	BOR:WISW (Wistar)
icr	ICR/Jcl	wsk	SK&F Wistar



**Appendix 3: Routes of administration**

Code	Route of Administration
eat	diet
gav	gavage
inh	inhalation
ipj	intraperitoneal injection
mix	gavage then diet
wat	water

**Appendix 4: Site codes**

Code	Site
---	all sites
adr	adrenal gland
amd	adrenal medulla
bon	bone
bra	brain
cec	cecum
cli	clitoral gland
cns	central nervous system
col	colon
fat	fat
for	forestomach
gam	gastric mucosa
gnv	gingiva
hag	Harderian gland
hed	head
k/p	kidney/pelvis
kid	kidney
lar	larynx
lcg	lacrimal gland
lgi	large intestine
liv	liver
lun	lung
lyd	lymph node
mam	mammary tissue (other than or including more than mammary gland)
mey	mesentery
mgl	mammary gland
mln	mesenteric lymph node
MXA	more than one site, combined by NCI/NTP
MXB	more than one site, combined by Berkeley
nas	nasal cavity
nof	nasal cavity, olfactory epithelium
nre	nasal cavity, respiratory epithelium
nsa	nasal cavity, adenoid
orc	oral cavity
orm	oral mucosa
ova	ovary
pae	pancreas, exocrine
pan	pancreas
per	peritoneum
phr	pharynx
pit	pituitary gland
pni	pancreatic islets
pre	preputial gland
pyl	pylorus
ski	skin
smi	small intestine
spd	spinal cord
spl	spleen

Code	Site
stf	stomach, fundic
stg	stomach, glandular
sub	subcutaneous tissue
TBA	all tumor bearing animals, NCI/NTP
tba	all tumor bearing animals, general literature
tes	testis
thy	thyroid gland
tnv	tunica vaginalis
ton	tongue
trh	trachea
tyf	thyroid follicle
ubl	urinary bladder
ute	uterus
vag	vagina
zym	Zymbal's gland

**Appendix 5: Histopathology**

Code	Histopathology
a/a	alveolar/bronchiolar adenoma
a/c	alveolar/bronchiolar carcinoma
abt	alveolar/bronchiolar tumor
acb	alveolar/bronchiolar adenocarcinoma
acc	acinar-cell carcinoma
adc	adenocarcinoma
ade	adenoma
adp	adenomatous polyp
ala	alveolar-cell adenoma
ana	acinar-cell adenoma
anb	adenoma, bilateral
ast	astrocytoma
ben	benign tumor
bhp	hepatoma, benign
car	carcinoma
caa	cholangioadenoma/carcinoma
cca	c-cell adenoma
cgf	cholangiofibroma
cho	cholangioma
clc	cholangiocarcinoma
cnb	carcinoma, bilateral
cnd	carcinoid tumor, malignant
coa	cortical adenoma
coc	cortical carcinoma
cye	cystadenoma
ene	esthesioneuroepithelioma
epc	epidermoid carcinoma
esp	endometrial stromal polyp
fba	fibroadenoma
fbs	fibrosarcoma
fca	follicular-cell adenoma
fcc	follicular-cell carcinoma
fdc	follicular adenocarcinoma
fib	fibroma
gli	glioma
glx	glial tumors (oligodendroglioma and astrocytoma)
hcs	histiocytic sarcoma
hct	hepatocellular tumor
hem	hemangioma
hes	hemangiosarcoma
hnd	hyperplastic nodule

Code	Histopathology	Code	Histopathology
hpa	hepatocellular adenoma	MXB	more than one tumor type, combined by Berkeley
hpb	hepatoblastoma	nnd	neoplastic nodule
hpc	hepatocellular carcinoma	oli	oligodendroglioma
hpt	hepatoma	ost	osteosarcoma
iab	interstitial-cell adenoma, bilateral	pam	papilloma
ica	interstitial-cell adenoma	pbb	pheochromocytoma benign, bilateral
ict	interstitial-cell tumor	pcy	papillary cystadenoma, NOS
idc	infiltrating duct carcinoma	pda	pars distalis adenoma
isa	islet-cell adenoma	phc	pheochromocytoma, complex
isc	islet-cell carcinoma	phe	pheochromocytoma
ldc	Leydig-cell tumor	phm	pheochromocytoma, malignant
leu	leukemia	pob	pheochromocytoma, benign
lip	lipoma	rab	renal tubule adenoma, bilateral
lkm	Lymphoma and leukemia combined	rca	renal-cell adenoma
lps	liposarcoma	rcc	renal-cell carcinoma
lya	Leydig-cell adenoma	rct	renal-cell tumor
lym	lymphoma	rhb	rhabdomyosarcoma
lys	lymphosarcoma	rua	tubule adenoma
mal	malignant tumor	ruc	tubule carcinoma
mix	more than one tumor type; tumor types specified in published paper	sar	sarcoma
mly	malignant lymphoma	sqc	squamous-cell carcinoma
mnl	mononuclear-cell leukemia	sqp	squamous-cell papilloma
mnp	mesenchymal neoplasm	srn	sarcoma, NOS
msb	mesothelioma, benign	ssc	squamous-cell carcinoma, sebaceous
msm	mesothelioma, malignant	tcc	transitional-cell carcinoma
mso	mesothelioma	tpp	transitional-cell papilloma
MXA	more than one tumor type, combined by NCI/NTP	tum	tumor or more than one tumor type; tumor types not specified in paper

#### Appendix 6: Notecodes and Definitions

Code	Definition
a	The exposure time reported on the plot is an average of the different exposure times of the individual dose groups.
A	Serial sacrifice experiments of aristolochic acid in the same paper were evaluated as positive at additional sites by the author but did not meet inclusion rules of the CPDB. Full data are reported in Table below.
C	Quantitative data are reported in the paper on cell division in this tissue in dosed and control animals (e.g., labeling index). C does not indicate whether or not there was an association between cell division and tumorigenesis.
e	For the general literature we have used an effective number of animals in a group whenever possible. This effective number is either: (1) the number of animals alive at the time of appearance of the first tumor, or (2) if that is not reported, then the number of animals examined.
g	Some or all of the animals were used as breeders during the course of the experiment.
j	Data for this test have been previously published in the CPDB. The experimental results have been revised either because of a later publication by the same authors or because of a personal communication. In the CPDB, we give the same reference number to the experiment in all plot publications.
k	For interim and serial sacrifice experiments, we have reported, as a separate experiment with a k notecode, each sacrifice time that otherwise met the inclusion rules of the database. We have included unscheduled deaths with the terminal sacrifice data, and when this has been done, there is no k notecode for the terminal sacrifice experiment.
L	Female mouse strain was mammary tumor virus positive (MTV+) with a high spontaneous incidence of mammary tumors; histopathology was restricted to mammary gland. The study was designed to measure tumor latency, and no author's opinion about carcinogenicity is given in the CPDB.
m	The calculated dose rate for a group is an average of a narrow range of dose-rates.
pool	Pooled controls are used and were reported in NCI Technical Report.
r	Restricted site analysis; the authors either examined or reported results for only one or a couple of tissues.
s	Authors noted that survival was decreased due to toxicity, disease, or accidental death.
v	Variable or irregular dosing schedules have been used, e.g. dose level changed during the experiment.
with step	NTP took additional sections of kidneys; tumor incidence for step results are reported separately as "with step."

**Notecode A: Aristolochic Acid**

For the test of aristolochic acid (AA) in Wistar rats (Mengs, 1982), the CPDB includes only results of the chronic, 69 week experiment in which AA was administered at 0.1 mg/kg/day for 52 weeks (daily dose-rate in CPDB=0.075 mg/kg/day). Other groups of rats were administered 1.0 or 10 mg/kg/day for only 13 weeks and were sacrificed at various times shown in the table below; this short dosing period and the short times to sacrifice do not meet the inclusion rules of the CPDB (at least 26 weeks dosing and 52 weeks experiment length). In the 69-week experiment that meets the inclusion rules, the only target site was forestomach. Kidney and bladder were additional target sites in the groups that were administered higher doses for 13 weeks; tumor incidence data are given in the table below for each sacrifice time. The table reports the dose as administered for 13 weeks and not the CPDB daily dose-rate or a TD<sub>50</sub> value, because the serial sacrifice experiments do not meet the CPDB inclusion rules.

Rat Sex	Tissue	Tumor	Weeks of Exposure duration	Weeks to Sacrifice	Administered dose by gavage (mg/kg/day)			
					0	0.1	1	10
f	Forestomach	sqp	13	13	0/9	0/9	8/9	10/10
		sqp, sqc	13	26	0/10	0/5	7/10	13/13
		sqp, sqc	13	39	0/7		9/11	4/4
		sqp, sqc	13	52	0/7	2/6		
		sqp, sqc	52 <sup>a</sup>	69 <sup>a</sup>	0/4	4/5		
	Kidney cortex	coc	13	26	0/10	0/5	0/10	2/13
		coa	13	39	0/7		0/11	4/4
	Urinary bladder	tpp, tcc	13	26	0/10	0/5	0/10	2/13
		tpp	13	39	0/7		0/11	1/4
	m	Forestomach	sqp	13	13	0/9	0/9	7/9
sqp, sqc			13	26	0/10	0/5	9/11	18/18
sqp, sqc			13	39	0/6		9/9	
sqp, sqc			13	52	0/6	4/7		
sqc			52 <sup>a</sup>	69 <sup>a</sup>	0/5	4/4		
Kidney/pelvis		tcc	13	26	0/10	0/5	0/11	8/18
Kidney cortex		coa	13	39	0/6		1/9	
Urinary bladder		tpp, tcc	13	26	0/10	0/5	0/11	6/18

<sup>a</sup> Experiment is included in CPDB since exposure and experiment length meet inclusion rules.

**Appendix 7: Dose-response curve and plot symbols**

Code	Chemical Symbol
***	Follows the chemical name in the plot to indicate that the chemical has additional earlier experiments in the CPDB
Code	Dose-Response Curve
*	Consistent with linearity
/	Significant departure from linearity, upward curvature
\	Significant departure from linearity, downward curvature
Z	Significant departure from linearity, more than three dose groups including controls
	For \ and Z, if there was significant downward departure from linearity, the TD <sub>50</sub> was calculated without the data from the highest dose group(s). In the plot, parentheses around the tumor incidence for a dose group indicate that the data were omitted from the final TD <sub>50</sub> calculation.
blank	Either no dose-related effect, or no curve shape could be determined because experiment had only two dose groups including controls

Code	Plot symbol (appears once per experiment, for the most potent TD <sub>50</sub> )
+	TD <sub>50</sub> p≤0.01
±	TD <sub>50</sub> 0.01<p≤0.1
<+	100% of dosed animals had the tumor and p<0.0005. Only an upper confidence limit could be calculated.
>	For all TD <sub>50</sub> s in the experiment p>0.10
:	TD <sub>50</sub> estimated with lifetable data, and “:” indicates 99% confidence limits
.	TD <sub>50</sub> estimated with summary data, and “.” indicates 99% confidence limits
#	For NTP bioassays evaluated as having no evidence of carcinogenicity, a statistically significant increase in tumors occurred in one or more sites (p<0.05). We have indicated this by placing a “-” in the opinion column and flagging the TD <sub>50</sub> with a “#” sign in the plot just to the left of the TD <sub>50</sub> value.

**Appendix 8: Author's opinion**

Code	Author's Opinion for Each Site
+	For general literature, the author evaluated site as positive.
-	NTP evaluation is <i>no evidence</i> of carcinogenic activity, i.e. "studies that are interpreted as showing no chemically related increases in malignant or benign neoplasms." In the general literature author evaluated the site or the experiment as negative.
blank	For NTP and general literature: a tissue and tumor combination for which no author's opinion is stated.
a	NCI evaluation is that the incidence of tumors at that site(s) was associated with administration of the compound.
c	NTP evaluation is <i>clear evidence</i> of carcinogenic activity, i.e. "studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy."
e	NTP evaluation is <i>equivocal evidence</i> of carcinogenic activity, i.e. "studies that are interpreted as showing a marginal increase of neoplasms that may be chemically related."
p	NTP evaluation is <i>some evidence</i> of carcinogenic activity, i.e. "studies that are interpreted as showing a chemically related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence."
+hist	Appears to the left of the TD <sub>50</sub> value when a positive opinion is based on a comparison of tumor incidence in dosed animals to historical control animals, e.g., for a rare tumor. The actual numbers of animals bearing such tumors may be quite low.

**Appendix 9: Berkeley codes for NCI/NTP Bioassays**

Code	Definitions of Berkeley Codes
C	The TD <sub>50</sub> includes all animals with a tumor at any site with a "c" opinion. The mix was created for the CPDB, and MXB appears on the left side of the plot.
M	The TD <sub>50</sub> includes all animals with a tumor at any site with a "c" or "p" opinion. The mix was created for the CPDB, and MXB appears on the left side of the plot.
P	The TD <sub>50</sub> includes all animals with a tumor at any site with a "p" opinion. The mix was created for the CPDB, and MXB appears on the left side of the plot.
S	The TD <sub>50</sub> has been included in the plot because the sites were statistically significant in the tables of analyses of primary tumors, and the TD <sub>50</sub> based on lifetable analysis was significant at the $p < 0.05$ level; however, the NCI/NTP report did not evaluate the site as evidence of carcinogenicity. The statistical sites reported in the CPDB are dependent upon the statistically significant results reported in NCI/NTP Technical Reports. Over time, the statistical tests included in Technical Reports have changed.

**Appendix 10: Journals**

Code	Reference
ahae	Acta Haematologica
aihm	Archives of Industrial Hygiene and Occupational Medicine
amjc	American Journal of Cardiology
ancl	Annals of Clinical and Laboratory Science
apab	Aspartame: Physiology and Biochemistry (L. D. Stegink and L. J. Filer, Jr., Eds.), Marcel Dekker, New York, 1984.
artx	Archives of Toxicology
arzn	Arzneimittel-Forschung
bjca	British Journal of Cancer
bnch	Bioinorganic Chemistry (journal name changed to Journal of Inorganic Chemistry in 1979)
canr	Cancer Research
carc	Carcinogenesis
clet	Cancer Letters
clnr	Kiso to Rinsho (The Clinical Report)
cthf	Comparative Toxicology of Hypolipidaemic Fibrates (M. J. Tucker, T. C. Orton), Taylor and Francis, London, 1995.
drug	Drug Investigation
eaes	Ecotoxicology and Environmental Safety
ejca	European Journal of Cancer and Clinical Oncology (formerly European Journal of Cancer until 1982)
ejtx	European Journal of Toxicology
expl	Experimental Pathology
extp	Experimental and Toxicologic Pathology
faat	Fundamental and Applied Toxicology (journal name changed to Toxicological Sciences in December 1997)
fctx	Food and Chemical Toxicology (formerly Food and Cosmetics Toxicology until 1982)
gann	Japanese Journal of Cancer Research (formerly Gann until 1984)
guts	Gut
hjkx	Huanjing Kexue Xuebao
huet	Human & Experimental Toxicology
icmr	Proceedings of the ICMR Seminar (International Center for Medical Research, Kobe, Japan)
ijeb	Indian Journal of Experimental Biology
iyke	Iyakuin Kenkyu
japa	Journal of American Pharmaceutical Association
jctx	Journal of Combustion Toxicology
jepo	Journal of Environmental Pathology, Toxicology and Oncology
jjpt	Japanese Pharmacology and Therapeutics (Yakuri to Chiryō)
jjvs	Japanese Journal of Veterinary Science
jnci	Journal of the National Cancer Institute
jnma	Journal of the Nara Medical Association
jnut	Journal of Nutrition
jsms	Journal of Saitama Medical School
jsol	Japanese Science of Labour
jtrl	Takeda Kenkyusho Ho (Journal of the Takeda Research Laboratory)
jtxe	Journal of Toxicology and Environmental Health
jtxp	Journal of Toxicologic Pathology
jtxs	Journal of Toxicological Sciences
lmdl	La Medicina del Lavoro

Code	Reference	CAS Number	Chemical Name
oncr	Oncology Reports	10190-99-5	ARISTOLOCHIC ACID, SODIUM SALT (77% AA I, 21% AA II)
phrm	Pharmacometrics (Oyo Yakuri)		
ponr	Pathology Oncology Research	1327-53-3	ARSENIC TRIOXIDE (see ARSENIUS OXIDE)
scch	Science in China		
srtu	The Science Reports of the Research Institutes, Tohoku University. Series C: Medicine	1327-53-3	ARSENIUS OXIDE***
		7784-46-5	ARSENITE, SODIUM***
stnd	Safety Testing of New Drugs: Laboratory Predictions and Clinical Performance (D. R. Laurence, A. E. M. McLean, and M. Weatherall, Eds.), Academic Press, Orlando, 1984.	22839-47-0	ASPARTAME***
		68844-77-9	ASTEMIZOLE
		123524-52-7	AZELNIDIPINE
		30516-87-1	3'-AZIDO-3'-DEOXYTHYMIDINE (see AZT)
surg	Surgery Today	30516-87-1	AZT
tcam	Teratogenesis, Carcinogenesis, and Mutagenesis	144-02-5	BARBITAL, SODIUM***
tmrl	Tokyo Metropolitan Research Laboratory of Public Health, Annual Report	83480-29-9	BASEN (see VOGLIBOSE)
		92-87-5	BENZIDINE***
txap	Toxicology and Applied Pharmacology	91-64-5	1,2-BENZOPYRONE*** (see COUMARIN)
txcy	Toxicology	14504-15-5	3-BENZYLSDNONE-4-ACETAMIDE
txpy	Toxicologic Pathology	25013-16-5	BHA*** (see BUTYLATED HYDROXY-ANISOLE)
vivo	In Vivo		
zkko	Journal of Cancer Research and Clinical Oncology (formerly Zeitschrift für Krebsforschung und Klinische Onkologie until 1979)	82657-04-3	BIFENTHRIN
		79520-77-7	5,5'-(1,1'-BIPHENYL)-2,5-DIYLBIS(OXY)(2,2-DIMETHYLPENTANOIC ACID)
		76150-91-9	1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE
		54381-16-7	N,N-BIS(2-HYDROXYETHYL)-p-PHENYLENEDIAMINE (see 2,2'-[(4-AMINO-PHENYL)IMINO]BIETHANOL SULFATE)
		---	BL-6341.HCl (see 3-AMINO-4-[2-[(2-GUANIDINOTHIAZOL-4-YL)METHYLTHIO], ETHYLAMINO]-1,2,5-THIADIAZOLE 1-OXIDE.HCl)

### Appendix 11: Chemical Names And Synonyms In This Plot

Chemicals with earlier experiments in the CPDB have "\*\*\*\*" following the name.

CAS Number	Chemical Name	CAS Number	Chemical Name
10190-99-5	AA (see ARISTOLOCHIC ACID, SODIUM SALT (77% AA I, 21% AA II))		
112665-43-7	AA-2414 (see (±)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYL-HEPTANOIC ACID)	7758-01-2	BROMATE, POTASSIUM***
56980-93-9	3-[3-ACETYL-4-[3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY]PHENYL]-1,1-DIETHYLUREA.HCl*** (see CELIPROLOL)	27753-52-2	BROMKAL 80-9D (see NONABROMOBIPHENYL)
18699-02-0	4-ACETYLAMINOPHENYLACETIC ACID	85-68-7	BUTYL BENZYL PHTHALATE***
616-91-1	N-ACETYLCYSTEINE	3817-11-6	BUTYL-BUTANOL-NITROSAMINE*** (see N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE)
79-06-1	ACRYLAMIDE***	25013-16-5	2(3)-tert-BUTYL-4-HYDROXYANISOLE*** (see BUTYLATED HYDROXYANISOLE)
22131-79-9	ALCLOFENAC	3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE***
64-17-5	ALCOHOL (see ETHYL ALCOHOL)	62774-96-3	(±)-4-(3-tert-BUTYLAMINO-2-HYDROXY-PROPOXY)-2-METHYL-1-(2H)-ISOQUINOLINONE.HCl (see TILISOLOL.HCl)
22131-79-9	(4-ALLYLOXY-3-CHLOROPHENYL)ACETIC ACID (see ALCLOFENAC)	25013-16-5	BUTYLATED HYDROXYANISOLE***
915-67-3	AMARANTH*** (see FD & C RED NO. 2)	1948-33-0	tert-BUTYLHYDROQUINONE
---	3-AMINO-4-[2-[(2-GUANIDINOTHIAZOL-4-YL)METHYLTHIO], ETHYLAMINO]-1,2,5-THIADIAZOLE 1-OXIDE.HCl	75-60-5	CACODYLIC ACID*** (see DIMETHYLARSINIC ACID)
---	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-b]-PYRIDINE.HCl*** (see PhIP.HCl)	7546-30-7	CALOMEL (see MERCUROUS CHLORIDE)
60142-96-3	1-(AMINOMETHYL)CYCLOHEXANE-ACETIC ACID***	136511-29-0	Camellia sinensis (see CATECHINS, COMMERCIAL MIXTURE FROM GREEN TEA (91% CATECHINS))
54381-16-7	2,2'-[(4-AMINOPHENYL)IMINO]BIS-ETHANOL SULFATE	145040-37-5	CANDESARTAN CILEXETIL
13265-60-6	AMIPHOS (see O,O-DIMETHYL S-2(ACETYLAMINO)ETHYL DITHIOPHOSPHATE, TECHNICAL GRADE)	1563-66-2	CARBOFURAN
427-51-0	ANDROCUR (see CYPROTERONE ACETATE)	7235-40-7	beta-CAROTENE
83480-29-9	AO-128 (see VOGLIBOSE)	136511-29-0	CATECHINS, COMMERCIAL MIXTURE FROM GREEN TEA (91% CATECHINS)
		56980-93-9	CELIPROLOL***
		7782-50-5	CHLORINE***

CAS Number	Chemical Name	CAS Number	Chemical Name
77439-76-0	3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE	---	(±)-4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-PHENYLACETATE.HCl MONOHYDRATE
127-00-4	1-CHLORO-2-PROPANOL, TECHNICAL GRADE (~75% 1-CHLORO-2-PROPANOL; ~25% 2-CHLORO-1-PROPANOL)	111-46-6	DIETHYLENE GLYCOL***
117279-73-9	(±)-(4)-(2-CHLOROPHENYL)-2-[2-(4-ISOBUTYLPHENYL)ETHYL]-6,9-DIMETHYL-6H-THIENO[3,2-f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINE	458-37-7	DIFERULOYLMETHANE (see TURMERIC (>98% CURCUMIN))
126-99-8	CHLOROPRENE	70052-12-9	2-(DIFLUOROMETHYL)-DL-ORNITHINE***
79520-77-7	CI-924 (see 5,5'-(1,1'-BIPHENYL)-2,5-DIYLBIS(OXY)(2,2-DIMETHYLPENTANOIC ACID))	1592-36-5	3,3'-DIHYDROXYBENZIDINE.2HCl
51481-61-9	CIMETIDINE***	55721-11-4	24R,25-DIHYDROXYVITAMIN D3 DIMETHOATE***
52214-84-3	CIPROFIBRATE***	60-51-5	3,3'-DIMETHOXYBENZIDINE.2HCl***
61477-94-9	cis-(±)-alpha-[3-(2,6-DIMETHYL-1-PIPERIDINYL)PROPYL]-alpha-PHENYL-2-PYRIDINEMETHANOL.HCl (see PIRMENOL.HCl)	20325-40-0	O,O-DIMETHYL S-2(ACETYLAMINO)ETHYL DITHIOPHOSPHATE, TECHNICAL GRADE
22494-47-9	CLOBUZARIT	13265-60-6	2,2-DIMETHYL-5-(2,5-XYLYLOXY)VALERIC ACID (see GEMFIBROZIL)
637-07-0	CLOFIBRATE***	127-19-5	DIMETHYLACETAMIDE
10026-24-1	COBALT SULFATE HEPTAHYDRATE	75-60-5	DIMETHYLARSINIC ACID***
91-64-5	COUMARIN***	123-91-1	1,4-DIOXANE***
458-37-7	CURCUMIN (see TURMERIC (>98% CURCUMIN))	123-91-1	p-DIOXANE*** (see 1,4-DIOXANE)
89667-40-3	CV-4151 (see (E)-7-PHENYL-7-(3-PYRIDYL)-6-HEPTENOIC ACID)	80702-47-2	DISODIUM 5'-RIBONUCLEOTIDE
157480-33-6	CYANOQUANIDINE	90-43-7	DOWICIDE 1*** (see o-PHENYLPHENOL)
31698-14-3	CYCLOCYTIDINE	150-69-6	DULCIN (see 4-ETHOXY-PHENYLUREA)
7585-39-9	beta-CYCLODEXTRIN	1406-66-2	E-MIX 80 (see DL-TOCOPHEROL, MIXTURE OF NATURAL ISOMERS (alpha, beta, gamma and delta))
1192-28-5	CYCLOPENTANONE OXIME	111011-76-8	EFONIDIPINE.HCl ETHANOLATE
427-51-0	CYPROTERONE ACETATE	115-29-7	ENDOSULFAN***
52-89-1	L-CYSTEINE.HCl	6673-35-4	ERALDIN (see PRACTOLOL)
13265-60-6	DAEP (see O,O-DIMETHYL S-2(ACETYLAMINO)ETHYL DITHIOPHOSPHATE, TECHNICAL GRADE)	16423-68-0	ERYTHROSINE*** (see FD & C RED NO. 3)
79-43-6	DCA (see DICHLOROACETIC ACID)	64-17-5	ETHANOL*** (see ETHYL ALCOHOL)
50-29-3	DDT***	67-21-0	DL-ETHIONINE***
1163-19-5	DECABROMODIPHENYL OXIDE, TECHNICAL GRADE (77.4% DBDPO, 21.8% NONABROMODIPHENYL OXIDE, 0.8% OCTABROMODIPHENYL OXIDE)	150-69-6	4-ETHOXY-PHENYLUREA
14484-47-0	DEFLAZACORT	64-17-5	ETHYL ALCOHOL***
117-81-7	DEHP*** (see DI(2-ETHYLHEXYL)PHTHALATE)	637-07-0	ETHYL-alpha-p-CHLOROPHENOXYISOBUTYRATE (see CLOFIBRATE)
53-43-0	DEHYDROEPIANDROSTERONE***	104-76-7	2-ETHYLHEXANOL
51481-10-8	DEOXYNIVALENOL	117-81-7	DI(2-ETHYLHEXYL)PHTHALATE***
1717-00-6	1,1-DICHLORO-1-FLUOROETHANE	77-09-8	EX-LAX (see PHENOLPHTHALEIN)
79-43-6	DICHLOROACETIC ACID***	102676-31-3	FADROZOLE.HCl
612-83-9	3,3'-DICHLOROBENZIDINE.2HCl	51-21-8	5-FLUOROURACIL***
94-75-7	2,4-DICHLOROPHENOXYACETIC ACID***	51-21-8	FLURACIL*** (see 5-FLUOROURACIL)
542-75-6	1,3-DICHLOROPROPENE (see TELONE II, TECHNICAL GRADE (WITHOUT EPICHLOROHYDRIN))	50-00-0	FORMALDEHYDE***
6724-53-4	2-(2-DICYCLOHEXYLETHYL)PIPERIDINE MALEATE (see PERHEXILINE MALEATE)	37076-68-9	FTORAFUR (see TEGAFUR)
		1563-66-2	FURADAN (see CARBOFURAN)
		37076-68-9	N1-2-FURAMIDYL-5-FLUOROURACIL (see TEGAFUR)
		21259-20-1	FUSARIOTOXIN T-2 (see T-2 TOXIN)
		60142-96-3	GABAPENTIN*** (see 1-(AMINOMETHYL)CYCLOHEXANEACETIC ACID)
		25812-30-0	GEMFIBROZIL***
		56-81-5	GLYCERIN, NATURAL
		56-81-5	GLYCERIN, SYNTHETIC
		55-63-0	GLYCERYL TRINITRATE*** (see TRINITROGLYCERIN)
		56-40-6	GLYCINE
		126-07-8	GRISEOFULVIN***
		811-97-2	HCFC 134a (see 1,1,1,2-TETRAFLUOROETHANE)

CAS Number	Chemical Name	CAS Number	Chemical Name
1717-00-6	HCFC 141b (see 1,1-DICHLORO-1-FLUORO-ETHANE)	91-59-8	beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)
89226-75-5	CV-4093.2HCl (see MANIDIPINE.2HCl)	2611-82-7	NEW COCCINE (see SX PURPLE)
680-31-9	HEXAMETHYLPHOSPHORAMIDE	7632-00-0	NITRITE, SODIUM***
68844-77-9	HISMANAL (see ASTEMIZOLE)	627-05-4	1-NITROBUTANE
645-35-2	L-HISTIDINE.HCl	600-24-8	2-NITROBUTANE
302-01-2	HYDRAZINE***	607-57-8	2-NITROFLUORENE
10034-93-2	HYDRAZINE SULFATE***	55-63-0	NITROGLYCERIN*** (see TRINITROGLYCERIN)
306-83-2	HYDROCHLOROFLUOROCARBON 123	75-52-5	NITROMETHANE
83480-29-9	(+)-1L-[1(OH),2,4,5/3]-5-[2-HYDROXY-1-(HYDROXYMETHYL)ETHYL]AMINO-1-C-(HYDROXYMETHYL)-1,2,3,4-CYCLO-HEXANETETROL (see VOGLIBOSE)	551-88-2	3-NITROPENTANE
129-43-1	1-HYDROXYANTHRAQUINONE***	27753-52-2	NONABROMOBIPHENYL
84545-30-2	ICI 162846 (see 3-((IMINO((2,2,2-TRIFLUOROETHYL)AMINO)METHYL)AMINO)-1H-PYRAZOLE-1-PENTAMIDE)	---	NS-21 (see (±)-4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLO-HEXYL-2-HYDROXY-PHENYL-ACETATE.HCl MONOHYDRATE)
84545-30-2	3-((IMINO((2,2,2-TRIFLUOROETHYL)AMINO)METHYL)AMINO)-1H-PYRAZOLE-1-PENTAMIDE	111011-76-8	NZ-105 ETHANOLATE (see EFONIDIPINE.HCl ETHANOLATE)
120-72-9	INDOLE	117-81-7	DI-sec-OCTYL PHTHALATE*** (see DI(2-ETHYLHEXYL)PHTHALATE)
53-86-1	INDOMETHACIN***	121854-29-3	OLESTRA
15503-86-3	ISATIDINE	64224-21-1	OLTIPRAZ***
89667-40-3	ISBOGREL (see (E)-7-PHENYL-7-(3-PYRIDYL)-6-HEPTENOIC ACID)	150821-03-7	ONO-1078 HYDRATE (see PRANLUKAST HYDRATE)
115-11-7	ISOBUTENE	90-43-7	ORTHOXENOL*** (see o-PHENYLPHENOL)
67-63-0	ISOPROPANOL	604-75-1	OXAZEPAM***
70374-39-9	LORNOXICAM	150821-03-7	4-OXO-8-[4-(4-PHENYLBUTOXY)BENZ-ZOYLAMINO]-2-(TETRAZOL-5-YL)-4H-1-BENZOPYRAN HYDRATE (see PRANLUKAST HYDRATE)
75330-75-5	LOVASTATIN	---	PALONIDIPINE.HCl
76956-02-0	LOXTIDINE	6724-53-4	PERHEXILINE MALEATE
72716-75-7	LUPITIDINE.3HCl	50-06-6	PHENOBARBITAL***
89226-75-5	MANIDIPINE.2HCl	50-06-6	PHENOBARBITONE*** (see PHENOBARBITAL)
71125-38-7	MELOXICAM	77-09-8	PHENOLPHTHALEIN***
7546-30-7	MERCUROUS CHLORIDE***	89667-40-3	(E)-7-PHENYL-7-(3-PYRIDYL)-6-HEPTENOIC ACID
115-09-3	MERCURYMETHYL CHLORIDE***	---	PHENYLETHYL-3-METHYLCAFFEATE
34661-75-1	6-[[3-[4-(o-METHOXYPHENYL)-1-PIPERAZINYL]PROPYL]AMINO]-1,3-DIMETHYLURACIL (see URAPIDIL)	50-06-6	PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)
21340-68-1	METHYL CLOFENAPATE***	133920-06-6	6-PHENYLHEXYL ISOTHIOCYANATE***
132907-72-3	(R)-5-[(1-METHYL-3-INDOLYL)CARBONYL]-4,5,6,7-TETRAHYDRO-1H-BENZIMIDAZOLE.HCl (see RAMOSETRON.HCl)	132-27-4	o-PHENYLPHENATE, SODIUM*** (see o-PHENYLPHENOL, SODIUM)
80-62-6	METHYL METHACRYLATE***	90-43-7	o-PHENYLPHENOL***
70-25-7	N-METHYL-N'-NITRO-N-NITROSO-GUANIDINE***	132-27-4	o-PHENYLPHENOL, SODIUM***
115-09-3	METHYLMERCURY CHLORIDE*** (see MERCURYMETHYL CHLORIDE)	---	PhIP.HCl***
91-57-6	2-METHYLNAPHTHALENE	61477-94-9	PIRMENOL.HCl
75330-75-5	MEVACOR (see LOVASTATIN)	136511-29-0	POLYPHENON 100 (see CATECHINS, COMMERCIAL MIXTURE FROM GREEN TEA (91% CATECHINS))
70-25-7	MNNG*** (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)	2611-82-7	PONCEAU 4R*** (see SX PURPLE)
1313-27-5	MOLYBDENUM TRIOXIDE	7758-01-2	POTASSIUM BROMATE (see BROMATE, POTASSIUM)
124-58-3	MONOMETHYLARSONIC ACID	6673-35-4	PRACTOLOL
3792-50-5	MONOSODIUM ASPARTATE	150821-03-7	PRANLUKAST HYDRATE
142-47-2	L-MONOSODIUM GLUTAMATE***	79-06-1	2-PROPENAMIDE*** (see ACRYLAMIDE)
77439-76-0	MX (see 3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE)	2611-82-7	SX PURPLE***
62774-96-3	N-696 (see TILISOLOL.HCl)	81-54-9	PURPURIN
134-32-7	1-NAPHTHYLAMINE		
91-59-8	2-NAPHTHYLAMINE***		

CAS Number	Chemical Name	CAS Number	Chemical Name
64224-21-1	5-(2-PYRAZINYL)-4-METHYL-1,2-DITHIOLE-3-THIONE*** (see OLTIPRAZ)	4964-54-6	TRIMETHYLARSINE OXIDE
82586-55-8	QUINAPRIL.HCl	512-56-1	TRIMETHYLPHOSPHATE***
132907-72-3	RAMOSETRON.HCl	99-35-4	1,3,5-TRINITROBENZENE
915-67-3	FD & C RED NO. 2***	55-63-0	TRINITROGLYCERIN***
16423-68-0	FD & C RED NO. 3***	115-96-8	TRIS(2-CHLOROETHYL)PHOSPHATE***
2611-82-7	FOOD RED NO. 102*** (see SX PURPLE)	122-20-3	TRIS(2-HYDROXYPROPYL)AMINE***
3520-42-1	FOOD RED NO. 106	458-37-7	TURMERIC (>98% CURCUMIN)
302-79-4	RETINOIC ACID***	11034-63-2	TYLOSIN LACTATE
79-81-2	RETINOL PALMITATE***	34661-75-1	URAPIDIL
480-54-6	RETRORSINE	75-02-5	VINYL FLUORIDE
80702-47-2	RIBOTIDE (see DISODIUM 5'-RIBONUCLEOTIDE)	75-38-7	VINYLDENE FLUORIDE
128-44-9	SACCHARIN, SODIUM***	88-12-0	N-VINYLPYRROLIDONE-2
599-79-1	SALICYLAZOSULFAPYRIDINE	302-79-4	VITAMIN A ACID*** (see RETINOIC ACID)
6533-68-2	SCOPOLAMINE HYDROBROMIDE TRIHYDRATE	79-81-2	VITAMIN A, PALMITATE*** (see RETINOL PALMITATE)
55721-11-4	SECALCIFEROL (see 24R,25-DIHYDROXY-VITAMIN D3)	1406-66-2	VITAMIN E, NATURAL (see DL-TOCOPHEROL, MIXTURE OF NATURAL ISOMERS (alpha, beta, gamma and delta))
7446-08-4	SELENITE (see SELENIUM DIOXIDE)	83480-29-9	VOGLIBOSE
7446-08-4	SELENIUM DIOXIDE	133743-71-2	WATANIDIPINE.2HCl
72716-75-7	SK&F 93479-A3 (see LUPITIDINE.3HCl)	68953-84-4	WINGSTAY 100
7784-46-5	SODIUM ARSENITE (see ARSENITE, SODIUM)	15263-30-6	XIBENOLOL.HCl
144-55-8	SODIUM BICARBONATE***	117279-73-9	Y-24180 (see (±)-(4)-(2-CHLOROPHENYL)-2-[2-(4-ISOBUTYLPHENYL)ETHYL]-6,9-DIMETHYL-6H-THIENO[3,2-f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINE)
7632-00-0	SODIUM NITRITE (see NITRITE, SODIUM)	94238-00-3	GARDENIA YELLOW
57817-89-7	STEVIOSIDE	30516-87-1	ZDV (see AZT)
27470-51-5	SUXIBUZONE	30516-87-1	ZIDOVUDINE (see AZT)
21259-20-1	T-2 TOXIN	5970-45-6	ZINC (II) ACETATE DIHYDRATE
---	TALTIRELIN TETRAHYDRATE		
107-35-7	TAURINE		
---	TC-81 (see PALONIDIPINE.HCl)		
145040-37-5	TCV-116 (see CANDESARTAN CILEXETIL)		
---	TEA, GREEN, CATECHINS (see CATECHINS, COMMERCIAL MIXTURE FROM GREEN TEA (91% CATECHINS))		
37076-68-9	TEGAFUR		
542-75-6	TELONE II, TECHNICAL GRADE (WITHOUT EPICHLOROHYDRIN)		
811-97-2	1,1,1,2-TETRAFLUOROETHANE		
116-14-3	TETRAFLUOROETHYLENE		
109-99-9	TETRAHYDROFURAN		
58-55-9	THEOPHYLLINE		
148-79-8	THIABENDAZOLE***		
15318-45-3	THIAMPHENICOL		
148-79-8	2-(4-THIAZOLYL)-BENZIMAZOLE *** (see THIABENDAZOLE)		
115-29-7	THIODAN*** (see ENDOSULFAN)		
62774-96-3	TILISOLOL.HCl		
1406-66-2	DL-TOCOPHEROL, MIXTURE OF NATURAL ISOMERS (alpha, beta, gamma and delta)		
8001-35-2	TOXAPHENE***		
6264-66-0	3,4,4'-TRIAMINODIPHENYL ETHER		
52-68-6	TRICHLOROPHONE		
51481-10-8	3-alpha,7-alpha,15-TRIHYDROXY-12-13-EPOXYTRICHOTHECENE-9-en-8-one (see DEOXYNIVALENOL)		
112665-43-7	(±)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID		

## Appendix 12. Bibliography: National Toxicology Program Technical Reports

Chemical name	Technical report number	Publication date
AZT	TR469	1999
Butyl benzyl phthalate	TR458	1997
tert-Butylhydroquinone	TR459	1997
1-Chloro-2-propanol, technical grade	TR477	1998
Chloroprene	TR467	1998
Cobalt sulfate heptahydrate	TR471	1998
Isobutene	TR487	1998
Molybdenum trioxide	TR462	1997
Nitromethane	TR461	1997
Oxazepam	TR468	1998
Salicylazosulfapyridine	TR457	1997
Scopolamine hydrobromide trihydrate	TR445	1997
Tetrafluoroethylene	TR450	1997
Tetrahydrofuran	TR475	1998
Theophylline	TR473	1998



**Appendix 13. Bibliography: General Literature**

1. Alexander, D. J., Libretto, S. E., Chevalier, H.-J., Imamura, T., Pappritz, G., and Wilson, J. HFA-134a (1,1,1,2-tetrafluoroethane): lack of oncogenicity in rodents after inhalation. *Human Exp. Toxicol.* 14: 706-714(1995).
2. Allen, P. T., and Poirier, L. A. Suppression by phenobarbital of ethionine-induced hepatocellular carcinoma formation and hepatic S-adenosylethionine levels. *Carcinogenesis* 18: 1103-1107(1997).
3. Arnold, L. L., Eldan, M., van Gemert, M., Capen, C. C., and Cohen, S. M. Chronic studies evaluating the carcinogenicity of monomethylarsonic acid in rats and mice. *Toxicology* 190: 197-219(2003).
4. Astill, B. D., Gingell, R., Guest, D., Hellwig, J., Hodgson, J. R., Kuettler, K., Mellert, W., Murphy, S. R., Sielken, R. L., Jr., and Tyler, T. R. Oncogenicity testing of 2-ethylhexanol in Fischer 344 rats and B6C3F<sub>1</sub> mice. *Fundam. Appl. Toxicol.* 31: 29-41(1996).
5. Atkinson, J. E., Daly, I. W., Saulog, T. M., Eukuda, R., Tanakamaru, Z., and Nonoyama, T. Oncogenicity study of AO-128 in mice. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 19: 4427-4438(1991).
6. Ayers, K. M., Clive, D., Tucker, W. E., Jr., Hajian, G., and De Miranda, P. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. *Fundam. Appl. Toxicol.* 32: 148-158(1996).
7. Bellringer, M. E., Smith, T. G., Read, R., Gopinath, C., and Oliver, P.  $\beta$ -Cyclodextrin: 52-week toxicity studies in the rat and dog. *Food Chem. Toxicol.* 33: 367-376(1995).
8. Benze, J., Gypen, L., Vandenberghe, J., Lampo, A., De Coster, R., Bowden, C., and Van Cauteren, H. Carcinogenicity studies of astemizole in mice and rats. *Cancer Res.* 55: 5589-5594(1995).
9. Betton, G. R., Dormer, C. S., Wells, T., Pert, P., Price, C. A., and Buckley, P. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H<sub>2</sub>-antagonists SK & F 93479 and omeprazole. *Toxicol. Pathol.* 16: 288-298(1988).
10. Bogdanffy, M. S., Makovec, G. T., and Frame, S. R. Inhalation oncogenicity bioassay in rats and mice with vinyl fluoride. *Fundam. Appl. Toxicol.* 26: 223-238(1995).
11. Bomhard, E. M., Krinke, G. J., Rossberg, and W. M., Skripsky, Th. Trimethylphosphate: a 30-month chronic toxicity/carcinogenicity study in Wistar rats with administration in drinking water. *Fundam. Appl. Toxicol.* 40: 75-89(1997).
12. Burleigh-Flayer, H., Garman, R., Neptun, D., Bevan, C., Gardiner, T., Kapp, R., Tyler, T., and Wright, G. Isopropanol vapor inhalation oncogenicity study in Fischer 344 rats and CD-1 mice. *Fundam. Appl. Toxicol.* 36: 95-111(1997).
13. Butler, W. H., Cohen, S. H., and Squire, R. A. Mesenchymal tumors of the mouse urinary bladder with vascular and smooth muscle differentiation. *Toxicol. Pathol.* 25: 268-274(1997).
14. Carlton, B. D., Aubrun, J.-C., and Simon, G. S. Effects of coumarin following perinatal and chronic exposure in Sprague-Dawley rats and CD-1 mice. *Fundam. Appl. Toxicol.* 30: 145-151(1996).
15. Cattle, R. C., Conway, J. G., and Popp, J. A. Association of persistent peroxisome proliferation and oxidative injury with hepatocarcinogenicity in female F-344 rats fed di(2-ethylhexyl) phthalate for 2 years. *Cancer Lett.* 38: 15-22(1987).
16. Charles, J. M., Bond, D. M., Jeffries, T. K., Yano, B. L., Stott, W. T., Johnson, K. A., Cunny, H. C., Wilson, R. D., and Bus, J. S. Chronic dietary toxicity/oncogenicity studies on 2,4-dichlorophenoxyacetic acid in rodents. *Fundam. Appl. Toxicol.* 33: 166-172(1996).
17. Chatani, F., Nishida, N., Shikata, M., Spicer, E. J. F., Drafta, R. E., Blair, M., Thorstenson, J. H., Gordon, D. E., and Geil, R. G. Two-year dietary carcinogenicity study of CV-4151 in mice. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 23: 1205-1223(1995).
18. Chatani, F., Nishida, N., Shikata, M., Spicer, E. J. F., Drafta, R. E., Blair, M., Thorstenson, J. H., Chandra, M., and Geil, R. G. Two-year dietary carcinogenicity study of CV-4152 in rats. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 23: 1225-1238(1995).
19. Chemical Industry Institute of Toxicology. *Formaldehyde: Hazard Characterization and Dose-Response Assessment for Carcinogenicity by the Route of Inhalation*. Revised Edition. Research Triangle Park, NC: CIIT (1999).
20. Chung, F. L., Kelloff, G., Steele, V., Pittman, B., Zang, E., Jiao, D., Rigotty, J., Choi, C. I., and Rivenson, A. Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. *Cancer Res.* 56: 772-778(1996).
21. Collins, M. A., Rusch, G. M., Sato, F., Hext, P. M., and Millischer, R.-J. 1,1,1,2-Tetrafluoroethane: repeat exposure inhalation toxicity in the rat, developmental toxicity in the rabbit, and genotoxicity in vitro and in vivo. *Fundam. Appl. Toxicol.* 25: 271-280(1995).
22. Cornell, R. G., Wolfe, R. A., and Sanders, P. G. Aspartame and brain tumors: statistical issues. In: *Aspartame: Physiology and Biochemistry*, L. G. Stegind and L. J. Filer, Jr., eds. New York: Marcel Dekker, pp. 459-479 (1984).
23. Crowell, J. A., Page, J. G., Rodman, L. E., Heath, J. E., Goldenthal, E. I., Hall, L. B., and Kelloff, G. J. Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. *Fundam. Appl. Toxicol.* 35: 9-21(1997).
24. Cruickshank, J. M., Fitzgerald, J. D., and Tucker, M.  $\beta$ -adrenoceptor blocking drugs: pronethalol, propranolol and practolol. In: *Safety Testing of New Drugs: Laboratory Predictions and Clinical Performance*, D. R. Laurence, A. E. M. McLean, and M. Weatherall, eds. Orlando, FL: Academic Press, pp. 93-123 (1984).
25. Cui, X.-S., Torndal, U.-B., Eriksson, L. C., and Moller, L. Early formation of DNA adducts compared with tumor formation in a long-term tumor study in rats after administration of 2-nitrofluorene. *Carcinogenesis* 16: 2135-2141(1995).
26. Damjanov, I. and Friedman, M. A. Mesotheliomas of tunica vaginalis testis of Fischer 344 (F344) rats treated with acrylamide: a light and electron microscopy study. *In Vivo* 12: 495-502 (1998).
27. David, R. M., Moore, M. R., Cifone, M. A., Finney, D. C., and Guest, D. Chronic peroxisome proliferation and hepatomegaly associated with the hepatocellular tumorigenesis of di(2-ethylhexyl)phthalate and the effects of recovery. *Toxicol. Sci.* 50: 195-205(1999).
28. David, R. M., Moore, M. R., Finney, D. C., and Guest, D. Chronic toxicity of di(2-ethylhexyl)phthalate in rats. *Toxicol. Sci.* 55: 433-443 (2000).
29. DeAngelo, A. B., Daniel, F. B., Most, B. M., and Olson, G. R. The carcinogenicity of dichloroacetic acid in the male Fischer 344 rat. *Toxicology* 114: 207-221 (1996).
30. DeAngelo, A. B., George, M. H., and House, D. E. Hepatocarcinogenicity in the male B6C3F<sub>1</sub> mouse following a lifetime exposure to dichloroacetic acid in the drinking water: dose-response determination and modes of action. *J. Toxicol. Environ. Health A* 58: 485-507 (1999).
31. DeAngelo, A. B., George, M. H., Kilburn, S. R., Moore, T. M., and Wolf, D. C. Carcinogenicity of potassium bromate administered in drinking water to male B6C3F<sub>1</sub> mice and F344/N rats. *Toxicol. Pathol.* 26: 587-594. (1998).
32. Diwan, B. A., Anderson, L. M., Ward, J. M., Henneman, J. R., and Rice, J. M. Transplacental carcinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. *Toxicol. Appl. Pharmacol.* 132: 115-121(1995).
33. Diwan, B. A., Henneman, J. R., and Rice, J. M. Further evidence for promoter-dependent development of hepatoblastoma in the mouse. *Cancer Lett.* 89: 29-35(1995).
34. Diwan, B. A., Henneman, J. R., Rice, J. M., and Nims, R. W. Enhancement of thyroid and hepatocarcinogenesis by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene in rats at doses that cause maximal induction of CYP2B. *Carcinogenesis* 17: 37-43(1996).
35. Dominick, M. A., Robertson, D. G., Bleavins, M. R., Sigler, R. E., Bobrowski, W. F., and Gough, A. W. Alpha 2 $\mu$ -globulin nephropathy without nephrocarcinogenesis in male Wistar rats administered 1-(aminomethyl)cyclohexaneacetic acid. *Toxicol. Appl. Pharmacol.* 111: 375-387(1991).
36. El-Aaser, A. A., Hassanein, S. M., El-Bolkainy, M. N., Omar, S., El-Sebai, I., and El-Merzabani, M. M. Bladder carcinogenesis using

- bilharzia-infested Swiss albino mice. *Eur. J. Cancer* 14: 645-648(1978).
37. El-Mofty, M. M., Shwaireb, M. H., Essaway, A. E., Rizk, A. M., and Abdel-Kerim, H. M. Induction of breast neoplasia and lung granulomas in mice by an antifungal drug (griseofulvin). *Oncology Reports* 1: 1079-1081(1994).
38. Everett, D. J., Jones, M., Perry, C. J., Rushton, B., Wilson, A. B., Fujii, O., and Roba, J. Carcinogenicity bioassay of Alclofenac in rats. *Iyakuhin Kenkyu* 18: 201-217(1987).
39. Fiala, E. S., Sodum, R. S., Hussain, N. S., Rivenson, A., and Dolan, L. Secondary nitroalkanes: induction of DNA repair in rat hepatocytes, activation by aryl sulfotransferase and hepatocarcinogenicity of 2-nitrobutane and 3-nitropentane in male F344 rats. *Toxicology* 99: 89-97(1995).
40. FitzGerald, B. E., and Shank, R. C. Methylation status of DNA cytosine during the course of induction of liver cancer in hamsters by hydrazine sulfate. *Carcinogenesis* 17: 2703-2709(1996).
41. Fitzgerald, J. E., Sanyer, J. L., Schardein, J. L., Lake, R. S., McGuire, E. J., de la Iglesia, F. A. Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. *J. Nat. Cancer Inst.* 67: 1105-1115 (1981).
42. Fitzhugh, O. G., Nelson, A. A., and Frawley, J. P. A comparison of the chronic toxicities of synthetic sweetening agents. *J. Am. Pharmaceut. Assn.* 40: 583-586(1951).
43. Food and Drug Administration. *New Drug Application 19-643 (Trade: Mevacor, Generic Lovastatin)*. Sponsor: Merck Sharp & Dohme. Washington, DC: FDA (1987).
44. Friedman, M. A., Dulak, L. H., and Stedham, M. A. A lifetime oncogenicity study in rats with acrylamide. *Fundam. Appl. Toxicol.* 27: 95-105(1995).
45. Fujii, T., and Hiraga, K. Carcinogenicity testing of sodium orthophenylphenate in F344 rats. *J. Saitama Med. Sch.* 12: 277-287(1985).
46. Fujii, T., Mikuriya, H., Yoneyama, M., Yano, N., Yuzawa, K., Nagasawa, A., and Sasaki, M. Dietary toxicity test of *o*-phenylphenol and sodium hydrogencarbonate by simultaneous administration to mice for 52 weeks. *Tokyo Metrop. Lab. Public Health* 40: 298-306(1989).
47. Fujimoto, N., Sakai, Y., Kurisu, K., Roy, G., Watanabe, H., and Ito, A. Chronic toxicity study of gardenia yellow color in C57BL mice. *J. Toxicol. Pathol.* 7: 455-460(1994).
48. Gao, F.-M., Jiang, H.-Y., Lu, Y., Li, X.-L., Wang, W.-H., Duan, Y.-B., and Zhou, H.-N. Studies on mechanisms and blockade of carcinogenic action of female sex hormones. *Sci. China* 37: 419-428(1994).
49. Gibel, W. and Lohs, Kh. Carcinogenic hematotoxic and hepatotoxic effects of organic phosphate pesticides. *Environ. Qual. Safety* 4: 232-234 (1975).
50. Gibel, W., Lohs, Kh., Wildner, G. P., Ziebarth, D., and Stieglitz, R. Über die kanzerogene, hämatotoxische und hepatotoxische Wirkung pestizider organischer. *Phosphorverbindungen. Arch. Geschwulstforsch.* 41: 311-328 (1973).
51. Goodman, J. I., Brusick, D. J., Busey, W. M., Cohen, S. M., Lamb, J. C., and Starr, T. B. Reevaluation of the cancer potency factor of toxaphene: recommendations from a peer review panel. *Toxicol. Sci.* 55: 3-16(2000).
52. Graillot, C., Gak, J.-C., Lancret, C., and Truhaut, R. Recherche sur les modalités et les mécanismes d'action toxique des insecticides organochlorés. II. Étude chez le hamster des effets de toxicité à long terme du DDT. *Eur. J. Toxicol.* 8: 353-359(1975).
53. Griciuté, L., and Domkiené, V. Experimental study on the carcinogenicity of the cytostatic drug ftorafur (tegafur). *Pathol. Oncol. Res.* 2: 69-70(1996).
54. Griffin, T. B., Coulston, F., and Stein, A. A. Chronic inhalation exposure of rats to nitromethane. *Ecotoxicol. Environ. Saf.* 34: 109-117(1996).
55. Gunson, D. E., Steele, R. E., and Chau, R. Y. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. *Br. J. Cancer* 72: 72-75(1995).
56. Hack, R., Ebert, E., and Leist, K.-H. Chronic toxicity and carcinogenicity studies with the insecticide endosulfan in rats and mice. *Food Chem. Toxicol.* 33: 941-950(1995).
57. Hagiwara, A., Miyata, E., Tamano, S., Shibata, M.-A., Sugimura, S., Inoue, M., and Hirose, M. Non-carcinogenicity of 2,2'-(4-aminophenyl)imino]bisethanol sulfate in a long-term feeding study in Fischer 344 rats. *Food Chem. Toxicol.* 34: 537-546(1996).
58. Hamada, N. N., Koka, M., Quander, R., Uno, H., Koyama, T., Izawa, Y., and Makita, T. Toxicity studies of palonidipine hydrochloride (TC-81) (14<sup>th</sup> report) — Two-year dietary oncogenicity study in rats. *Clin. Rep. (Kiso to Rinscho)* 26: 3075-3096(1992).
59. Hamm, T. E., Jr., Guest, D., and Dent, J. G. Chronic toxicity and oncogenicity bioassay of inhaled ethylene in Fischer-344 rats. *Fundam. Appl. Toxicol.* 4: 473-478(1984).
60. Hashimoto, Y., Makita, T., Nishibe, T., Mori, T., Noguchi, T., and Ohta, G. Chronic oral toxicity studies of DAEP, *O,O*-dimethyl *S*-2-(acetylamino)ethyl dithiophosphate (active ingredients of amiphos) in Sprague-Dawley strain rats. *Pharmacometrics (Oyo Yakuri)* 6: 1189-1205(1972).
61. Hatch, R. C., Regan, K. S., Ishibashi, S., Nakazawa, M., Iwakura, K., and Sumi, N. Seventy-eight-week dietary carcinogenicity study of (±)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice. *J. Toxicol. Sci.* 22: 275-287(1997).
62. Hatch, R. C., Regan, K. S., Ishibashi, S., Nakazawa, M., Iwakura, K., and Sumi, N. Two-year dietary carcinogenicity study of (±)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats. *J. Toxicol. Sci.* 22: 289-309(1997).
63. Hawkes, C. H., Cavanagh, J. B., Darling, J. L., Watkins, B. A., and Thomas, D. G. T. Chronic low-dose exposure of sodium nitrite in VM-strain mice: central nervous system changes. *Hum. Exp. Toxicol.* 11: 279-281(1992).
64. Hazleton Laboratories. [Aspartame] *Final Report: Two-year Toxicity Study in the Rat*. Project No. 700-233. Sponsor: Searle Laboratories (1973).
65. Heywood, R., Palmer, A. K., Gregson, R. L., and Hummler, H. The toxicity of β-carotene. *Toxicology* 36: 91-100(1985).
66. Heywood, R., Palmer, A. K., Gregson, R. L., and Hummler, H. *The Toxicity of β-Carotene*. Huntingdon, England: Huntingdon Research Center (1985a).
67. Hiasa, Y., Kitahori, Y., Morimoto, J., Konishi, N., and Ohshima, M. Absence of carcinogenic or promoting effects of diethylene glycol on renal tumorigenesis in rats. *J. Toxicol. Pathol.* 3: 97-104(1990).
68. Hine, C. H., Anderson, H. H., Moon, H. D., Dunlap, M. K., and Morse, M. S. Comparative toxicity of synthetic and natural glycerin. *Arch. Ind. Hyg. Occup. Med.* 7: 282-291(1953).
69. Hirano, M., Mitsumori, K., Maita, K., and Shirasu, Y. Further carcinogenicity study on methylmercury chloride in ICR mice. *Jpn. J. Vet. Sci.* 48: 127-135(1986).
70. Hirayama, H., Sugihara, T., Sugihara, K., Wakigawa, K., Hikita, J., and Ohkuma, H. Carcinogenicity and long-term toxicity study on cyclocytidine, a new antitumor agent. *Pharmacometrics (Oyo Yakuri)* 8: 1693-1712(1974).
71. Hirose, M., Akagi, K., Hasegawa, R., Yaono, M., Satoh, T., Hara, Y., Wakabayashi, K., and Ito, N. Chemoprevention of 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]-pyridine (PhIP)-induced mammary gland carcinogenesis by antioxidants in F344 female rats. *Carcinogenesis* 16: 217-221(1995).
72. Hirth, R. S., Evans, L. D., Buroker, R. A., and Oleson, F. B. Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: an indirect effect of the histamine H<sub>2</sub>-receptor antagonist, BL-6341. *Toxicol. Pathol.* 16: 273-287(1988).
73. Ho, S. B., Lyftogt, C. T., Shekels, L. L., and Niehans, G. A. Experimental model of upper intestinal adenocarcinoma induced by *N*-methyl-*N*'-nitro-*N*-nitrosoguanidine in C57BL/6 mice. *Cancer Lett.* 91: 177-183(1995).

74. Holmång, S., Cano, M., Grenabo, L., Hedelin, H., and Johansson, S. L. Effect of indomethacin on *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced urinary tract carcinogenesis. *Carcinogenesis* 16: 1493-1498(1995).
75. Horiuchi, T., Masuda, S., Iwasaka, T., Ito, K., Nakayama, T., Eguchi, K., Usui, T., Makino, M., Yamamoto, T., Hisada, S., and Suzuki, M. Carcinogenicity test of a potent  $\beta$ -blocking agent, xibenolol hydrochloride, on B6C3F<sub>1</sub> mice. *Pharmacometrics (Oyo Yakuri)* 30: 705-721(1985).
76. Iatropoulos, M. J., Williams, G. M., Wang, C.-X., Brunnemann, K. D., and Leber, A. P. Assessment of chronic toxicity and carcinogenicity in rats of Wingstay 100, a rubber antioxidant/antiozonant. *Exp. Toxicol. Pathol.* 49: 153-165(1997).
77. Ikezaki, S., Nishikawa, A., Furukawa, F., Enami, T., Mitsui, M., Tanakamaru, Z., Kim, H.-C., Lee, I.-S., Imazawa, T., and Takahashi, M. Long-term toxicity/carcinogenicity study of *l*-histidine monohydrochloride in F344 rats. *Food Chem. Toxicol.* 34: 687-691(1996).
78. Ikezaki, S., Nishikawa, A., Furukawa, F., Tanakamura, Z.-Y., Kim, H.-C., Mori, H., and Takahashi, M. Chemopreventive effects of 24*R*,25-dihydroxyvitamin D<sub>3</sub>, a vitamin D<sub>3</sub> derivative, on glandular stomach carcinogenesis induced in rats by *N*-methyl-*N*-nitro-*N*-nitrosoguanidine and sodium chloride. *Cancer Res.* 56: 2767-2770(1996).
79. Inai, K., Aoki, Y., and Tokuoka, S. Chronic toxicity of sodium nitrite in mice, with reference to its tumorigenicity. *Jpn. J. Cancer Res.* 70: 203-208(1979).
80. Inoue, H., Shoji, A., Yamamoto, T., Watari, N., Hirouchi, Y., Enomoto, M., Sakashita, M., and Nishi, N. Test of NZ-105 in rats carcinogenicity. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 20: 1775-1803(1992).
81. Inoue, H., Shoji, A., Yamamoto, T., Watari, N., Shiga, A., Enomoto, M., Sakashita, M., and Nishi, N. Test of NZ-105 in mice carcinogenicity. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 20: 1747-1773(1992).
82. Inoue, H., Yamamoto, T., Hirouchi, Y., Iwata, H., Kobayashi, K., and Enomoto, M. Carcinogenicity test of suxibuzone in rats. *Iyakuhin Kenkyū* 18: 345-359(1987).
83. Ishida, S., Ikeya, M., Fukuzumi, H., Tamura, K., Hatayama, K., Ishii, S., Kawabata, Y., Koshihara, H., and Abe, S. Carcinogenicity study of watanidipine hydrochloride in mice by dietary administration. *Jpn. Pharmacol. Ther.* 25: 227-246(1997).
84. Ishida, S., Ikeya, M., Fukuzumi, H., Tamura, K., Hatayama, K., Ishii, S., Kawabata, Y., Koshihara, H., and Abe, S. Carcinogenicity study of watanidipine hydrochloride in rats by dietary administration. *Jpn. Pharmacol. Ther.* 25: 247-270(1997).
85. Ito, N., Shirai, T., Fukushima, S., and Hirose, M. Dose-response study of urinary bladder carcinogenesis in rats by *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine. *J. Cancer Res. Clin. Oncol.* 108: 169-173(1984).
86. Iverson, F., Armstrong, C., Nera, E., Truelove, J., Fernie, S., Scott, P., Stapley, R., Hayward, S., and Gunner, S. Chronic feeding study of deoxynivalenol in B6C3F<sub>1</sub> male and female mice. *Teratog. Carcinog. Mutagen.* 15: 283-306(1995).
87. Iwagawa, M., Nakamura, M., Izumi, K., and Otsuka, H. Carcinogenicity testing of 5-fluorouracil in (C57BL/6×C3H)F<sub>1</sub> mice. *J. Toxicol. Pathol.* 4: 129-135(1991).
88. James, R. W., Hooks, W. N., Gopinath, C., Lewis, D. J., and Kawase, S. Tumorigenicity study of orally administered (±)-4-(3-tert-butylamino-2-hydroxypropoxy)-2-methyl-1(2*H*)-isoquinolinone hydrochloride (N-696), a  $\beta$ -adrenergic blocking agent, in CD-1 mice. *Pharmacometrics (Oyo Yakuri)* 36: 261-270(1988).
89. James, R. W., Hooks, W. N., Gopinath, C., Lewis, D. J., and Kawase, S. Tumorigenicity study of orally administered (±)-4-(3-tert-butylamino-2-hydroxypropoxy)-2-methyl-1(2*H*)-isoquinolinone hydrochloride (N-696), a  $\beta$ -adrenergic blocking agent, in Sprague-Dawley rats. *Pharmacometrics (Oyo Yakuri)* 35: 425-435(1988).
90. Johnson, K. A., Gorzinski, S. J., Bodner, K. M., Campbell, R. A., Wolf, C. H., Friedman, M. A., and Mast, R. W. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. *Toxicol. Appl. Pharmacol.* 85: 154-168(1986).
91. Jones, R. C., Sugie, S., Braley, J., and Weisburger, J. H. Dietary  $\beta$ -carotene in rat models of gastrointestinal cancer. *J. Nutr.* 119: 508-514(1989).
92. Kamata, E., Nakadate, M., Uchida, O., Ogawa, Y., Suzuki, S., Kaneko, T., Saito, M., and Kurokawa, Y. Results of a 28-month chronic inhalation toxicity study of formaldehyde in male Fisher-344 rats. *J. Toxicol. Sci.* 22: 239-254(1997).
93. Kitahori, Y., Kitamura, M., Konishi, N., Matsuda, H., Tao, M., Matsui, E., Naito, H., Nakamura, Y., and Hiasa, Y. Carcinogenicity study of monosodium aspartate in Fischer 344 rats: 100 weeks treatment. *J. Toxicol. Pathol.* 9: 161-168(1996).
94. Kitahori, Y., Konishi, N., Hayashi, I., Nakahashi, K., Kitamura, M., Nakamura, Y., Matsuda, H., Fukushima, Y., Yoshioka, N., and Hiasa, Y. Carcinogenicity study of glycine in Fischer 344 rats. *J. Toxicol. Pathol.* 7: 471-480(1994).
95. Kitahori, Y., Konishi, N., Nakagawa, Y., Cho, M., Naitoh, H., Yamamoto, K., Matsui, E., and Hiasa, Y. Lack of carcinogenicity of *L*-cysteine monohydrochloride in Fischer 344 rats. *J. Toxicol. Pathol.* 10: 83-89(1997).
96. Kitamura, T., Ando, J., Ishihara, R., Takano, S., Iijima, T., Nishimura, S., Yoshida, M., Takahashi, M., and Maekawa, A. Lack of carcinogenicity of thiamphenicol in F344 rats. *Food Chem. Toxicol.* 35: 1075-1080(1997).
97. Klimisch, H.-J., Deckardt, K., Gembardt, Chr., Hildebrand, B., Küttler, K., and Roe, F. J. C. Long-term inhalation toxicity of *N*-vinylpyrrolidone-2 vapours. Studies in rats. *Food Chem. Toxicol.* 35: 1041-1060(1997).
98. Klimisch, H.-J., Deckardt, K., Gembardt, Chr., Hildebrand, B., Küttler, K., and Roe, F. J. C. Subchronic inhalation and oral toxicity of *N*-vinylpyrrolidone-2. Studies in rodents. *Food Chem. Toxicol.* 35: 1061-1074(1997a).
99. Kociba, R. J., Frauson, L. O., Humiston, C. G., Norris, J. M., Wade, C. E., Lisowe, R. W., Quast, J. F., Jersey, G. C., and Jewett, G. L. Results of a two-year dietary feeding study with decabromodiphenyl oxide (DBDPO) in rats. *J. Combust. Toxicol.* 2: 267-285(1975).
100. Koestner, A. Aspartame and brain tumors: pathology issues. In: *Aspartame: Physiology and Biochemistry*, L. G. Stegink and L. J. Filer, Jr., eds. New York: Marcel Dekker, pp. 447-457 (1984).
101. Komulainen, H., Kosma, V.-M., Vaittinen, S.-L., Vartiainen, T., Kaliste-Korhonen, E., Lötjönen, S., Tuominen, R. K., and Tuomisto, J. Carcinogenicity of the drinking water mutagen 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5*H*)-furanone in the rat. *J. Nat. Cancer Inst.* 89: 848-856(1997).
102. Konishi, N., Kitahori, Y., Nishioka, H., Yane, K., and Hiasa, Y. Carcinogenicity testing of food red no. 106 (acid red) in Fischer 344 rats. *J. Toxicol. Pathol.* 5: 157-165(1992).
103. Kudo, M., Ohkawa, T., Nakamura, M., Maruyama, K., and Ikai, M. Toxicological study of urapidil. (2) Twelve-month chronic oral toxicity in rats. *Pharmacometrics (Oyo Yakuri)* 33: 473-500(1987).
104. Lafranconi, W. M., Long, P. H., Atkinson, J. E., Knezevich, A. L., and Wooding, W. L. Chronic toxicity and carcinogenicity of olestra in Swiss CD-1 mice. *Food Chem. Toxicol.* 32: 789-798(1994).
105. Lee, K. P., and Trochimowicz, H. J. Induction of nasal tumors in rats exposed to hexamethylphosphoramide by inhalation. *J. Nat. Cancer Inst.* 68: 157-164 (1982).
106. Lee, K. P., and Trochimowicz, H. J. Metaplastic changes of nasal respiratory epithelium in rats exposed to hexamethylphosphoramide (HMPA) by inhalation. *Am. J. Pathol.* 106: 8-19 (1982a).
107. Lee, K. P., and Trochimowicz, H. J. Morphogenesis of nasal tumors in rats exposed to hexamethylphosphoramide by inhalation. *Environ. Res.* 33: 106-118 (1984).
108. Litton Bionetics. *Carcinogenic Evaluation in Mice: Toxaphene. Final Report.* Prepared by Litton Bionetics, Inc., Kensington, MD for Hercules, Inc., Wilmington, DE. LBI Project No. 20602 (1978).

109. Lomax, L. G., Krivanek, N. D., and Frame, S. R. Chronic inhalation toxicity and oncogenicity of methyl methacrylate in rats and hamsters. *Food Chem. Toxicol.* 35: 393-407(1997).
110. Lomax, L. G., Stott, W. T., Johnson, K. A., Calhoun, L. L., Yano, B. L., and Quast, J. F. The chronic toxicity and oncogenicity of inhaled technical-grade 1,3-dichloropropene in rats and mice. *Fundam. Appl. Toxicol.* 12: 418-431(1989).
111. Macallum, G. E., Rothwell, C. E., and Smith, G. S. Carcinogenicity studies of pirlmenol in mice and rats. *Drug Investig.* 3: 278-289(1991).
112. MacDonald, J. S., Gerson, R. J., Kornbrust, D. J., Kloss, M. W., Prahallada, S., Berry, P. H., Alberts, A. W., and Bokelman, D. L. Preclinical evaluation of lovastatin. *Am. J. Cardiol.* 62:16J-27J (1988).
113. Malley, L. A., Carakostas, M., Hansen, J. F., Rusch, G. M., Kelly, D. P., and Trochimowicz, H. J. Two-year inhalation toxicity study in rats with hydrochlorofluorocarbon 123. *Fundam. Appl. Toxicol.* 25: 101-114(1995).
114. Malley, L. A., Slone, T. W., Jr., Makovec, G. T., Elliott, G. S., Kennedy, and G. L., Jr. Chronic toxicity/oncogenicity of dimethylacetamide in rats and mice following inhalation exposure. *Fundam. Appl. Toxicol.* 28: 80-93(1995).
115. Maltoni, C., and Tovoli, D. First experimental evidence of the carcinogenic effects of vinylidene fluoride. *Med. Lav.* 5: 363-368(1979).
116. Markiewicz, V., Tompkins, C., Mehdi, N., Hubmer, S., Payne, B. J., and Sumi, N. Rangefinding toxicity and carcinogenicity studies of a new  $\beta$ -adrenoceptor blocking agent celiprolol in rats. *Pharmacometrics (Oyo Yakuri)* 38: 407-420(1989).
117. McCoy, G. D., Hecht, S. S., and Furuya, K. The effect of chronic ethanol consumption on the tumorigenicity of *N*-nitrosopyrrolidine in male Syrian golden hamsters. *Cancer Lett.* 33: 151-159(1986).
118. McDonald, T. A. *Evidence on the Carcinogenicity of MX (3-Chloro-4-dichloromethyl)-f-hydroxy-2(5H)-furanone*. Office of Environmental Health Hazard Assessment, California Environmental Protection Agency (2000). [http://www.oehha.ca.gov/prop65/CRNR\\_notices/admin\\_listing/intent\\_to\\_list/referenced\\_docs/HID-MX.html](http://www.oehha.ca.gov/prop65/CRNR_notices/admin_listing/intent_to_list/referenced_docs/HID-MX.html)
119. McGuire, E. J., Anderson, J. A., Gough, A. W., Herman, J. R., Pegg, D. G., Theiss, J. C., and de la Iglesia, F. A. Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril). *J. Toxicol. Sci.* 21: 207-214(1996).
120. Mengs, U., Lang, W., and Poch, J.-A. The carcinogenic action of aristolochic acid in rats. *Arch. Toxicol.* 51: 107-119(1982).
121. Metzger, C., Bannasch, P., and Mayer, D. Enhancement and phenotypic modulation of *N*-nitrosomorpholine-induced hepatocarcinogenesis by dehydroepiandrosterone. *Cancer Lett.* 121: 125-131(1997).
122. Mikuriya, H., Fujii, T., Yoneyama, M., Yano, N., Yuzawa, K., Nagasawa, A., and Sasaki, M. Toxicity of *o*-phenylphenol by dietary administration to mice for 52 weeks. *Tokyo Metrop. Res. Lab. Public Health* 40: 281-288(1989).
123. Mikuriya, H., Fujii, T., Yoneyama, M., Yano, N., Yuzawa, K., Nagasawa, A., and Sasaki, M. Toxicity of thiabendazole and *o*-phenylphenol by simultaneous administration to mice for 52 weeks. *Tokyo Metrop. Res. Lab. Public Health* 40: 289-297(1989).
124. Millischer, R.-J., de Rooij, C. G., Rush, G. M., Farr, C. H., Bendyke, R., Hardy, C. J., Lewis, D. J., and Hodson-Walker, G. Evaluation of the genotoxicity potential and chronic inhalation toxicity of 1,1-dichloro-1-fluoroethane (HCFC-141b). *Food Chem. Toxicol.* 33: 491-500(1995).
125. Mitsumori, K., Maita, K., and Shirasu, Y. Chronic toxicity of methylmercury chloride in rats: pathological study. *Jpn. J. Vet. Sci.* 46: 549-557(1984).
126. Momma, J. Studies on the carcinogenicity and chronic toxicity of nonabromobiphenyl (NBB) in mice in comparison with those of polychlorinated biphenyl (PCB). *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 14: 5541-5563(1986).
127. Monticello, T. M., Swenberg, J. A., Gross, E. A., Leininger, J. R., Kimbell, J. S., Seilkop, S., Starr, T. B., Gibson, J. E. and Morgan, K. T. Correlation of regional and nonlinear formaldehyde-induced nasal cancer with proliferating populations of cells. *Cancer Res.* 56: 1012-1022 (1996).
128. Mori, H., Ohnishi, M., Kawamori, T., Sugie, S., Tanaka, T., Ino, N., and Kawai, K. Toxicity and tumorigenicity of purpurin, a natural hydroxyanthraquinone in rats: induction of bladder neoplasms. *Cancer Lett.* 102: 193-198(1996).
129. Murata, Y., Denda, A., Maruyama, H., Nakae, D., Tsutsumi, M., Tsujiuchi, T., and Konishi, Y. Chronic toxicity and carcinogenicity studies of 2-methylnaphthalene in B6C3F<sub>1</sub> mice. *Fundam. Appl. Toxicol.* 36: 90-93(1997).
130. Murata, Y., Denda, Y., Maruyama, H., and Konishi, Y. Chronic toxicity and carcinogenicity studies of 1-methylnaphthalene in B6C3F<sub>1</sub> mice. *Fundam. Appl. Toxicol.* 21: 44-51(1993).
131. Nagata, T., Nagata, T., Aramaki, Y., Enomoto, M., Sato, M., and Isaka, H. Subacute and chronic toxicity and recovery test with perhexiline maleate (PHX) in rats. *Pharmacometrics (Oyo Yakuri)* 20: 541-566(1980).
132. National Cancer Institute (1979). *Bioassay of Toxaphene for Possible Carcinogenicity*. Bethesda, MD: National Institutes of Health. Technical Report 37.
133. Nishimura, N., Hatayama, K., Tamura, K., Miyakawa, Y., Nagaoka, T., and Horio, H. Twelve-month oral toxicity study of ( $\pm$ )-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (Y-24180) in rats. *Pharmacometrics* 53: 259-280(1997).
134. Nitta, Y., Kamiya, K., Tanimoto, M., Kagimoto, O., Niwa, O., and Yokoro, K. Effects of administration of natural vitamin E on spontaneous hepatocarcinogenesis and *N*-nitrosodiethylamine initiated tumors in mice. *J. Toxicol. Pathol.* 4: 55-61(1991).
135. Nonoyama, T., Imai, R., Kondo, M., Hayashi, S., Nakai, Y., and Shikata, M. Fifty-two-week dietary toxicity study of AA-2414 in rats. *Jpn. Pharmacol. Therapeut.* 21: S1723-S1738 (1993).
136. Nonoyama, T., Imai, R., Tensha, S., Nagai, H., Sakura, Y., and Wada, T. Oncogenicity study of AO-128 in rats. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 19: 4415-4425(1991).
137. Nonoyama, T., Tanakamaru, Z.-Y., Sasano, K., Hamamoto, S., Kondo, M., Kandori, H., and Mitani, M. Oncogenicity study of TCV-116 in rats. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 24: S899-S913 (1996).
138. O'Gara, R. W. Biologic screening of selected plant material for carcinogens. *Cancer Res.* 28: 2272-2275(1968).
139. Ogawa, K., Sun, T.-T., and Cohen, S. M. Analysis of differentiation-associated proteins in rat bladder carcinogenesis. *Carcinogenesis* 17: 961-965(1996).
140. Ohtsubo, K. Hepatotoxic and hepatocarcinogenic effects of a sydnone derivative, 3-benzylsydnone-4-acetamide, on mice: differences in susceptibility by strain and sex. *J. Toxicol. Pathol.* 4: 45-54(1991).
141. Ohtsubo, K., Hatanaka, Y., Ueno, I., Enomoto, M., and Saito, M. Effects of dosage and sex on the liver injury and incidence of hepatocellular tumors induced by 3-benzylsydnone-4-acetamide in rats. *J. Toxicol. Pathol.* 7: 35-41(1994).
142. Osanai, H. An experimental study on hepatoma caused by aromatic amines. *J. Sci. Labour* 52: 179-201(1976).
143. Osheroff, M. R., Ando, T., and Miyajima, H. Oncogenicity study in mice with manidipine hydrochloride. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 17: 1205-1216(1989).
144. Osheroff, M. R., Ando, T., and Miyajima, H. Oncogenicity study in rats with manidipine hydrochloride. *Jpn. Pharmacol. Therapeut. (Yakuri to Chiryō)* 17: 1217-1231(1989).
145. Pohlmeier-Esch, G., Mehdi, N., Clarke, D., and Radhofer-Welte, S. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats. *Food Chem. Toxicol.* 35: 909-922(1997).
146. Popp, J. A. *A Chronic Inhalation Toxicity Study of Chlorine in Female and Male B6C3F<sub>1</sub> Mice and Fischer 344 Rats*. CIIT protocol numbers 8321, 8436 and 8437. Research Triangle Park, NC: Chemical Industry Institute of Toxicology (1993).
147. Poynter, D., Pick, C. R., Harcourt, R. A., Selway, S. A. M., Ainge, G., Harman, I. W., Spurling, N. W., Fluck, P. A., and Cook, J. L.

- Association of long lasting unsurmountable histamine H<sub>2</sub> blockade and gastric carcinoid tumours in the rat. *Gut* 26: 1284-1295(1985).
148. Rao, C. V., Desai, D., Rivenson, A., Simi, B., Amin, S., and Reddy, B. S. Chemoprevention of colon carcinogenesis by phenylethyl-3-methylcaffeate. *Cancer Res.* 55: 2310-2315(1995).
  149. Rao, C. V., Rivenson, A., Simi, B., and Reddy, B. S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. *Cancer Res.* 55: 259-266(1995).
  150. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Hamid, R., Kelloff, G. J., Steele, V., and Reddy, B. S. Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate. *Cancer Res.* 55: 4311-4318(1995).
  151. Rao, M. S., and Subbarao, V. Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator. *Cancer Lett.* 97: 185-188(1995).
  152. Rao, M. S., and Subbarao, V. The effect of deferroxamine on ciprofibrate-induced hepatocarcinogenesis in the rat. *in vivo* 11: 495-498(1997).
  153. Reddy, G., Reddy, T. V., Choudhury, H., Daniel, F. B., and Leach, G. J. Assessment of environmental hazards of 1,3,5-trinitrobenzene. *J. Toxicol. Environ. Health* 52: 447-460(1997).
  154. Reddy, T. V., Olson, G. R., Wiechman, B., Reddy, G., Torsella, J. A., Daniel, F. B., and Leach, G. J. Chronic toxicity of 1,3,5-trinitrobenzene in Fischer 344 rats. *Int. J. Toxicol.* 20: 59-67(2001).
  155. Schiefer, H. B., Rousseaux, C. G., Hancock, D. S., and Blakley, B. R. Effects of low-level long-term oral exposure to T-2 toxin in CD-1 mice. *Food Chem. Toxicol.* 25: 593-601(1987).
  156. Schoental, R., Head, M. A., and Peacock, P. R. Senecio alkaloids: primary liver tumours in rats as a result of treatment with (1) a mixture of alkaloids from *S. jacobaea* Lin.; (2) retrorsine; (3) isatidine. *Br. J. Cancer* 8: 458-465(1954).
  157. Schrauzer, G. N., White, D. A., and Schneider, C. J. Inhibition of the genesis of spontaneous mammary tumors in C3H mice: effects of selenium and of selenium-antagonistic elements and their possible role in human breast cancer. *Ann. Clin. Lab. Sci.* 4: 441-447(1974).
  158. Schrauzer, G. N., White, D. A., and Schneider, C. J. Inhibition of the genesis of spontaneous mammary tumors in C3H mice: effects of selenium and of selenium-antagonistic elements and their possible role in human breast cancer. *Bioinorg. Chem.* 6: 265-270(1976).
  159. Schrauzer, G. N., White, D. A., McGinness, J. E., Schneider, C. J., and Bell, L. J. Arsenic and cancer: effects of joint administration of arsenite and selenite on the genesis of mammary adenocarcinoma in inbred female C3H/St mice. *Bioinorg. Chem.* 9: 245-253(1978).
  160. Sekigawa, S., Imai, S., Yamamoto, H., Ohno, Y., Morimoto, J., Okuyama, T., and Tsubura, Y. Additive toxicity test of food red no. 3 (erythrosine) and no. 102 (new cocine) in Wistar rats. *J. Nara Med. Assoc.* 30: 179-191(1979).
  161. Sekigawa, S., Shimomura, H., Yamamoto, H., Okuyama, T., and Tsubura, Y. Additive toxicity test of food red no. 2 and no. 3 in rats. *J. Nara Med. Assoc.* 29: 709-721(1978).
  162. Shen, J., Wanibuchi, H., Salim, E. I., Wei, M., Doi, K., Yoshida, K., Endo, G., Morimura, K., and Fukushima, S. Induction of glutathione S-transferase placental form positive foci in liver and epithelial hyperplasia in urinary bladder, but no tumor development in male Fischer 344 rats treated with monomethylarsonic acid for 104 weeks. *Toxicol. Appl. Pharmacol.* 193: 335-345(2003).
  163. Shen, J., Wanibuchi, H., Salim, E. I., Wei, M., Kinoshita, A., Yoshida, K., Endo, G., and Fukushima, S. Liver tumorigenicity of trimethylarsine oxide in male Fischer 344 rats — association with oxidative DNA damage and enhanced cell proliferation. *Carcinogenesis* 24: 1827-1835(2003).
  164. Shibata, M. A., Tanaka, H., Kawabe, M., Sano, M., Hagiwara, A., and Shirai, T. Lack of carcinogenicity of monosodium L-glutamate in Fischer 344 rats. *Food Chem. Toxicol.* 33: 383-391(1995).
  165. Shibata, M.-A., Kurata, Y., Hagiwara, A., and Shirai, T. Lack of tumorigenic effects on rat renal pelvic transitional epithelium of life-span exposure to low doses of a bladder carcinogen. *J. Toxicol. Pathol.* 6 (Suppl.): 47-53(1993).
  166. Sigler, R. E., Gough, A. W., and de la Iglesia, F. A. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. *Toxicology* 98: 73-82(1995).
  167. Steinhoff, D., and Mohr, U. The question of carcinogenic effects of hydrazine. *Exp. Pathol.* 33: 133-143(1988).
  168. Stieglitz, R., Gibel, W., Werner, W., and Stobbe, H. Experimental study on haematotoxic and leukaemogenic effects of trichlorophone and dimethoate. *Acta Hematol.* 52: 70-76(1974).
  169. Streett, C. S., Robertson, J. L., and Crissman, J. W. Morphological stomach findings in rats and mice treated with the H<sub>2</sub> receptor antagonists, ICI 125,211 and ICI 162,846. *Toxicol. Pathol.* 16: 299-304(1988).
  170. Tabata, H., Sakai, T., Miki, H., Suzuki, H., Ruckman, S. A., Read, R. M., Gopinath, C., Healey, G. F., Barker, M. H., Chasseaud, L. F., Gazeley, M. J. S., Ince, G., and Hedge, A. Oncogenicity studies of the new serotonin (5-HT)<sub>3</sub>-receptor antagonist ramosetron in mice and rats. *Arzneim. -Forsch.* 46: 560-566(1996).
  171. Takada, K., Yasuhara, K., Nakaji, Y., Yoshimoto, H., Momma, J., and Kurokawa, Y. Carcinogenicity study of tris (2-chloroethyl) phosphate in ddY mice. *J. Toxicol. Pathol.* 2: 213-222(1989).
  172. Takahashi, H., Mori, T., Fujihira, E., and Nakazawa, M. Long-term feeding of taurine in rats. *Pharmacometrics (Oyo Yakuri)* 6: 529-534(1972).
  173. Takamura, N., Kurokawa, Y., Matsushima, Y., Imazawa, T., Onodera, H., and Hayashi, Y. Long-term oral administration of potassium bromate in male Syrian golden hamsters. *Sci. Rep. Res. Inst. Tohoku Univ. Ser. C Med.* 32: 43-46(1985).
  174. Takaoka, M., Matsuura, T., Yamashita, K., Ohashi, Y., and Matsunuma, N. Oncogenicity studies in mice and rats with azelnidipine. *Jpn. Pharmacol. Therapeut.* 25: S1113-S1126(1997).
  175. Tamano, S., Ward, J. M., Diwan, B. A., Keefer, L. K., Weghorst, C. M., Calvert, R. J., Henneman, J. R., Ramljak, D., and Rice, J. M. Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats. *Carcinogenesis* 17: 2477-2486(1996).
  176. Tanakamaru, Z., Nishikawa, A., Furukawa, F., Imazawa, T., Lee, I.-S., Kasahara, K.-I., Tanaka, T., and Takahashi, M. Failure of dietary  $\alpha$ -difluoromethylornithine to inhibit gastric carcinogenesis in rats after 8 weeks of treatment with N-methyl-N'-nitro-N-nitrosoguanidine and sodium chloride. *Cancer Lett.* 120: 95-100(1997).
  177. Toyoda, K., Matsui, H., Shoda, T., Uneyama, C., Takada, K., and Takahashi, M. Assessment of carcinogenicity of stevioside in F344 rats. *Food Chem. Toxicol.* 35: 597-603(1997).
  178. Toyoda, K., Shoda, T., Uneyama, C., Takada, K., and Takahashi, M. Carcinogenicity study of  $\beta$ -cyclodextrin in F344 rats. *Food Chem. Toxicol.* 35: 331-336(1997).
  179. Trutter, J. A., Machotka, S. V., Alsaker, R. D., Sumi, N., and Tshida, K. Carcinogenicity study of a new orally active antirheumatic drug 4-acetylamino phenylacetic acid (MS-932) in mice. *Pharmacometrics (Oyo Yakuri)* 40: 325-335(1990).
  180. Trutter, J. A., Machotka, S. V., Alsaker, R. D., Sumi, N., and Tshida, K. Carcinogenicity study of a new orally active antirheumatic drug 4-acetylamino phenylacetic acid (MS-932) in rats. *Pharmacometrics (Oyo Yakuri)* 40: 337-349(1990).
  181. Tsubura, Y. Chronic oral toxicity test of tylosin lactate in C57BL/6 mice. *J. Nara Med. Assoc.* 30: 506-517(1979).
  182. Tucker, M. J., and Orton, T. C. *Comparative Toxicology of Hypolipidaemic Fibrates*. Section 1.6. Oncogenicity studies in mice (1970, 1976). London: Taylor and Francis, pp. 13-16 (1995).
  183. Tucker, M. J., and Orton, T. C. *Comparative Toxicology of Hypolipidaemic Fibrates*. Section 2.5. Oncogenicity studies in mice (1966-67, 1968-70). London: Taylor and Francis, pp. 39-53 (1995).
  184. Tucker, M. J., and Orton, T. C. *Comparative toxicology of hypolipidaemic fibrates*. 3.8 Oncogenicity study in the rat (1971-73). London: Taylor and Francis, pp. 74-81 (1995).

185. Tucker, M. J., Kalinowski, A. E., and Orton, T. C. Carcinogenicity of cyproterone acetate in the mouse. *Carcinogenesis* 17: 1473-1476(1996).
186. Usui, T., Ogiwara, S., Kaziwara, K., and Shimamoto, K. Oral toxicity studies of disodium 5'-ribonucleotide in the rat. *J. Takeda Res. Lab. (Takeda Kenkyusho Ho)* 30: 614-635(1971).
187. Verschuuren, H. G., Kroes, R., den Tonkelaar, E. M., Berkvens, J. M., Helleman, P. W., Rauws, G., Schuller, P. L., and van Esch, G. J. Toxicity studies with methylmercury chloride in rats (short-term, long-term and reproductive studies). *Rijks Instituut voor de Volksgezondheit. Report 80/74 Tox* (1974).
188. Verschuuren, H. G., Kroes, R., den, E. M., Tonkelaar, Berkvens, J. M., Helleman, P. W., Rauws, G., Schuller, P. L., and van Esch, G. J. Toxicity studies with methylmercury chloride in rats (short-term, long-term and reproduction studies). *Toxicology* 6: 107-123(1976).
189. Waalkes, M. P., Rehm, S., Riggs, C. W., Bare, R. M., Devor, D. E., Poirier, L. A., Wenk, M. L., and Henneman, J. R. Cadmium carcinogenesis in male Wistar [CrI:(WI)BR] rats: dose-response analysis of effects of zinc on tumor induction in the prostate, in the testes, and at the injection site. *Cancer Res.* 49: 4282-4288(1989).
190. Walker, R. M., Wojcinski, Z. W., Hofstra, A. H., King, L. M., Rogers, J. E., Baker, K. W., Chang, P.-K., and Smith, G. S. Hepatotumorigenicity and peroxisome proliferation induced by the hypolipidemic CI-924 in a two-year study in male and female B6C3F<sub>1</sub> mice. *Toxicol. Pathol.* 24: 265-272(1996).
191. Waner, T., Borelli, G., Cadel, S., Privman, I., and Nyska, A. Investigation of potential oncogenic effects of beta-cyclodextrin in the rat and mouse. *Arch. Toxicol.* 69: 631-639(1995).
192. Wang, D. Studies on carcinogenicity of furadan in ICR mice by chronic ingestion. *Acta Sci. Circumst.* 9: 505-508(1989).
193. Wei, M., Wanibuchi, H., Morimura, K., Iwai, S., Yoshida, K., Endo, G., Nakae, D., and Fukushima, S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. *Carcinogenesis* 23: 1387-1397(2002).
194. Wei, M., Wanibuchi, H., Yamamoto, S., Li, W., and Fukushima, S. Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. *Carcinogenesis* 20: 1873-1876(1999).
195. Weisburger, J. H., Rivenson, A., Marcus, L. A., Lang, J., Zang, E., Pittman, B., Nagao, M., and Sugimura, T. Modification by dietary fat of mammary gland carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in female SD x F344 F<sub>1</sub> hybrid rats. *J. Environ. Pathol. Toxicol. Oncol.* 16: 329-334(1997).
196. Wolf, D. C., Morgan, K. T., Gross, E. A., Barrow, C., Moss, O. R., James, R. A., and Popp, J. A. Two-year inhalation exposure of female and male B6C3F<sub>1</sub> mice and F344 rats to chlorine gas induces lesions confined to the nose. *Fundam. Appl. Toxicol.* 24: 111-131(1995).
197. Wood, F. E., Tierney, W. J., Knezevich, A. L., Bolte, H. F., Maurer, J. K., and Bruce, R. D. Chronic toxicity and carcinogenicity studies of olestra in Fischer 344 rats. *Food Chem. Toxicol.* 29: 223-230(1991).
198. Yabe, T., Honma, M., Katsuki, S., Luetzen, L., Wiegler, J., Poeschner, H., and Lehmann, H. Oral toxicity studies of meloxicam in rats. *Pharmacometrics (Oyo Yakuri)* 53: 29-49(1997).
199. Yamada, T., Kuwano, H., Matsuda, H., Sugimachi, K., and Ishinishi, N. Effect of dietary vitamin A on forestomach tumorigenesis during the total and postinitiation stages in mice treated with high- or low-dose benzo(a)pyrene. *Surg. Today* 25: 729-736(1995).
200. Yamamoto, H., Imai, S., and Tsubura, Y. Chronic toxicity of vitamin A acid in NIH Swiss mice by oral administration. *J. Nara Med. Assoc.* 27: 437-451(1976).
201. Yamamoto, K., Eimoto, H., Takashima, Y., Tsutsumi, M., Maruyama, H., Denda, A., Mori, Y., and Konishi, Y. Initiation activity of endogenously synthesized *N*-nitrosobis(2-hydroxypropyl)amine in the rat liver. *Cancer Lett.* 45: 221-225(1989).
202. Yamamoto, K., Tsutsumi, M., Tsujiuchi, T., Kobitsu, K., Okajima, E., Takahama, M., Mori, Y., and Konishi, Y. Lack of significant tumor induction by endogenously formed *N*-nitrosobis(2-hydroxypropyl)amine in rats fed tris(2-hydroxypropyl)amine and sodium nitrite. *J. Toxicol. Pathol.* 9: 199-204(1996).
203. Yamamura, T., Nishimura, T., Kuwamura, Y., Inui, T., Aughton, P., and Kawai, Y. Oncogenicity studies of taltirelin tetrahydrate (TA-0910) by oral (gavage) administration in CD-1 mice and CD rats. *J. Toxicol. Sci.* 22(Suppl. II): 419-430(1997).
204. Yamazaki, K., Ohno, H., Asakura, M., Narumi, A., Ohbayashi, H., Fujita, H., Ohnishi, M., Katagiri, T., Senoh, H., Yamanouchi, K., Nakayama, E., Yamamoto, S., Noguchi, T., Nagano, K., Enomoto, M., and Sakabe, H. Two-year toxicological and carcinogenesis studies of 1,4-dioxane in F344 rats and BDF<sub>1</sub> mice. Drinking studies. *Proc. Int. Center Med. Res. Seminar* 1993: 193-198(1994).
205. Yasuhara, K., Shimo, T., Mitsumori, K., Onodera, H., Kitaura, K., and Takahashi, M. Lack of carcinogenicity of cyanoguanidine in F344 rats. *Food Chem. Toxicol.* 35: 475-480(1997).
206. Yonezawa, H., Yamaguchi, K., Shinomiya, K., Koide, T., Suzuki, Y., Ueda, H., Murakata, S., Tanimoto, T., Tanaka, M., Yanagi, H., Shichino, Y., Sakai, M., Shirakawa, R., Itagaki, I., Chihara, N., Kanazawa, H., and Matsuoka, Y. Toxicological study of 4-oxo-8-[4-(4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemidrate (ONO-1078). (3) Twelve-month oral toxicity study in rats. *Pharmacometrics (Oyo Yakuri)* 44: 219-242(1992).
207. Yoshimi, N., Ino, N., Suzui, M., Tanaka, T., Nakashima, S., Nakamura, M., Nozawa, Y., and Mori, H. The mRNA overexpression of inflammatory enzymes, phospholipase A<sub>2</sub> and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone. *Cancer Lett.* 97: 75-82(1995).
208. Zariwala, M. B. A., Lalitha, V. S., and Bhide, S. V. Carcinogenic potential of Indian alcoholic beverage (country liquor). *Indian J. Exp. Biol.* 29: 738-743(1991).
209. Zwicker, G. M., and Eyster, R. C. Proliferative bone lesions in rats fed a diet containing glucocorticoid for up to two years. *Toxicol. Pathol.* 24: 246-250(1996).